,Sentence,ESG BERT Topic 1,ESG BERT Topic 2,ESG BERT Topic 3,Mapped Criteria Topic 1,Mapped Criteria Topic 2,Mapped Criteria Topic 3
Line 1,"2021 Environmental, Social and Governance Report Progress against 16+ indicators in accordance with the BioPharma Alliance, SASB and GRITable of Contents 3 About Bristol Myers Squibb 9 Ethics, Integrity, Quality and Governance 19 Innovation, Equity and Access to Healthcare 27 Our People 38 Environmental Responsibility 50 AppendixAbout This Report This report is written in accordance with the Biopharma Investor ESG Communications Guidance 2.0, which was developed by the Biopharma Investor ESG Communications Initiative, part of the Biopharma Sustainability Roundtable (BSRT).","('Business_Ethics', 0.8922206163406372)","('Management_Of_Legal_And_Regulatory_Framework', 0.0256842952221632)","('Human_Rights_And_Community_Relations', 0.014649632386863232)","(['Business Ethics'], 0.8922206163406372)","('NON-ESG', 0.0256842952221632)","('NON-ESG', 0.014649632386863232)"
Line 2,"2021 Environmental, Social and Governance Report Progress against 16+ indicators in accordance with the BioPharma Alliance, SASB and GRITable of Contents 3 About Bristol Myers Squibb 9 Ethics, Integrity, Quality and Governance 19 Innovation, Equity and Access to Healthcare 27 Our People 38 Environmental Responsibility 50 AppendixAbout This Report This report is written in accordance with the Biopharma Investor ESG Communications Guidance 2.0, which was developed by the Biopharma Investor ESG Communications Initiative, part of the Biopharma Sustainability Roundtable (BSRT).","('Business_Model_Resilience', 0.33641424775123596)","('Supply_Chain_Management', 0.17274585366249084)","('Product_Design_And_Lifecycle_Management', 0.0713873878121376)","('NON-ESG', 0.33641424775123596)","('NON-ESG', 0.17274585366249084)","('NON-ESG', 0.0713873878121376)"
Line 3,It was prepared with reference to the Global Reporting Initiative (GRI) standards and the Sustainability Accounting Standards Board (SASB) standards for the biopharmaceutical sector.,"('Management_Of_Legal_And_Regulatory_Framework', 0.34821614623069763)","('Systemic_Risk_Management', 0.11607182025909424)","('Product_Quality_And_Safety', 0.10569489747285843)","('NON-ESG', 0.34821614623069763)","('NON-ESG', 0.11607182025909424)","('NON-ESG', 0.10569489747285843)"
Line 4,"This report also includes our Anti-Corruption report using the Norges Bank Investment Management (NBIM) guidance, providing additional transparency to our progress in this critical area.","('Business_Ethics', 0.9733656048774719)","('Management_Of_Legal_And_Regulatory_Framework', 0.003366334130987525)","('Data_Security', 0.0022233128547668457)","(['Business Ethics'], 0.9733656048774719)","('NON-ESG', 0.003366334130987525)","('NON-ESG', 0.0022233128547668457)"
Line 5,"Unless otherwise stated, this report details our performance on ESG topics and contains nonfinancial disclosures covering the period from January 1, 2021, through December 31, 2021.","('Business_Model_Resilience', 0.5264720320701599)","('Systemic_Risk_Management', 0.1814279556274414)","('Management_Of_Legal_And_Regulatory_Framework', 0.04183906689286232)","(['Human Capital Development', 'Innovation Management'], 0.5264720320701599)","('NON-ESG', 0.1814279556274414)","('NON-ESG', 0.04183906689286232)"
Line 6,"2021 ESG REPORT | 2About Bristol Myers Squibb Transforming patients lives through scienceTM We are a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.","('Customer_Welfare', 0.2620183229446411)","('Access_And_Affordability', 0.15335039794445038)","('Selling_Practices_And_Product_Labeling', 0.08208104223012924)","('NON-ESG', 0.2620183229446411)","('NON-ESG', 0.15335039794445038)","('NON-ESG', 0.08208104223012924)"
Line 7,"At Bristol Myers Squibb (BMS), we are in the business of medical breakthroughsthe kinds that transform and save patients lives.","('Employee_Health_And_Safety', 0.4439254105091095)","('Critical_Incident_Risk_Management', 0.19129326939582825)","('Access_And_Affordability', 0.11281950026750565)","('NON-ESG', 0.4439254105091095)","('NON-ESG', 0.19129326939582825)","('NON-ESG', 0.11281950026750565)"
Line 8,Our business combines the agility of biotech with the reach and resources of an established pharmaceutical company to create a leading global biopharma company.,"('Business_Model_Resilience', 0.24578210711479187)","('Competitive_Behavior', 0.19193768501281738)","('Customer_Welfare', 0.12254969030618668)","('NON-ESG', 0.24578210711479187)","('NON-ESG', 0.19193768501281738)","('NON-ESG', 0.12254969030618668)"
Line 9,We bring a human touch to every treatment we pioneer.,"('Access_And_Affordability', 0.45494189858436584)","('Employee_Health_And_Safety', 0.09976992011070251)","('Human_Rights_And_Community_Relations', 0.08342533558607101)","('NON-ESG', 0.45494189858436584)","('NON-ESG', 0.09976992011070251)","('NON-ESG', 0.08342533558607101)"
Line 10,"With a diverse and promising R&D pipeline, we focus on innovations that drive meaningful change.","('Business_Model_Resilience', 0.44376835227012634)","('Product_Design_And_Lifecycle_Management', 0.14323794841766357)","('Employee_Engagement_Inclusion_And_Diversity', 0.06460456550121307)","('NON-ESG', 0.44376835227012634)","('NON-ESG', 0.14323794841766357)","('NON-ESG', 0.06460456550121307)"
Line 11,"Our therapeutic areas in which we have marketed products include: ONCOLOGY CARDIOVASCULAR HEMATOLOGYIMMUNOLOGY FIBROTIC DISEASES NEUROSCIENCE Our Mission To discover, develop and deliver innovative medicines that help patients prevail over serious diseases Our Vision To be the worlds leading biopharma company that transforms patients lives through science Our Values Integrity | Innovation | Urgency Passion | Accountability | Inclusion2021 Highlights $46.4B Total revenues, representing 9% year-over-year (YOY) growth from 2020$11.4B Invested in R&D including Acquired IPRD Strong revenue growth across portfolio: 17% Eliquis (apixaban) YoY growth 8%Opdivo (nivolumab) YoY growth 20%Yer voy (ipilimumab) YoY growth $1.1B in new product portfolio1 sales Robust early-stage pipeline with 50+ assets across leading drug discovery platforms: small molecules, protein homeostasis, biologics, cell and gene therapy $3.12 GAAP EPS$7.16 Non-GAAP EPS21 New Product Portfolio includes Reblozyl (luspatercept-aamt), Inrebic (fedratinib), Onureg (azacitidine tablets), Zeposia (ozanimod), Breyanzi (lisocabtagene maraleucel) and Abecma (idecabtagene vicleucel).","('Customer_Welfare', 0.30297335982322693)","('Business_Model_Resilience', 0.09156753867864609)","('Competitive_Behavior', 0.0909687951207161)","('NON-ESG', 0.30297335982322693)","('NON-ESG', 0.09156753867864609)","('NON-ESG', 0.0909687951207161)"
Line 12,"Our therapeutic areas in which we have marketed products include: ONCOLOGY CARDIOVASCULAR HEMATOLOGYIMMUNOLOGY FIBROTIC DISEASES NEUROSCIENCE Our Mission To discover, develop and deliver innovative medicines that help patients prevail over serious diseases Our Vision To be the worlds leading biopharma company that transforms patients lives through science Our Values Integrity | Innovation | Urgency Passion | Accountability | Inclusion2021 Highlights $46.4B Total revenues, representing 9% year-over-year (YOY) growth from 2020$11.4B Invested in R&D including Acquired IPRD Strong revenue growth across portfolio: 17% Eliquis (apixaban) YoY growth 8%Opdivo (nivolumab) YoY growth 20%Yer voy (ipilimumab) YoY growth $1.1B in new product portfolio1 sales Robust early-stage pipeline with 50+ assets across leading drug discovery platforms: small molecules, protein homeostasis, biologics, cell and gene therapy $3.12 GAAP EPS$7.16 Non-GAAP EPS21 New Product Portfolio includes Reblozyl (luspatercept-aamt), Inrebic (fedratinib), Onureg (azacitidine tablets), Zeposia (ozanimod), Breyanzi (lisocabtagene maraleucel) and Abecma (idecabtagene vicleucel).","('Customer_Welfare', 0.3948778808116913)","('Product_Design_And_Lifecycle_Management', 0.09763307869434357)","('Selling_Practices_And_Product_Labeling', 0.08658251166343689)","('NON-ESG', 0.3948778808116913)","('NON-ESG', 0.09763307869434357)","('NON-ESG', 0.08658251166343689)"
Line 13,"Our therapeutic areas in which we have marketed products include: ONCOLOGY CARDIOVASCULAR HEMATOLOGYIMMUNOLOGY FIBROTIC DISEASES NEUROSCIENCE Our Mission To discover, develop and deliver innovative medicines that help patients prevail over serious diseases Our Vision To be the worlds leading biopharma company that transforms patients lives through science Our Values Integrity | Innovation | Urgency Passion | Accountability | Inclusion2021 Highlights $46.4B Total revenues, representing 9% year-over-year (YOY) growth from 2020$11.4B Invested in R&D including Acquired IPRD Strong revenue growth across portfolio: 17% Eliquis (apixaban) YoY growth 8%Opdivo (nivolumab) YoY growth 20%Yer voy (ipilimumab) YoY growth $1.1B in new product portfolio1 sales Robust early-stage pipeline with 50+ assets across leading drug discovery platforms: small molecules, protein homeostasis, biologics, cell and gene therapy $3.12 GAAP EPS$7.16 Non-GAAP EPS21 New Product Portfolio includes Reblozyl (luspatercept-aamt), Inrebic (fedratinib), Onureg (azacitidine tablets), Zeposia (ozanimod), Breyanzi (lisocabtagene maraleucel) and Abecma (idecabtagene vicleucel).","('Selling_Practices_And_Product_Labeling', 0.3371635973453522)","('Customer_Welfare', 0.26134729385375977)","('Product_Quality_And_Safety', 0.048058297485113144)","('NON-ESG', 0.3371635973453522)","('NON-ESG', 0.26134729385375977)","('NON-ESG', 0.048058297485113144)"
Line 14,"Risk- adjusted sales figure also includes potential for Opdualag (relatlimab plus nivolumab fixed-dose combination), CamzyosTM (mavacamten) and Sotyktu (deucravacitinib).","('Customer_Welfare', 0.3923097252845764)","('Selling_Practices_And_Product_Labeling', 0.13236857950687408)","('Competitive_Behavior', 0.0807795450091362)","('NON-ESG', 0.3923097252845764)","('NON-ESG', 0.13236857950687408)","('NON-ESG', 0.0807795450091362)"
Line 15,"2 This non-GAAP amount excludes certain costs, expenses, gains and losses and other specified items.","('Management_Of_Legal_And_Regulatory_Framework', 0.8656706213951111)","('Systemic_Risk_Management', 0.028874650597572327)","('Business_Ethics', 0.014730960130691528)","([], 0.8656706213951111)","('NON-ESG', 0.028874650597572327)","('NON-ESG', 0.014730960130691528)"
Line 16,"GAAP and non-GAAP earnings per share include the net impact of certain in-process research and development (""Acquired IPRD"") charges resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property right and licensing income.","('Competitive_Behavior', 0.4968779683113098)","('Management_Of_Legal_And_Regulatory_Framework', 0.25515514612197876)","('Business_Ethics', 0.048010896891355515)","('NON-ESG', 0.4968779683113098)","('NON-ESG', 0.25515514612197876)","('NON-ESG', 0.048010896891355515)"
Line 17,A reconciliation of GAAP to non-GAAP measures can be found on our website at bms.com.,"('Management_Of_Legal_And_Regulatory_Framework', 0.9403086304664612)","('GHG_Emissions', 0.0064530447125434875)","('Business_Ethics', 0.005927754566073418)","([], 0.9403086304664612)","('NON-ESG', 0.0064530447125434875)","('NON-ESG', 0.005927754566073418)"
Line 18,See Quarterly Package of Financial Information available on bms.com/investors for information on the list of specified items excluded from non-GAAP EPS.,"('Management_Of_Legal_And_Regulatory_Framework', 0.9267333745956421)","('Systemic_Risk_Management', 0.011107778176665306)","('Business_Ethics', 0.006911231204867363)","([], 0.9267333745956421)","('NON-ESG', 0.011107778176665306)","('NON-ESG', 0.006911231204867363)"
Line 19,"2021 ESG REPORT | 3A Letter from Giovanni Caforio At Bristol Myers Squibb, we use science to transform patients lives.","('Access_And_Affordability', 0.32825717329978943)","('GHG_Emissions', 0.07473661750555038)","('Business_Model_Resilience', 0.0661187544465065)","('NON-ESG', 0.32825717329978943)","('NON-ESG', 0.07473661750555038)","('NON-ESG', 0.0661187544465065)"
Line 20,"While 2021 was another year of significant external challenges, our global workforce never wavered on discovering, developing and delivering innovative medicines that help patients prevail over serious diseases.","('Access_And_Affordability', 0.2572343647480011)","('Customer_Welfare', 0.13209059834480286)","('Product_Quality_And_Safety', 0.07122699171304703)","('NON-ESG', 0.2572343647480011)","('NON-ESG', 0.13209059834480286)","('NON-ESG', 0.07122699171304703)"
Line 21,"Throughout the year, we delivered strong financial results, including across our new product portfolio.","('Product_Design_And_Lifecycle_Management', 0.9351901412010193)","('Product_Quality_And_Safety', 0.008060669526457787)","('Customer_Welfare', 0.006742007564753294)","([], 0.9351901412010193)","('NON-ESG', 0.008060669526457787)","('NON-ESG', 0.006742007564753294)"
Line 22,We used this momentum to fuel our innovation enginedoubling our research and development (R&D) pipeline compared to 2019 and deepening our use of digital technology to accelerate drug discovery and development.,"('Competitive_Behavior', 0.2125815898180008)","('Business_Model_Resilience', 0.16547982394695282)","('Customer_Welfare', 0.12080314755439758)","('NON-ESG', 0.2125815898180008)","('NON-ESG', 0.16547982394695282)","('NON-ESG', 0.12080314755439758)"
Line 23,"Critically, we have evolved our core strategy for business growth tointegrate environmental, social and governance (ESG) factors.","('Business_Model_Resilience', 0.5194299221038818)","('Human_Rights_And_Community_Relations', 0.12545916438102722)","('Management_Of_Legal_And_Regulatory_Framework', 0.05526359751820564)","(['Human Capital Development', 'Innovation Management'], 0.5194299221038818)","('NON-ESG', 0.12545916438102722)","('NON-ESG', 0.05526359751820564)"
Line 24,Thisstrategy guides us to further incorporate sustainability into our corporate culture and daily business operations so that we can continue to innovate life-saving medicines in a way that is environmentally and socially responsible.,"('Product_Design_And_Lifecycle_Management', 0.39560866355895996)","('Business_Model_Resilience', 0.23900635540485382)","('Ecological_Impacts', 0.05935273319482803)","('NON-ESG', 0.39560866355895996)","('NON-ESG', 0.23900635540485382)","('NON-ESG', 0.05935273319482803)"
Line 25,"Advancing our strategy As we execute our strategy, were engaging our global workforce to make progress toward ambitious, ESG-focused goals.","('Business_Model_Resilience', 0.6673239469528198)","('Employee_Engagement_Inclusion_And_Diversity', 0.094202421605587)","('Systemic_Risk_Management', 0.03226184472441673)","(['Human Capital Development', 'Innovation Management'], 0.6673239469528198)","('NON-ESG', 0.094202421605587)","('NON-ESG', 0.03226184472441673)"
Line 26,"Together, we are working to accelerate innovation; enhance patient access to medicines; build an inclusive, diverse and equitable work environment; and strengthen our environmental sustainabilityall while operating with the highest levels of quality, integrity and ethics.","('Employee_Engagement_Inclusion_And_Diversity', 0.3971717953681946)","('Business_Ethics', 0.20034508407115936)","('Human_Rights_And_Community_Relations', 0.07739201933145523)","('NON-ESG', 0.3971717953681946)","('NON-ESG', 0.20034508407115936)","('NON-ESG', 0.07739201933145523)"
Line 27,Our North Star is to ensure that every patient who needs our medicines has access to them.,"('Access_And_Affordability', 0.841710090637207)","('Energy_Management', 0.016962790861725807)","('Human_Rights_And_Community_Relations', 0.015596638433635235)","(['Access to Healthcare'], 0.841710090637207)","('NON-ESG', 0.016962790861725807)","('NON-ESG', 0.015596638433635235)"
Line 28,"In 2021, we made progress across our commitments to health equity and inclusion and diversity (I&D).","('Employee_Engagement_Inclusion_And_Diversity', 0.9730081558227539)","('Human_Rights_And_Community_Relations', 0.0022384009789675474)","('Employee_Health_And_Safety', 0.0022013168781995773)","(['Talent Attraction & Retention'], 0.9730081558227539)","('NON-ESG', 0.0022384009789675474)","('NON-ESG', 0.0022013168781995773)"
Line 29,A focus on diversity during discovery and development leads to better science.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9704369306564331)","('Human_Rights_And_Community_Relations', 0.0024030101485550404)","('Employee_Health_And_Safety', 0.002196751069277525)","(['Talent Attraction & Retention'], 0.9704369306564331)","('NON-ESG', 0.0024030101485550404)","('NON-ESG', 0.002196751069277525)"
Line 30,"In 2021, we exceeded the target set to increase diverse patient participation in clinical trials, with more than half of our clinical trial sites now located in highly diverse U.","('Access_And_Affordability', 0.20938874781131744)","('Competitive_Behavior', 0.14109265804290771)","('Customer_Welfare', 0.12947723269462585)","('NON-ESG', 0.20938874781131744)","('NON-ESG', 0.14109265804290771)","('NON-ESG', 0.12947723269462585)"
Line 31,S. communities.,"('Human_Rights_And_Community_Relations', 0.41636529564857483)","('Business_Model_Resilience', 0.12729796767234802)","('Employee_Engagement_Inclusion_And_Diversity', 0.054900892078876495)","('NON-ESG', 0.41636529564857483)","('NON-ESG', 0.12729796767234802)","('NON-ESG', 0.054900892078876495)"
Line 32,"In another initiative aimed at improving I&D, we expanded our Tomorrows Innovators program.","('Business_Model_Resilience', 0.497265487909317)","('Product_Design_And_Lifecycle_Management', 0.09894180297851562)","('Supply_Chain_Management', 0.0710652619600296)","('NON-ESG', 0.497265487909317)","('NON-ESG', 0.09894180297851562)","('NON-ESG', 0.0710652619600296)"
Line 33,This two-way leadership exchange program opens collaboration and research opportunities and will enhance ourefforts to recruit talent from historically Black colleges and universitiesand attract Black and African American leaders for our executive-levelpositions.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9617778062820435)","('Employee_Health_And_Safety', 0.002763755852356553)","('Business_Model_Resilience', 0.0024642720818519592)","(['Talent Attraction & Retention'], 0.9617778062820435)","('NON-ESG', 0.002763755852356553)","('NON-ESG', 0.0024642720818519592)"
Line 34,Our commitment to health equity underscores our approach to environmental stewardship.,"('Business_Model_Resilience', 0.6973796486854553)","('Ecological_Impacts', 0.04291802644729614)","('Supply_Chain_Management', 0.040257424116134644)","(['Human Capital Development', 'Innovation Management'], 0.6973796486854553)","('NON-ESG', 0.04291802644729614)","('NON-ESG', 0.040257424116134644)"
Line 35,"As a company driven by science, we understand that human health is inextricably linked to the health of the planet, therefore we consider environmental responsibility to be imperative for doing business and expanding health equity around theworld.","('Employee_Health_And_Safety', 0.9008429646492004)","('Critical_Incident_Risk_Management', 0.02678079344332218)","('Human_Rights_And_Community_Relations', 0.008055443875491619)","(['Health Outcome Contribution'], 0.9008429646492004)","('NON-ESG', 0.02678079344332218)","('NON-ESG', 0.008055443875491619)"
Line 36,"In 2021, our facilities took action to reduce greenhouse gas (GHG) emissions, increase energy efficiency and reduce waste and water usein line with our 2030 and 2040 environmental goals.","('GHG_Emissions', 0.9689648747444153)","('Ecological_Impacts', 0.003722287015989423)","('Air_Quality', 0.003122020047158003)","(['Operational Eco-Efficiency'], 0.9689648747444153)","('NON-ESG', 0.003722287015989423)","('NON-ESG', 0.003122020047158003)"
Line 37,Our efforts were recognized on the Forbes Green Growth 50 list of U.,"('Product_Design_And_Lifecycle_Management', 0.20145246386528015)","('Supply_Chain_Management', 0.1822642683982849)","('Business_Model_Resilience', 0.18123607337474823)","('NON-ESG', 0.20145246386528015)","('NON-ESG', 0.1822642683982849)","('NON-ESG', 0.18123607337474823)"
Line 38,"S.-based companies that have reduced GHG emissions while growing earnings, and our scientists received the U.","('GHG_Emissions', 0.9672854542732239)","('Air_Quality', 0.004182274919003248)","('Ecological_Impacts', 0.0032590420451015234)","(['Operational Eco-Efficiency'], 0.9672854542732239)","('NON-ESG', 0.004182274919003248)","('NON-ESG', 0.0032590420451015234)"
Line 39,S. Environmental Protection Agencys Green Chemistry Award for innovating new ways to conduct science in a more sustainable way.,"('Ecological_Impacts', 0.21543510258197784)","('Product_Design_And_Lifecycle_Management', 0.15622133016586304)","('Business_Model_Resilience', 0.09259992092847824)","('NON-ESG', 0.21543510258197784)","('NON-ESG', 0.15622133016586304)","('NON-ESG', 0.09259992092847824)"
Line 40,"Looking ahead Keeping ESG integrated into our strategy, we remain steadfast in our focus on robust topline and bottomline growth, financial flexibility and a strong innovation engine.","('Business_Model_Resilience', 0.6722721457481384)","('Systemic_Risk_Management', 0.16299134492874146)","('Competitive_Behavior', 0.03402005881071091)","(['Human Capital Development', 'Innovation Management'], 0.6722721457481384)","('NON-ESG', 0.16299134492874146)","('NON-ESG', 0.03402005881071091)"
Line 41,"These factors constitute asolid foundation for sustained long-term growth, which enables usto continue to advance our pipeline, invest in future sources of innovation and, ultimately, deliver on our promise to transform patients lives through science.","('Business_Model_Resilience', 0.32973530888557434)","('Product_Design_And_Lifecycle_Management', 0.1638040691614151)","('Customer_Welfare', 0.061372410506010056)","('NON-ESG', 0.32973530888557434)","('NON-ESG', 0.1638040691614151)","('NON-ESG', 0.061372410506010056)"
Line 42,"Giovanni Caforio, M.","('Employee_Engagement_Inclusion_And_Diversity', 0.10806308686733246)","('Business_Ethics', 0.08042101562023163)","('Ecological_Impacts', 0.07420813292264938)","('NON-ESG', 0.10806308686733246)","('NON-ESG', 0.08042101562023163)","('NON-ESG', 0.07420813292264938)"
Line 43,D.,"('Employee_Engagement_Inclusion_And_Diversity', 0.11258140206336975)","('Management_Of_Legal_And_Regulatory_Framework', 0.08865229040384293)","('Access_And_Affordability', 0.06962209194898605)","('NON-ESG', 0.11258140206336975)","('NON-ESG', 0.08865229040384293)","('NON-ESG', 0.06962209194898605)"
Line 44,", Board Chair and CEO 2021 ESG REPORT | 454% of U.","('Business_Model_Resilience', 0.47328054904937744)","('Systemic_Risk_Management', 0.14358898997306824)","('Director_Removal', 0.06357219815254211)","('NON-ESG', 0.47328054904937744)","('NON-ESG', 0.14358898997306824)","('NON-ESG', 0.06357219815254211)"
Line 45,"S. clinical trial sites were located in highly diverse communities, exceeding our goal Tomorrows Innovators expanded program to recruit talent from Historically Black Colleges and Universities 60% of Board Directors comprise women or underrepresented racial and ethnic groups2021 ESG Progress & Highlights 45.5% global executives are women, a 2.9% YOY increase 619,000 people reached through Health Equity grants >$704M product donations in U.","('Employee_Engagement_Inclusion_And_Diversity', 0.9716765284538269)","('Business_Model_Resilience', 0.001980113098397851)","('Customer_Welfare', 0.001732053468003869)","(['Talent Attraction & Retention'], 0.9716765284538269)","('NON-ESG', 0.001980113098397851)","('NON-ESG', 0.001732053468003869)"
Line 46,"S. through the independent BMS Patient Assistance Foundation mapped sustainability efforts to 11 of the UN SDGs7% reduction in energy use since 2019 10.9% reduction in overall waste generated 2021 ESG REPORT | 5Our Approach to ESG At Bristol Myers Squibb, our vision is to transform the lives of patients through science.","('Waste_And_Hazardous_Materials_Management', 0.8708500862121582)","('Energy_Management', 0.03504778817296028)","('Water_And_Wastewater_Management', 0.013216805644333363)","([], 0.8708500862121582)","('NON-ESG', 0.03504778817296028)","('NON-ESG', 0.013216805644333363)"
Line 47,"As a leading Biopharma Company, our passion for making an impact extends well beyond the discovery, development and delivery of innovative medicines that help patients prevail over serious diseases.","('Access_And_Affordability', 0.22036036849021912)","('Customer_Welfare', 0.19029895961284637)","('Selling_Practices_And_Product_Labeling', 0.1143403947353363)","('NON-ESG', 0.22036036849021912)","('NON-ESG', 0.19029895961284637)","('NON-ESG', 0.1143403947353363)"
Line 48,"We believe that driving long-term business value is at the heart of living our purpose, being leaders and difference-makers for generations to come.","('Business_Model_Resilience', 0.6305218935012817)","('Product_Design_And_Lifecycle_Management', 0.06444550305604935)","('Human_Rights_And_Community_Relations', 0.05141602084040642)","(['Human Capital Development', 'Innovation Management'], 0.6305218935012817)","('NON-ESG', 0.06444550305604935)","('NON-ESG', 0.05141602084040642)"
Line 49,"Through our Environment, Social and Governance (ESG) strategy we seek to mobilize our capabilities and resources to positively impact the communities where we live, work, and serve.","('Human_Rights_And_Community_Relations', 0.9339886903762817)","('Ecological_Impacts', 0.008176230825483799)","('Business_Model_Resilience', 0.005887629929929972)","([], 0.9339886903762817)","('NON-ESG', 0.008176230825483799)","('NON-ESG', 0.005887629929929972)"
Line 50,"We are committed to quality, integrity and ethics in everything we do.","('Business_Ethics', 0.9446161389350891)","('Employee_Engagement_Inclusion_And_Diversity', 0.00485580088570714)","('Customer_Privacy', 0.00484165595844388)","(['Business Ethics'], 0.9446161389350891)","('NON-ESG', 0.00485580088570714)","('NON-ESG', 0.00484165595844388)"
Line 51,"We operate with effective governance and the highest ethical standards, and we seek transparency and dialogue with our stakeholders to improve our understanding of their needs.","('Business_Ethics', 0.9706057906150818)","('Management_Of_Legal_And_Regulatory_Framework', 0.00395131716504693)","('Competitive_Behavior', 0.0021184273064136505)","(['Business Ethics'], 0.9706057906150818)","('NON-ESG', 0.00395131716504693)","('NON-ESG', 0.0021184273064136505)"
Line 52,"We seek to actively improve the health of the communities where we live, work and serve.","('Human_Rights_And_Community_Relations', 0.47912776470184326)","('Employee_Health_And_Safety', 0.20401853322982788)","('Access_And_Affordability', 0.13597558438777924)","('NON-ESG', 0.47912776470184326)","('NON-ESG', 0.20401853322982788)","('NON-ESG', 0.13597558438777924)"
Line 53,"Around the globe, we promote health equity and seek to improve health outcomes for populations disproportionately affected by serious diseases.","('Employee_Health_And_Safety', 0.6978727579116821)","('Access_And_Affordability', 0.08201146870851517)","('Critical_Incident_Risk_Management', 0.05476566404104233)","(['Health Outcome Contribution'], 0.6978727579116821)","('NON-ESG', 0.08201146870851517)","('NON-ESG', 0.05476566404104233)"
Line 54,"ESG Governance Our ESG strategy is meaningfully tied to our companys core strategy, as the opportunities and potential impacts of ESG issues are directly interrelated to our business.","('Business_Model_Resilience', 0.7376210689544678)","('Systemic_Risk_Management', 0.1028849333524704)","('Physical_Impacts_Of_Climate_Change', 0.017841529101133347)","(['Human Capital Development', 'Innovation Management'], 0.7376210689544678)","('NON-ESG', 0.1028849333524704)","('NON-ESG', 0.017841529101133347)"
Line 55,"Accordingly, our governance model links core business considerations with our ESG framework and ensures engagement and alignment from BMS most senior leaders, with core support from key functional areas such as Corporate Affairs and Legal, including Environment, Occupational Health, Safety and Sustainability (EOHSS) and is integrated into our enterprise risk management (ERM) program as described below.","('Employee_Health_And_Safety', 0.8790208101272583)","('Product_Quality_And_Safety', 0.025253530591726303)","('Employee_Engagement_Inclusion_And_Diversity', 0.009914380498230457)","(['Health Outcome Contribution'], 0.8790208101272583)","('NON-ESG', 0.025253530591726303)","('NON-ESG', 0.009914380498230457)"
Line 56,"Led by our Board Chair and CEO, our ESG efforts are overseen by the Board of Directors (Board).","('Director_Removal', 0.5466950535774231)","('Business_Model_Resilience', 0.09615771472454071)","('Management_Of_Legal_And_Regulatory_Framework', 0.058509983122348785)","(['Business Ethics'], 0.5466950535774231)","('NON-ESG', 0.09615771472454071)","('NON-ESG', 0.058509983122348785)"
Line 57,Our Board members discuss pertinent ESG topics multiple times per year.,"('Business_Model_Resilience', 0.47225823998451233)","('Systemic_Risk_Management', 0.1311667114496231)","('Management_Of_Legal_And_Regulatory_Framework', 0.04902515187859535)","('NON-ESG', 0.47225823998451233)","('NON-ESG', 0.1311667114496231)","('NON-ESG', 0.04902515187859535)"
Line 58,"The Boards Committee on Directors and Corporate Governance provides detailed oversight of these topics, and, in accordance with their respective charter responsibilities, the Boards other committees may also provide oversight on certain topics.","('Director_Removal', 0.3923591077327728)","('Management_Of_Legal_And_Regulatory_Framework', 0.3754619359970093)","('Business_Ethics', 0.03675929456949234)","('NON-ESG', 0.3923591077327728)","('NON-ESG', 0.3754619359970093)","('NON-ESG', 0.03675929456949234)"
Line 59,Recent agenda items included discussing details about external and emerging trends and weighing internal performance against predetermined objectives and opportunities to extend or modify our programs.,"('Business_Model_Resilience', 0.3802972733974457)","('Management_Of_Legal_And_Regulatory_Framework', 0.19914576411247253)","('Systemic_Risk_Management', 0.11816132068634033)","('NON-ESG', 0.3802972733974457)","('NON-ESG', 0.19914576411247253)","('NON-ESG', 0.11816132068634033)"
Line 60,Our ESG strategy encompasses the following priority areas:We lead with our Value of Inclusion.,"('Employee_Engagement_Inclusion_And_Diversity', 0.940270185470581)","('Human_Rights_And_Community_Relations', 0.010010970756411552)","('Business_Model_Resilience', 0.006102588959038258)","(['Talent Attraction & Retention'], 0.940270185470581)","('NON-ESG', 0.010010970756411552)","('NON-ESG', 0.006102588959038258)"
Line 61,We foster an environment of inclusion and belonging and build a globally diverse workforce to drive equitable advancement and outcomes for all.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9742387533187866)","('Human_Rights_And_Community_Relations', 0.002243399154394865)","('Employee_Health_And_Safety', 0.0019035222940146923)","(['Talent Attraction & Retention'], 0.9742387533187866)","('NON-ESG', 0.002243399154394865)","('NON-ESG', 0.0019035222940146923)"
Line 62,We honor our longstanding pledge to environmental sustainability.,"('Human_Rights_And_Community_Relations', 0.27290090918540955)","('Product_Design_And_Lifecycle_Management', 0.13066266477108002)","('Business_Model_Resilience', 0.12100986391305923)","('NON-ESG', 0.27290090918540955)","('NON-ESG', 0.13066266477108002)","('NON-ESG', 0.12100986391305923)"
Line 63,We understand our responsibility to create a maximum positive impact while minimizing our environmental footprint.,"('Human_Rights_And_Community_Relations', 0.3928926885128021)","('Business_Model_Resilience', 0.17332501709461212)","('Ecological_Impacts', 0.09101898968219757)","('NON-ESG', 0.3928926885128021)","('NON-ESG', 0.17332501709461212)","('NON-ESG', 0.09101898968219757)"
Line 64,"We leverage sustainability to drive innovation, build resiliency and manage nonfinancial risks.","('Business_Model_Resilience', 0.9066902995109558)","('Systemic_Risk_Management', 0.01355163473635912)","('Physical_Impacts_Of_Climate_Change', 0.01252218522131443)","(['Human Capital Development', 'Innovation Management'], 0.9066902995109558)","('NON-ESG', 0.01355163473635912)","('NON-ESG', 0.01252218522131443)"
Line 65,"Ethical Business Business ethics, integrity and compliance Corporate governance ESG governance Product quality Risk and crisis management Supply chain management COVID-19 responseInnovation, Health Equity and Patient Access Pipeline and digital innovation Health Equity initiatives Clinical trial diversity and execution Access to healthcare and drug pricingOur People Inclusion and Diversity (I&D) Employee safety Employee training and development Employee wellness Occupational healthEnvironmental Responsibility Climate change Environmental impacts Pharmaceuticals in the Environment (PiE) and Anti-Microbial resistance (AMR) 2021 ESG REPORT | 6UN Sustainable Development Goals BMS mission, vision and values fully align with the United Nations Sustainable Development Goals (UN SDGs).","('Employee_Engagement_Inclusion_And_Diversity', 0.9014521241188049)","('Business_Ethics', 0.024192210286855698)","('Employee_Health_And_Safety', 0.009989914484322071)","(['Talent Attraction & Retention'], 0.9014521241188049)","('NON-ESG', 0.024192210286855698)","('NON-ESG', 0.009989914484322071)"
Line 66,"Ethical Business Business ethics, integrity and compliance Corporate governance ESG governance Product quality Risk and crisis management Supply chain management COVID-19 responseInnovation, Health Equity and Patient Access Pipeline and digital innovation Health Equity initiatives Clinical trial diversity and execution Access to healthcare and drug pricingOur People Inclusion and Diversity (I&D) Employee safety Employee training and development Employee wellness Occupational healthEnvironmental Responsibility Climate change Environmental impacts Pharmaceuticals in the Environment (PiE) and Anti-Microbial resistance (AMR) 2021 ESG REPORT | 6UN Sustainable Development Goals BMS mission, vision and values fully align with the United Nations Sustainable Development Goals (UN SDGs).","('Physical_Impacts_Of_Climate_Change', 0.9061537981033325)","('Business_Model_Resilience', 0.019452786073088646)","('GHG_Emissions', 0.01756148226559162)","([], 0.9061537981033325)","('NON-ESG', 0.019452786073088646)","('NON-ESG', 0.01756148226559162)"
Line 67,"We use a transparent process to set, prioritize and measure the success of SDGs that are relevant toour business and the ways we strive to positively impact society.","('Management_Of_Legal_And_Regulatory_Framework', 0.4178946316242218)","('Human_Rights_And_Community_Relations', 0.1599273830652237)","('Business_Ethics', 0.13397611677646637)","('NON-ESG', 0.4178946316242218)","('NON-ESG', 0.1599273830652237)","('NON-ESG', 0.13397611677646637)"
Line 68,"In 2010, BMS signed the UN Global Compact and submitted our annual Communication of Progress under the Advancedcategory.","('Management_Of_Legal_And_Regulatory_Framework', 0.6129533648490906)","('Human_Rights_And_Community_Relations', 0.14371997117996216)","('Ecological_Impacts', 0.02846132591366768)","([], 0.6129533648490906)","('NON-ESG', 0.14371997117996216)","('NON-ESG', 0.02846132591366768)"
Line 69,"Since 2016, we have also reported progress toward seventargets within Goal 3, Good Health and Well-Being.","('Employee_Health_And_Safety', 0.4024955630302429)","('Access_And_Affordability', 0.31598782539367676)","('Product_Quality_And_Safety', 0.043634701520204544)","('NON-ESG', 0.4024955630302429)","('NON-ESG', 0.31598782539367676)","('NON-ESG', 0.043634701520204544)"
Line 70,Mapping SDG Alignment We leveraged the SDG Compass to best map our sustainability efforts across the enterprise and align our strategy to the realization of the SDGs.,"('Business_Model_Resilience', 0.6791390776634216)","('Product_Design_And_Lifecycle_Management', 0.03595000132918358)","('Systemic_Risk_Management', 0.03409059718251228)","(['Human Capital Development', 'Innovation Management'], 0.6791390776634216)","('NON-ESG', 0.03595000132918358)","('NON-ESG', 0.03409059718251228)"
Line 71,"Through this exercise, we identified 11 SDGs, defined by our primary and secondary alignment and mapped to the efforts and impact to both our business and our patients.","('Access_And_Affordability', 0.2090616524219513)","('Management_Of_Legal_And_Regulatory_Framework', 0.14631983637809753)","('Business_Model_Resilience', 0.11915376037359238)","('NON-ESG', 0.2090616524219513)","('NON-ESG', 0.14631983637809753)","('NON-ESG', 0.11915376037359238)"
Line 72,We actively track our progress using the UN SDG Action Manager.,"('Human_Rights_And_Community_Relations', 0.7091074585914612)","('Management_Of_Legal_And_Regulatory_Framework', 0.07327872514724731)","('Access_And_Affordability', 0.022719988599419594)","([], 0.7091074585914612)","('NON-ESG', 0.07327872514724731)","('NON-ESG', 0.022719988599419594)"
Line 73,Primary Goals correspond to efforts that support our core value chain.,"('Business_Model_Resilience', 0.6142829060554504)","('Supply_Chain_Management', 0.13796527683734894)","('Product_Design_And_Lifecycle_Management', 0.06604018062353134)","(['Human Capital Development', 'Innovation Management'], 0.6142829060554504)","('NON-ESG', 0.13796527683734894)","('NON-ESG', 0.06604018062353134)"
Line 74,"These efforts are directly involved in the identification, development and distribution of life-saving medicines to ourpatients.","('Access_And_Affordability', 0.2900114059448242)","('Selling_Practices_And_Product_Labeling', 0.13676951825618744)","('Customer_Welfare', 0.09519670903682709)","('NON-ESG', 0.2900114059448242)","('NON-ESG', 0.13676951825618744)","('NON-ESG', 0.09519670903682709)"
Line 75,Secondary Goals correspond to programs driving Diversity and Inclusion and Environmental Responsibility within our sites and in the communities in which we operate.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9657281041145325)","('Human_Rights_And_Community_Relations', 0.00583012867718935)","('Employee_Health_And_Safety', 0.0023043700493872166)","(['Talent Attraction & Retention'], 0.9657281041145325)","('NON-ESG', 0.00583012867718935)","('NON-ESG', 0.0023043700493872166)"
Line 76,"In 2021, we expanded our secondary goal alignment to include SDG 4: QualityEducation.","('Management_Of_Legal_And_Regulatory_Framework', 0.34797707200050354)","('Systemic_Risk_Management', 0.11071218550205231)","('Competitive_Behavior', 0.06817317754030228)","('NON-ESG', 0.34797707200050354)","('NON-ESG', 0.11071218550205231)","('NON-ESG', 0.06817317754030228)"
Line 77,"Investing in and developing the next generation of leaders As part of our support for UN SDG 4, we seek to reduce gender disparities globally to create a more gender-equitable education system and empower girls to transform communities around the world.","('Employee_Engagement_Inclusion_And_Diversity', 0.8807826042175293)","('Access_And_Affordability', 0.030518122017383575)","('Human_Rights_And_Community_Relations', 0.017413904890418053)","(['Talent Attraction & Retention'], 0.8807826042175293)","('NON-ESG', 0.030518122017383575)","('NON-ESG', 0.017413904890418053)"
Line 78,"To this end, we are the ongoing sponsor for the One Young World Lead2030 Challenge, which invites young innovators to design solutions to break down barriers that girls face in regard to STEM education.","('Access_And_Affordability', 0.701307475566864)","('Employee_Engagement_Inclusion_And_Diversity', 0.08550938218832016)","('Human_Rights_And_Community_Relations', 0.040093470364809036)","(['Access to Healthcare'], 0.701307475566864)","('NON-ESG', 0.08550938218832016)","('NON-ESG', 0.040093470364809036)"
Line 79,"Our 2021 sponsorship included a $50,000 grant and a years worth of mentorship to the winning organization, Smart Cheli, which provides robotics training and mentorship to young girls and women in Nepal.","('Access_And_Affordability', 0.5951263904571533)","('Employee_Engagement_Inclusion_And_Diversity', 0.13358160853385925)","('Human_Rights_And_Community_Relations', 0.05975731462240219)","(['Access to Healthcare'], 0.5951263904571533)","('NON-ESG', 0.13358160853385925)","('NON-ESG', 0.05975731462240219)"
Line 80,"We are also the ongoing sponsor for the One Young World Lead2030 Challenge for SDG 10with a focus on advancing equality within the LGBTQ community in businessesand a member of the inaugural Young SDG Innovators Program, which supports SDG 3.","('Employee_Engagement_Inclusion_And_Diversity', 0.9541633129119873)","('Human_Rights_And_Community_Relations', 0.008063116110861301)","('Employee_Health_And_Safety', 0.0033061420544981956)","(['Talent Attraction & Retention'], 0.9541633129119873)","('NON-ESG', 0.008063116110861301)","('NON-ESG', 0.0033061420544981956)"
Line 81,"Standing up for human rights In October, our Law Department partnered with one of our preferred law firm partners on a virtual, anti-human trafficking law clinic as part of the departments Day of Service.","('Human_Rights_And_Community_Relations', 0.7828691601753235)","('Labor_Practices', 0.03520789369940758)","('Business_Ethics', 0.029452618211507797)","([], 0.7828691601753235)","('NON-ESG', 0.03520789369940758)","('NON-ESG', 0.029452618211507797)"
Line 82,"The BMS team contributed to the development of a global compendium of key human trafficking and modern slavery laws, focusing on Belize, Zambia and South Africa.","('Business_Ethics', 0.3025648295879364)","('Employee_Health_And_Safety', 0.16617725789546967)","('Labor_Practices', 0.16583596169948578)","('NON-ESG', 0.3025648295879364)","('NON-ESG', 0.16617725789546967)","('NON-ESG', 0.16583596169948578)"
Line 83,"The compendium chapters are made available to NGOs, governments, prosecutors, community members, victims and public interest lawyers at no cost.","('Management_Of_Legal_And_Regulatory_Framework', 0.8432579040527344)","('Human_Rights_And_Community_Relations', 0.06836431473493576)","('Business_Ethics', 0.009692929685115814)","([], 0.8432579040527344)","('NON-ESG', 0.06836431473493576)","('NON-ESG', 0.009692929685115814)"
Line 84,"This event extended our internal education about human rights issues, sustaining the momentum behind our support for Truckers Against Trafficking, a nonprofit organization that exists to educate, equip, empower and mobilize members of the trucking, bus and energy industries to combat human trafficking.","('Human_Rights_And_Community_Relations', 0.6196552515029907)","('Employee_Health_And_Safety', 0.0871984213590622)","('Labor_Practices', 0.05078643560409546)","([], 0.6196552515029907)","('NON-ESG', 0.0871984213590622)","('NON-ESG', 0.05078643560409546)"
Line 85,"2021 ESG REPORT | 7Public Commitments For the year 2021, we are on track toward achieving all of our public commitments.","('Management_Of_Legal_And_Regulatory_Framework', 0.4606938660144806)","('Business_Model_Resilience', 0.20806127786636353)","('Human_Rights_And_Community_Relations', 0.046877000480890274)","('NON-ESG', 0.4606938660144806)","('NON-ESG', 0.20806127786636353)","('NON-ESG', 0.046877000480890274)"
Line 86,Environmental Responsibility1 By 2024 Receive validation of science-based emissionsreductiontargets.,"('Human_Rights_And_Community_Relations', 0.33370015025138855)","('Management_Of_Legal_And_Regulatory_Framework', 0.19988636672496796)","('Ecological_Impacts', 0.11309099197387695)","('NON-ESG', 0.33370015025138855)","('NON-ESG', 0.19988636672496796)","('NON-ESG', 0.11309099197387695)"
Line 87,By 2030 100% of our purchased electricity will be obtainedfromrenewable sources.,"('Energy_Management', 0.9697628617286682)","('Management_Of_Legal_And_Regulatory_Framework', 0.005171382799744606)","('Water_And_Wastewater_Management', 0.002683549653738737)","(['Operational Eco-Efficiency'], 0.9697628617286682)","('NON-ESG', 0.005171382799744606)","('NON-ESG', 0.002683549653738737)"
Line 88,By 2040 Achieve net neutrality in Scope 1 (direct) and Scope2(indirect) GHG emissions.,"('GHG_Emissions', 0.9671594500541687)","('Ecological_Impacts', 0.003488876624032855)","('Air_Quality', 0.003411482786759734)","(['Operational Eco-Efficiency'], 0.9671594500541687)","('NON-ESG', 0.003488876624032855)","('NON-ESG', 0.003411482786759734)"
Line 89,Reach the target of zero waste to landfill.,"('Waste_And_Hazardous_Materials_Management', 0.9825248122215271)","('Data_Security', 0.0014223881298676133)","('Air_Quality', 0.0014011956518515944)","([], 0.9825248122215271)","('NON-ESG', 0.0014223881298676133)","('NON-ESG', 0.0014011956518515944)"
Line 90,Ensure 100% of vehicles in our commercial fleet areelectric.,"('Energy_Management', 0.47683581709861755)","('Product_Design_And_Lifecycle_Management', 0.2201565057039261)","('Customer_Privacy', 0.030223237350583076)","('NON-ESG', 0.47683581709861755)","('NON-ESG', 0.2201565057039261)","('NON-ESG', 0.030223237350583076)"
Line 91,Achieve equitable water use.,"('Water_And_Wastewater_Management', 0.9721274375915527)","('Energy_Management', 0.0035953025799244642)","('GHG_Emissions', 0.0028521243948489428)","([], 0.9721274375915527)","('NON-ESG', 0.0035953025799244642)","('NON-ESG', 0.0028521243948489428)"
Line 92,Our People Aspirational Representation Goals By year-end 2022 Achieve gender parity at the executive level globally.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9556881189346313)","('Human_Rights_And_Community_Relations', 0.006797426380217075)","('Labor_Practices', 0.00404942873865366)","(['Talent Attraction & Retention'], 0.9556881189346313)","('NON-ESG', 0.006797426380217075)","('NON-ESG', 0.00404942873865366)"
Line 93,Double representation from June 2020 levels of both Black/African American executives (3.0% to 6.0%) and Latino/Hispanic executives (3.7% to 7.4%) in the U.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9711452722549438)","('Director_Removal', 0.0018366643926128745)","('Labor_Practices', 0.0018111570971086621)","(['Talent Attraction & Retention'], 0.9711452722549438)","('NON-ESG', 0.0018366643926128745)","('NON-ESG', 0.0018111570971086621)"
Line 94,S. By 2025 Spend $1 billion globally with diverse suppliers.,"('Supply_Chain_Management', 0.8804993629455566)","('Product_Design_And_Lifecycle_Management', 0.03087628446519375)","('Labor_Practices', 0.007036118768155575)","([], 0.8804993629455566)","('NON-ESG', 0.03087628446519375)","('NON-ESG', 0.007036118768155575)"
Line 95,Health Equity and Inclusion & Diversity2 Starting in 2021 Locate at least 25% of U.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9754008054733276)","('Human_Rights_And_Community_Relations', 0.0018697730265557766)","('Employee_Health_And_Safety', 0.001850192784331739)","(['Talent Attraction & Retention'], 0.9754008054733276)","('NON-ESG', 0.0018697730265557766)","('NON-ESG', 0.001850192784331739)"
Line 96,S. sites participating in new BMS clinical trials in racially and ethnically diverse metroareas.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9737894535064697)","('Human_Rights_And_Community_Relations', 0.0018452067160978913)","('Customer_Privacy', 0.0016436638543382287)","(['Talent Attraction & Retention'], 0.9737894535064697)","('NON-ESG', 0.0018452067160978913)","('NON-ESG', 0.0016436638543382287)"
Line 97,Bristol Myers Squibb Foundation* Commitments to Health Equity and Inclusion&Diversity By 2025 Award $50 million in U.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9735680818557739)","('Employee_Health_And_Safety', 0.0021971657406538725)","('Human_Rights_And_Community_Relations', 0.0021323359105736017)","(['Talent Attraction & Retention'], 0.9735680818557739)","('NON-ESG', 0.0021971657406538725)","('NON-ESG', 0.0021323359105736017)"
Line 98,S. health equity grants in BMS therapeutic areas.,"('Access_And_Affordability', 0.458640456199646)","('Customer_Welfare', 0.09134408831596375)","('Management_Of_Legal_And_Regulatory_Framework', 0.041908878833055496)","('NON-ESG', 0.458640456199646)","('NON-ESG', 0.09134408831596375)","('NON-ESG', 0.041908878833055496)"
Line 99,By 2027 Train and develop 250 new investigators who are racially and ethnically diverse or who have demonstrated commitment to serving diverse and medically underserved communities through a $100 million training and development program.,"('Employee_Engagement_Inclusion_And_Diversity', 0.5305295586585999)","('Access_And_Affordability', 0.2937501072883606)","('Human_Rights_And_Community_Relations', 0.03099904954433441)","(['Talent Attraction & Retention'], 0.5305295586585999)","('NON-ESG', 0.2937501072883606)","('NON-ESG', 0.03099904954433441)"
Line 100,Provide 250 medical students from groups underrepresented in medicine (URM) a six-week summer immersion experience in community-based clinical trialrecruitment.,"('Employee_Engagement_Inclusion_And_Diversity', 0.41734907031059265)","('Access_And_Affordability', 0.30260810256004333)","('Customer_Welfare', 0.028574958443641663)","('NON-ESG', 0.41734907031059265)","('NON-ESG', 0.30260810256004333)","('NON-ESG', 0.028574958443641663)"
Line 101,Starting in 2020 Provide a two-to-one match for U.,"('Competitive_Behavior', 0.3642865717411041)","('Management_Of_Legal_And_Regulatory_Framework', 0.18052034080028534)","('Employee_Engagement_Inclusion_And_Diversity', 0.041172292083501816)","('NON-ESG', 0.3642865717411041)","('NON-ESG', 0.18052034080028534)","('NON-ESG', 0.041172292083501816)"
Line 102,S. and Puerto Rico employee donationsto designated organizations that fight disparities and discrimination.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9568873047828674)","('Labor_Practices', 0.006931393872946501)","('Employee_Health_And_Safety', 0.005567651707679033)","(['Talent Attraction & Retention'], 0.9568873047828674)","('NON-ESG', 0.006931393872946501)","('NON-ESG', 0.005567651707679033)"
Line 103,"* Bristol Myers Squibb is the primary donor to the Bristol Myers Squibb Foundation, anindependent charitable entity.","('Management_Of_Legal_And_Regulatory_Framework', 0.41902047395706177)","('Customer_Welfare', 0.08875807374715805)","('Selling_Practices_And_Product_Labeling', 0.061592619866132736)","('NON-ESG', 0.41902047395706177)","('NON-ESG', 0.08875807374715805)","('NON-ESG', 0.061592619866132736)"
Line 104,"1 Announced Dec 2020 2 Announced Aug 2020 2021 ESG REPORT | 8Ethics, Integrity, Quality and Governance IN THIS SECTION Ethical Business Ethical and SafeProducts Cybersecurity Governance and Risk Management 2021 ESG REPORT | 9Ethics, Integrity, Quality andGovernance From the way we grow our business to the products we make, our values and principles of integrity guide our every decision.","('Business_Ethics', 0.9630501866340637)","('Data_Security', 0.003294553142040968)","('Competitive_Behavior', 0.002999713411554694)","(['Business Ethics'], 0.9630501866340637)","('NON-ESG', 0.003294553142040968)","('NON-ESG', 0.002999713411554694)"
Line 105,"They commit us to the highest standards of ethics, integrity and quality in everything we do for patients, customers, colleagues and our communities.","('Business_Ethics', 0.9409754276275635)","('Employee_Engagement_Inclusion_And_Diversity', 0.005050663370639086)","('Competitive_Behavior', 0.004493039567023516)","(['Business Ethics'], 0.9409754276275635)","('NON-ESG', 0.005050663370639086)","('NON-ESG', 0.004493039567023516)"
Line 106,"We recognize that good governance is fundamental to our success, both in building long-term value for shareholders and in maximizing the benefits we deliver for our patients, customers, colleagues and communities.","('Human_Rights_And_Community_Relations', 0.41643908619880676)","('Business_Model_Resilience', 0.145067498087883)","('Management_Of_Legal_And_Regulatory_Framework', 0.06589920818805695)","('NON-ESG', 0.41643908619880676)","('NON-ESG', 0.145067498087883)","('NON-ESG', 0.06589920818805695)"
Line 107,"We are committed to meeting standards of governance, including taking steps to achieve greater transparency and accountability to our shareholders.","('Business_Ethics', 0.9594156742095947)","('Management_Of_Legal_And_Regulatory_Framework', 0.0054294392466545105)","('Director_Removal', 0.0042967828921973705)","(['Business Ethics'], 0.9594156742095947)","('NON-ESG', 0.0054294392466545105)","('NON-ESG', 0.0042967828921973705)"
Line 108,"Our Board is composed of a diverse and independent group of individuals who bring a depth of expertise, a broad range of skills and a strong sense of integrity to our business.","('Business_Ethics', 0.24065940082073212)","('Employee_Engagement_Inclusion_And_Diversity', 0.20590117573738098)","('Director_Removal', 0.19165903329849243)","('NON-ESG', 0.24065940082073212)","('NON-ESG', 0.20590117573738098)","('NON-ESG', 0.19165903329849243)"
Line 109,"Together with our senior management and other employees, BMS Board members have adopted our Principles of Integrity (Principles), which reflect who we are as a company and provide a common framework for how we interact with our employees, customers, patients, shareholders, partners and the global community.","('Business_Ethics', 0.4901651442050934)","('Director_Removal', 0.16754457354545593)","('Employee_Engagement_Inclusion_And_Diversity', 0.052350785583257675)","('NON-ESG', 0.4901651442050934)","('NON-ESG', 0.16754457354545593)","('NON-ESG', 0.052350785583257675)"
Line 110,"Our compliance program meets or exceeds guidance issued by regulatory authorities, including the U.","('Management_Of_Legal_And_Regulatory_Framework', 0.9615170955657959)","('Business_Ethics', 0.006320623680949211)","('Director_Removal', 0.0031608904246240854)","([], 0.9615170955657959)","('NON-ESG', 0.006320623680949211)","('NON-ESG', 0.0031608904246240854)"
Line 111,"S. Department of Justice, applicable laws and regulations, and industry codes.","('Management_Of_Legal_And_Regulatory_Framework', 0.9655550718307495)","('Business_Ethics', 0.0032886916305869818)","('Director_Removal', 0.0031675456557422876)","([], 0.9655550718307495)","('NON-ESG', 0.0032886916305869818)","('NON-ESG', 0.0031675456557422876)"
Line 112,This further ensures that we build and nurture a culture of integrity in everything we do.,"('Business_Ethics', 0.8652175068855286)","('Human_Rights_And_Community_Relations', 0.01846286654472351)","('Employee_Engagement_Inclusion_And_Diversity', 0.01563965529203415)","(['Business Ethics'], 0.8652175068855286)","('NON-ESG', 0.01846286654472351)","('NON-ESG', 0.01563965529203415)"
Line 113,"27,059 employees assigned with Principlesof Integrity course 98.5% employees completed Principles ofIntegrity course 2020-2021 (2-year cadence) 2021 ESG REPORT | 10Ethical Business Operating with ethics and integrity is foundational to our business and our commitment to sustainable growth.","('Business_Ethics', 0.9712209105491638)","('Data_Security', 0.0020530696492642164)","('Product_Quality_And_Safety', 0.0020250920206308365)","(['Business Ethics'], 0.9712209105491638)","('NON-ESG', 0.0020530696492642164)","('NON-ESG', 0.0020250920206308365)"
Line 114,We are dedicated to promoting an ethical and compliant culture and maintaining a work environment where all employees feel comfortable raising issues and voicing their concerns.,"('Human_Rights_And_Community_Relations', 0.7426899671554565)","('Business_Ethics', 0.06011971831321716)","('Employee_Health_And_Safety', 0.03990009054541588)","([], 0.7426899671554565)","('NON-ESG', 0.06011971831321716)","('NON-ESG', 0.03990009054541588)"
Line 115,"In 2021, we improved an already robust Conflicts of Interest (COI) system throughout BMS global enterprise.","('Competitive_Behavior', 0.30351370573043823)","('Business_Ethics', 0.296683132648468)","('Management_Of_Legal_And_Regulatory_Framework', 0.22630688548088074)","('NON-ESG', 0.30351370573043823)","('NON-ESG', 0.296683132648468)","('NON-ESG', 0.22630688548088074)"
Line 116,We centralized our COI systems and automated our processes to enable greater visibility and access to real-time data insights.,"('Data_Security', 0.5384079217910767)","('Customer_Privacy', 0.13866177201271057)","('Systemic_Risk_Management', 0.06775765120983124)","([], 0.5384079217910767)","('NON-ESG', 0.13866177201271057)","('NON-ESG', 0.06775765120983124)"
Line 117,"To support our anti-corruption program, robust anti-bribery policies apply to all BMS employees and relevant contractors, and all undergo comprehensive education and training on the subject.","('Business_Ethics', 0.974898636341095)","('Management_Of_Legal_And_Regulatory_Framework', 0.002873961813747883)","('Competitive_Behavior', 0.0018182749627158046)","(['Business Ethics'], 0.974898636341095)","('NON-ESG', 0.002873961813747883)","('NON-ESG', 0.0018182749627158046)"
Line 118,We continue to complement these actions with risk assessments and regular monitoring and auditing of our relevant activities.,"('Systemic_Risk_Management', 0.3879143297672272)","('Management_Of_Legal_And_Regulatory_Framework', 0.26044169068336487)","('Business_Ethics', 0.17634806036949158)","('NON-ESG', 0.3879143297672272)","('NON-ESG', 0.26044169068336487)","('NON-ESG', 0.17634806036949158)"
Line 119,"Additionally, we maintain ongoing communication on ethics and compliance throughout the year.","('Business_Ethics', 0.9625046253204346)","('Management_Of_Legal_And_Regulatory_Framework', 0.005146467592567205)","('Product_Quality_And_Safety', 0.0035475706681609154)","(['Business Ethics'], 0.9625046253204346)","('NON-ESG', 0.005146467592567205)","('NON-ESG', 0.0035475706681609154)"
Line 120,"For instance, our CEO and Chief Compliance and Ethics Officer (CCEO) circulate communications on integrity-related topics, including our company values, principles of integrity, and compliance and training surrounding our anti-bribery policies.","('Business_Ethics', 0.9752335548400879)","('Competitive_Behavior', 0.0020631079096347094)","('Management_Of_Legal_And_Regulatory_Framework', 0.0020297833252698183)","(['Business Ethics'], 0.9752335548400879)","('NON-ESG', 0.0020631079096347094)","('NON-ESG', 0.0020297833252698183)"
Line 121,"Similarly, our Compliance and Ethics Department regularly publishes articles on our internal news platform.","('Business_Ethics', 0.9390040636062622)","('Management_Of_Legal_And_Regulatory_Framework', 0.01520512718707323)","('Director_Removal', 0.005546071100980043)","(['Business Ethics'], 0.9390040636062622)","('NON-ESG', 0.01520512718707323)","('NON-ESG', 0.005546071100980043)"
Line 122,These include articles based on real-world incidents that provide employees with agreater awareness of how to identify and escalate potentialconcerns.,"('Critical_Incident_Risk_Management', 0.6065787672996521)","('Business_Ethics', 0.13592778146266937)","('Systemic_Risk_Management', 0.07009946554899216)","([], 0.6065787672996521)","('NON-ESG', 0.13592778146266937)","('NON-ESG', 0.07009946554899216)"
Line 123,"In 2021 we celebrated the 100th anniversary of our first print advertisement, which honored the integrity of our company and employees.","('Business_Ethics', 0.5187591910362244)","('Director_Removal', 0.0819411352276802)","('Labor_Practices', 0.0790565237402916)","(['Business Ethics'], 0.5187591910362244)","('NON-ESG', 0.0819411352276802)","('NON-ESG', 0.0790565237402916)"
Line 124,Integrity continues to be our core value.,"('Business_Ethics', 0.856016218662262)","('Customer_Privacy', 0.01718190126121044)","('Human_Rights_And_Community_Relations', 0.016192076727747917)","(['Business Ethics'], 0.856016218662262)","('NON-ESG', 0.01718190126121044)","('NON-ESG', 0.016192076727747917)"
Line 125,Celebrating 35 years of The BMS Pledge Economic Progress Shareholder value Profitable growth Safe and effective productsBusiness integration Safe workplaceSocial Responsibility Conscientious citizenshipEnvironmental Protection Clean and healthy environmentThe Pledge The BMS Pledge has long been a fundamental element of our corporate culture.,"('Business_Model_Resilience', 0.27394306659698486)","('Human_Rights_And_Community_Relations', 0.20504756271839142)","('Employee_Engagement_Inclusion_And_Diversity', 0.055315472185611725)","('NON-ESG', 0.27394306659698486)","('NON-ESG', 0.20504756271839142)","('NON-ESG', 0.055315472185611725)"
Line 126,It sets forth the interests and expectations that we consider alongside our stakeholders and is the foundation on which Our Commitment was built.,"('Human_Rights_And_Community_Relations', 0.4750545918941498)","('Management_Of_Legal_And_Regulatory_Framework', 0.22434550523757935)","('Business_Model_Resilience', 0.05433891713619232)","('NON-ESG', 0.4750545918941498)","('NON-ESG', 0.22434550523757935)","('NON-ESG', 0.05433891713619232)"
Line 127,"Ultimately, The Pledge is a formal commitment to conscientious citizenship.","('Employee_Engagement_Inclusion_And_Diversity', 0.47508570551872253)","('Human_Rights_And_Community_Relations', 0.09343945980072021)","('Customer_Privacy', 0.054297640919685364)","('NON-ESG', 0.47508570551872253)","('NON-ESG', 0.09343945980072021)","('NON-ESG', 0.054297640919685364)"
Line 128,"It supports social responsibility, environmental protection and economic progress and guides us toward policies and practices that fully embody the responsibility, integrity and decency required of our free enterprise.1 1 Bristol Myers Squibb Company Report on Environmental Health and Safety Progress, May 1999, page 8.","('Human_Rights_And_Community_Relations', 0.9295466542243958)","('Management_Of_Legal_And_Regulatory_Framework', 0.010849906131625175)","('Ecological_Impacts', 0.007789922412484884)","([], 0.9295466542243958)","('NON-ESG', 0.010849906131625175)","('NON-ESG', 0.007789922412484884)"
Line 129,2021 ESG REPORT | 11Ethical and Safe Products Patients trust us to provide the medicines they need.,"('Selling_Practices_And_Product_Labeling', 0.23321564495563507)","('Product_Design_And_Lifecycle_Management', 0.20181669294834137)","('Customer_Welfare', 0.18090321123600006)","('NON-ESG', 0.23321564495563507)","('NON-ESG', 0.20181669294834137)","('NON-ESG', 0.18090321123600006)"
Line 130,"They rely on us to provide products and services that are effective, ethical and safe.","('Product_Design_And_Lifecycle_Management', 0.8893054723739624)","('Product_Quality_And_Safety', 0.03099009394645691)","('Selling_Practices_And_Product_Labeling', 0.01455757301300764)","([], 0.8893054723739624)","('NON-ESG', 0.03099009394645691)","('NON-ESG', 0.01455757301300764)"
Line 131,That is why our unwavering commitment to product safety and quality is so essentialit is at the core of our work to bring forward medicines that transform patients lives.,"('Product_Quality_And_Safety', 0.8625427484512329)","('Product_Design_And_Lifecycle_Management', 0.024620937183499336)","('Selling_Practices_And_Product_Labeling', 0.022363711148500443)","(['Product Quality & Recall Management'], 0.8625427484512329)","('NON-ESG', 0.024620937183499336)","('NON-ESG', 0.022363711148500443)"
Line 132,"We are committed to delivering superior value and quality as we provide safe, ethical products and services that meet or exceed all regulatory requirements.","('Product_Design_And_Lifecycle_Management', 0.7581648826599121)","('Product_Quality_And_Safety', 0.1211944967508316)","('Customer_Welfare', 0.020629949867725372)","([], 0.7581648826599121)","('NON-ESG', 0.1211944967508316)","('NON-ESG', 0.020629949867725372)"
Line 133,"Throughout our value chain, we take special care to ensure that we meet safety, efficacy, purity and quality standardsfrom design and development to manufacturing and distribution to proper methods of disposal.","('Product_Quality_And_Safety', 0.91402667760849)","('Product_Design_And_Lifecycle_Management', 0.01563599519431591)","('Employee_Health_And_Safety', 0.009385655634105206)","(['Product Quality & Recall Management'], 0.91402667760849)","('NON-ESG', 0.01563599519431591)","('NON-ESG', 0.009385655634105206)"
Line 134,"To deliver truly ethical products, it is imperative that we conduct our business in an environmentally sustainable manner.","('Product_Design_And_Lifecycle_Management', 0.9647424221038818)","('Product_Quality_And_Safety', 0.004430207423865795)","('Selling_Practices_And_Product_Labeling', 0.0028206489514559507)","([], 0.9647424221038818)","('NON-ESG', 0.004430207423865795)","('NON-ESG', 0.0028206489514559507)"
Line 135,"We take a precautionary approach when there is potential harm to human health or the environment, and we integrate principles of resource conservation, pollution prevention and environmental responsibility across our global operations.","('Ecological_Impacts', 0.9737235307693481)","('Human_Rights_And_Community_Relations', 0.0029823470395058393)","('Water_And_Wastewater_Management', 0.002749136183410883)","([], 0.9737235307693481)","('NON-ESG', 0.0029823470395058393)","('NON-ESG', 0.002749136183410883)"
Line 136,"We also collaborate with the public, along with government, industry and educational organizations, to support regulations, research and programs that address environmental, health and safety concerns throughout our industry.","('Employee_Health_And_Safety', 0.8398730158805847)","('Product_Quality_And_Safety', 0.07181841880083084)","('Access_And_Affordability', 0.009851131588220596)","(['Health Outcome Contribution'], 0.8398730158805847)","('NON-ESG', 0.07181841880083084)","('NON-ESG', 0.009851131588220596)"
Line 137,Regulations and standards Our sector is one of the most highly regulated industries because human health and lives are at stake.,"('Employee_Health_And_Safety', 0.9716317653656006)","('Critical_Incident_Risk_Management', 0.005318616516888142)","('Access_And_Affordability', 0.0023931548930704594)","(['Health Outcome Contribution'], 0.9716317653656006)","('NON-ESG', 0.005318616516888142)","('NON-ESG', 0.0023931548930704594)"
Line 138,"We comply with all applicable laws and regulations in the jurisdictions in which we operate, including the regulations for current Good Laboratory Practice, Good Manufacturing Practice, Good Clinical Practice, Pharmacovigilance and Good Distribution Practice.","('Management_Of_Legal_And_Regulatory_Framework', 0.9243224263191223)","('Product_Quality_And_Safety', 0.011355835013091564)","('Business_Ethics', 0.010050796903669834)","([], 0.9243224263191223)","('NON-ESG', 0.011355835013091564)","('NON-ESG', 0.010050796903669834)"
Line 139,"Product security From development to commercial manufacturing to distribution to disposal, we protect the entire product life cycle with a variety of controls and monitoring tools.","('Product_Design_And_Lifecycle_Management', 0.9490876793861389)","('Product_Quality_And_Safety', 0.008712416514754295)","('Selling_Practices_And_Product_Labeling', 0.005893210414797068)","([], 0.9490876793861389)","('NON-ESG', 0.008712416514754295)","('NON-ESG', 0.005893210414797068)"
Line 140,"We employ an integrated team to address counterfeiting, product tampering, theft and diversion issues, including through the following measures: Implementing security technologies that make our packaging and products less vulnerable to counterfeiting and secure their movement within the supply chain.","('Business_Ethics', 0.5515108704566956)","('Data_Security', 0.1419418305158615)","('Product_Quality_And_Safety', 0.07045010477304459)","(['Business Ethics'], 0.5515108704566956)","('NON-ESG', 0.1419418305158615)","('NON-ESG', 0.07045010477304459)"
Line 141,Participating in industry coalitions focused on product security.,"('Data_Security', 0.6528505086898804)","('Product_Design_And_Lifecycle_Management', 0.04187174141407013)","('Supply_Chain_Management', 0.03688556328415871)","([], 0.6528505086898804)","('NON-ESG', 0.04187174141407013)","('NON-ESG', 0.03688556328415871)"
Line 142,Collaborating with our supply chain vendors and law enforcement agencies on product security matters.,"('Supply_Chain_Management', 0.7555736303329468)","('Product_Design_And_Lifecycle_Management', 0.10984039306640625)","('Product_Quality_And_Safety', 0.016609760001301765)","([], 0.7555736303329468)","('NON-ESG', 0.10984039306640625)","('NON-ESG', 0.016609760001301765)"
Line 143,Addressing counterfeit drugs: customer and partner communications SASB - HC-BP-260a.2 We take the risks related to counterfeit medicines very seriously and do all we can to build safety into our medicines and into the supply chain.,"('Product_Quality_And_Safety', 0.46336162090301514)","('Business_Ethics', 0.09313357621431351)","('Selling_Practices_And_Product_Labeling', 0.08769337832927704)","('NON-ESG', 0.46336162090301514)","('NON-ESG', 0.09313357621431351)","('NON-ESG', 0.08769337832927704)"
Line 144,"We evaluate potential risks across the value chain and apply scientific and technical controls to try to reduce the ability to produce counterfeits, but also to enhance our ability to detect counterfeits.","('Business_Ethics', 0.40024569630622864)","('Data_Security', 0.26365697383880615)","('Systemic_Risk_Management', 0.058686669915914536)","('NON-ESG', 0.40024569630622864)","('NON-ESG', 0.26365697383880615)","('NON-ESG', 0.058686669915914536)"
Line 145,"This requires that we work with multiple global authorities, including the U.","('Management_Of_Legal_And_Regulatory_Framework', 0.9023919701576233)","('Business_Ethics', 0.017879044637084007)","('Competitive_Behavior', 0.00974426232278347)","([], 0.9023919701576233)","('NON-ESG', 0.017879044637084007)","('NON-ESG', 0.00974426232278347)"
Line 146,"S. Department of Homeland Security and Customs and Border Protection, to share information and collaborate on the detection and removal of counterfeits and unsafe medicines from the market.","('Business_Ethics', 0.3587932884693146)","('Product_Quality_And_Safety', 0.17250053584575653)","('Data_Security', 0.11525791138410568)","('NON-ESG', 0.3587932884693146)","('NON-ESG', 0.17250053584575653)","('NON-ESG', 0.11525791138410568)"
Line 147,We also have robust drug safety and surveillance programs and support global reporting of any suspected counterfeits.,"('Product_Quality_And_Safety', 0.38954466581344604)","('Business_Ethics', 0.3437418043613434)","('Competitive_Behavior', 0.0469442717730999)","('NON-ESG', 0.38954466581344604)","('NON-ESG', 0.3437418043613434)","('NON-ESG', 0.0469442717730999)"
Line 148,Interwoven into the reporting or detection programs are time-bound processes that initiate product recall and subsequent testing as appropriate and in concert with the regulatory authorities.,"('Product_Quality_And_Safety', 0.7600449323654175)","('Selling_Practices_And_Product_Labeling', 0.10005765408277512)","('Product_Design_And_Lifecycle_Management', 0.02164309099316597)","(['Product Quality & Recall Management'], 0.7600449323654175)","('NON-ESG', 0.10005765408277512)","('NON-ESG', 0.02164309099316597)"
Line 149,2021 ESG REPORT | 12Single integrated quality management system Robust product and data |Culture of excellence | Urgency with rigor | Competitive compliance | Reliable supply |Operational excellence Digital qualityOrganization and culture Processes and proceduresPatients Quality management system Our quality management system (QMS) consists of a series of standards and business processes that ensure we ethically and rigorously achieve quality outcomes across the spectra of regulatory frameworks.,"('Product_Quality_And_Safety', 0.3677956163883209)","('Business_Ethics', 0.23041455447673798)","('Systemic_Risk_Management', 0.0526372492313385)","('NON-ESG', 0.3677956163883209)","('NON-ESG', 0.23041455447673798)","('NON-ESG', 0.0526372492313385)"
Line 150,"It defines our ways of working; our strict specifications for product manufacturing, testing and packaging; and the controls we use to make sure we consistently achieve the quality outcomes we intend and expect.","('Product_Design_And_Lifecycle_Management', 0.9373128414154053)","('Product_Quality_And_Safety', 0.019379789009690285)","('Selling_Practices_And_Product_Labeling', 0.00566991837695241)","([], 0.9373128414154053)","('NON-ESG', 0.019379789009690285)","('NON-ESG', 0.00566991837695241)"
Line 151,"To further enhance our QMS, we are well into a multi-year journey to transform it across the product life cycle into a common GxP or good practiceframework.","('Product_Design_And_Lifecycle_Management', 0.957075834274292)","('Business_Model_Resilience', 0.005701791495084763)","('Product_Quality_And_Safety', 0.004014357924461365)","([], 0.957075834274292)","('NON-ESG', 0.005701791495084763)","('NON-ESG', 0.004014357924461365)"
Line 152,"As we integrate our quality philosophy across the product life cycle, we are driving progress toward cloud-based quality applications.","('Product_Design_And_Lifecycle_Management', 0.9464409351348877)","('Product_Quality_And_Safety', 0.00666274968534708)","('Business_Model_Resilience', 0.004660893697291613)","([], 0.9464409351348877)","('NON-ESG', 0.00666274968534708)","('NON-ESG', 0.004660893697291613)"
Line 153,These are the first steps in building a foundation for our predictive quality vision.,"('Business_Model_Resilience', 0.6212244629859924)","('Systemic_Risk_Management', 0.045533157885074615)","('Product_Design_And_Lifecycle_Management', 0.033134788274765015)","(['Human Capital Development', 'Innovation Management'], 0.6212244629859924)","('NON-ESG', 0.045533157885074615)","('NON-ESG', 0.033134788274765015)"
Line 154,"In 2021, we continued to advance our QMS to meet or exceed the expectations of regulators in the development and life cycle management of combination products.","('Product_Design_And_Lifecycle_Management', 0.9592567086219788)","('Product_Quality_And_Safety', 0.0053440541960299015)","('Customer_Welfare', 0.004397073294967413)","([], 0.9592567086219788)","('NON-ESG', 0.0053440541960299015)","('NON-ESG', 0.004397073294967413)"
Line 155,"This included implementing continuous improvement initiatives on essential QMS processes relevant to devices including Design Control and Post-Market Surveillance, which provide the foundation for our streamlined approach.","('Competitive_Behavior', 0.3034864664077759)","('Business_Model_Resilience', 0.23045998811721802)","('Systemic_Risk_Management', 0.1714932769536972)","('NON-ESG', 0.3034864664077759)","('NON-ESG', 0.23045998811721802)","('NON-ESG', 0.1714932769536972)"
Line 156,"Pharmaceutical companies are also regulated by health authorities worldwide, such as the U.","('Management_Of_Legal_And_Regulatory_Framework', 0.5780314207077026)","('Competitive_Behavior', 0.19813357293605804)","('Business_Ethics', 0.033960070461034775)","([], 0.5780314207077026)","('NON-ESG', 0.19813357293605804)","('NON-ESG', 0.033960070461034775)"
Line 157,S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).,"('Management_Of_Legal_And_Regulatory_Framework', 0.7020390629768372)","('Product_Quality_And_Safety', 0.04039660841226578)","('GHG_Emissions', 0.03980708494782448)","([], 0.7020390629768372)","('NON-ESG', 0.04039660841226578)","('NON-ESG', 0.03980708494782448)"
Line 158,"These health authorities audit our operations on a regular basis, and in 2021, we completed more than 100 regulatory inspections.","('Management_Of_Legal_And_Regulatory_Framework', 0.9228342175483704)","('Business_Ethics', 0.023562366142868996)","('Director_Removal', 0.006971184629946947)","([], 0.9228342175483704)","('NON-ESG', 0.023562366142868996)","('NON-ESG', 0.006971184629946947)"
Line 159,"Our QMS is designed to meet or exceed global, industry-recognized standards and guidelines to build a comprehensive quality framework that is agile enough to respond to change, and robust enough to advance novel and differentiating technologies inclusive of devices and combination products.","('Product_Quality_And_Safety', 0.6371748447418213)","('Product_Design_And_Lifecycle_Management', 0.16365188360214233)","('Management_Of_Legal_And_Regulatory_Framework', 0.019945338368415833)","(['Product Quality & Recall Management'], 0.6371748447418213)","('NON-ESG', 0.16365188360214233)","('NON-ESG', 0.019945338368415833)"
Line 160,Product safety Providing safe products is a top priority at BMS.,"('Product_Quality_And_Safety', 0.895463764667511)","('Product_Design_And_Lifecycle_Management', 0.022373531013727188)","('Employee_Health_And_Safety', 0.013135340064764023)","(['Product Quality & Recall Management'], 0.895463764667511)","('NON-ESG', 0.022373531013727188)","('NON-ESG', 0.013135340064764023)"
Line 161,"In this regard, one of the most important actions we take is to monitor and evaluate safety data associated with our marketed medicines and our investigational drugs in clinical trials.","('Product_Quality_And_Safety', 0.7538003325462341)","('Selling_Practices_And_Product_Labeling', 0.0800354853272438)","('Customer_Welfare', 0.01932443678379059)","(['Product Quality & Recall Management'], 0.7538003325462341)","('NON-ESG', 0.0800354853272438)","('NON-ESG', 0.01932443678379059)"
Line 162,"To ensure that we meet our worldwide safety reporting requirements, employees, consultants, and independent contractors must promptly report any potential or actual adverse events, as well as other events associated with our products when they become aware of them.","('Product_Quality_And_Safety', 0.6353523135185242)","('Employee_Health_And_Safety', 0.24543148279190063)","('Product_Design_And_Lifecycle_Management', 0.018123488873243332)","(['Product Quality & Recall Management'], 0.6353523135185242)","('NON-ESG', 0.24543148279190063)","('NON-ESG', 0.018123488873243332)"
Line 163,"These events include any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product, whether or not the event is considered to be directly related to the medicinal product.","('Selling_Practices_And_Product_Labeling', 0.7102358937263489)","('Customer_Welfare', 0.09690240025520325)","('Product_Quality_And_Safety', 0.03737910836935043)","(['Business Ethics'], 0.7102358937263489)","('NON-ESG', 0.09690240025520325)","('NON-ESG', 0.03737910836935043)"
Line 164,"We also embed technology and systems to identify and protect our brands from instances of counterfeiting, tampering, theft or diversion.","('Business_Ethics', 0.9104276299476624)","('Data_Security', 0.02458704262971878)","('Customer_Privacy', 0.008784300647675991)","(['Business Ethics'], 0.9104276299476624)","('NON-ESG', 0.02458704262971878)","('NON-ESG', 0.008784300647675991)"
Line 165,"In addition, employees are required to promptly report possible diversion instances by notifying Corporate Security and Quality and Compliance representatives and business unit senior management within 24 hours.","('Business_Ethics', 0.9235594272613525)","('Data_Security', 0.017810214310884476)","('Management_Of_Legal_And_Regulatory_Framework', 0.006877338048070669)","(['Business Ethics'], 0.9235594272613525)","('NON-ESG', 0.017810214310884476)","('NON-ESG', 0.006877338048070669)"
Line 166,"2021 product safety highlights At BMS, we believe that one safety incident is one too many.","('Product_Quality_And_Safety', 0.913545548915863)","('Employee_Health_And_Safety', 0.015982965007424355)","('Product_Design_And_Lifecycle_Management', 0.009466275572776794)","(['Product Quality & Recall Management'], 0.913545548915863)","('NON-ESG', 0.015982965007424355)","('NON-ESG', 0.009466275572776794)"
Line 167,"In 2021, we continued to achieve exceptional product safety performance and results with zero incidents, maintaining the quality of our products for the patients who rely on them.","('Product_Quality_And_Safety', 0.9032220840454102)","('Product_Design_And_Lifecycle_Management', 0.02037656493484974)","('Selling_Practices_And_Product_Labeling', 0.011468914337456226)","(['Product Quality & Recall Management'], 0.9032220840454102)","('NON-ESG', 0.02037656493484974)","('NON-ESG', 0.011468914337456226)"
Line 168,"2021 product safety results Zero1No observable impact from COVID-19, including no drug shortages impactingpatients Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP) by type.","('Product_Quality_And_Safety', 0.9096408486366272)","('Selling_Practices_And_Product_Labeling', 0.015090517699718475)","('Customer_Welfare', 0.007976962253451347)","(['Product Quality & Recall Management'], 0.9096408486366272)","('NON-ESG', 0.015090517699718475)","('NON-ESG', 0.007976962253451347)"
Line 169,SASB-HC-BP- 250A.5 .,"('Management_Of_Legal_And_Regulatory_Framework', 0.4474131464958191)","('GHG_Emissions', 0.07873303443193436)","('Competitive_Behavior', 0.04765214025974274)","('NON-ESG', 0.4474131464958191)","('NON-ESG', 0.07873303443193436)","('NON-ESG', 0.04765214025974274)"
Line 170,Products listed in the FDA MedWatch Safety Alerts for Human Medical Products database.,"('Product_Quality_And_Safety', 0.8744693398475647)","('Selling_Practices_And_Product_Labeling', 0.02611755207180977)","('Product_Design_And_Lifecycle_Management', 0.016464516520500183)","(['Product Quality & Recall Management'], 0.8744693398475647)","('NON-ESG', 0.02611755207180977)","('NON-ESG', 0.016464516520500183)"
Line 171,SASB-HC-BP-250A.1Number of fatalities associated with products as reported in theFDA Adverse Event Reporting System.,"('Employee_Health_And_Safety', 0.835277795791626)","('Product_Quality_And_Safety', 0.05731409415602684)","('Product_Design_And_Lifecycle_Management', 0.012690077535808086)","(['Health Outcome Contribution'], 0.835277795791626)","('NON-ESG', 0.05731409415602684)","('NON-ESG', 0.012690077535808086)"
Line 172,SASB-HC-BP- 250A.2Number of recalls issued; total units recalled.,"('Critical_Incident_Risk_Management', 0.4383382201194763)","('Employee_Health_And_Safety', 0.07092456519603729)","('Product_Quality_And_Safety', 0.061228808015584946)","('NON-ESG', 0.4383382201194763)","('NON-ESG', 0.07092456519603729)","('NON-ESG', 0.061228808015584946)"
Line 173,"SASB-HC-BP-250A.3 1 Data as per SASB requirements from source www.fda.gov/safety 2021 ESG REPORT | 13 Ethical and Safe ProductsMaintaining product traceability, preventing counterfeiting SASB - HC-BP-260a.1 Supply chain digitization (previously known as global serialization) ensures that BMS is compliant with track and trace regulations.","('Product_Quality_And_Safety', 0.7184178233146667)","('Selling_Practices_And_Product_Labeling', 0.05665981397032738)","('Product_Design_And_Lifecycle_Management', 0.04520697519183159)","(['Product Quality & Recall Management'], 0.7184178233146667)","('NON-ESG', 0.05665981397032738)","('NON-ESG', 0.04520697519183159)"
Line 174,"In line with these regulations, all BMS medicines in serialized markets are now required to have a unique identifier in the packaging, which enables each saleable unit of a product to be tracked throughout the entire supply chain.","('Product_Design_And_Lifecycle_Management', 0.5150321125984192)","('Selling_Practices_And_Product_Labeling', 0.17769518494606018)","('Customer_Welfare', 0.07641135156154633)","([], 0.5150321125984192)","('NON-ESG', 0.17769518494606018)","('NON-ESG', 0.07641135156154633)"
Line 175,"During the serialization process, a unique 2D data matrix is placed on each carton of product.","('Product_Design_And_Lifecycle_Management', 0.8199537396430969)","('Selling_Practices_And_Product_Labeling', 0.04210147634148598)","('Product_Quality_And_Safety', 0.028705928474664688)","([], 0.8199537396430969)","('NON-ESG', 0.04210147634148598)","('NON-ESG', 0.028705928474664688)"
Line 176,"As the product moves through the supply chain, wholesalers, distributors and dispensers can scan this code to confirm that the product is legitimate.","('Product_Design_And_Lifecycle_Management', 0.6423224210739136)","('Selling_Practices_And_Product_Labeling', 0.15213535726070404)","('Product_Quality_And_Safety', 0.05502361059188843)","([], 0.6423224210739136)","('NON-ESG', 0.15213535726070404)","('NON-ESG', 0.05502361059188843)"
Line 177,"Serialization data is then exchanged between nodes in the supply chain, in accordance with market regulations.","('Supply_Chain_Management', 0.935364842414856)","('Labor_Practices', 0.006084459833800793)","('Energy_Management', 0.0059964475221931934)","([], 0.935364842414856)","('NON-ESG', 0.006084459833800793)","('NON-ESG', 0.0059964475221931934)"
Line 178,"Combined with our experience exchanging data with internal and external partners, the ability to encode more information including unit-level identificationon our packaging offers valuable new capabilities for BMS.","('Customer_Privacy', 0.8582136034965515)","('Selling_Practices_And_Product_Labeling', 0.02211451344192028)","('Data_Security', 0.0186539925634861)","([], 0.8582136034965515)","('NON-ESG', 0.02211451344192028)","('NON-ESG', 0.0186539925634861)"
Line 179,"Nearly all our internal and external packaging lines are serialization capable, and moving forward, we expect to focus on improving supply chain visibility and enhancing customer experience.","('Supply_Chain_Management', 0.939943253993988)","('Product_Design_And_Lifecycle_Management', 0.01050263736397028)","('Employee_Health_And_Safety', 0.004117165692150593)","([], 0.939943253993988)","('NON-ESG', 0.01050263736397028)","('NON-ESG', 0.004117165692150593)"
Line 180,"By 2023, the U.","('Management_Of_Legal_And_Regulatory_Framework', 0.3093024790287018)","('GHG_Emissions', 0.12850672006607056)","('Business_Model_Resilience', 0.05640231817960739)","('NON-ESG', 0.3093024790287018)","('NON-ESG', 0.12850672006607056)","('NON-ESG', 0.05640231817960739)"
Line 181,S. is expected to have a system that will enable transactional data to be gathered across the supply chain for each unique identifier.,"('Supply_Chain_Management', 0.9361475706100464)","('Energy_Management', 0.00566829415038228)","('Systemic_Risk_Management', 0.005032658111304045)","([], 0.9361475706100464)","('NON-ESG', 0.00566829415038228)","('NON-ESG', 0.005032658111304045)"
Line 182,This will establish full end-to-end visibility if a suspect product is detected.,"('Product_Design_And_Lifecycle_Management', 0.734620988368988)","('Selling_Practices_And_Product_Labeling', 0.06870519369840622)","('Product_Quality_And_Safety', 0.06565053015947342)","([], 0.734620988368988)","('NON-ESG', 0.06870519369840622)","('NON-ESG', 0.06565053015947342)"
Line 183,These capabilitiesoriginally developed to meet government regulations aimed at protecting patient safetymay be leveraged to enable a customer-specific experience and the delivery of patient-specific medicines.,"('Product_Quality_And_Safety', 0.8982872366905212)","('Selling_Practices_And_Product_Labeling', 0.012604198418557644)","('Employee_Health_And_Safety', 0.011504936031997204)","(['Product Quality & Recall Management'], 0.8982872366905212)","('NON-ESG', 0.012604198418557644)","('NON-ESG', 0.011504936031997204)"
Line 184,"Takeback, reuse and product disposal SASB - HC-BP-250a.4 The Pharmaceutical Product Stewardship Work Group (PPSWG) manages the takeback of BMS medications from patients.","('Product_Design_And_Lifecycle_Management', 0.890123724937439)","('Selling_Practices_And_Product_Labeling', 0.0268954336643219)","('Product_Quality_And_Safety', 0.01543030608445406)","([], 0.890123724937439)","('NON-ESG', 0.0268954336643219)","('NON-ESG', 0.01543030608445406)"
Line 185,"The PPSWG coordinates these efforts through MED-Project , a stewardship organization that implements and operates mandated household unwanted medicine and sharps takeback programs.","('Access_And_Affordability', 0.6833251118659973)","('Customer_Welfare', 0.03853953629732132)","('Product_Quality_And_Safety', 0.03479338064789772)","(['Access to Healthcare'], 0.6833251118659973)","('NON-ESG', 0.03853953629732132)","('NON-ESG', 0.03479338064789772)"
Line 186,"Due to regulations, pharmaceutical products are not sorted after collection, making it difficult for BMS to calculate the amount of unused BMS products collected from U.","('Product_Design_And_Lifecycle_Management', 0.7077606320381165)","('Waste_And_Hazardous_Materials_Management', 0.07345059514045715)","('Product_Quality_And_Safety', 0.05651387199759483)","([], 0.7077606320381165)","('NON-ESG', 0.07345059514045715)","('NON-ESG', 0.05651387199759483)"
Line 187,S. patients.,"('Business_Ethics', 0.13510102033615112)","('Access_And_Affordability', 0.12826254963874817)","('Customer_Welfare', 0.09639126807451248)","('NON-ESG', 0.13510102033615112)","('NON-ESG', 0.12826254963874817)","('NON-ESG', 0.09639126807451248)"
Line 188,"However, in 2021, we know that residents in California, Massachusetts, Oregon and Washington disposed of 357 tons of unwanted, household-generated materials collected through MED-Projects programs.","('Waste_And_Hazardous_Materials_Management', 0.948714554309845)","('Energy_Management', 0.006234654691070318)","('Product_Design_And_Lifecycle_Management', 0.005550425499677658)","([], 0.948714554309845)","('NON-ESG', 0.006234654691070318)","('NON-ESG', 0.005550425499677658)"
Line 189,This included more than 93 tons of unused medicines that were disposed of via Med-Projects sharps programs and 264 tons that were disposed of via its unwanted medicine programs.,"('Waste_And_Hazardous_Materials_Management', 0.7183054089546204)","('Access_And_Affordability', 0.03418441489338875)","('Ecological_Impacts', 0.025027889758348465)","([], 0.7183054089546204)","('NON-ESG', 0.03418441489338875)","('NON-ESG', 0.025027889758348465)"
Line 190,"In addition to our work with MED-Project, we collaborate with other organizations to facilitate takeback in our industry.","('Management_Of_Legal_And_Regulatory_Framework', 0.4256788492202759)","('Access_And_Affordability', 0.16099628806114197)","('GHG_Emissions', 0.05733943730592728)","('NON-ESG', 0.4256788492202759)","('NON-ESG', 0.16099628806114197)","('NON-ESG', 0.05733943730592728)"
Line 191,"Examples include the websites myoldmeds.com and medsdisposal.eu, which create an easy way for patients to identify a nearby location where they can properly dispose of unwanted, unused or expired household medicines.","('Waste_And_Hazardous_Materials_Management', 0.5368223786354065)","('Selling_Practices_And_Product_Labeling', 0.10639546811580658)","('Product_Quality_And_Safety', 0.0836484506726265)","([], 0.5368223786354065)","('NON-ESG', 0.10639546811580658)","('NON-ESG', 0.0836484506726265)"
Line 192,The websites also highlight how important it is for patients to securely store household medicines and follow the labeling information and medication guides that companies provide.,"('Selling_Practices_And_Product_Labeling', 0.9174529314041138)","('Customer_Welfare', 0.0161359254270792)","('Product_Quality_And_Safety', 0.006786494515836239)","(['Business Ethics'], 0.9174529314041138)","('NON-ESG', 0.0161359254270792)","('NON-ESG', 0.006786494515836239)"
Line 193,"In 2021, there were >20 active unwanted medicine programs and nine sharps programs throughout the U.","('Access_And_Affordability', 0.5395512580871582)","('Management_Of_Legal_And_Regulatory_Framework', 0.06501571089029312)","('Product_Quality_And_Safety', 0.06130366399884224)","(['Access to Healthcare'], 0.5395512580871582)","('NON-ESG', 0.06501571089029312)","('NON-ESG', 0.06130366399884224)"
Line 194,S.,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 195,Learn more in BMS Household-Generated Sharps Management Plan .,"('Energy_Management', 0.8641481995582581)","('Management_Of_Legal_And_Regulatory_Framework', 0.020549556240439415)","('GHG_Emissions', 0.012617821805179119)","(['Operational Eco-Efficiency'], 0.8641481995582581)","('NON-ESG', 0.020549556240439415)","('NON-ESG', 0.012617821805179119)"
Line 196,"2021 ESG REPORT | 14 Ethical and Safe ProductsCybersecurity Our patients, partners, employees, suppliers and other third parties rely on us to securely store their information.","('Product_Design_And_Lifecycle_Management', 0.3449068069458008)","('Product_Quality_And_Safety', 0.22935016453266144)","('Selling_Practices_And_Product_Labeling', 0.10458458960056305)","('NON-ESG', 0.3449068069458008)","('NON-ESG', 0.22935016453266144)","('NON-ESG', 0.10458458960056305)"
Line 197,Maintaining their trust is fundamental to our values of accountability and integrity and critical to our business success.,"('Business_Ethics', 0.8502815365791321)","('Human_Rights_And_Community_Relations', 0.01763865165412426)","('Director_Removal', 0.014954639598727226)","(['Business Ethics'], 0.8502815365791321)","('NON-ESG', 0.01763865165412426)","('NON-ESG', 0.014954639598727226)"
Line 198,Our cybersecurity and data privacy programs are aligned to the U.,"('Data_Security', 0.9601349830627441)","('Customer_Privacy', 0.004687727428972721)","('Systemic_Risk_Management', 0.0038159345276653767)","([], 0.9601349830627441)","('NON-ESG', 0.004687727428972721)","('NON-ESG', 0.0038159345276653767)"
Line 199,S. National Institute of Standards and Technology Cybersecurity Framework (NIST CSF) and informed by and tailored to address a specific set of cyber risk scenarios relevant to BMS.,"('Data_Security', 0.8010427951812744)","('Systemic_Risk_Management', 0.0951860100030899)","('Management_Of_Legal_And_Regulatory_Framework', 0.011051232926547527)","([], 0.8010427951812744)","('NON-ESG', 0.0951860100030899)","('NON-ESG', 0.011051232926547527)"
Line 200,We leverage data analytics and artificial intelligence to help us identify and defend against cyber threats and to constantly learn how these threats evolve.,"('Data_Security', 0.9445003271102905)","('Systemic_Risk_Management', 0.006126426160335541)","('Physical_Impacts_Of_Climate_Change', 0.005912617314606905)","([], 0.9445003271102905)","('NON-ESG', 0.006126426160335541)","('NON-ESG', 0.005912617314606905)"
Line 201,"We maintain strong industry relationships and collaborate to defend against cyber threats, including with our third-party providers and with government agencies, such as the U.","('Data_Security', 0.9551407694816589)","('Systemic_Risk_Management', 0.005352805368602276)","('Physical_Impacts_Of_Climate_Change', 0.0039055347442626953)","([], 0.9551407694816589)","('NON-ESG', 0.005352805368602276)","('NON-ESG', 0.0039055347442626953)"
Line 202,S. Federal Bureau of Investigation and the Cybersecurity & Infrastructure Security Agency.,"('Data_Security', 0.931816816329956)","('Systemic_Risk_Management', 0.010182859376072884)","('Management_Of_Legal_And_Regulatory_Framework', 0.007367425598204136)","([], 0.931816816329956)","('NON-ESG', 0.010182859376072884)","('NON-ESG', 0.007367425598204136)"
Line 203,"To further mitigate potential security and privacy risks related to cyber threats, we engage in real-time education of our global workforce.","('Data_Security', 0.9617518186569214)","('Customer_Privacy', 0.003714707214385271)","('Systemic_Risk_Management', 0.002958624856546521)","([], 0.9617518186569214)","('NON-ESG', 0.003714707214385271)","('NON-ESG', 0.002958624856546521)"
Line 204,"For example, in the U.","('Competitive_Behavior', 0.21200397610664368)","('Management_Of_Legal_And_Regulatory_Framework', 0.15005233883857727)","('Systemic_Risk_Management', 0.06071009114384651)","('NON-ESG', 0.21200397610664368)","('NON-ESG', 0.15005233883857727)","('NON-ESG', 0.06071009114384651)"
Line 205,S. our employees receive a monthly snapshot of their cyber behaviors and are given an overall rating for their cyber vigilance.,"('Data_Security', 0.9335200190544128)","('Business_Ethics', 0.009699012152850628)","('Systemic_Risk_Management', 0.006640909239649773)","([], 0.9335200190544128)","('NON-ESG', 0.009699012152850628)","('NON-ESG', 0.006640909239649773)"
Line 206,"Following a gamification approach, we have seen measurable improvement in employees behaviors across scored areas and increased organic dialogue on cyber vigilance.","('Critical_Incident_Risk_Management', 0.332701712846756)","('Employee_Health_And_Safety', 0.16684235632419586)","('Human_Rights_And_Community_Relations', 0.13589398562908173)","('NON-ESG', 0.332701712846756)","('NON-ESG', 0.16684235632419586)","('NON-ESG', 0.13589398562908173)"
Line 207,Cyber vigilance and preparedness The U.,"('Critical_Incident_Risk_Management', 0.7677715420722961)","('Physical_Impacts_Of_Climate_Change', 0.03904591128230095)","('Systemic_Risk_Management', 0.02114454284310341)","([], 0.7677715420722961)","('NON-ESG', 0.03904591128230095)","('NON-ESG', 0.02114454284310341)"
Line 208,"S. Securities and Exchange Commission (SEC) suggests that future credit ratings may consider cyber preparedness, in addition to the disclosure of cyber risks and incidents.","('Data_Security', 0.9109066724777222)","('Systemic_Risk_Management', 0.019383467733860016)","('Physical_Impacts_Of_Climate_Change', 0.01071273721754551)","([], 0.9109066724777222)","('NON-ESG', 0.019383467733860016)","('NON-ESG', 0.01071273721754551)"
Line 209,"Ratings agencies are still in the process of staffing cybersecurity experts to carry out this task, but they expect it to become a meaningful component of their credit ratings in the coming years.","('Data_Security', 0.4640694260597229)","('Systemic_Risk_Management', 0.3407154083251953)","('Business_Model_Resilience', 0.025852598249912262)","('NON-ESG', 0.4640694260597229)","('NON-ESG', 0.3407154083251953)","('NON-ESG', 0.025852598249912262)"
Line 210,Addressing emerging cybersecurity risks Geo-Political Risk Russias invasion of Ukraine has increased focus on geo-political threats and the response/continuity planning required.,"('Data_Security', 0.42159974575042725)","('Systemic_Risk_Management', 0.3402480483055115)","('Physical_Impacts_Of_Climate_Change', 0.06954630464315414)","('NON-ESG', 0.42159974575042725)","('NON-ESG', 0.3402480483055115)","('NON-ESG', 0.06954630464315414)"
Line 211,Associated increases in sabotage and espionage have been observed across various industry sectors and companies with operations in the region and are expected to continue.,"('Business_Ethics', 0.7164705395698547)","('Data_Security', 0.0786033496260643)","('Critical_Incident_Risk_Management', 0.04207037389278412)","(['Business Ethics'], 0.7164705395698547)","('NON-ESG', 0.0786033496260643)","('NON-ESG', 0.04207037389278412)"
Line 212,Our response: Bolstering defense measures against threat actors and tactics.,"('Critical_Incident_Risk_Management', 0.30711886286735535)","('Business_Model_Resilience', 0.10035095363855362)","('Physical_Impacts_Of_Climate_Change', 0.09646624326705933)","('NON-ESG', 0.30711886286735535)","('NON-ESG', 0.10035095363855362)","('NON-ESG', 0.09646624326705933)"
Line 213,Transitioning commercial operations in Russia (including workforce) to third party.,"('Employee_Engagement_Inclusion_And_Diversity', 0.21809443831443787)","('Supply_Chain_Management', 0.16210100054740906)","('Customer_Welfare', 0.08940210193395615)","('NON-ESG', 0.21809443831443787)","('NON-ESG', 0.16210100054740906)","('NON-ESG', 0.08940210193395615)"
Line 214,Third-Party Supply Chain Risks Threat actors continue to target supply chains to compromise a greater number of victims and maximize harm.,"('Supply_Chain_Management', 0.9521650075912476)","('Labor_Practices', 0.0049951267428696156)","('Systemic_Risk_Management', 0.004223369061946869)","([], 0.9521650075912476)","('NON-ESG', 0.0049951267428696156)","('NON-ESG', 0.004223369061946869)"
Line 215,Cloud providers are a likely target focus due to potential impact.,"('Data_Security', 0.4555940330028534)","('Systemic_Risk_Management', 0.108815997838974)","('Business_Model_Resilience', 0.07028760761022568)","('NON-ESG', 0.4555940330028534)","('NON-ESG', 0.108815997838974)","('NON-ESG', 0.07028760761022568)"
Line 216,Our response: Continuing to evolve our third-party risk management program and conducting table-top exercises to identify gaps in and improve our supply chain resilience.,"('Supply_Chain_Management', 0.8850732445716858)","('Business_Model_Resilience', 0.039069391787052155)","('Product_Design_And_Lifecycle_Management', 0.011226573027670383)","([], 0.8850732445716858)","('NON-ESG', 0.039069391787052155)","('NON-ESG', 0.011226573027670383)"
Line 217,Human Risk Phishing attacks remain the most common cause of data breaches.,"('Data_Security', 0.9547989964485168)","('Systemic_Risk_Management', 0.005404047202318907)","('Physical_Impacts_Of_Climate_Change', 0.0035760956816375256)","([], 0.9547989964485168)","('NON-ESG', 0.005404047202318907)","('NON-ESG', 0.0035760956816375256)"
Line 218,"Threat actors continue to expand tactics, employing SMS and Microsoft Teams-based attacks to avoid detection on corporate networks.","('Data_Security', 0.9357678890228271)","('Systemic_Risk_Management', 0.008316670544445515)","('Business_Ethics', 0.006084989756345749)","([], 0.9357678890228271)","('NON-ESG', 0.008316670544445515)","('NON-ESG', 0.006084989756345749)"
Line 219,"Our response: Rolled out cybersecurity snapshots which provide a cyber vigilance score much like a credit report to our employees, based on various behavior categories (e.g., reporting phishing emails or visiting risky websites).","('Data_Security', 0.9571157097816467)","('Systemic_Risk_Management', 0.005160617642104626)","('Business_Ethics', 0.004254173953086138)","([], 0.9571157097816467)","('NON-ESG', 0.005160617642104626)","('NON-ESG', 0.004254173953086138)"
Line 220,"2021 ESG REPORT | 15In response, we are partnering with the Healthcare and Public Health Sector Coordinating Council Cybersecurity Working Group and the Health Information Sharing and Analysis Center to determine any operational adjustments that may be required.","('Data_Security', 0.9133623838424683)","('Systemic_Risk_Management', 0.011286556720733643)","('Physical_Impacts_Of_Climate_Change', 0.007282368838787079)","([], 0.9133623838424683)","('NON-ESG', 0.011286556720733643)","('NON-ESG', 0.007282368838787079)"
Line 221,This work includes assessing the potential impact of the SECs new practices on our current SEC reporting requirements and exploring options for addressing existing gaps.,"('Management_Of_Legal_And_Regulatory_Framework', 0.9378257989883423)","('Systemic_Risk_Management', 0.007810014300048351)","('Business_Ethics', 0.0074714249931275845)","([], 0.9378257989883423)","('NON-ESG', 0.007810014300048351)","('NON-ESG', 0.0074714249931275845)"
Line 222,"Across industries, organizations struggle to deal with the human element of cybersecurity and adaptation of secure behaviors.","('Data_Security', 0.9288044571876526)","('Systemic_Risk_Management', 0.013141320087015629)","('Physical_Impacts_Of_Climate_Change', 0.0062474776059389114)","([], 0.9288044571876526)","('NON-ESG', 0.013141320087015629)","('NON-ESG', 0.0062474776059389114)"
Line 223,"To pinpoint human security risk, BMS has implemented a human risk management program across our global enterprise to translate our behaviors into personalized and aggregated scorecards.","('Data_Security', 0.8324971199035645)","('Systemic_Risk_Management', 0.07106532901525497)","('Business_Ethics', 0.02019624412059784)","([], 0.8324971199035645)","('NON-ESG', 0.07106532901525497)","('NON-ESG', 0.02019624412059784)"
Line 224,"The scorecards, shown below, measure five cyber behaviors and enable analysis at the organizational, departmental and individual levels.","('Data_Security', 0.8169116377830505)","('Business_Ethics', 0.06626866012811661)","('Systemic_Risk_Management', 0.02140572853386402)","([], 0.8169116377830505)","('NON-ESG', 0.06626866012811661)","('NON-ESG', 0.02140572853386402)"
Line 225,"The results are used by the BMS cybersecurity team to achieve a targeted change in behavior, and effectively communicate expectations to all employees through a targeted learning approach.","('Data_Security', 0.8828980922698975)","('Business_Ethics', 0.030378470197319984)","('Systemic_Risk_Management', 0.022224076092243195)","([], 0.8828980922698975)","('NON-ESG', 0.030378470197319984)","('NON-ESG', 0.022224076092243195)"
Line 226,"Addressing the Human Element of Cybersecurity at BMS Cyber Vigilance ProgramImproving cyber hygiene of our workforce through data-driven cybersecurity awareness campaigns, global educational courses and an activated Champion Network Phishing Protection ProgramEnabling our workforce to better identify and report suspicious emails, leveraging simulations that reflect the increasingly complex nature of real-life attacks Cyber Resiliency Table-Top ExercisesStress testing cyber resilience and our ability to respond in a cyber event through collaborative preparedness exercises across business units Cybersecurity Snapshot & ScorecardTranslating BMS' security data into personalized and aggregated scorecards that pinpoint human security risk through a human risk management platform Data Protection & Insider Risk ProgramSafeguarding BMS information to reduce risk of intellectual property and crown jewels data from being exfiltrated from the organizationBMS Human Risk Management Program 2021 ESG REPORT | 16 CybersecurityGovernance and Risk Management Our business thrives because of the unwavering commitment of our workforce to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.","('Data_Security', 0.9019861221313477)","('Systemic_Risk_Management', 0.01614132709801197)","('Business_Model_Resilience', 0.0136484419927001)","([], 0.9019861221313477)","('NON-ESG', 0.01614132709801197)","('NON-ESG', 0.0136484419927001)"
Line 227,"Addressing the Human Element of Cybersecurity at BMS Cyber Vigilance ProgramImproving cyber hygiene of our workforce through data-driven cybersecurity awareness campaigns, global educational courses and an activated Champion Network Phishing Protection ProgramEnabling our workforce to better identify and report suspicious emails, leveraging simulations that reflect the increasingly complex nature of real-life attacks Cyber Resiliency Table-Top ExercisesStress testing cyber resilience and our ability to respond in a cyber event through collaborative preparedness exercises across business units Cybersecurity Snapshot & ScorecardTranslating BMS' security data into personalized and aggregated scorecards that pinpoint human security risk through a human risk management platform Data Protection & Insider Risk ProgramSafeguarding BMS information to reduce risk of intellectual property and crown jewels data from being exfiltrated from the organizationBMS Human Risk Management Program 2021 ESG REPORT | 16 CybersecurityGovernance and Risk Management Our business thrives because of the unwavering commitment of our workforce to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.","('Data_Security', 0.9599200487136841)","('Systemic_Risk_Management', 0.006134137976914644)","('Business_Ethics', 0.003462517401203513)","([], 0.9599200487136841)","('NON-ESG', 0.006134137976914644)","('NON-ESG', 0.003462517401203513)"
Line 228,"Addressing the Human Element of Cybersecurity at BMS Cyber Vigilance ProgramImproving cyber hygiene of our workforce through data-driven cybersecurity awareness campaigns, global educational courses and an activated Champion Network Phishing Protection ProgramEnabling our workforce to better identify and report suspicious emails, leveraging simulations that reflect the increasingly complex nature of real-life attacks Cyber Resiliency Table-Top ExercisesStress testing cyber resilience and our ability to respond in a cyber event through collaborative preparedness exercises across business units Cybersecurity Snapshot & ScorecardTranslating BMS' security data into personalized and aggregated scorecards that pinpoint human security risk through a human risk management platform Data Protection & Insider Risk ProgramSafeguarding BMS information to reduce risk of intellectual property and crown jewels data from being exfiltrated from the organizationBMS Human Risk Management Program 2021 ESG REPORT | 16 CybersecurityGovernance and Risk Management Our business thrives because of the unwavering commitment of our workforce to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.","('Access_And_Affordability', 0.411011278629303)","('Customer_Welfare', 0.09422435611486435)","('Selling_Practices_And_Product_Labeling', 0.055445607751607895)","('NON-ESG', 0.411011278629303)","('NON-ESG', 0.09422435611486435)","('NON-ESG', 0.055445607751607895)"
Line 229,This commitment is based on a foundation of robust governance and risk management.,"('Systemic_Risk_Management', 0.5037742257118225)","('Management_Of_Legal_And_Regulatory_Framework', 0.22307710349559784)","('Business_Model_Resilience', 0.06071479246020317)","([], 0.5037742257118225)","('NON-ESG', 0.22307710349559784)","('NON-ESG', 0.06071479246020317)"
Line 230,"Further, we consider our ESG risks and opportunities as integral to our strategy for doing business around the world.","('Systemic_Risk_Management', 0.8174999952316284)","('Business_Model_Resilience', 0.09260880202054977)","('Physical_Impacts_Of_Climate_Change', 0.014291634783148766)","([], 0.8174999952316284)","('NON-ESG', 0.09260880202054977)","('NON-ESG', 0.014291634783148766)"
Line 231,"Our strong governance profile includes direct oversight by our Committee on Directors and Corporate Governance of ESG risks, assessment and disclosure.","('Business_Ethics', 0.26665911078453064)","('Management_Of_Legal_And_Regulatory_Framework', 0.25956037640571594)","('Systemic_Risk_Management', 0.19769039750099182)","('NON-ESG', 0.26665911078453064)","('NON-ESG', 0.25956037640571594)","('NON-ESG', 0.19769039750099182)"
Line 232,"Oversight by this committee strengthens our ability to operate with the highest levels of quality, integrity and ethics, which are foundational to our business.","('Business_Ethics', 0.9687128663063049)","('Management_Of_Legal_And_Regulatory_Framework', 0.002752853324636817)","('Competitive_Behavior', 0.0025617785286158323)","(['Business Ethics'], 0.9687128663063049)","('NON-ESG', 0.002752853324636817)","('NON-ESG', 0.0025617785286158323)"
Line 233,"Board diversity Our Board is focused on ensuring that it has the best mix of skill sets, proficiencies and perspectives to deal with the ever-changing business dynamics of our company and external environment.","('Director_Removal', 0.3344404399394989)","('Employee_Engagement_Inclusion_And_Diversity', 0.2571370601654053)","('Business_Model_Resilience', 0.12461774051189423)","('NON-ESG', 0.3344404399394989)","('NON-ESG', 0.2571370601654053)","('NON-ESG', 0.12461774051189423)"
Line 234,"In line with this focus, they are prioritizing efforts to increase inclusion and diversityboth at the Board member level and throughout the organization.","('Employee_Engagement_Inclusion_And_Diversity', 0.974239706993103)","('Human_Rights_And_Community_Relations', 0.0020168828777968884)","('Employee_Health_And_Safety', 0.0018918314017355442)","(['Talent Attraction & Retention'], 0.974239706993103)","('NON-ESG', 0.0020168828777968884)","('NON-ESG', 0.0018918314017355442)"
Line 235,"In particular, in connection with its identification and selection of potential director nominees, the Board is committed to identifying and evaluating highly qualified women and historically underrepresented ethnic group candidates, as well as candidates with other diverse backgrounds and experiences.","('Employee_Engagement_Inclusion_And_Diversity', 0.975024402141571)","('Business_Model_Resilience', 0.0016925933305174112)","('Customer_Privacy', 0.001597082824446261)","(['Talent Attraction & Retention'], 0.975024402141571)","('NON-ESG', 0.0016925933305174112)","('NON-ESG', 0.001597082824446261)"
Line 236,"Board accountability and shareholder rights Our Board meets on a regularly scheduled basis, with members convening nine times in 2021.","('Director_Removal', 0.7311156392097473)","('Management_Of_Legal_And_Regulatory_Framework', 0.05771772935986519)","('Business_Ethics', 0.02200879529118538)","(['Business Ethics'], 0.7311156392097473)","('NON-ESG', 0.05771772935986519)","('NON-ESG', 0.02200879529118538)"
Line 237,"During the year, the average aggregate attendance of directors at Board and committee meetings was over 98%.","('Director_Removal', 0.7642194628715515)","('Management_Of_Legal_And_Regulatory_Framework', 0.032132990658283234)","('Labor_Practices', 0.024689581245183945)","(['Business Ethics'], 0.7642194628715515)","('NON-ESG', 0.032132990658283234)","('NON-ESG', 0.024689581245183945)"
Line 238,No director attended fewer than 90% of the aggregate number of Board and committee meetings during the period that they served.,"('Director_Removal', 0.7608628869056702)","('Management_Of_Legal_And_Regulatory_Framework', 0.033170610666275024)","('Labor_Practices', 0.021232131868600845)","(['Business Ethics'], 0.7608628869056702)","('NON-ESG', 0.033170610666275024)","('NON-ESG', 0.021232131868600845)"
Line 239,"During these meetings, our independent directors met in executive sessions to discuss many topics, such as the companys integration of the Celgene and MyoKardia businesses, the execution of our strategy to renew our product pipeline with new life-changing medicines, and the execution of key launches to replace revenues from upcoming losses of exclusivity, among other things.","('Product_Design_And_Lifecycle_Management', 0.33955273032188416)","('Customer_Welfare', 0.25107458233833313)","('Selling_Practices_And_Product_Labeling', 0.10914985835552216)","('NON-ESG', 0.33955273032188416)","('NON-ESG', 0.25107458233833313)","('NON-ESG', 0.10914985835552216)"
Line 240,"The Board and Board committees also held numerous information sessions throughout the year, which supplemented the regularly scheduled Board and committee meetings.","('Director_Removal', 0.5242193341255188)","('Management_Of_Legal_And_Regulatory_Framework', 0.14608564972877502)","('Labor_Practices', 0.03642674535512924)","(['Business Ethics'], 0.5242193341255188)","('NON-ESG', 0.14608564972877502)","('NON-ESG', 0.03642674535512924)"
Line 241,"These information sessions were especially important during 2021, and allowed the Board to provide effective oversight and support to our management team during the ongoing pandemic.","('Management_Of_Legal_And_Regulatory_Framework', 0.401388019323349)","('Systemic_Risk_Management', 0.15732918679714203)","('Physical_Impacts_Of_Climate_Change', 0.05276607349514961)","('NON-ESG', 0.401388019323349)","('NON-ESG', 0.15732918679714203)","('NON-ESG', 0.05276607349514961)"
Line 242,"BMS also placed a high priority on our proactive engagement with shareholders, reaching out to more than 50 of our top shareholders, who represented roughly 49% of our shares outstanding.","('Director_Removal', 0.20021963119506836)","('Management_Of_Legal_And_Regulatory_Framework', 0.15755340456962585)","('Business_Model_Resilience', 0.1550361067056656)","('NON-ESG', 0.20021963119506836)","('NON-ESG', 0.15755340456962585)","('NON-ESG', 0.1550361067056656)"
Line 243,Tenure and diversity of BMS Board Director Tenure Board Diversity 4Female Directors 2Black/African American Directors 1Latino/Hispanic Director60% of our directors comprise women or underrepresented racial and ethnic groups1 1 Deepak L.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9715917110443115)","('Human_Rights_And_Community_Relations', 0.0018203614745289087)","('Business_Model_Resilience', 0.001783160143531859)","(['Talent Attraction & Retention'], 0.9715917110443115)","('NON-ESG', 0.0018203614745289087)","('NON-ESG', 0.001783160143531859)"
Line 244,"Bhatt, MD, MPH is our newest director and he was appointed to the Board on June 14, 2022.","('Director_Removal', 0.662236750125885)","('Management_Of_Legal_And_Regulatory_Framework', 0.04947401210665703)","('Business_Model_Resilience', 0.04278721660375595)","(['Business Ethics'], 0.662236750125885)","('NON-ESG', 0.04947401210665703)","('NON-ESG', 0.04278721660375595)"
Line 245,Dr. Bhatt is the Director of Mount Sinai Heart and the Valentin Fuster Professor of Cardiovascular Medicine at Icahn School of Medicine.,"('Customer_Welfare', 0.13632984459400177)","('Employee_Engagement_Inclusion_And_Diversity', 0.13402147591114044)","('Access_And_Affordability', 0.08584527671337128)","('NON-ESG', 0.13632984459400177)","('NON-ESG', 0.13402147591114044)","('NON-ESG', 0.08584527671337128)"
Line 246,Dr. Bhatt identifies as an Asian American.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9581637978553772)","('Business_Model_Resilience', 0.003321336582303047)","('Customer_Privacy', 0.00312711950391531)","(['Talent Attraction & Retention'], 0.9581637978553772)","('NON-ESG', 0.003321336582303047)","('NON-ESG', 0.00312711950391531)"
Line 247,"2021 ESG REPORT | 17Enterprise risk management Our enterprise risk management (ERM) program helps us identify and manage risks and opportunities by providing a framework for identification, assessmentin terms of likelihood and magnitude of impactand the determination of a response strategy and monitoring process.","('Systemic_Risk_Management', 0.8777889013290405)","('Business_Model_Resilience', 0.04826880246400833)","('Physical_Impacts_Of_Climate_Change', 0.018808845430612564)","([], 0.8777889013290405)","('NON-ESG', 0.04826880246400833)","('NON-ESG', 0.018808845430612564)"
Line 248,"By identifying and proactively addressing our risks and opportunities, BMS protects and creates value for all our stakeholders, including our shareholders, patients, employees and globalcommunities.","('Systemic_Risk_Management', 0.9039269089698792)","('Business_Model_Resilience', 0.01395043358206749)","('Business_Ethics', 0.011804075911641121)","([], 0.9039269089698792)","('NON-ESG', 0.01395043358206749)","('NON-ESG', 0.011804075911641121)"
Line 249,Our cross-functional Enterprise Risk Committee (ERC) leads BMS ERM governance and reporting and assists the company in its responsibilities relating to risk management.,"('Systemic_Risk_Management', 0.7991856336593628)","('Business_Model_Resilience', 0.08767705410718918)","('Management_Of_Legal_And_Regulatory_Framework', 0.013169841840863228)","([], 0.7991856336593628)","('NON-ESG', 0.08767705410718918)","('NON-ESG', 0.013169841840863228)"
Line 250,"This includes compliance with applicable laws, regulatory requirements and upholding our Principles of Integrity .","('Management_Of_Legal_And_Regulatory_Framework', 0.9661397337913513)","('Business_Ethics', 0.006571710575371981)","('Director_Removal', 0.002162730786949396)","([], 0.9661397337913513)","('NON-ESG', 0.006571710575371981)","('NON-ESG', 0.002162730786949396)"
Line 251,"With its relevant sub-committee, the ERC also provides ongoing updates to our Leadership Teamand Board regarding BMS enterprise risk profile and risk mitigation strategies.","('Systemic_Risk_Management', 0.7191097736358643)","('Business_Model_Resilience', 0.15009622275829315)","('Physical_Impacts_Of_Climate_Change', 0.040254078805446625)","([], 0.7191097736358643)","('NON-ESG', 0.15009622275829315)","('NON-ESG', 0.040254078805446625)"
Line 252,"ERC priorities Ensuring enterprise risk mitigations are captured, reviewed andmonitored Surfacing and evaluating emerging risks and enterprise risk trends to inform risk drivers or scenarios Reviewing progress and providing input on risk management activities led by functional risk committees or risk managementfunctions The ERC is supported by the Enterprise Risk Analytics team.","('Systemic_Risk_Management', 0.9249288439750671)","('Business_Model_Resilience', 0.017960773780941963)","('Physical_Impacts_Of_Climate_Change', 0.013735317625105381)","([], 0.9249288439750671)","('NON-ESG', 0.017960773780941963)","('NON-ESG', 0.013735317625105381)"
Line 253,"This team manages a continuous and dynamic process that leverages metrics, considers emerging risk information and evolves risk-based annual internal audit assessment through enriched information, to articulate explicit linkage between risk function activities and enterprise risks through integration of cross-functional competencies.","('Systemic_Risk_Management', 0.9044173359870911)","('Business_Model_Resilience', 0.017459679394960403)","('Competitive_Behavior', 0.015876529738307)","([], 0.9044173359870911)","('NON-ESG', 0.017459679394960403)","('NON-ESG', 0.015876529738307)"
Line 254,"Enterprise Risk Management Governance Board Oversight and Corporate Governance Leadership Team Enterprise Risk Committee (ERC) Functional Risk Committees 2021 ESG REPORT | 18 Governance and Risk ManagementInnovation, Equity and Access to Healthcare IN THIS SECTION Innovation Health Equity Clinical Trials Access to Healthcare 2021 ESG REPORT | 19Innovation, Equity and Access to Healthcare Patients are at the center of everything we do.","('Systemic_Risk_Management', 0.2804619073867798)","('Business_Model_Resilience', 0.13920870423316956)","('Access_And_Affordability', 0.12155430018901825)","('NON-ESG', 0.2804619073867798)","('NON-ESG', 0.13920870423316956)","('NON-ESG', 0.12155430018901825)"
Line 255,They inspire us and are the reason we come to work each day.,"('Human_Rights_And_Community_Relations', 0.16191568970680237)","('Employee_Health_And_Safety', 0.09632574021816254)","('Employee_Engagement_Inclusion_And_Diversity', 0.09629649668931961)","('NON-ESG', 0.16191568970680237)","('NON-ESG', 0.09632574021816254)","('NON-ESG', 0.09629649668931961)"
Line 256,We leverage our scientific and research expertise to accelerate drug discovery and development as we work to help more patients around the world prevail over serious diseases.,"('Access_And_Affordability', 0.22425496578216553)","('Customer_Welfare', 0.15905849635601044)","('Competitive_Behavior', 0.08421862125396729)","('NON-ESG', 0.22425496578216553)","('NON-ESG', 0.15905849635601044)","('NON-ESG', 0.08421862125396729)"
Line 257,BMS invests heavily in our R&D pipeline to accelerate the next wave of scientific breakthroughs for our patients.,"('Access_And_Affordability', 0.21676552295684814)","('Business_Model_Resilience', 0.12203924357891083)","('Supply_Chain_Management', 0.0808437168598175)","('NON-ESG', 0.21676552295684814)","('NON-ESG', 0.12203924357891083)","('NON-ESG', 0.0808437168598175)"
Line 258,"Each year, we leverage our business success and deepen our use of cutting-edge digital technologies to strengthen and fuel our companys innovation engine.","('Business_Model_Resilience', 0.6426679491996765)","('Product_Design_And_Lifecycle_Management', 0.0808107778429985)","('Systemic_Risk_Management', 0.040155984461307526)","(['Human Capital Development', 'Innovation Management'], 0.6426679491996765)","('NON-ESG', 0.0808107778429985)","('NON-ESG', 0.040155984461307526)"
Line 259,"Today, we continue to innovate next-generation medicines that transform patients lives.","('Product_Design_And_Lifecycle_Management', 0.2542994022369385)","('Customer_Welfare', 0.21611614525318146)","('Business_Model_Resilience', 0.0809955820441246)","('NON-ESG', 0.2542994022369385)","('NON-ESG', 0.21611614525318146)","('NON-ESG', 0.0809955820441246)"
Line 260,"Our portfolio focuses on areas of high unmet medical need in oncology, hematology, immunology, cardiovascular, fibrotic and neuroscience disease.","('Access_And_Affordability', 0.2526555359363556)","('Customer_Welfare', 0.1350644826889038)","('Systemic_Risk_Management', 0.07254248112440109)","('NON-ESG', 0.2526555359363556)","('NON-ESG', 0.1350644826889038)","('NON-ESG', 0.07254248112440109)"
Line 261,Innovations in these areas can be truly transformativebut only if they reach as many patients as possible in the timeframe they need.,"('Access_And_Affordability', 0.3617253303527832)","('Business_Model_Resilience', 0.1118023470044136)","('Product_Design_And_Lifecycle_Management', 0.06947117298841476)","('NON-ESG', 0.3617253303527832)","('NON-ESG', 0.1118023470044136)","('NON-ESG', 0.06947117298841476)"
Line 262,BMS is deeply committed to working alongside our partners to advance access and health equity in countries around the world.,"('Access_And_Affordability', 0.8621124029159546)","('Employee_Health_And_Safety', 0.015945905819535255)","('Product_Quality_And_Safety', 0.015021704137325287)","(['Access to Healthcare'], 0.8621124029159546)","('NON-ESG', 0.015945905819535255)","('NON-ESG', 0.015021704137325287)"
Line 263,"This will ensure that more patients can benefit from our breakthrough science and live longer, healthier lives.","('Access_And_Affordability', 0.5586490631103516)","('Employee_Health_And_Safety', 0.15667688846588135)","('Product_Design_And_Lifecycle_Management', 0.03182440623641014)","(['Access to Healthcare'], 0.5586490631103516)","('NON-ESG', 0.15667688846588135)","('NON-ESG', 0.03182440623641014)"
Line 264,54% of U.,"('Management_Of_Legal_And_Regulatory_Framework', 0.42785724997520447)","('Competitive_Behavior', 0.058009807020425797)","('GHG_Emissions', 0.050674136728048325)","('NON-ESG', 0.42785724997520447)","('NON-ESG', 0.058009807020425797)","('NON-ESG', 0.050674136728048325)"
Line 265,"S. clinical trial sites were located in highly diverse communities by the end of 2021, exceeding our goal.","('Employee_Engagement_Inclusion_And_Diversity', 0.8177740573883057)","('Access_And_Affordability', 0.020174477249383926)","('Customer_Welfare', 0.019840333610773087)","(['Talent Attraction & Retention'], 0.8177740573883057)","('NON-ESG', 0.020174477249383926)","('NON-ESG', 0.019840333610773087)"
Line 266,Diversity in clinical trials is a key driver of health equity.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9684187769889832)","('Employee_Health_And_Safety', 0.0021668218541890383)","('Business_Model_Resilience', 0.002126679290086031)","(['Talent Attraction & Retention'], 0.9684187769889832)","('NON-ESG', 0.0021668218541890383)","('NON-ESG', 0.002126679290086031)"
Line 267,2021 ESG REPORT | 20Innovation BMS is a company heavily steeped in science and research.,"('Business_Model_Resilience', 0.5213257074356079)","('Systemic_Risk_Management', 0.05783802643418312)","('Supply_Chain_Management', 0.04439470171928406)","(['Human Capital Development', 'Innovation Management'], 0.5213257074356079)","('NON-ESG', 0.05783802643418312)","('NON-ESG', 0.04439470171928406)"
Line 268,"Supported by robust capabilities, unmatched collective experience and a global presence, we bring therapies to market with a strong sense of urgency and the utmost precision and care.","('Access_And_Affordability', 0.25890567898750305)","('Business_Model_Resilience', 0.09598074108362198)","('Customer_Welfare', 0.07972768694162369)","('NON-ESG', 0.25890567898750305)","('NON-ESG', 0.09598074108362198)","('NON-ESG', 0.07972768694162369)"
Line 269,Our portfolio We continue to expand our robust portfolio with solutions to save and transform patients lives.,"('Access_And_Affordability', 0.38916343450546265)","('Product_Design_And_Lifecycle_Management', 0.13364823162555695)","('Business_Model_Resilience', 0.0654255822300911)","('NON-ESG', 0.38916343450546265)","('NON-ESG', 0.13364823162555695)","('NON-ESG', 0.0654255822300911)"
Line 270,"For instance, we are currently leading a revolutionary change in the treatment of more than 28 types of cancer.","('Access_And_Affordability', 0.15097081661224365)","('Product_Quality_And_Safety', 0.13503631949424744)","('Employee_Health_And_Safety', 0.13503392040729523)","('NON-ESG', 0.15097081661224365)","('NON-ESG', 0.13503631949424744)","('NON-ESG', 0.13503392040729523)"
Line 271,"Clinical trials have demonstrated the survival benefits of our immunotherapies in patients with metastatic disease, as well as earlier stages of cancer.","('Access_And_Affordability', 0.3637915253639221)","('Product_Quality_And_Safety', 0.09394571185112)","('Customer_Welfare', 0.0737377479672432)","('NON-ESG', 0.3637915253639221)","('NON-ESG', 0.09394571185112)","('NON-ESG', 0.0737377479672432)"
Line 272,"By combining our immunotherapies with other medicines, as well as chemotherapies, we continue to improve response rates for certain patients.","('Access_And_Affordability', 0.2387230098247528)","('Customer_Welfare', 0.20665867626667023)","('Competitive_Behavior', 0.05555262044072151)","('NON-ESG', 0.2387230098247528)","('NON-ESG', 0.20665867626667023)","('NON-ESG', 0.05555262044072151)"
Line 273,We are progressing cell therapies from pipeline to certain patients and are the only company with two approved cell therapies directed against two distinct targets.,"('Access_And_Affordability', 0.257168710231781)","('Customer_Welfare', 0.15423545241355896)","('GHG_Emissions', 0.08357193320989609)","('NON-ESG', 0.257168710231781)","('NON-ESG', 0.15423545241355896)","('NON-ESG', 0.08357193320989609)"
Line 274,"Building on this momentum, we continue to invest in cutting-edge technologies and manufacturing methods, such as using novel constructs to make CAR T cells more consistent and persistent in our pursuit of the next treatment frontiers.","('Product_Design_And_Lifecycle_Management', 0.1962347775697708)","('Energy_Management', 0.15563702583312988)","('Customer_Welfare', 0.12353842705488205)","('NON-ESG', 0.1962347775697708)","('NON-ESG', 0.15563702583312988)","('NON-ESG', 0.12353842705488205)"
Line 275,"Leveraging one of the largest datasets of CAR T translational and clinical data in the industry, were also evaluating a broad portfolio of cell therapy treatments across earlier lines of therapy.","('Customer_Welfare', 0.2051316499710083)","('Access_And_Affordability', 0.15539070963859558)","('Selling_Practices_And_Product_Labeling', 0.07918857783079147)","('NON-ESG', 0.2051316499710083)","('NON-ESG', 0.15539070963859558)","('NON-ESG', 0.07918857783079147)"
Line 276,All of these actions add up to our purposeful pursuit of better patient outcomes.,"('Access_And_Affordability', 0.680280864238739)","('Management_Of_Legal_And_Regulatory_Framework', 0.03482896462082863)","('Customer_Welfare', 0.030775543302297592)","(['Access to Healthcare'], 0.680280864238739)","('NON-ESG', 0.03482896462082863)","('NON-ESG', 0.030775543302297592)"
Line 277,"In 2021, our immunology franchise encompassed two marketed products and a robust pipeline of more than 20 programs across nearly 20 diseases.","('Customer_Welfare', 0.4328482151031494)","('Selling_Practices_And_Product_Labeling', 0.15164659917354584)","('Product_Design_And_Lifecycle_Management', 0.07880581170320511)","('NON-ESG', 0.4328482151031494)","('NON-ESG', 0.15164659917354584)","('NON-ESG', 0.07880581170320511)"
Line 278,"As we continuously build and expand our portfolio, our teams work to identify mechanisms that may help the body control inflammation, reset the immune system and promote balance in immune responsea three-point approach with the goal of achieving long-term remission and, ultimately, curative therapies.","('Access_And_Affordability', 0.15625570714473724)","('Employee_Health_And_Safety', 0.10878544300794601)","('Customer_Welfare', 0.1037643775343895)","('NON-ESG', 0.15625570714473724)","('NON-ESG', 0.10878544300794601)","('NON-ESG', 0.1037643775343895)"
Line 279,Developing our pipeline Our investment in R&D remains among the highest in the industry.,"('Business_Model_Resilience', 0.29007506370544434)","('Supply_Chain_Management', 0.22843816876411438)","('Product_Design_And_Lifecycle_Management', 0.07050885260105133)","('NON-ESG', 0.29007506370544434)","('NON-ESG', 0.22843816876411438)","('NON-ESG', 0.07050885260105133)"
Line 280,"Our R&D pipeline includes potential medicines in various modalities, including small (chemically manufactured) molecules and large (protein) moleculesalso known as biologicsas well as millamolecules, antibody drug conjugates and cellular therapies.","('Customer_Welfare', 0.5557224750518799)","('Selling_Practices_And_Product_Labeling', 0.088100366294384)","('Competitive_Behavior', 0.054080501198768616)","([], 0.5557224750518799)","('NON-ESG', 0.088100366294384)","('NON-ESG', 0.054080501198768616)"
Line 281,"In addition to discovering and developing new molecular entities, we look for ways to expand the value of existing products through new indications and formulations that can provide additional benefits to patients.","('Product_Design_And_Lifecycle_Management', 0.4383929967880249)","('Customer_Welfare', 0.26945552229881287)","('Selling_Practices_And_Product_Labeling', 0.13554362952709198)","('NON-ESG', 0.4383929967880249)","('NON-ESG', 0.26945552229881287)","('NON-ESG', 0.13554362952709198)"
Line 282,"Through advances in genetic engineering, we are now able to create T cells that target specific proteins in cancer cells, enlisting the bodys natural immune system in the defeat of cancer.","('Ecological_Impacts', 0.16623730957508087)","('Access_And_Affordability', 0.16533470153808594)","('Customer_Welfare', 0.12077506631612778)","('NON-ESG', 0.16623730957508087)","('NON-ESG', 0.16533470153808594)","('NON-ESG', 0.12077506631612778)"
Line 283,We have seen similar extraordinary gains in the prognosis of patients with multiple myeloma.,"('Access_And_Affordability', 0.22673363983631134)","('Employee_Engagement_Inclusion_And_Diversity', 0.1027495339512825)","('Product_Quality_And_Safety', 0.09512364864349365)","('NON-ESG', 0.22673363983631134)","('NON-ESG', 0.1027495339512825)","('NON-ESG', 0.09512364864349365)"
Line 284,"We continue to be an industry leader in R&D investment, investing $11.4 billion including Acquired IPRD (or approximately $11 billion) or approximately 24% of our revenue in 2021.","('Business_Model_Resilience', 0.3757235109806061)","('Systemic_Risk_Management', 0.19090373814105988)","('Competitive_Behavior', 0.05900172144174576)","('NON-ESG', 0.3757235109806061)","('NON-ESG', 0.19090373814105988)","('NON-ESG', 0.05900172144174576)"
Line 285,2021 ESG REPORT | 21Advancing treatments in 2021 11 positive Phase3 clinical trial readouts7 high-potential mid- to late- stage assets50+ early-stage assets8 approvals across new Product Portfolio in the U.,"('Customer_Welfare', 0.30826807022094727)","('Selling_Practices_And_Product_Labeling', 0.14505138993263245)","('Product_Design_And_Lifecycle_Management', 0.0770864486694336)","('NON-ESG', 0.30826807022094727)","('NON-ESG', 0.14505138993263245)","('NON-ESG', 0.0770864486694336)"
Line 286,"S., E.","('Product_Design_And_Lifecycle_Management', 0.10190002620220184)","('Waste_And_Hazardous_Materials_Management', 0.09062127768993378)","('Management_Of_Legal_And_Regulatory_Framework', 0.07614707201719284)","('NON-ESG', 0.10190002620220184)","('NON-ESG', 0.09062127768993378)","('NON-ESG', 0.07614707201719284)"
Line 287,U.,"('Management_Of_Legal_And_Regulatory_Framework', 0.14571937918663025)","('Product_Design_And_Lifecycle_Management', 0.12332227826118469)","('Employee_Engagement_Inclusion_And_Diversity', 0.06306221336126328)","('NON-ESG', 0.14571937918663025)","('NON-ESG', 0.12332227826118469)","('NON-ESG', 0.06306221336126328)"
Line 288,"and Japan 16 new Opdivo approvals2 new cell therapies1: Abecma (idecabtagene vicleucel) and Breyanzi (lisocabtagene maraleucel)New oral medicine1 for ulcerative colitis: Zeposia (ozanimod) Amplifying R&D through partnership Collaboration is essential to our strategy, as we advance science through internally discovered medicines as well as external partnerships.","('Customer_Welfare', 0.19960099458694458)","('Access_And_Affordability', 0.16702675819396973)","('Selling_Practices_And_Product_Labeling', 0.07629266381263733)","('NON-ESG', 0.19960099458694458)","('NON-ESG', 0.16702675819396973)","('NON-ESG', 0.07629266381263733)"
Line 289,"2 Mechanisms of cancer resistance 8 Tumor micro-environment 13 Immuno-oncology and cell therapy 5 Oncogenesis 4 Discovery biotherapeutics 4 Small molecule drug discovery 6 Neuroscience 16 Inflammation, CV and fibrosis 18 Informatics and predictive sciences 16 Cross-therapeutic 90+ Total active collaborations 1 Subsets of the eight approvals across new Product Portfolio in the U.","('Customer_Welfare', 0.45811209082603455)","('Selling_Practices_And_Product_Labeling', 0.10117197036743164)","('Competitive_Behavior', 0.06785275042057037)","('NON-ESG', 0.45811209082603455)","('NON-ESG', 0.10117197036743164)","('NON-ESG', 0.06785275042057037)"
Line 290,"S., E.","('Product_Design_And_Lifecycle_Management', 0.10190002620220184)","('Waste_And_Hazardous_Materials_Management', 0.09062127768993378)","('Management_Of_Legal_And_Regulatory_Framework', 0.07614707201719284)","('NON-ESG', 0.10190002620220184)","('NON-ESG', 0.09062127768993378)","('NON-ESG', 0.07614707201719284)"
Line 291,U.,"('Management_Of_Legal_And_Regulatory_Framework', 0.14571937918663025)","('Product_Design_And_Lifecycle_Management', 0.12332227826118469)","('Employee_Engagement_Inclusion_And_Diversity', 0.06306221336126328)","('NON-ESG', 0.14571937918663025)","('NON-ESG', 0.12332227826118469)","('NON-ESG', 0.06306221336126328)"
Line 292,and Japan.,"('Ecological_Impacts', 0.13342759013175964)","('Management_Of_Legal_And_Regulatory_Framework', 0.0947159081697464)","('Product_Design_And_Lifecycle_Management', 0.0706522986292839)","('NON-ESG', 0.13342759013175964)","('NON-ESG', 0.0947159081697464)","('NON-ESG', 0.0706522986292839)"
Line 293,2021 ESG REPORT | 22 InnovationHealth Equity Health equity is a strategic priority for BMS.,"('Access_And_Affordability', 0.2848358154296875)","('Product_Quality_And_Safety', 0.1250283569097519)","('Customer_Welfare', 0.12003064155578613)","('NON-ESG', 0.2848358154296875)","('NON-ESG', 0.1250283569097519)","('NON-ESG', 0.12003064155578613)"
Line 294,"By applying a health equity lens to our work, we drive inclusive innovation, high-quality science and the expanded reach and impact of our medicines.","('Product_Design_And_Lifecycle_Management', 0.1615275740623474)","('Business_Model_Resilience', 0.12561489641666412)","('Competitive_Behavior', 0.09968205541372299)","('NON-ESG', 0.1615275740623474)","('NON-ESG', 0.12561489641666412)","('NON-ESG', 0.09968205541372299)"
Line 295,"As we integrate ESG into our strategy for growth, we consider an emphasis on health equity to be a business imperativenot only because it is central to our vision, but also because it is simply the right thing to do.","('Business_Model_Resilience', 0.8461776375770569)","('Systemic_Risk_Management', 0.046319760382175446)","('Employee_Engagement_Inclusion_And_Diversity', 0.012443129904568195)","(['Human Capital Development', 'Innovation Management'], 0.8461776375770569)","('NON-ESG', 0.046319760382175446)","('NON-ESG', 0.012443129904568195)"
Line 296,"As one of the worlds largest healthcare companies, we have a responsibility to address global health inequities.","('Systemic_Risk_Management', 0.4772506654262543)","('Business_Model_Resilience', 0.09805675595998764)","('Physical_Impacts_Of_Climate_Change', 0.09071182459592819)","('NON-ESG', 0.4772506654262543)","('NON-ESG', 0.09805675595998764)","('NON-ESG', 0.09071182459592819)"
Line 297,"We aim to provide comprehensive, equitable care for our patients and communities by ensuring that everyoneregardless of their race, gender, socioeconomic status or geographyhas access to the medicines and care they need, notonly to survive but to thrive.","('Employee_Engagement_Inclusion_And_Diversity', 0.6972718834877014)","('Human_Rights_And_Community_Relations', 0.12332803010940552)","('Access_And_Affordability', 0.06042487174272537)","(['Talent Attraction & Retention'], 0.6972718834877014)","('NON-ESG', 0.12332803010940552)","('NON-ESG', 0.06042487174272537)"
Line 298,BMS has been on a health equity journey for many yearscontinuously building new tools and partnerships to tackle health inequities throughout the U.,"('Systemic_Risk_Management', 0.471091628074646)","('Access_And_Affordability', 0.08918146789073944)","('Business_Model_Resilience', 0.05303885042667389)","('NON-ESG', 0.471091628074646)","('NON-ESG', 0.08918146789073944)","('NON-ESG', 0.05303885042667389)"
Line 299,S. and around the world.,"('Product_Design_And_Lifecycle_Management', 0.2638230621814728)","('Business_Model_Resilience', 0.1487814486026764)","('Management_Of_Legal_And_Regulatory_Framework', 0.06469136476516724)","('NON-ESG', 0.2638230621814728)","('NON-ESG', 0.1487814486026764)","('NON-ESG', 0.06469136476516724)"
Line 300,"Our work to achieve health equity touches on a variety of overlapping issues, such as access gaps and health disparities; government policy; clinical trial and supplier diversity; and many more.","('Employee_Engagement_Inclusion_And_Diversity', 0.8384053111076355)","('Access_And_Affordability', 0.03089410625398159)","('Customer_Welfare', 0.011696790345013142)","(['Talent Attraction & Retention'], 0.8384053111076355)","('NON-ESG', 0.03089410625398159)","('NON-ESG', 0.011696790345013142)"
Line 301,"Our National Health Equity Advisory Board advises our two-pillared health equity strategy, which drives us to further the inclusive discovery, development and delivery of innovative medicines and advance health equity solutions beyond the pill.","('Systemic_Risk_Management', 0.25872233510017395)","('Business_Model_Resilience', 0.14587564766407013)","('Competitive_Behavior', 0.09814420342445374)","('NON-ESG', 0.25872233510017395)","('NON-ESG', 0.14587564766407013)","('NON-ESG', 0.09814420342445374)"
Line 302,"Examples of beyond the pill solutions include improving the quality of care that patients receive and helping them navigate the healthcare landscape, particularly in specialty care settings, in a way that helps them best meet their needs.","('Access_And_Affordability', 0.6218862533569336)","('Customer_Welfare', 0.0559220090508461)","('Product_Design_And_Lifecycle_Management', 0.030903033912181854)","(['Access to Healthcare'], 0.6218862533569336)","('NON-ESG', 0.0559220090508461)","('NON-ESG', 0.030903033912181854)"
Line 303,"Health equity commitment BMS is deeply invested in programs to enhance health and social equity, both in our organization and in the communities where we live and work.","('Human_Rights_And_Community_Relations', 0.7359891533851624)","('Access_And_Affordability', 0.13829606771469116)","('Employee_Engagement_Inclusion_And_Diversity', 0.016880443319678307)","([], 0.7359891533851624)","('NON-ESG', 0.13829606771469116)","('NON-ESG', 0.016880443319678307)"
Line 304,"In August of 2020, we launched our I&D and Health Equity Commitments , with a $150 million, five-year investment to help address disparities in healthcare, increase diversity in clinical trials, expand the supply chain to include more diverse suppliers, enhance our employees ability to give back to the community and increase the diversity of our own workforce.","('Employee_Engagement_Inclusion_And_Diversity', 0.970203697681427)","('Employee_Health_And_Safety', 0.0023076024372130632)","('Business_Model_Resilience', 0.002114958595484495)","(['Talent Attraction & Retention'], 0.970203697681427)","('NON-ESG', 0.0023076024372130632)","('NON-ESG', 0.002114958595484495)"
Line 305,"In 2021, we provided a total of $27.9 million for 107 health equity grants.","('Management_Of_Legal_And_Regulatory_Framework', 0.5382646918296814)","('Access_And_Affordability', 0.23199523985385895)","('GHG_Emissions', 0.027930542826652527)","([], 0.5382646918296814)","('NON-ESG', 0.23199523985385895)","('NON-ESG', 0.027930542826652527)"
Line 306,"The grants aimedto scale effective health equity solutions, including 24grants for proposals focused on community health workers and patient navigators.","('Access_And_Affordability', 0.5097483992576599)","('Employee_Health_And_Safety', 0.20480546355247498)","('Human_Rights_And_Community_Relations', 0.04851870983839035)","(['Access to Healthcare'], 0.5097483992576599)","('NON-ESG', 0.20480546355247498)","('NON-ESG', 0.04851870983839035)"
Line 307,"Together, the projects address BMStherapeutic areas of oncology, cardiovascular, hematology, immunology, fibrotic diseaseand neuroscience.","('Access_And_Affordability', 0.22743436694145203)","('Customer_Welfare', 0.14206449687480927)","('Systemic_Risk_Management', 0.06905128061771393)","('NON-ESG', 0.22743436694145203)","('NON-ESG', 0.14206449687480927)","('NON-ESG', 0.06905128061771393)"
Line 308,"Additionally, as part of our commitment to tackle health inequities in the U.","('Systemic_Risk_Management', 0.2790415585041046)","('Physical_Impacts_Of_Climate_Change', 0.11772174388170242)","('Critical_Incident_Risk_Management', 0.08675645291805267)","('NON-ESG', 0.2790415585041046)","('NON-ESG', 0.11772174388170242)","('NON-ESG', 0.08675645291805267)"
Line 309,"S., we advocate to shape and inform effective health equity public policies.","('Access_And_Affordability', 0.3984066843986511)","('Management_Of_Legal_And_Regulatory_Framework', 0.21826820075511932)","('Human_Rights_And_Community_Relations', 0.08484256267547607)","('NON-ESG', 0.3984066843986511)","('NON-ESG', 0.21826820075511932)","('NON-ESG', 0.08484256267547607)"
Line 310,"We have numerous programs and initiatives in place designed to listen and create spaces for patient advocates and community partners to come together, and to deliver inclusive, multilingual and culturally competent disease education and quality of care programs.","('Access_And_Affordability', 0.5364446640014648)","('Human_Rights_And_Community_Relations', 0.16602538526058197)","('Employee_Engagement_Inclusion_And_Diversity', 0.12252543866634369)","(['Access to Healthcare'], 0.5364446640014648)","('NON-ESG', 0.16602538526058197)","('NON-ESG', 0.12252543866634369)"
Line 311,"In 2021, our grants resulted in: >619,000 people reached >4,000 people trained 530+ educational events and convenings 85 resources and platforms created to expand disease awareness and education We view our work through the lens of health equity We see health equity as a critical opportunity to modernize and deepen our patient-centered purpose.","('Access_And_Affordability', 0.6864020824432373)","('Human_Rights_And_Community_Relations', 0.0569116473197937)","('Employee_Engagement_Inclusion_And_Diversity', 0.04347902908921242)","(['Access to Healthcare'], 0.6864020824432373)","('NON-ESG', 0.0569116473197937)","('NON-ESG', 0.04347902908921242)"
Line 312,"By applying a health equity lens across the product life cycle, we can accelerate inclusive innovation and expand the impact of our medicines to support medically underserved and diverse patient populations around the world.","('Access_And_Affordability', 0.9463293552398682)","('Human_Rights_And_Community_Relations', 0.0049155279994010925)","('Critical_Incident_Risk_Management', 0.004618944600224495)","(['Access to Healthcare'], 0.9463293552398682)","('NON-ESG', 0.0049155279994010925)","('NON-ESG', 0.004618944600224495)"
Line 313,2021 ESG REPORT | 23Clinical Trials Clinical trials and research are essential to our work of bringing innovative medicines to patients.,"('Customer_Welfare', 0.21660347282886505)","('Competitive_Behavior', 0.1364424079656601)","('Access_And_Affordability', 0.09411279112100601)","('NON-ESG', 0.21660347282886505)","('NON-ESG', 0.1364424079656601)","('NON-ESG', 0.09411279112100601)"
Line 314,"They afford patients an opportunity for hope, irrespective of their socioeconomic status, geographical region, gender or race.","('Employee_Engagement_Inclusion_And_Diversity', 0.9626854658126831)","('Human_Rights_And_Community_Relations', 0.004708780907094479)","('Labor_Practices', 0.0030451735947281122)","(['Talent Attraction & Retention'], 0.9626854658126831)","('NON-ESG', 0.004708780907094479)","('NON-ESG', 0.0030451735947281122)"
Line 315,The data that we generate from clinical trials helps us answer important scientific questions and evaluate the efficacy and safety of various medicines and treatment options.,"('Product_Quality_And_Safety', 0.494479775428772)","('Selling_Practices_And_Product_Labeling', 0.193502277135849)","('Customer_Welfare', 0.06602152436971664)","('NON-ESG', 0.494479775428772)","('NON-ESG', 0.193502277135849)","('NON-ESG', 0.06602152436971664)"
Line 316,"While accounting for the complexity and length of clinical trials, we design and launch programs to determine product safety and efficacy and meet health authority expectations for new product or indication applications.","('Product_Quality_And_Safety', 0.8036513924598694)","('Selling_Practices_And_Product_Labeling', 0.0462055467069149)","('Customer_Welfare', 0.02617301605641842)","(['Product Quality & Recall Management'], 0.8036513924598694)","('NON-ESG', 0.0462055467069149)","('NON-ESG', 0.02617301605641842)"
Line 317,Diversity in clinical trials Diversity in clinical trials is a key driver of health equity.,"('Employee_Engagement_Inclusion_And_Diversity', 0.964301586151123)","('Employee_Health_And_Safety', 0.0024806594010442495)","('Business_Model_Resilience', 0.0024198107421398163)","(['Talent Attraction & Retention'], 0.964301586151123)","('NON-ESG', 0.0024806594010442495)","('NON-ESG', 0.0024198107421398163)"
Line 318,Clinical trials present opportunities for patients to receive high-quality care while deepening clinicians understanding of the safety and efficacy of exploratory medicines for diverse populations.,"('Product_Quality_And_Safety', 0.45357173681259155)","('Customer_Welfare', 0.14887773990631104)","('Selling_Practices_And_Product_Labeling', 0.12675940990447998)","('NON-ESG', 0.45357173681259155)","('NON-ESG', 0.14887773990631104)","('NON-ESG', 0.12675940990447998)"
Line 319,"Under BMS Diversity in Clinical Trials Commitment, we established the goal to locate 25% of new clinical trials in racially and ethnically diverse areas in the U.","('Employee_Engagement_Inclusion_And_Diversity', 0.975159764289856)","('Employee_Health_And_Safety', 0.00168812635820359)","('Human_Rights_And_Community_Relations', 0.0015858585247769952)","(['Talent Attraction & Retention'], 0.975159764289856)","('NON-ESG', 0.00168812635820359)","('NON-ESG', 0.0015858585247769952)"
Line 320,S.,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 321,Doing so will help us enroll clinical trial populations that are more reflective of broader patient populations and aligned with the epidemiology of the diseases we study.,"('Competitive_Behavior', 0.15488097071647644)","('Access_And_Affordability', 0.14367865025997162)","('Customer_Welfare', 0.13703012466430664)","('NON-ESG', 0.15488097071647644)","('NON-ESG', 0.14367865025997162)","('NON-ESG', 0.13703012466430664)"
Line 322,BMS currently follows six formal Diversity in Clinical Trials workstreams: Protocol Design Patient Support Site and Investigator Support Internal and External Training Communication and Engagement Metrics and MeasurementsInnovating to advance clinical trials Our experience during the COVID-19 pandemic led us to enhance efficiencies in our clinical trials and offer new options that are more convenient for many participants.,"('Access_And_Affordability', 0.20953227579593658)","('Customer_Welfare', 0.1135643720626831)","('Employee_Engagement_Inclusion_And_Diversity', 0.10704508423805237)","('NON-ESG', 0.20953227579593658)","('NON-ESG', 0.1135643720626831)","('NON-ESG', 0.10704508423805237)"
Line 323,"For instance, we began offering remote check-in for patients via telemedicine-streamlined trials and facilitating direct-to-patient shipping for some medications.","('Access_And_Affordability', 0.26541587710380554)","('Customer_Welfare', 0.18095819652080536)","('Competitive_Behavior', 0.06650715321302414)","('NON-ESG', 0.26541587710380554)","('NON-ESG', 0.18095819652080536)","('NON-ESG', 0.06650715321302414)"
Line 324,"These changes, while initially disruptive, are now helping us to accelerate our clinical trial diversity efforts.","('Employee_Engagement_Inclusion_And_Diversity', 0.9496086239814758)","('Business_Model_Resilience', 0.004618441686034203)","('Systemic_Risk_Management', 0.0036081750877201557)","(['Talent Attraction & Retention'], 0.9496086239814758)","('NON-ESG', 0.004618441686034203)","('NON-ESG', 0.0036081750877201557)"
Line 325,"For example, with geography decreasing as a barrier, we are able to accept applicants from a broader patient base.","('Employee_Engagement_Inclusion_And_Diversity', 0.4694679379463196)","('Competitive_Behavior', 0.09353937953710556)","('Access_And_Affordability', 0.08534584939479828)","('NON-ESG', 0.4694679379463196)","('NON-ESG', 0.09353937953710556)","('NON-ESG', 0.08534584939479828)"
Line 326,I&D are essential for better health outcomes for our patients.,"('Access_And_Affordability', 0.6454657912254333)","('Employee_Health_And_Safety', 0.11298702657222748)","('Product_Quality_And_Safety', 0.043636783957481384)","(['Access to Healthcare'], 0.6454657912254333)","('NON-ESG', 0.11298702657222748)","('NON-ESG', 0.043636783957481384)"
Line 327,"In 2021, 54% of our U.","('Management_Of_Legal_And_Regulatory_Framework', 0.36883845925331116)","('Competitive_Behavior', 0.16530922055244446)","('Employee_Engagement_Inclusion_And_Diversity', 0.07517128437757492)","('NON-ESG', 0.36883845925331116)","('NON-ESG', 0.16530922055244446)","('NON-ESG', 0.07517128437757492)"
Line 328,"S. clinical trial sites were located in highly diverse communities, with a goal of making these trials more accessible, diverse and inclusive.","('Employee_Engagement_Inclusion_And_Diversity', 0.9576072692871094)","('Human_Rights_And_Community_Relations', 0.004677223972976208)","('Access_And_Affordability', 0.0032679622527211905)","(['Talent Attraction & Retention'], 0.9576072692871094)","('NON-ESG', 0.004677223972976208)","('NON-ESG', 0.0032679622527211905)"
Line 329,"2021 ESG REPORT | 24Bristol Myers Squibb Foundation* Diversity in Clinical Trials Award Program The Bristol Myers Squibb Foundation, an independent charitable entity, established a program to increase the participation of diverse and underserved patents in clinical trials in the United States.","('Access_And_Affordability', 0.9317447543144226)","('Product_Quality_And_Safety', 0.0071187131106853485)","('Customer_Welfare', 0.004664645064622164)","(['Access to Healthcare'], 0.9317447543144226)","('NON-ESG', 0.0071187131106853485)","('NON-ESG', 0.004664645064622164)"
Line 330,"The program, called the Robert A.","('Management_Of_Legal_And_Regulatory_Framework', 0.3793364465236664)","('Access_And_Affordability', 0.09260226786136627)","('Ecological_Impacts', 0.05697634443640709)","('NON-ESG', 0.3793364465236664)","('NON-ESG', 0.09260226786136627)","('NON-ESG', 0.05697634443640709)"
Line 331,"Winn Diversity in Clinical Trials Award Program, is administered in partnership with the Virginia Commonwealth University and the American Association for Cancer Research.","('Employee_Engagement_Inclusion_And_Diversity', 0.7791121006011963)","('Access_And_Affordability', 0.04509023576974869)","('Customer_Welfare', 0.019374186173081398)","(['Talent Attraction & Retention'], 0.7791121006011963)","('NON-ESG', 0.04509023576974869)","('NON-ESG', 0.019374186173081398)"
Line 332,"Through a five-year, $100+ million investment, the groundbreaking program will develop and train community-oriented clinical trial investigators.","('Access_And_Affordability', 0.4109984338283539)","('Customer_Welfare', 0.06968533247709274)","('Competitive_Behavior', 0.06231037154793739)","('NON-ESG', 0.4109984338283539)","('NON-ESG', 0.06968533247709274)","('NON-ESG', 0.06231037154793739)"
Line 333,"Participants will gain the knowledge, skills and competencies needed to administer best-in-class clinical trials, while also learning to engage effectively with diverse communities to foster active participation.","('Employee_Engagement_Inclusion_And_Diversity', 0.9010728597640991)","('Human_Rights_And_Community_Relations', 0.014279126189649105)","('Access_And_Affordability', 0.012695146724581718)","(['Talent Attraction & Retention'], 0.9010728597640991)","('NON-ESG', 0.014279126189649105)","('NON-ESG', 0.012695146724581718)"
Line 334,The program has two awards: the Robert A.,"('Management_Of_Legal_And_Regulatory_Framework', 0.3990185260772705)","('Ecological_Impacts', 0.07950970530509949)","('Business_Ethics', 0.05908936634659767)","('NON-ESG', 0.3990185260772705)","('NON-ESG', 0.07950970530509949)","('NON-ESG', 0.05908936634659767)"
Line 335,"Winn Career Development Award (Winn CDA) for mid-career investigator physicians, and the Robert A.","('Employee_Engagement_Inclusion_And_Diversity', 0.4703627824783325)","('Access_And_Affordability', 0.04579879343509674)","('Employee_Health_And_Safety', 0.044625721871852875)","('NON-ESG', 0.4703627824783325)","('NON-ESG', 0.04579879343509674)","('NON-ESG', 0.044625721871852875)"
Line 336,Winn Clinical Investigator Pathway Program for medical students from groups underrepresented in medicine (Winn CIPP).,"('Access_And_Affordability', 0.37807461619377136)","('Employee_Engagement_Inclusion_And_Diversity', 0.19037917256355286)","('Customer_Welfare', 0.04606654495000839)","('NON-ESG', 0.37807461619377136)","('NON-ESG', 0.19037917256355286)","('NON-ESG', 0.04606654495000839)"
Line 337,The Winn CIPP provides URM medical students a summer immersion experience in community-based clinical research in select cities with a high disease burden.,"('Access_And_Affordability', 0.5917348861694336)","('Customer_Welfare', 0.0487794354557991)","('Product_Quality_And_Safety', 0.033895693719387054)","(['Access to Healthcare'], 0.5917348861694336)","('NON-ESG', 0.0487794354557991)","('NON-ESG', 0.033895693719387054)"
Line 338,"In October 2021, the program announced the first cohort of participating scholars52 physicians working at a broad range of healthcare institutions in 22 states across the U.","('Access_And_Affordability', 0.35461941361427307)","('Employee_Engagement_Inclusion_And_Diversity', 0.18689709901809692)","('Customer_Welfare', 0.04931941628456116)","('NON-ESG', 0.35461941361427307)","('NON-ESG', 0.18689709901809692)","('NON-ESG', 0.04931941628456116)"
Line 339,"S. An independent committee selected the cohort, which represents a diverse cross-section of races and ethnicities.","('Employee_Engagement_Inclusion_And_Diversity', 0.9736260175704956)","('Human_Rights_And_Community_Relations', 0.0019222775008529425)","('Customer_Privacy', 0.0015720009105280042)","(['Talent Attraction & Retention'], 0.9736260175704956)","('NON-ESG', 0.0019222775008529425)","('NON-ESG', 0.0015720009105280042)"
Line 340,"Together, the scholars bring a range of perspectives and experiences to the program, as well as to their therapeutic focus areas of cancer (hematologic or solid tumors), immunologic disorders and cardiovascular diseases.","('Access_And_Affordability', 0.17570431530475616)","('Customer_Welfare', 0.11083141714334488)","('Employee_Engagement_Inclusion_And_Diversity', 0.08896797895431519)","('NON-ESG', 0.17570431530475616)","('NON-ESG', 0.11083141714334488)","('NON-ESG', 0.08896797895431519)"
Line 341,"* Bristol Myers Squibb is the primary donor to the Bristol Myers Squibb Foundation, anindependent charitable entity.","('Management_Of_Legal_And_Regulatory_Framework', 0.41902047395706177)","('Customer_Welfare', 0.08875807374715805)","('Selling_Practices_And_Product_Labeling', 0.061592619866132736)","('NON-ESG', 0.41902047395706177)","('NON-ESG', 0.08875807374715805)","('NON-ESG', 0.061592619866132736)"
Line 342,Participating healthcare institutions locations Self-reported scholar demographicsETHNICIT Y GENDER DEGRE E SPECIAL TY%36.5 % Other identity * (14)Latino/Hispanic (19) Black/Afric an Americ an (19) 35%65% 0%Other (0)Male (18)Female (34)8%92% 27%M.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9719958305358887)","('Customer_Privacy', 0.001959078712388873)","('Business_Model_Resilience', 0.0016934220911934972)","(['Talent Attraction & Retention'], 0.9719958305358887)","('NON-ESG', 0.001959078712388873)","('NON-ESG', 0.0016934220911934972)"
Line 343,D./Ph.D .,"('Access_And_Affordability', 0.26608750224113464)","('Ecological_Impacts', 0.11086950451135635)","('Management_Of_Legal_And_Regulatory_Framework', 0.0877663642168045)","('NON-ESG', 0.26608750224113464)","('NON-ESG', 0.11086950451135635)","('NON-ESG', 0.0877663642168045)"
Line 344,(4)M.,"('Access_And_Affordability', 0.10276157408952713)","('GHG_Emissions', 0.0911773070693016)","('Competitive_Behavior', 0.08434141427278519)","('NON-ESG', 0.10276157408952713)","('NON-ESG', 0.0911773070693016)","('NON-ESG', 0.08434141427278519)"
Line 345,D.,"('Employee_Engagement_Inclusion_And_Diversity', 0.11258140206336975)","('Management_Of_Legal_And_Regulatory_Framework', 0.08865229040384293)","('Access_And_Affordability', 0.06962209194898605)","('NON-ESG', 0.11258140206336975)","('NON-ESG', 0.08865229040384293)","('NON-ESG', 0.06962209194898605)"
Line 346,"(48) 12%67% Immunologic Disor ders (6) 12%Cancer Hemat olog y (6) 10%Cardiovascular Disease (5)Cancer Onc olog y (35)*Other Identity (not NSF-Dened Underrepresented in Medicine) = Asian (1), Caucasian (5), Middle Eastern (1 ), South Asian (6), W est Asian (1).","('Employee_Engagement_Inclusion_And_Diversity', 0.9290348887443542)","('Business_Model_Resilience', 0.007861674763262272)","('Customer_Privacy', 0.005577444564551115)","(['Talent Attraction & Retention'], 0.9290348887443542)","('NON-ESG', 0.007861674763262272)","('NON-ESG', 0.005577444564551115)"
Line 347,"36.5 Self-reported scholar demographics Black/African American (19)36.5% Latino/Hispanic (19)36.5%Other Identity* (14)27%Ethnicity * Other Identity (not NSF-Defined Underrepresented in Medicine) = Asian (1), Caucasian (5), Middle Eastern (1), South Asian (6), West Asian (1).8% M.","('Employee_Engagement_Inclusion_And_Diversity', 0.9705080986022949)","('Customer_Privacy', 0.0026343506760895252)","('Business_Model_Resilience', 0.0020058569498360157)","(['Talent Attraction & Retention'], 0.9705080986022949)","('NON-ESG', 0.0026343506760895252)","('NON-ESG', 0.0020058569498360157)"
Line 348,D./Ph.D.,"('Access_And_Affordability', 0.26608750224113464)","('Ecological_Impacts', 0.11086950451135635)","('Management_Of_Legal_And_Regulatory_Framework', 0.0877663642168045)","('NON-ESG', 0.26608750224113464)","('NON-ESG', 0.11086950451135635)","('NON-ESG', 0.0877663642168045)"
Line 349,(4) 92% M.,"('GHG_Emissions', 0.2061784416437149)","('Energy_Management', 0.14774717390537262)","('Management_Of_Legal_And_Regulatory_Framework', 0.08524540811777115)","('NON-ESG', 0.2061784416437149)","('NON-ESG', 0.14774717390537262)","('NON-ESG', 0.08524540811777115)"
Line 350,D.,"('Employee_Engagement_Inclusion_And_Diversity', 0.11258140206336975)","('Management_Of_Legal_And_Regulatory_Framework', 0.08865229040384293)","('Access_And_Affordability', 0.06962209194898605)","('NON-ESG', 0.11258140206336975)","('NON-ESG', 0.08865229040384293)","('NON-ESG', 0.06962209194898605)"
Line 351,(48)Degree 35% Male (18) 65% Female (34)Gender 67% Cancer Oncology (35)12% Immunologic Disorders (6)12% Cancer Hematology (6)10% Cardiovascular Disease (5)Specialty 2021 ESG REPORT | 25Access to Healthcare Expanding access to healthcare is one of the most important steps to helping communities thrive.,"('Access_And_Affordability', 0.7387584447860718)","('Employee_Engagement_Inclusion_And_Diversity', 0.040468644350767136)","('Customer_Welfare', 0.028177980333566666)","(['Access to Healthcare'], 0.7387584447860718)","('NON-ESG', 0.040468644350767136)","('NON-ESG', 0.028177980333566666)"
Line 352,"At BMS, we remain wholly committed to facilitating broader healthcare access to help more patients prevail over serious diseases and live fuller, healthier and longer lives.","('Access_And_Affordability', 0.8544737696647644)","('Employee_Health_And_Safety', 0.022640036419034004)","('Product_Quality_And_Safety', 0.017078543081879616)","(['Access to Healthcare'], 0.8544737696647644)","('NON-ESG', 0.022640036419034004)","('NON-ESG', 0.017078543081879616)"
Line 353,"Our product portfolio includes truly differentiated medicinesmedicines that have improved patient outcomes, saved peoples lives and elevated the standard of care.","('Product_Design_And_Lifecycle_Management', 0.3043676018714905)","('Customer_Welfare', 0.2664053738117218)","('Selling_Practices_And_Product_Labeling', 0.07645802944898605)","('NON-ESG', 0.3043676018714905)","('NON-ESG', 0.2664053738117218)","('NON-ESG', 0.07645802944898605)"
Line 354,"We advocate for healthcare policies and infrastructure that are both sustainable and patient-centered, and we continue to advocate for improved access for vulnerable patients through our partnerships and demonstration projects.","('Access_And_Affordability', 0.9155261516571045)","('Human_Rights_And_Community_Relations', 0.011369624175131321)","('Critical_Incident_Risk_Management', 0.0074620796367526054)","(['Access to Healthcare'], 0.9155261516571045)","('NON-ESG', 0.011369624175131321)","('NON-ESG', 0.0074620796367526054)"
Line 355,"In 2021, we increased transparency on this important topic by publishing the BMS Global Access Report , which outlines our efforts, as well as our partnerships with stakeholders, to advance global healthcare access and health equity.","('Access_And_Affordability', 0.8552098274230957)","('Product_Quality_And_Safety', 0.01703869365155697)","('Human_Rights_And_Community_Relations', 0.015371602028608322)","(['Access to Healthcare'], 0.8552098274230957)","('NON-ESG', 0.01703869365155697)","('NON-ESG', 0.015371602028608322)"
Line 356,"This report publicly discloses commitments, measurable goals, objectives and sustainability targets, including enhancing patient access to medicines.","('Access_And_Affordability', 0.7902758121490479)","('Selling_Practices_And_Product_Labeling', 0.028663111850619316)","('Customer_Welfare', 0.024677908048033714)","(['Access to Healthcare'], 0.7902758121490479)","('NON-ESG', 0.028663111850619316)","('NON-ESG', 0.024677908048033714)"
Line 357,It facilitates accountability and transparency by consistently sharing the outcomes of our access-to-medicine activities in a centralized manner.,"('Business_Ethics', 0.943924605846405)","('Management_Of_Legal_And_Regulatory_Framework', 0.01365477405488491)","('Data_Security', 0.004192294552922249)","(['Business Ethics'], 0.943924605846405)","('NON-ESG', 0.01365477405488491)","('NON-ESG', 0.004192294552922249)"
Line 358,"Highlights Advancing healthcare capacity & infrastructure >31,000 participants from 148 countries & 300 advocacy organizations have visited the Advocacy Exchange, the largest cross-disease, cross-cultural knowledge exchange platform of its kind, co-launched in 2020 by BMS and GRYT Health.","('Access_And_Affordability', 0.43775686621665955)","('Human_Rights_And_Community_Relations', 0.09598362445831299)","('Management_Of_Legal_And_Regulatory_Framework', 0.09358835965394974)","('NON-ESG', 0.43775686621665955)","('NON-ESG', 0.09598362445831299)","('NON-ESG', 0.09358835965394974)"
Line 359,"100,000 healthcare professionals in Africa, Asia and Latin America: With BMS support, the Ecancer Global Foundation is planning oncology educational events and state- of-the-art e-learning courses in multiple languages, focusing on clinical decision making for patients with cancer.2,000 healthcare professionals involved & now >61,000 followers of the first Facebook page dedicated to Black/African Americans affected by Multiple Myeloma: The Standing in the Gaap initiative increases awareness about how Multiple Myeloma affects Black/African Americans differently.","('Employee_Engagement_Inclusion_And_Diversity', 0.36989471316337585)","('Access_And_Affordability', 0.34350842237472534)","('Employee_Health_And_Safety', 0.05998697131872177)","('NON-ESG', 0.36989471316337585)","('NON-ESG', 0.34350842237472534)","('NON-ESG', 0.05998697131872177)"
Line 360,"100,000 healthcare professionals in Africa, Asia and Latin America: With BMS support, the Ecancer Global Foundation is planning oncology educational events and state- of-the-art e-learning courses in multiple languages, focusing on clinical decision making for patients with cancer.2,000 healthcare professionals involved & now >61,000 followers of the first Facebook page dedicated to Black/African Americans affected by Multiple Myeloma: The Standing in the Gaap initiative increases awareness about how Multiple Myeloma affects Black/African Americans differently.","('Employee_Engagement_Inclusion_And_Diversity', 0.9494584798812866)","('Human_Rights_And_Community_Relations', 0.004545693285763264)","('Access_And_Affordability', 0.0036169004160910845)","(['Talent Attraction & Retention'], 0.9494584798812866)","('NON-ESG', 0.004545693285763264)","('NON-ESG', 0.0036169004160910845)"
Line 361,"14,000 expected participants across Africa and India Oncology knowledge repository for healthcare professionals by the King Baudouin Foundation with BMS support.>200 patient outreach programs, >150 healthcare professionals trained by world-leading cancer centers and societies through the Cancer Care Links program, to address cancer care capacity building in resource-constrained countries.","('Access_And_Affordability', 0.7321259379386902)","('Customer_Welfare', 0.03489123657345772)","('Employee_Health_And_Safety', 0.024444114416837692)","(['Access to Healthcare'], 0.7321259379386902)","('NON-ESG', 0.03489123657345772)","('NON-ESG', 0.024444114416837692)"
Line 362,"Expanding access to our medicines BMS is committed to providing access to its prescription medicines, including for underserved communities.","('Access_And_Affordability', 0.9439741969108582)","('Product_Quality_And_Safety', 0.005160669330507517)","('Critical_Incident_Risk_Management', 0.0049772909842431545)","(['Access to Healthcare'], 0.9439741969108582)","('NON-ESG', 0.005160669330507517)","('NON-ESG', 0.0049772909842431545)"
Line 363,>$704M product donations in U.,"('Management_Of_Legal_And_Regulatory_Framework', 0.7918363213539124)","('Business_Ethics', 0.01990356855094433)","('GHG_Emissions', 0.01906522363424301)","([], 0.7918363213539124)","('NON-ESG', 0.01990356855094433)","('NON-ESG', 0.01906522363424301)"
Line 364,S. through the independent BMS Patient Assistance Foundation.,"('Access_And_Affordability', 0.8213900923728943)","('Critical_Incident_Risk_Management', 0.030444389209151268)","('Employee_Health_And_Safety', 0.016623878851532936)","(['Access to Healthcare'], 0.8213900923728943)","('NON-ESG', 0.030444389209151268)","('NON-ESG', 0.016623878851532936)"
Line 365,122 countries 26M packs 2.1M patient years of treatmentBMS agreement with the Medicine Patent Pool (MPP) allows for generic manufacturing of the HIV product atazanavir.143 countries 1.2M patient years of treatmentBMS agreement with the Medicine Patent Pool (MPP) allows for generic manufacturing of the HepatitisC product daclatasvir.,"('Competitive_Behavior', 0.8835220336914062)","('Management_Of_Legal_And_Regulatory_Framework', 0.014121757820248604)","('Customer_Welfare', 0.013236567378044128)","([], 0.8835220336914062)","('NON-ESG', 0.014121757820248604)","('NON-ESG', 0.013236567378044128)"
Line 366,"2021 ESG REPORT | 26Our People IN THIS SECTION Global Inclusion and Diversity Accelerated Leadership Development and Advancement Employee Health andWellbeing Employee Health andSafety Learning and Development Supply Chain 2021 ESG REPORT | 27Our People We do our best work when our colleagues feel supported, included and inspired.","('Employee_Engagement_Inclusion_And_Diversity', 0.9693610072135925)","('Employee_Health_And_Safety', 0.002991512417793274)","('Human_Rights_And_Community_Relations', 0.0027585753705352545)","(['Talent Attraction & Retention'], 0.9693610072135925)","('NON-ESG', 0.002991512417793274)","('NON-ESG', 0.0027585753705352545)"
Line 367,"We lead with our Value of Inclusion to advance a workplace where our more than 32,000 employees feel they belong, and their unique perspectives are valued and rewarded.","('Employee_Engagement_Inclusion_And_Diversity', 0.9613543748855591)","('Human_Rights_And_Community_Relations', 0.00459655188024044)","('Employee_Health_And_Safety', 0.003445887239649892)","(['Talent Attraction & Retention'], 0.9613543748855591)","('NON-ESG', 0.00459655188024044)","('NON-ESG', 0.003445887239649892)"
Line 368,"We're also building a global workforce that reflects the diverse cultures, backgrounds and experiences of our patients and communities globally.","('Employee_Engagement_Inclusion_And_Diversity', 0.9675922989845276)","('Human_Rights_And_Community_Relations', 0.004858397413045168)","('Employee_Health_And_Safety', 0.0029954463243484497)","(['Talent Attraction & Retention'], 0.9675922989845276)","('NON-ESG', 0.004858397413045168)","('NON-ESG', 0.0029954463243484497)"
Line 369,We prioritize their wellbeing and encourage them toshow up authentically as they continue to learn and evolve.,"('Human_Rights_And_Community_Relations', 0.18664923310279846)","('Employee_Health_And_Safety', 0.18003691732883453)","('Access_And_Affordability', 0.15775515139102936)","('NON-ESG', 0.18664923310279846)","('NON-ESG', 0.18003691732883453)","('NON-ESG', 0.15775515139102936)"
Line 370,"By supporting our people, we strengthen our companys foundationunleashing our collective ability to realize the promise and power of science for all.","('Human_Rights_And_Community_Relations', 0.3046005070209503)","('Access_And_Affordability', 0.12341601401567459)","('Employee_Engagement_Inclusion_And_Diversity', 0.09279787540435791)","('NON-ESG', 0.3046005070209503)","('NON-ESG', 0.12341601401567459)","('NON-ESG', 0.09279787540435791)"
Line 371,Our success is a collective effort in which we share knowledge and local expertise to better understand and meet the unique needs of various regions and patients.,"('Access_And_Affordability', 0.3276480734348297)","('Human_Rights_And_Community_Relations', 0.14503498375415802)","('Employee_Engagement_Inclusion_And_Diversity', 0.13513341546058655)","('NON-ESG', 0.3276480734348297)","('NON-ESG', 0.14503498375415802)","('NON-ESG', 0.13513341546058655)"
Line 372,We seek partnerships and providers who share our companys ideals and are inspired by our purpose.,"('Human_Rights_And_Community_Relations', 0.22905869781970978)","('Business_Model_Resilience', 0.13755035400390625)","('Employee_Engagement_Inclusion_And_Diversity', 0.08765880018472672)","('NON-ESG', 0.22905869781970978)","('NON-ESG', 0.13755035400390625)","('NON-ESG', 0.08765880018472672)"
Line 373,"Our partner and supplier networks are integral to enhancing BMS geographic reach, focused technical capabilities and network flexibility.","('Supply_Chain_Management', 0.926758348941803)","('Business_Model_Resilience', 0.010137394070625305)","('Systemic_Risk_Management', 0.005771897733211517)","([], 0.926758348941803)","('NON-ESG', 0.010137394070625305)","('NON-ESG', 0.005771897733211517)"
Line 374,>32K employees worldwide >12.2K members of our eight People and Business Resource Groups representing 44 countries 2021 ESG REPORT | 28Global Inclusion and Diversity We are guided by a single vision to transform patients lives through science.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9750564098358154)","('Employee_Health_And_Safety', 0.0020889039151370525)","('Human_Rights_And_Community_Relations', 0.0019304468296468258)","(['Talent Attraction & Retention'], 0.9750564098358154)","('NON-ESG', 0.0020889039151370525)","('NON-ESG', 0.0019304468296468258)"
Line 375,"To fully realize this vision, we have relied on the strength of our rich history and longstanding commitment to inclusion and diversity to ensure that we can drive meaningful impact and outcomes for our patients and communities, our colleagues, and our business and industry.","('Employee_Engagement_Inclusion_And_Diversity', 0.9742124080657959)","('Human_Rights_And_Community_Relations', 0.0021744687110185623)","('Employee_Health_And_Safety', 0.0021248934790492058)","(['Talent Attraction & Retention'], 0.9742124080657959)","('NON-ESG', 0.0021744687110185623)","('NON-ESG', 0.0021248934790492058)"
Line 376,Doing so helps us drive equitable advancements and outcomes for all.,"('Human_Rights_And_Community_Relations', 0.2834516167640686)","('Employee_Engagement_Inclusion_And_Diversity', 0.2035769373178482)","('Access_And_Affordability', 0.12648437917232513)","('NON-ESG', 0.2834516167640686)","('NON-ESG', 0.2035769373178482)","('NON-ESG', 0.12648437917232513)"
Line 377,Our evolved Global Inclusion & Diversity (GI&D) strategy and priorities are the first steps on the path forward to meaningful change.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9717676043510437)","('Human_Rights_And_Community_Relations', 0.0029113157652318478)","('Employee_Health_And_Safety', 0.0022010980173945427)","(['Talent Attraction & Retention'], 0.9717676043510437)","('NON-ESG', 0.0029113157652318478)","('NON-ESG', 0.0022010980173945427)"
Line 378,"This strategy, along with workforce representation data, isdetailed in our Global Inclusion & Diversity Report .","('Employee_Engagement_Inclusion_And_Diversity', 0.9757823944091797)","('Employee_Health_And_Safety', 0.0019608871079981327)","('Human_Rights_And_Community_Relations', 0.0016036882298067212)","(['Talent Attraction & Retention'], 0.9757823944091797)","('NON-ESG', 0.0019608871079981327)","('NON-ESG', 0.0016036882298067212)"
Line 379,Workforce representation Harnessing the collective power of a globally diverse workforce requires transparency and accountability.,"('Employee_Engagement_Inclusion_And_Diversity', 0.8570846319198608)","('Labor_Practices', 0.05589400231838226)","('Business_Ethics', 0.013352210633456707)","(['Talent Attraction & Retention'], 0.8570846319198608)","('NON-ESG', 0.05589400231838226)","('NON-ESG', 0.013352210633456707)"
Line 380,"Working from that premise, we leverage best practices in talent management, accelerated leadership development and inclusive leadership to create an environment where every individual with the skills our company requires can succeed.","('Employee_Engagement_Inclusion_And_Diversity', 0.9325588941574097)","('Human_Rights_And_Community_Relations', 0.00645610224455595)","('Employee_Health_And_Safety', 0.005967758595943451)","(['Talent Attraction & Retention'], 0.9325588941574097)","('NON-ESG', 0.00645610224455595)","('NON-ESG', 0.005967758595943451)"
Line 381,Workforce aspirational representation goals We value an executive team that reflects the perspectives and backgrounds of the patients and communities we serve.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9684498310089111)","('Human_Rights_And_Community_Relations', 0.0035768337547779083)","('Employee_Health_And_Safety', 0.0031872126273810863)","(['Talent Attraction & Retention'], 0.9684498310089111)","('NON-ESG', 0.0035768337547779083)","('NON-ESG', 0.0031872126273810863)"
Line 382,"In 2020, we made a series of commitments to advance I&D and health equityboth in our own business and in communities around the world.","('Access_And_Affordability', 0.44072282314300537)","('Human_Rights_And_Community_Relations', 0.17918720841407776)","('Employee_Engagement_Inclusion_And_Diversity', 0.05042112246155739)","('NON-ESG', 0.44072282314300537)","('NON-ESG', 0.17918720841407776)","('NON-ESG', 0.05042112246155739)"
Line 383,Our stated aspirations were to achieve gender parity at the executive level globally; double executive representation of Black/African American employees in the U.,"('Employee_Engagement_Inclusion_And_Diversity', 0.96292644739151)","('Labor_Practices', 0.006969335023313761)","('Employee_Health_And_Safety', 0.0022354796528816223)","(['Talent Attraction & Retention'], 0.96292644739151)","('NON-ESG', 0.006969335023313761)","('NON-ESG', 0.0022354796528816223)"
Line 384,S.; and double executive representation of Hispanic/Latino employees in the U.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9727018475532532)","('Labor_Practices', 0.0025800480507314205)","('Human_Rights_And_Community_Relations', 0.0016821210738271475)","(['Talent Attraction & Retention'], 0.9727018475532532)","('NON-ESG', 0.0025800480507314205)","('NON-ESG', 0.0016821210738271475)"
Line 385,S. by 2022.,"('Management_Of_Legal_And_Regulatory_Framework', 0.2747751474380493)","('Business_Model_Resilience', 0.11191561818122864)","('Physical_Impacts_Of_Climate_Change', 0.08405859768390656)","('NON-ESG', 0.2747751474380493)","('NON-ESG', 0.11191561818122864)","('NON-ESG', 0.08405859768390656)"
Line 386,We have made progress toward each of these aspirational goals in 2021: 45.5% global executives were women in 2021 vs. 42.6% in 2020 4.5% of U.,"('Employee_Engagement_Inclusion_And_Diversity', 0.3197912573814392)","('Business_Model_Resilience', 0.22982804477214813)","('Director_Removal', 0.0676284208893776)","('NON-ESG', 0.3197912573814392)","('NON-ESG', 0.22982804477214813)","('NON-ESG', 0.0676284208893776)"
Line 387,S. executives were Black/African American in 2021 vs. 2.4% in 2020 7.2% of U.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9593811631202698)","('Labor_Practices', 0.00410329457372427)","('Human_Rights_And_Community_Relations', 0.002565430011600256)","(['Talent Attraction & Retention'], 0.9593811631202698)","('NON-ESG', 0.00410329457372427)","('NON-ESG', 0.002565430011600256)"
Line 388,"S. executives were Hispanic/Latino in 2021 vs. 4.2% in 2020Veteran, people with disabilities and LGBTQ+ status self-identification: Everybody Counts In the U.","('Employee_Engagement_Inclusion_And_Diversity', 0.973524808883667)","('Human_Rights_And_Community_Relations', 0.0017759299371391535)","('Customer_Privacy', 0.0017278343439102173)","(['Talent Attraction & Retention'], 0.973524808883667)","('NON-ESG', 0.0017759299371391535)","('NON-ESG', 0.0017278343439102173)"
Line 389,"S. and Puerto Rico, employees can disclose their veteran status, disability status and LGBTQ+ status in our Human Resources system of record.","('Employee_Engagement_Inclusion_And_Diversity', 0.9489337801933289)","('Employee_Health_And_Safety', 0.011241232976317406)","('Labor_Practices', 0.005958672612905502)","(['Talent Attraction & Retention'], 0.9489337801933289)","('NON-ESG', 0.011241232976317406)","('NON-ESG', 0.005958672612905502)"
Line 390,"Through Everybody Counts, an amplified self- identification program that includes leader messages and employee videos, we are seeing an increased number of employees who voluntarily participate in this disclosure.","('Employee_Engagement_Inclusion_And_Diversity', 0.45586737990379333)","('Customer_Privacy', 0.22976788878440857)","('Employee_Health_And_Safety', 0.07543168216943741)","('NON-ESG', 0.45586737990379333)","('NON-ESG', 0.22976788878440857)","('NON-ESG', 0.07543168216943741)"
Line 391,"For example, from 2019 to 2021, the percentage of employees who disclosed their disability status grew from 36.7% to 44.4%an increase of 7.7%.","('Employee_Engagement_Inclusion_And_Diversity', 0.8039692044258118)","('Employee_Health_And_Safety', 0.10940345376729965)","('Labor_Practices', 0.0177810899913311)","(['Talent Attraction & Retention'], 0.8039692044258118)","('NON-ESG', 0.10940345376729965)","('NON-ESG', 0.0177810899913311)"
Line 392,"In addition, the percentage of employees who disclosed their gender identification and sexual orientation status grew from 6.4% to 14.8%an increase of 8.4%.","('Employee_Engagement_Inclusion_And_Diversity', 0.9690201878547668)","('Employee_Health_And_Safety', 0.0034404483158141375)","('Labor_Practices', 0.003031057072803378)","(['Talent Attraction & Retention'], 0.9690201878547668)","('NON-ESG', 0.0034404483158141375)","('NON-ESG', 0.003031057072803378)"
Line 393,These results indicate that we are creating an environment of trust and psychological safety where employees feel they can disclose the full spectrum of their identity at BMS.,"('Employee_Health_And_Safety', 0.6660594344139099)","('Customer_Privacy', 0.0828884020447731)","('Employee_Engagement_Inclusion_And_Diversity', 0.08232028037309647)","(['Health Outcome Contribution'], 0.6660594344139099)","('NON-ESG', 0.0828884020447731)","('NON-ESG', 0.08232028037309647)"
Line 394,Our People and Business Resource Groups BMS is committed to sustaining a culture of inclusion.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9579272270202637)","('Human_Rights_And_Community_Relations', 0.007976592518389225)","('Employee_Health_And_Safety', 0.003948747180402279)","(['Talent Attraction & Retention'], 0.9579272270202637)","('NON-ESG', 0.007976592518389225)","('NON-ESG', 0.003948747180402279)"
Line 395,We know that our patient-focused mission and business objectives rely on bringing together and supporting diverse people with unique experiences and perspectives.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9142111539840698)","('Human_Rights_And_Community_Relations', 0.017614226788282394)","('Access_And_Affordability', 0.010935957543551922)","(['Talent Attraction & Retention'], 0.9142111539840698)","('NON-ESG', 0.017614226788282394)","('NON-ESG', 0.010935957543551922)"
Line 396,Our People and Business Resource Groups (PBRGs) help us meet this commitment in a way that directly impacts our business performance.,"('Business_Model_Resilience', 0.49753013253211975)","('Human_Rights_And_Community_Relations', 0.14404356479644775)","('Product_Design_And_Lifecycle_Management', 0.04515083134174347)","('NON-ESG', 0.49753013253211975)","('NON-ESG', 0.14404356479644775)","('NON-ESG', 0.04515083134174347)"
Line 397,Each of our eight PBRGs is integrated into the business and led by a full-time business leader who reports directly to members of our Leadership Team.,"('Director_Removal', 0.29583001136779785)","('Business_Model_Resilience', 0.23777399957180023)","('Employee_Engagement_Inclusion_And_Diversity', 0.13270848989486694)","('NON-ESG', 0.29583001136779785)","('NON-ESG', 0.23777399957180023)","('NON-ESG', 0.13270848989486694)"
Line 398,"They serve as a trusted advisory group, providing critical support on key business initiatives while amplifying the voice of our workforce and fueling innovation through diverse insights andknowledge.","('Employee_Engagement_Inclusion_And_Diversity', 0.6430542469024658)","('Business_Model_Resilience', 0.11031842231750488)","('Human_Rights_And_Community_Relations', 0.028305796906352043)","(['Talent Attraction & Retention'], 0.6430542469024658)","('NON-ESG', 0.11031842231750488)","('NON-ESG', 0.028305796906352043)"
Line 399,"Our PBRGs accelerate the development of many members, empowering them to become business leaders who add value by helping to execute BMS business plans.","('Business_Model_Resilience', 0.7893954515457153)","('Systemic_Risk_Management', 0.028628600761294365)","('Product_Design_And_Lifecycle_Management', 0.020544536411762238)","(['Human Capital Development', 'Innovation Management'], 0.7893954515457153)","('NON-ESG', 0.028628600761294365)","('NON-ESG', 0.020544536411762238)"
Line 400,PBRGs also offer opportunities to closely collaborate with our Diversity in Clinical Trials and Health Equity teams.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9517396688461304)","('Customer_Welfare', 0.004045807756483555)","('Employee_Health_And_Safety', 0.0035634066443890333)","(['Talent Attraction & Retention'], 0.9517396688461304)","('NON-ESG', 0.004045807756483555)","('NON-ESG', 0.0035634066443890333)"
Line 401,"In 2021, our PBRGswhich are open to our entire global workforcegrew to include more than 12,200 unique members serving across more than 200 chapters in 44 countries.","('Employee_Engagement_Inclusion_And_Diversity', 0.8136029243469238)","('Director_Removal', 0.028115620836615562)","('Business_Model_Resilience', 0.026489276438951492)","(['Talent Attraction & Retention'], 0.8136029243469238)","('NON-ESG', 0.028115620836615562)","('NON-ESG', 0.026489276438951492)"
Line 402,Nearly 40% of our employees worldwide are members of PBRGs.,"('Director_Removal', 0.2847149670124054)","('Employee_Engagement_Inclusion_And_Diversity', 0.11815766990184784)","('Labor_Practices', 0.07874356210231781)","('NON-ESG', 0.2847149670124054)","('NON-ESG', 0.11815766990184784)","('NON-ESG', 0.07874356210231781)"
Line 403,Visit the 2021 Global Inclusion & Diversity Report for more information.,"('Employee_Engagement_Inclusion_And_Diversity', 0.973058819770813)","('Human_Rights_And_Community_Relations', 0.0023424250539392233)","('Employee_Health_And_Safety', 0.002259072382003069)","(['Talent Attraction & Retention'], 0.973058819770813)","('NON-ESG', 0.0023424250539392233)","('NON-ESG', 0.002259072382003069)"
Line 404,2021 ESG REPORT | 29Accelerated Leadership Development and Advancement We have enhanced our longstanding investments in accelerated leadership development and have developed unique and relevant content for women globally and for underrepresented racial and ethnic groups in the U.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9737538695335388)","('Human_Rights_And_Community_Relations', 0.002444666577503085)","('Employee_Health_And_Safety', 0.0018749270820990205)","(['Talent Attraction & Retention'], 0.9737538695335388)","('NON-ESG', 0.002444666577503085)","('NON-ESG', 0.0018749270820990205)"
Line 405,S.,"('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 406,These initiatives include creating differentiated development opportunities and development plans that prepare our leaders for future global challenges.,"('Human_Rights_And_Community_Relations', 0.30806803703308105)","('Business_Model_Resilience', 0.28423672914505005)","('Systemic_Risk_Management', 0.056694962084293365)","('NON-ESG', 0.30806803703308105)","('NON-ESG', 0.28423672914505005)","('NON-ESG', 0.056694962084293365)"
Line 407,"Our Global Inclusion & Diversity focus plays a key role in our global reputation as an employer of choice among top, diverse talent in science, technology, engineering, and math (STEM).","('Employee_Engagement_Inclusion_And_Diversity', 0.9761374592781067)","('Employee_Health_And_Safety', 0.0021947554778307676)","('Human_Rights_And_Community_Relations', 0.0014281512703746557)","(['Talent Attraction & Retention'], 0.9761374592781067)","('NON-ESG', 0.0021947554778307676)","('NON-ESG', 0.0014281512703746557)"
Line 408,But our commitment to STEM goes far beyond developing future employees for our business.,"('Business_Model_Resilience', 0.2870855927467346)","('Product_Design_And_Lifecycle_Management', 0.157174751162529)","('Human_Rights_And_Community_Relations', 0.13696064054965973)","('NON-ESG', 0.2870855927467346)","('NON-ESG', 0.157174751162529)","('NON-ESG', 0.13696064054965973)"
Line 409,We support STEM because we believe in the power of science and its ability to do good for our society.,"('Management_Of_Legal_And_Regulatory_Framework', 0.3741466701030731)","('Human_Rights_And_Community_Relations', 0.10580472648143768)","('Access_And_Affordability', 0.09937901794910431)","('NON-ESG', 0.3741466701030731)","('NON-ESG', 0.10580472648143768)","('NON-ESG', 0.09937901794910431)"
Line 410,"We leverage a broad suite of programs to identify and develop future talent Insights for Success Our Insights for Success program is offered to diverse employees women, Black/African American, Latino/Hispanic and Asian Americansto enhance their organizational and personal career success and ensure equitable leadership opportunities.","('Employee_Engagement_Inclusion_And_Diversity', 0.9735177755355835)","('Business_Model_Resilience', 0.0019285762682557106)","('Employee_Health_And_Safety', 0.0019220984540879726)","(['Talent Attraction & Retention'], 0.9735177755355835)","('NON-ESG', 0.0019285762682557106)","('NON-ESG', 0.0019220984540879726)"
Line 411,"During 2021, we hosted several cohorts in this program and offered our first cohort focused on LGBTQ+ employees.","('Employee_Engagement_Inclusion_And_Diversity', 0.9687425494194031)","('Human_Rights_And_Community_Relations', 0.002967269392684102)","('Employee_Health_And_Safety', 0.0027020901907235384)","(['Talent Attraction & Retention'], 0.9687425494194031)","('NON-ESG', 0.002967269392684102)","('NON-ESG', 0.0027020901907235384)"
Line 412,The BMS Connections Our Mentoring Program leverages intra-company global group mentoring capabilities to build relationships and learn from the diverse perspectives of others.,"('Employee_Engagement_Inclusion_And_Diversity', 0.8547374606132507)","('Human_Rights_And_Community_Relations', 0.030305270105600357)","('Access_And_Affordability', 0.0181565098464489)","(['Talent Attraction & Retention'], 0.8547374606132507)","('NON-ESG', 0.030305270105600357)","('NON-ESG', 0.0181565098464489)"
Line 413,"Launched in 2007, Connections Mentoring has been a hallmark of how BMS enhances and accelerates the development of leadership capabilities for members of our PBRGs.","('Employee_Engagement_Inclusion_And_Diversity', 0.6687929630279541)","('Business_Model_Resilience', 0.07328382134437561)","('Director_Removal', 0.03647143766283989)","(['Talent Attraction & Retention'], 0.6687929630279541)","('NON-ESG', 0.07328382134437561)","('NON-ESG', 0.03647143766283989)"
Line 414,Our research shows a positive impact on promotion and retention among program participants.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9159678220748901)","('Employee_Health_And_Safety', 0.0110948970541358)","('Competitive_Behavior', 0.006098082754760981)","(['Talent Attraction & Retention'], 0.9159678220748901)","('NON-ESG', 0.0110948970541358)","('NON-ESG', 0.006098082754760981)"
Line 415,"One Young World (OYW) A global non-profit that unites young leaders, from every country and sector, working to accelerate the change they want to see.","('Employee_Engagement_Inclusion_And_Diversity', 0.45924124121665955)","('Human_Rights_And_Community_Relations', 0.14537884294986725)","('Business_Model_Resilience', 0.13749338686466217)","('NON-ESG', 0.45924124121665955)","('NON-ESG', 0.14537884294986725)","('NON-ESG', 0.13749338686466217)"
Line 416,"A participating organization since 2012, BMS supports OYW as an opportunity to provide leadership development and demonstrate our commitment to nurture and grow emerging leaders at the company.","('Employee_Engagement_Inclusion_And_Diversity', 0.6398028135299683)","('Business_Model_Resilience', 0.09392936527729034)","('Human_Rights_And_Community_Relations', 0.040786802768707275)","(['Talent Attraction & Retention'], 0.6398028135299683)","('NON-ESG', 0.09392936527729034)","('NON-ESG', 0.040786802768707275)"
Line 417,Partnering with Historically Black Colleges and Universities (HBCUs) Preparing Black/African American students for success in STEM requires resources and guidance they may not have exposure to before college.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9572706818580627)","('Access_And_Affordability', 0.004489449318498373)","('Human_Rights_And_Community_Relations', 0.0031243462581187487)","(['Talent Attraction & Retention'], 0.9572706818580627)","('NON-ESG', 0.004489449318498373)","('NON-ESG', 0.0031243462581187487)"
Line 418,"The number of STEM graduates has grown, especially at the bachelors and masters levels.","('Employee_Engagement_Inclusion_And_Diversity', 0.5830678343772888)","('Director_Removal', 0.03067619539797306)","('Business_Model_Resilience', 0.030130639672279358)","(['Talent Attraction & Retention'], 0.5830678343772888)","('NON-ESG', 0.03067619539797306)","('NON-ESG', 0.030130639672279358)"
Line 419,"However, Black/African American and Latino/ Hispanic talent remain underrepresented in the STEM workforce compared with their share of all workers.","('Employee_Engagement_Inclusion_And_Diversity', 0.965428352355957)","('Labor_Practices', 0.006428689230233431)","('Employee_Health_And_Safety', 0.0025410624220967293)","(['Talent Attraction & Retention'], 0.965428352355957)","('NON-ESG', 0.006428689230233431)","('NON-ESG', 0.0025410624220967293)"
Line 420,HBCUs help address this disparity as evidenced by the fact that 20% of the graduates from these institutions receive a STEM-related degree.,"('Employee_Engagement_Inclusion_And_Diversity', 0.6428571343421936)","('Access_And_Affordability', 0.06655827164649963)","('Management_Of_Legal_And_Regulatory_Framework', 0.026256604120135307)","(['Talent Attraction & Retention'], 0.6428571343421936)","('NON-ESG', 0.06655827164649963)","('NON-ESG', 0.026256604120135307)"
Line 421,"For more information, see the Bristol Myers Squibb Global Inclusion & Diversity Report 2022 2021 ESG REPORT | 30Global management level by gender As we build representation at senior levels of our organization, we will continue to focus on the advancement of our pipeline of female talent.","('Employee_Engagement_Inclusion_And_Diversity', 0.9761307239532471)","('Employee_Health_And_Safety', 0.0018753123003989458)","('Human_Rights_And_Community_Relations', 0.0015596544835716486)","(['Talent Attraction & Retention'], 0.9761307239532471)","('NON-ESG', 0.0018753123003989458)","('NON-ESG', 0.0015596544835716486)"
Line 422,U.,"('Management_Of_Legal_And_Regulatory_Framework', 0.14571937918663025)","('Product_Design_And_Lifecycle_Management', 0.12332227826118469)","('Employee_Engagement_Inclusion_And_Diversity', 0.06306221336126328)","('NON-ESG', 0.14571937918663025)","('NON-ESG', 0.12332227826118469)","('NON-ESG', 0.06306221336126328)"
Line 423,S. ethnicity by management level At the executive level Global executive gender parity U.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9688615798950195)","('Customer_Privacy', 0.0024474228266626596)","('Labor_Practices', 0.002140236785635352)","(['Talent Attraction & Retention'], 0.9688615798950195)","('NON-ESG', 0.0024474228266626596)","('NON-ESG', 0.002140236785635352)"
Line 424,"S. executive representation by race/ethnicity 2021 ESG REPORT | 31 Accelerated Leadership Development and Advancement Employee Health and Wellbeing During 2021, we continued to invest in our Living Life Better strategy that encourages wellbeing at BMS for ourselves, our families, our patients and our community.","('Employee_Engagement_Inclusion_And_Diversity', 0.6525530815124512)","('Employee_Health_And_Safety', 0.16541831195354462)","('Access_And_Affordability', 0.04274045303463936)","(['Talent Attraction & Retention'], 0.6525530815124512)","('NON-ESG', 0.16541831195354462)","('NON-ESG', 0.04274045303463936)"
Line 425,Our strategy allows employees to choose offerings that best suit their unique needs.,"('Employee_Engagement_Inclusion_And_Diversity', 0.25604966282844543)","('Business_Model_Resilience', 0.16155651211738586)","('Product_Design_And_Lifecycle_Management', 0.14704574644565582)","('NON-ESG', 0.25604966282844543)","('NON-ESG', 0.16155651211738586)","('NON-ESG', 0.14704574644565582)"
Line 426,"To further our support of emotional wellbeing, we created a Mental Health Allies program to train BMS employees to provide onsite real-time emotional support on a peer-to-peer basis.","('Employee_Health_And_Safety', 0.409168541431427)","('Access_And_Affordability', 0.2366812378168106)","('Human_Rights_And_Community_Relations', 0.07907302677631378)","('NON-ESG', 0.409168541431427)","('NON-ESG', 0.2366812378168106)","('NON-ESG', 0.07907302677631378)"
Line 427,We also recognize that financial security plays a critically important role in the wellbeing of our colleagues.,"('Systemic_Risk_Management', 0.5438448190689087)","('Business_Ethics', 0.100287064909935)","('Employee_Health_And_Safety', 0.056775618344545364)","([], 0.5438448190689087)","('NON-ESG', 0.100287064909935)","('NON-ESG', 0.056775618344545364)"
Line 428,"BMS provides competitive compensation, insurance, and retirement offerings, as well as counseling to assist employees in meeting their financial goals.","('Employee_Engagement_Inclusion_And_Diversity', 0.4309394955635071)","('Labor_Practices', 0.2628704011440277)","('Competitive_Behavior', 0.05611472576856613)","('NON-ESG', 0.4309394955635071)","('NON-ESG', 0.2628704011440277)","('NON-ESG', 0.05611472576856613)"
Line 429,"Our Mission To define and encourage wellbeing at Bristol Myers Squibb for ourselves, our families, our patients and our community.","('Employee_Health_And_Safety', 0.3501170575618744)","('Access_And_Affordability', 0.3484794497489929)","('Human_Rights_And_Community_Relations', 0.05175146460533142)","('NON-ESG', 0.3501170575618744)","('NON-ESG', 0.3484794497489929)","('NON-ESG', 0.05175146460533142)"
Line 430,"Our Vision Living Life Better connects us with resources, opportunities and support to improve our wellbeing.","('Access_And_Affordability', 0.3818065822124481)","('Employee_Health_And_Safety', 0.31119513511657715)","('Human_Rights_And_Community_Relations', 0.061508215963840485)","('NON-ESG', 0.3818065822124481)","('NON-ESG', 0.31119513511657715)","('NON-ESG', 0.061508215963840485)"
Line 431,"Every small change makes a difference, from how we feel, to how we interact with others, to our performance at work.","('Business_Model_Resilience', 0.3358992636203766)","('Employee_Engagement_Inclusion_And_Diversity', 0.15435808897018433)","('Human_Rights_And_Community_Relations', 0.09872498363256454)","('NON-ESG', 0.3358992636203766)","('NON-ESG', 0.15435808897018433)","('NON-ESG', 0.09872498363256454)"
Line 432,"Whether we get involved with a group of coworkers or become more in tune with our personal needs, we can all find a way to start living life better today.","('Employee_Engagement_Inclusion_And_Diversity', 0.2906985282897949)","('Human_Rights_And_Community_Relations', 0.09177640080451965)","('Business_Model_Resilience', 0.08748631924390793)","('NON-ESG', 0.2906985282897949)","('NON-ESG', 0.09177640080451965)","('NON-ESG', 0.08748631924390793)"
Line 433,BMS Supports Wellbeing We understand that our employees have unique personal priorities outside of work as well.,"('Employee_Health_And_Safety', 0.7189871668815613)","('Labor_Practices', 0.044790156185626984)","('Human_Rights_And_Community_Relations', 0.03956955298781395)","(['Health Outcome Contribution'], 0.7189871668815613)","('NON-ESG', 0.044790156185626984)","('NON-ESG', 0.03956955298781395)"
Line 434,"To that end, we provide support for: Welcoming and nurturing family members through paid parental leave, bridge back parent leave, adoption/ surrogacy reimbursement Fertility/infertility benefits Support for traveling mothers Paid family care leave Child, elder and pet care resources Commuter accounts Paid sick time, vacation, holidays and annual paid volunteer days Paid bereavement leave Paid military leave and military family care leave 2021 ESG REPORT | 32Our vision to transform patients lives through science is made possible by the talent, passion and hard work of our employees.","('Access_And_Affordability', 0.568593442440033)","('Labor_Practices', 0.09146527945995331)","('Employee_Engagement_Inclusion_And_Diversity', 0.07688983529806137)","(['Access to Healthcare'], 0.568593442440033)","('NON-ESG', 0.09146527945995331)","('NON-ESG', 0.07688983529806137)"
Line 435,"To that end, we provide support for: Welcoming and nurturing family members through paid parental leave, bridge back parent leave, adoption/ surrogacy reimbursement Fertility/infertility benefits Support for traveling mothers Paid family care leave Child, elder and pet care resources Commuter accounts Paid sick time, vacation, holidays and annual paid volunteer days Paid bereavement leave Paid military leave and military family care leave 2021 ESG REPORT | 32Our vision to transform patients lives through science is made possible by the talent, passion and hard work of our employees.","('Employee_Engagement_Inclusion_And_Diversity', 0.8050164580345154)","('Employee_Health_And_Safety', 0.038401614874601364)","('Human_Rights_And_Community_Relations', 0.02459297515451908)","(['Talent Attraction & Retention'], 0.8050164580345154)","('NON-ESG', 0.038401614874601364)","('NON-ESG', 0.02459297515451908)"
Line 436,"Tofuel their success, we provide a variety of opportunities aimed atsupporting their overall wellbeing.","('Human_Rights_And_Community_Relations', 0.18039122223854065)","('Employee_Health_And_Safety', 0.17328815162181854)","('Access_And_Affordability', 0.12397440522909164)","('NON-ESG', 0.18039122223854065)","('NON-ESG', 0.17328815162181854)","('NON-ESG', 0.12397440522909164)"
Line 437,Occupational Health Our Occupational Health approach involves a team of doctors and nurses that execute key occupational and medical interventions in support of our global community.,"('Employee_Health_And_Safety', 0.9805512428283691)","('Critical_Incident_Risk_Management', 0.003068688092753291)","('Employee_Engagement_Inclusion_And_Diversity', 0.0015532337129116058)","(['Health Outcome Contribution'], 0.9805512428283691)","('NON-ESG', 0.003068688092753291)","('NON-ESG', 0.0015532337129116058)"
Line 438,"The physicians and nurses in these departments provide a range of health services including: Emergency medical care Treatment of work-related illness and injuries Safety awareness training Work-site health evaluations Risk-based medical surveillance Urgent medical care Reproductive health program Wellness consultations We truly believe our people are our differentiators, and we reflect that in the way we support our employees.","('Employee_Health_And_Safety', 0.97865891456604)","('Critical_Incident_Risk_Management', 0.00606257701292634)","('Employee_Engagement_Inclusion_And_Diversity', 0.0013915211893618107)","(['Health Outcome Contribution'], 0.97865891456604)","('NON-ESG', 0.00606257701292634)","('NON-ESG', 0.0013915211893618107)"
Line 439,"BMSapproach to wellbeing transcends the traditional wellness profilefocusing on the confluence of emotional, financial and physical wellbeing.","('Employee_Health_And_Safety', 0.6902108788490295)","('Access_And_Affordability', 0.03317579627037048)","('Product_Design_And_Lifecycle_Management', 0.02752147987484932)","(['Health Outcome Contribution'], 0.6902108788490295)","('NON-ESG', 0.03317579627037048)","('NON-ESG', 0.02752147987484932)"
Line 440,Our wellbeing program is global and features a suite of tools that employees can easily access.,"('Employee_Health_And_Safety', 0.4982829988002777)","('Access_And_Affordability', 0.11785593628883362)","('Human_Rights_And_Community_Relations', 0.08882088959217072)","('NON-ESG', 0.4982829988002777)","('NON-ESG', 0.11785593628883362)","('NON-ESG', 0.08882088959217072)"
Line 441,"The program centers around our Living Life Better platform, which connects employees to resources and opportunities that support improved individual and collective wellbeing.","('Employee_Health_And_Safety', 0.3931552469730377)","('Access_And_Affordability', 0.12955687940120697)","('Human_Rights_And_Community_Relations', 0.1292872279882431)","('NON-ESG', 0.3931552469730377)","('NON-ESG', 0.12955687940120697)","('NON-ESG', 0.1292872279882431)"
Line 442,"In 2021, 68% of our employees used the Living Life Better platform.","('Product_Design_And_Lifecycle_Management', 0.3023553192615509)","('Access_And_Affordability', 0.13252751529216766)","('Employee_Health_And_Safety', 0.1206396073102951)","('NON-ESG', 0.3023553192615509)","('NON-ESG', 0.13252751529216766)","('NON-ESG', 0.1206396073102951)"
Line 443,We continue to expand the platform and our wellbeing program to help more employees thrive.,"('Employee_Health_And_Safety', 0.44333067536354065)","('Employee_Engagement_Inclusion_And_Diversity', 0.10561078786849976)","('Access_And_Affordability', 0.10280628502368927)","('NON-ESG', 0.44333067536354065)","('NON-ESG', 0.10561078786849976)","('NON-ESG', 0.10280628502368927)"
Line 444,"Supporting mental health In 2021, our myVoice survey results indicated an opportunity to adjust our programs and deploy interventions to meet the needs of our workforce, and ultimately, patients.","('Access_And_Affordability', 0.5429314970970154)","('Employee_Health_And_Safety', 0.2009422928094864)","('Product_Quality_And_Safety', 0.030300507321953773)","(['Access to Healthcare'], 0.5429314970970154)","('NON-ESG', 0.2009422928094864)","('NON-ESG', 0.030300507321953773)"
Line 445,"We introduced BMS Mental Health Ally, a volunteer-led program that seeks to destigmatize and normalize conversations around mental health and promote the successful management of mental wellbeing.","('Employee_Health_And_Safety', 0.8491265773773193)","('Access_And_Affordability', 0.024140162393450737)","('Product_Quality_And_Safety', 0.014170226640999317)","(['Health Outcome Contribution'], 0.8491265773773193)","('NON-ESG', 0.024140162393450737)","('NON-ESG', 0.014170226640999317)"
Line 446,"As part of the Mental Health First Aid program from Mental Health First Aid International , allies are trained to identify, understand and respond to signs of mental distress, illness and addiction issues.","('Employee_Health_And_Safety', 0.8570336103439331)","('Access_And_Affordability', 0.03171780705451965)","('Critical_Incident_Risk_Management', 0.01667962782084942)","(['Health Outcome Contribution'], 0.8570336103439331)","('NON-ESG', 0.03171780705451965)","('NON-ESG', 0.01667962782084942)"
Line 447,They help colleagues find appropriate resources and support.,"('Access_And_Affordability', 0.2895337641239166)","('Human_Rights_And_Community_Relations', 0.15920743346214294)","('Management_Of_Legal_And_Regulatory_Framework', 0.11186370998620987)","('NON-ESG', 0.2895337641239166)","('NON-ESG', 0.15920743346214294)","('NON-ESG', 0.11186370998620987)"
Line 448,Allies are not trained therapists and do not diagnose mental health illness.,"('Employee_Health_And_Safety', 0.917287290096283)","('Product_Quality_And_Safety', 0.012427234090864658)","('Employee_Engagement_Inclusion_And_Diversity', 0.007505159359425306)","(['Health Outcome Contribution'], 0.917287290096283)","('NON-ESG', 0.012427234090864658)","('NON-ESG', 0.007505159359425306)"
Line 449,"BMS has 150+ trained allies in 10 locations, with more in training.","('Employee_Engagement_Inclusion_And_Diversity', 0.23220856487751007)","('Access_And_Affordability', 0.2143426090478897)","('Employee_Health_And_Safety', 0.09485252946615219)","('NON-ESG', 0.23220856487751007)","('NON-ESG', 0.2143426090478897)","('NON-ESG', 0.09485252946615219)"
Line 450,"Interest has grown rapidly, and we have built an easily scalable turnkey program with consistency, standards, measurements for success and visibility, and plan to continue to roll out the Mental Health Ally program across our company.2021 highlights MyBMS global wellbeing page launch, consolidating wellness resources into one platform Mental Health Ally expansion to eight new sites Wellbeing Wednesday Virgin Pulse challenges to improve health literacy in the U.","('Employee_Health_And_Safety', 0.3493412137031555)","('Access_And_Affordability', 0.31458547711372375)","('Product_Quality_And_Safety', 0.06205613538622856)","('NON-ESG', 0.3493412137031555)","('NON-ESG', 0.31458547711372375)","('NON-ESG', 0.06205613538622856)"
Line 451,"S., PR, Canada and Japan Wellbeing and burnout presentations and Wellbeing Mindset initiatives Gympass, offering access to gyms and fitness classes, launched in the U.","('Employee_Health_And_Safety', 0.5130820274353027)","('Access_And_Affordability', 0.15879453718662262)","('Customer_Welfare', 0.04505480080842972)","(['Health Outcome Contribution'], 0.5130820274353027)","('NON-ESG', 0.15879453718662262)","('NON-ESG', 0.04505480080842972)"
Line 452,"S. and PR 2021 ESG REPORT | 33 Employee Health and WellbeingEmployee Health and Safety At Bristol Myers Squibb, the health, safety and wellbeing of our workforces are our priority.","('Employee_Health_And_Safety', 0.9794684052467346)","('Employee_Engagement_Inclusion_And_Diversity', 0.00231182761490345)","('Product_Quality_And_Safety', 0.0017350707203149796)","(['Health Outcome Contribution'], 0.9794684052467346)","('NON-ESG', 0.00231182761490345)","('NON-ESG', 0.0017350707203149796)"
Line 453,"We work every day to create an environment that is devoid of work-related injuries and illnesses, predicated on proactive risk identification and systemic solutioning.","('Employee_Health_And_Safety', 0.9837952852249146)","('Critical_Incident_Risk_Management', 0.00261225295253098)","('Employee_Engagement_Inclusion_And_Diversity', 0.0011996239190921187)","(['Health Outcome Contribution'], 0.9837952852249146)","('NON-ESG', 0.00261225295253098)","('NON-ESG', 0.0011996239190921187)"
Line 454,"Our wellbeing programs are designed to care for the whole person and support social, physical, emotional and financial outcomes.","('Access_And_Affordability', 0.37748754024505615)","('Employee_Health_And_Safety', 0.33341309428215027)","('Human_Rights_And_Community_Relations', 0.09449800848960876)","('NON-ESG', 0.37748754024505615)","('NON-ESG', 0.33341309428215027)","('NON-ESG', 0.09449800848960876)"
Line 455,We believe that a culture that shows care and respect for its people in all facets is best positioned to deliver exceptional results.,"('Human_Rights_And_Community_Relations', 0.7946822643280029)","('Access_And_Affordability', 0.041868314146995544)","('Employee_Health_And_Safety', 0.022577421739697456)","([], 0.7946822643280029)","('NON-ESG', 0.041868314146995544)","('NON-ESG', 0.022577421739697456)"
Line 456,"We are on a journey to create a best-in-class environment, health, safety, sustainability and wellbeing program that is scientifically sound and forward leaning.","('Employee_Health_And_Safety', 0.9340075850486755)","('Access_And_Affordability', 0.00911320373415947)","('Product_Quality_And_Safety', 0.007346278987824917)","(['Health Outcome Contribution'], 0.9340075850486755)","('NON-ESG', 0.00911320373415947)","('NON-ESG', 0.007346278987824917)"
Line 457,Our governance for all programs is global and our results and metrics are monitored routinely.,"('Management_Of_Legal_And_Regulatory_Framework', 0.9293525218963623)","('Business_Ethics', 0.013518917374312878)","('Director_Removal', 0.01162305660545826)","([], 0.9293525218963623)","('NON-ESG', 0.013518917374312878)","('NON-ESG', 0.01162305660545826)"
Line 458,"Performance is shared across all workgroups and to the senior-most levels of the company, and oversight of these issues is provided by our Board of Directors Committee on Directors and CorporateGovernance.","('Director_Removal', 0.7674886584281921)","('Management_Of_Legal_And_Regulatory_Framework', 0.03413860872387886)","('Business_Model_Resilience', 0.020926522091031075)","(['Business Ethics'], 0.7674886584281921)","('NON-ESG', 0.03413860872387886)","('NON-ESG', 0.020926522091031075)"
Line 459,Our EHS management system and our occupational health manual outline the regulatory and company requirements that underpin our operations globally.,"('Employee_Health_And_Safety', 0.9751649498939514)","('Product_Quality_And_Safety', 0.0027184351347386837)","('Employee_Engagement_Inclusion_And_Diversity', 0.0022336309775710106)","(['Health Outcome Contribution'], 0.9751649498939514)","('NON-ESG', 0.0027184351347386837)","('NON-ESG', 0.0022336309775710106)"
Line 460,Bristol Myers Squibb uses common definitions and criteria established by the U.,"('Customer_Welfare', 0.3273996412754059)","('Selling_Practices_And_Product_Labeling', 0.1306118667125702)","('Product_Quality_And_Safety', 0.07598967850208282)","('NON-ESG', 0.3273996412754059)","('NON-ESG', 0.1306118667125702)","('NON-ESG', 0.07598967850208282)"
Line 461,S. Occupational Safety and Health Administration (OSHA) for recording occupational accidents and illnesses worldwide.,"('Employee_Health_And_Safety', 0.9824674725532532)","('Critical_Incident_Risk_Management', 0.003372445935383439)","('Employee_Engagement_Inclusion_And_Diversity', 0.0012678136117756367)","(['Health Outcome Contribution'], 0.9824674725532532)","('NON-ESG', 0.003372445935383439)","('NON-ESG', 0.0012678136117756367)"
Line 462,Our EHS metrics for 2021 can be found in the Appendix .,"('Management_Of_Legal_And_Regulatory_Framework', 0.7240504622459412)","('Systemic_Risk_Management', 0.06262200325727463)","('Energy_Management', 0.020345943048596382)","([], 0.7240504622459412)","('NON-ESG', 0.06262200325727463)","('NON-ESG', 0.020345943048596382)"
Line 463,Adherence to our management system is managed through internal controls as well as internal and external assessment.,"('Systemic_Risk_Management', 0.17124241590499878)","('Human_Rights_And_Community_Relations', 0.13790884613990784)","('Management_Of_Legal_And_Regulatory_Framework', 0.1365554928779602)","('NON-ESG', 0.17124241590499878)","('NON-ESG', 0.13790884613990784)","('NON-ESG', 0.1365554928779602)"
Line 464,"Audits, performed by internal and external experts, are a key mechanism for independent performance monitoring.","('Business_Ethics', 0.3803667724132538)","('Management_Of_Legal_And_Regulatory_Framework', 0.3334770202636719)","('Systemic_Risk_Management', 0.1136627122759819)","('NON-ESG', 0.3803667724132538)","('NON-ESG', 0.3334770202636719)","('NON-ESG', 0.1136627122759819)"
Line 465,"In support of our internal network and key external partners, we have global teams of experts who work across the business to embed our practices and ensure performance.","('Systemic_Risk_Management', 0.19752569496631622)","('Business_Ethics', 0.1229199543595314)","('Business_Model_Resilience', 0.12115805596113205)","('NON-ESG', 0.19752569496631622)","('NON-ESG', 0.1229199543595314)","('NON-ESG', 0.12115805596113205)"
Line 466,"These include: a Safety Center of Excellence, an Environmental Center of Excellence, a Systems and Assurance Center of Excellence, an Occupational Health and Wellbeing Center of Excellence and a Sustainability Center of Excellence.","('Employee_Health_And_Safety', 0.9774739146232605)","('Employee_Engagement_Inclusion_And_Diversity', 0.0026044114492833614)","('Product_Quality_And_Safety', 0.0018733690958470106)","(['Health Outcome Contribution'], 0.9774739146232605)","('NON-ESG', 0.0026044114492833614)","('NON-ESG', 0.0018733690958470106)"
Line 467,These experts work with local teams in support of our compliance and company objectives.,"('Management_Of_Legal_And_Regulatory_Framework', 0.8871302604675293)","('Human_Rights_And_Community_Relations', 0.023941805586218834)","('Business_Ethics', 0.020084967836737633)","([], 0.8871302604675293)","('NON-ESG', 0.023941805586218834)","('NON-ESG', 0.020084967836737633)"
Line 468,For more information please visit our EHS management system page.,"('Data_Security', 0.08856277912855148)","('Energy_Management', 0.08682429790496826)","('Product_Quality_And_Safety', 0.07738630473613739)","('NON-ESG', 0.08856277912855148)","('NON-ESG', 0.08682429790496826)","('NON-ESG', 0.07738630473613739)"
Line 469,"2021 ESG REPORT | 34Learning and Development To further our mission and support our employees growth, we invest in a strong culture of learningand development.","('Employee_Engagement_Inclusion_And_Diversity', 0.5938235521316528)","('Business_Model_Resilience', 0.06415270268917084)","('Human_Rights_And_Community_Relations', 0.061994634568691254)","(['Talent Attraction & Retention'], 0.5938235521316528)","('NON-ESG', 0.06415270268917084)","('NON-ESG', 0.061994634568691254)"
Line 470,"By providing valuable learning opportunities and connecting employees to their passions, we help them achieve their personal aspirations and make a meaningful contribution to our mission for ourpatients around the world.","('Employee_Engagement_Inclusion_And_Diversity', 0.5362741947174072)","('Human_Rights_And_Community_Relations', 0.16385917365550995)","('Access_And_Affordability', 0.050518736243247986)","(['Talent Attraction & Retention'], 0.5362741947174072)","('NON-ESG', 0.16385917365550995)","('NON-ESG', 0.050518736243247986)"
Line 471,"BMS emphasizes a culture of continuous learning, in which we empower employees to learn during the flow of their everyday work.","('Employee_Engagement_Inclusion_And_Diversity', 0.40161460638046265)","('Employee_Health_And_Safety', 0.17491179704666138)","('Access_And_Affordability', 0.08228114247322083)","('NON-ESG', 0.40161460638046265)","('NON-ESG', 0.17491179704666138)","('NON-ESG', 0.08228114247322083)"
Line 472,"We leverage a variety of self-driven, collaborative and on-the-job learning experiencessuch as digital classes, stimulating work assignments and special projects, tours of duty into different parts of the business and skills-based volunteeringto help employees find their purpose, strengthen their skillsets and enhance our business performance.","('Employee_Engagement_Inclusion_And_Diversity', 0.8137087225914001)","('Employee_Health_And_Safety', 0.03873630240559578)","('Access_And_Affordability', 0.024575693532824516)","(['Talent Attraction & Retention'], 0.8137087225914001)","('NON-ESG', 0.03873630240559578)","('NON-ESG', 0.024575693532824516)"
Line 473,"Additionally, we provide tuition reimbursements globally to eligible employees who, through their own initiative and desire for development, participate in accredited educational programs.","('Access_And_Affordability', 0.34230536222457886)","('Management_Of_Legal_And_Regulatory_Framework', 0.320517361164093)","('Labor_Practices', 0.06433889269828796)","('NON-ESG', 0.34230536222457886)","('NON-ESG', 0.320517361164093)","('NON-ESG', 0.06433889269828796)"
Line 474,These programs provide an opportunity for employees to gain a broader understanding of the organization and advance BMS important work.,"('Employee_Engagement_Inclusion_And_Diversity', 0.5666781067848206)","('Human_Rights_And_Community_Relations', 0.07763645797967911)","('Employee_Health_And_Safety', 0.05608227476477623)","(['Talent Attraction & Retention'], 0.5666781067848206)","('NON-ESG', 0.07763645797967911)","('NON-ESG', 0.05608227476477623)"
Line 475,"Leadership development Through our Enterprise Manager Development programs, we cultivate the growth of our managers and BMS senior leaders.","('Employee_Engagement_Inclusion_And_Diversity', 0.5154622793197632)","('Director_Removal', 0.09736420959234238)","('Business_Model_Resilience', 0.07851848751306534)","(['Talent Attraction & Retention'], 0.5154622793197632)","('NON-ESG', 0.09736420959234238)","('NON-ESG', 0.07851848751306534)"
Line 476,The programs include virtual and in-classroom learning opportunities for new and experienced managers and senior leaders.,"('Employee_Engagement_Inclusion_And_Diversity', 0.7546050548553467)","('Access_And_Affordability', 0.03856135159730911)","('Human_Rights_And_Community_Relations', 0.03257623314857483)","(['Talent Attraction & Retention'], 0.7546050548553467)","('NON-ESG', 0.03856135159730911)","('NON-ESG', 0.03257623314857483)"
Line 477,"In 2021, there were more than 2,500 participants.","('Employee_Engagement_Inclusion_And_Diversity', 0.11245373636484146)","('Competitive_Behavior', 0.10909081995487213)","('Management_Of_Legal_And_Regulatory_Framework', 0.08961694687604904)","('NON-ESG', 0.11245373636484146)","('NON-ESG', 0.10909081995487213)","('NON-ESG', 0.08961694687604904)"
Line 478,Most of our development programs bring together multi-month cohorts.,"('Access_And_Affordability', 0.7054843306541443)","('Employee_Engagement_Inclusion_And_Diversity', 0.06136498227715492)","('Human_Rights_And_Community_Relations', 0.046665534377098083)","(['Access to Healthcare'], 0.7054843306541443)","('NON-ESG', 0.06136498227715492)","('NON-ESG', 0.046665534377098083)"
Line 479,"We identify targeted candidates through our talent planning processes, and in some cases, through succession planning.","('Employee_Engagement_Inclusion_And_Diversity', 0.9491126537322998)","('Employee_Health_And_Safety', 0.004789579194039106)","('Business_Model_Resilience', 0.004537925124168396)","(['Talent Attraction & Retention'], 0.9491126537322998)","('NON-ESG', 0.004789579194039106)","('NON-ESG', 0.004537925124168396)"
Line 480,"Of the 550 leaders who participated in 2020 and 2021, 68% were women and 51% were from underrepresented ethnic groups (UEGs).","('Employee_Engagement_Inclusion_And_Diversity', 0.9727081656455994)","('Human_Rights_And_Community_Relations', 0.0027179101016372442)","('Customer_Privacy', 0.0017658837605267763)","(['Talent Attraction & Retention'], 0.9727081656455994)","('NON-ESG', 0.0027179101016372442)","('NON-ESG', 0.0017658837605267763)"
Line 481,"2021 progress and impact 7,700+ leaders and managers had the opportunity to attend unconscious bias education training in 2021, and 1 in5 managers attended that training last yearExpanded employee access and adoption to on-demand digital learning by 52% Employees used video learning vs. e-learning heavily; resulting in a ratio of 25:1258,962 manager training video views68% of our participants were women and 51% were from UEGs 100% of our Leadership Development programs are inclusive and address topics relevant to women and UEGs15% more Leadership Development Program enrollments in 2021 versus 2020Enrollment across all programs is accounted to women by more than 50% 2021 ESG REPORT | 35Supply Chain Our promise to our patients, as well as their families and healthcare providers, is to maintain an unencumbered and uninterrupted supply of medicines that can be delivered wherever and whenever they are needed.","('Employee_Engagement_Inclusion_And_Diversity', 0.6030991077423096)","('Access_And_Affordability', 0.1469692885875702)","('Human_Rights_And_Community_Relations', 0.027197828516364098)","(['Talent Attraction & Retention'], 0.6030991077423096)","('NON-ESG', 0.1469692885875702)","('NON-ESG', 0.027197828516364098)"
Line 482,"2021 progress and impact 7,700+ leaders and managers had the opportunity to attend unconscious bias education training in 2021, and 1 in5 managers attended that training last yearExpanded employee access and adoption to on-demand digital learning by 52% Employees used video learning vs. e-learning heavily; resulting in a ratio of 25:1258,962 manager training video views68% of our participants were women and 51% were from UEGs 100% of our Leadership Development programs are inclusive and address topics relevant to women and UEGs15% more Leadership Development Program enrollments in 2021 versus 2020Enrollment across all programs is accounted to women by more than 50% 2021 ESG REPORT | 35Supply Chain Our promise to our patients, as well as their families and healthcare providers, is to maintain an unencumbered and uninterrupted supply of medicines that can be delivered wherever and whenever they are needed.","('Access_And_Affordability', 0.5525926351547241)","('Customer_Welfare', 0.11242224276065826)","('Selling_Practices_And_Product_Labeling', 0.05112176761031151)","(['Access to Healthcare'], 0.5525926351547241)","('NON-ESG', 0.11242224276065826)","('NON-ESG', 0.05112176761031151)"
Line 483,"BMS Global Supply Chain organization manages the development, launch and supply life cycle of our products to help fulfill that promise.","('Supply_Chain_Management', 0.5516021847724915)","('Product_Design_And_Lifecycle_Management', 0.314698725938797)","('Waste_And_Hazardous_Materials_Management', 0.011789069510996342)","([], 0.5516021847724915)","('NON-ESG', 0.314698725938797)","('NON-ESG', 0.011789069510996342)"
Line 484,Strategic sourcing and procurement are core to our global enterpriseconnecting our business units through a world-class network of suppliers and value-creating partnerships.,"('Supply_Chain_Management', 0.9160457849502563)","('Product_Design_And_Lifecycle_Management', 0.0209665410220623)","('Customer_Welfare', 0.006420386489480734)","([], 0.9160457849502563)","('NON-ESG', 0.0209665410220623)","('NON-ESG', 0.006420386489480734)"
Line 485,"We source hundreds of direct and indirect goods and services around the world for our various teams, including R&D, packaging and a multitude of professional services.","('Product_Design_And_Lifecycle_Management', 0.9299427270889282)","('Supply_Chain_Management', 0.011335640214383602)","('Customer_Welfare', 0.007347621023654938)","([], 0.9299427270889282)","('NON-ESG', 0.011335640214383602)","('NON-ESG', 0.007347621023654938)"
Line 486,"This makes our partner and supplier networks an integral part of achieving heightened geographic reach, focused technical capabilities and increased network flexibility.","('Supply_Chain_Management', 0.8566012978553772)","('Business_Model_Resilience', 0.02958419919013977)","('Systemic_Risk_Management', 0.019029775634407997)","([], 0.8566012978553772)","('NON-ESG', 0.02958419919013977)","('NON-ESG', 0.019029775634407997)"
Line 487,"To maintain a robust supply chain that aligns with our ESG strategy, we seek partnerships and providers that share our ideals and commit to transparency.","('Supply_Chain_Management', 0.949462354183197)","('Systemic_Risk_Management', 0.005535983946174383)","('Labor_Practices', 0.004230021964758635)","([], 0.949462354183197)","('NON-ESG', 0.005535983946174383)","('NON-ESG', 0.004230021964758635)"
Line 488,"Our operating model also includes capabilities related to risk management, supply chain resilience and suppliermanagement.","('Supply_Chain_Management', 0.9036905765533447)","('Business_Model_Resilience', 0.026452988386154175)","('Product_Design_And_Lifecycle_Management', 0.012551610358059406)","([], 0.9036905765533447)","('NON-ESG', 0.026452988386154175)","('NON-ESG', 0.012551610358059406)"
Line 489,"Having strong global partners who understand our company, products and patients made a difference in our ability to maintain product quality, stability and security amid the COVID-19 pandemic.","('Product_Design_And_Lifecycle_Management', 0.9389600157737732)","('Product_Quality_And_Safety', 0.016430487856268883)","('Selling_Practices_And_Product_Labeling', 0.0056684911251068115)","([], 0.9389600157737732)","('NON-ESG', 0.016430487856268883)","('NON-ESG', 0.0056684911251068115)"
Line 490,"By effectively managing the highly dynamic and unpredictable nature of the pandemic, we ensured that BMS products could continue to reach active clinical trial study participants, as well as patients beginning or continuing medical therapies.","('Customer_Welfare', 0.18926900625228882)","('Systemic_Risk_Management', 0.1102135106921196)","('Product_Quality_And_Safety', 0.10508959740400314)","('NON-ESG', 0.18926900625228882)","('NON-ESG', 0.1102135106921196)","('NON-ESG', 0.10508959740400314)"
Line 491,We are proud of our ability to creatively solve and respond to challenges posed by the pandemic and are pleased to report that we did not see significant disruptions in our clinical or commercial supply chains as a result.,"('Supply_Chain_Management', 0.950875997543335)","('Systemic_Risk_Management', 0.005946988705545664)","('Physical_Impacts_Of_Climate_Change', 0.0044462839141488075)","([], 0.950875997543335)","('NON-ESG', 0.005946988705545664)","('NON-ESG', 0.0044462839141488075)"
Line 492,The pandemic highlighted for our industry that a successful global supply chain requires a collective and organized effort.,"('Supply_Chain_Management', 0.9374412894248962)","('Labor_Practices', 0.007601200137287378)","('Physical_Impacts_Of_Climate_Change', 0.006517258007079363)","([], 0.9374412894248962)","('NON-ESG', 0.007601200137287378)","('NON-ESG', 0.006517258007079363)"
Line 493,"Knowledge sharing and local expertise are critical to understanding the unique situations of various countries and patients, and we believe that information sharing, supply and sourcing agility and the ability to cultivate strong and reliable partnerships will be key to our continued success.","('Supply_Chain_Management', 0.9428941607475281)","('Water_And_Wastewater_Management', 0.005333892069756985)","('Product_Design_And_Lifecycle_Management', 0.004604875575751066)","([], 0.9428941607475281)","('NON-ESG', 0.005333892069756985)","('NON-ESG', 0.004604875575751066)"
Line 494,"Our purpose-driven supply chain pillars Patient-centric mindset empowering and creating an agile supply chain network so patients receive the medications they need, when and where they need them.","('Supply_Chain_Management', 0.9410777688026428)","('Product_Design_And_Lifecycle_Management', 0.006513415835797787)","('Water_And_Wastewater_Management', 0.004515587817877531)","([], 0.9410777688026428)","('NON-ESG', 0.006513415835797787)","('NON-ESG', 0.004515587817877531)"
Line 495,"Science and technology leaders leveraging data, digital applications and cutting-edge systems for best performance across service, quality, capital and cost.","('Business_Model_Resilience', 0.3236786723136902)","('Systemic_Risk_Management', 0.12010390311479568)","('Product_Design_And_Lifecycle_Management', 0.11629028618335724)","('NON-ESG', 0.3236786723136902)","('NON-ESG', 0.12010390311479568)","('NON-ESG', 0.11629028618335724)"
Line 496,"Seamless interconnection serving as an integrator that brings together the voices of clinical, development and commercial to optimize our supply and logistics network.","('Supply_Chain_Management', 0.9106366038322449)","('Product_Design_And_Lifecycle_Management', 0.012748307548463345)","('Energy_Management', 0.008725261315703392)","([], 0.9106366038322449)","('NON-ESG', 0.012748307548463345)","('NON-ESG', 0.008725261315703392)"
Line 497,Operating model agility creating nimble processes for a exible supply chain to meet the needs of patients with both precision and large-scale medicines.,"('Supply_Chain_Management', 0.8654093146324158)","('Energy_Management', 0.02134821005165577)","('Customer_Welfare', 0.014391103759407997)","([], 0.8654093146324158)","('NON-ESG', 0.02134821005165577)","('NON-ESG', 0.014391103759407997)"
Line 498,"Culture of excellence growing our people by encouraging curiosity, providing best experiences and fostering continuous improvement to support our talent.","('Employee_Engagement_Inclusion_And_Diversity', 0.9221601486206055)","('Employee_Health_And_Safety', 0.008034054189920425)","('Human_Rights_And_Community_Relations', 0.006612421479076147)","(['Talent Attraction & Retention'], 0.9221601486206055)","('NON-ESG', 0.008034054189920425)","('NON-ESG', 0.006612421479076147)"
Line 499,2021 ESG REPORT | 36Supplier diversity Driving excellence across our supply chain requires a culture of inclusion at every touch point.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9685015082359314)","('Employee_Health_And_Safety', 0.002527248580008745)","('Human_Rights_And_Community_Relations', 0.002239739755168557)","(['Talent Attraction & Retention'], 0.9685015082359314)","('NON-ESG', 0.002527248580008745)","('NON-ESG', 0.002239739755168557)"
Line 500,"By partnering with diverse suppliers, we strengthen and drive stability in the communities where we operate while maintaining the resilient, competitive and innovative supply chain required to fulfill our promise to patients, their family members and healthcare providers.","('Supply_Chain_Management', 0.9389992356300354)","('Business_Model_Resilience', 0.007647555787116289)","('Product_Design_And_Lifecycle_Management', 0.006374567747116089)","([], 0.9389992356300354)","('NON-ESG', 0.007647555787116289)","('NON-ESG', 0.006374567747116089)"
Line 501,We provide business school scholarships for diverse suppliers to attend programs at Dartmouths Tuck School of Business.,"('Supply_Chain_Management', 0.3398395776748657)","('Product_Design_And_Lifecycle_Management', 0.1340017318725586)","('Access_And_Affordability', 0.11749082803726196)","('NON-ESG', 0.3398395776748657)","('NON-ESG', 0.1340017318725586)","('NON-ESG', 0.11749082803726196)"
Line 502,BMS is a founding member of the Tuck School of Business Residential program and sponsors five suppliers each year from Minority Supplier Development UK (MSDUK).,"('Supply_Chain_Management', 0.9086236357688904)","('Product_Design_And_Lifecycle_Management', 0.015008239075541496)","('Labor_Practices', 0.0066323899663984776)","([], 0.9086236357688904)","('NON-ESG', 0.015008239075541496)","('NON-ESG', 0.0066323899663984776)"
Line 503,"Through Tucks virtual as well as in-person programs, we support minority-owned businesses to grow, strengthen capacity/ capability, develop a peer-peer network, venture into joint partnerships and more.","('Employee_Engagement_Inclusion_And_Diversity', 0.9328626394271851)","('Business_Model_Resilience', 0.006332718301564455)","('Human_Rights_And_Community_Relations', 0.006292641628533602)","(['Talent Attraction & Retention'], 0.9328626394271851)","('NON-ESG', 0.006332718301564455)","('NON-ESG', 0.006292641628533602)"
Line 504,"Starting in 2021, the supplier diversity team sponsored 10 Ethnic Minority Businesses (EMBs) to this executive education program based in the United States.","('Employee_Engagement_Inclusion_And_Diversity', 0.9763774275779724)","('Employee_Health_And_Safety', 0.0016665864968672395)","('Human_Rights_And_Community_Relations', 0.0015055449912324548)","(['Talent Attraction & Retention'], 0.9763774275779724)","('NON-ESG', 0.0016665864968672395)","('NON-ESG', 0.0015055449912324548)"
Line 505,"In 2021, BMS hosted its first international supplier development executive education programs by co-sponsoring 25 EMBs to Leadership in a Technology Driven World delivered by Imperial Business School,London.","('Supply_Chain_Management', 0.8603785037994385)","('Product_Design_And_Lifecycle_Management', 0.03576609492301941)","('Business_Model_Resilience', 0.012214410118758678)","([], 0.8603785037994385)","('NON-ESG', 0.03576609492301941)","('NON-ESG', 0.012214410118758678)"
Line 506,The program equipped participants with the skills to lead their teams through the digital age and offered a practical and personalized learning approach backed by theory.,"('Employee_Engagement_Inclusion_And_Diversity', 0.30592042207717896)","('Access_And_Affordability', 0.2918999493122101)","('Human_Rights_And_Community_Relations', 0.08361965417861938)","('NON-ESG', 0.30592042207717896)","('NON-ESG', 0.2918999493122101)","('NON-ESG', 0.08361965417861938)"
Line 507,"Delivered through interactive coaching elements, the participants were encouraged to leave their comfort zone and view their leadership style from new perspectives.","('Employee_Engagement_Inclusion_And_Diversity', 0.685129702091217)","('Access_And_Affordability', 0.08485189825296402)","('Human_Rights_And_Community_Relations', 0.03328428789973259)","(['Talent Attraction & Retention'], 0.685129702091217)","('NON-ESG', 0.08485189825296402)","('NON-ESG', 0.03328428789973259)"
Line 508,Participants worked closely with their peers to navigate the digital landscape and become adaptive leaders.,"('Business_Model_Resilience', 0.45500877499580383)","('Employee_Engagement_Inclusion_And_Diversity', 0.1305425465106964)","('Human_Rights_And_Community_Relations', 0.04775766655802727)","('NON-ESG', 0.45500877499580383)","('NON-ESG', 0.1305425465106964)","('NON-ESG', 0.04775766655802727)"
Line 509,"To identify those suppliers with the greatest need and potential, we partner with nongovernmental organizations (NGOs), engage with our suppliers and follow up on our supplier assessments.","('Supply_Chain_Management', 0.941245973110199)","('Labor_Practices', 0.005289555061608553)","('Water_And_Wastewater_Management', 0.004318333230912685)","([], 0.941245973110199)","('NON-ESG', 0.005289555061608553)","('NON-ESG', 0.004318333230912685)"
Line 510,"In 2021, we provided 15 scholarships, totaling $60,000, which helped suppliers learn new skills while strengthening their businesses and BMS supply chain.","('Supply_Chain_Management', 0.9451677799224854)","('Physical_Impacts_Of_Climate_Change', 0.004396404139697552)","('Labor_Practices', 0.004390957299619913)","([], 0.9451677799224854)","('NON-ESG', 0.004396404139697552)","('NON-ESG', 0.004390957299619913)"
Line 511,"Our supplier diversity commitment Since announcing our $1 billion supplier diversity commitment in 2020, our diverse supplier spend has increased by more than 29%from $695 million in 2020 to $899 million in 2021.","('Employee_Engagement_Inclusion_And_Diversity', 0.8871095180511475)","('Supply_Chain_Management', 0.016745775938034058)","('Labor_Practices', 0.010997067205607891)","(['Talent Attraction & Retention'], 0.8871095180511475)","('NON-ESG', 0.016745775938034058)","('NON-ESG', 0.010997067205607891)"
Line 512,The tenets of our commitment include: Value to Business: We harness the power of diversity through our suppliers.,"('Employee_Engagement_Inclusion_And_Diversity', 0.968877375125885)","('Employee_Health_And_Safety', 0.0024649687111377716)","('Human_Rights_And_Community_Relations', 0.0022960789501667023)","(['Talent Attraction & Retention'], 0.968877375125885)","('NON-ESG', 0.0024649687111377716)","('NON-ESG', 0.0022960789501667023)"
Line 513,Value to Community: We champion economic empowerment in the community.,"('Human_Rights_And_Community_Relations', 0.9497976303100586)","('Access_And_Affordability', 0.00873914547264576)","('Employee_Engagement_Inclusion_And_Diversity', 0.0033245477825403214)","([], 0.9497976303100586)","('NON-ESG', 0.00873914547264576)","('NON-ESG', 0.0033245477825403214)"
Line 514,Value to BMS Culture: Our suppliers must reflect our values and the patients we serve.,"('Supply_Chain_Management', 0.7997317910194397)","('Product_Design_And_Lifecycle_Management', 0.046326037496328354)","('Customer_Welfare', 0.0210861973464489)","([], 0.7997317910194397)","('NON-ESG', 0.046326037496328354)","('NON-ESG', 0.0210861973464489)"
Line 515,"Strategic sourcing and procurement are core to our global enterprise, connecting all our business units through a world-class network of suppliers who share our unwavering passion and commitment to patients.","('Supply_Chain_Management', 0.8991353511810303)","('Product_Design_And_Lifecycle_Management', 0.026532677933573723)","('Customer_Welfare', 0.007085069548338652)","([], 0.8991353511810303)","('NON-ESG', 0.026532677933573723)","('NON-ESG', 0.007085069548338652)"
Line 516,"Tuck School Program Key Impact Metrics 95% gained effective leadership skills and techniques to lead teams through digital age90% benefited through case studies, coaching and self-reflection into their personal leadership style79% found key areas to workon and develop post program 2021 ESG REPORT | 37 Supply ChainEnvironmental Responsibility IN THIS SECTION Energy and Emissions Waste and Recycling Water and Wastewater Green and SustainableScience Packaging and Transportation Sustainable Facility Design Employee Engagement in Sustainability 2021 ESG REPORT | 38Environmental Responsibility At the heart of our global business strategy is a commitment to create the maximum positive impact on society while minimizing our companys environmental footprint.","('Supply_Chain_Management', 0.4677583575248718)","('Product_Design_And_Lifecycle_Management', 0.19458135962486267)","('Business_Model_Resilience', 0.06571002304553986)","('NON-ESG', 0.4677583575248718)","('NON-ESG', 0.19458135962486267)","('NON-ESG', 0.06571002304553986)"
Line 517,"Tuck School Program Key Impact Metrics 95% gained effective leadership skills and techniques to lead teams through digital age90% benefited through case studies, coaching and self-reflection into their personal leadership style79% found key areas to workon and develop post program 2021 ESG REPORT | 37 Supply ChainEnvironmental Responsibility IN THIS SECTION Energy and Emissions Waste and Recycling Water and Wastewater Green and SustainableScience Packaging and Transportation Sustainable Facility Design Employee Engagement in Sustainability 2021 ESG REPORT | 38Environmental Responsibility At the heart of our global business strategy is a commitment to create the maximum positive impact on society while minimizing our companys environmental footprint.","('Human_Rights_And_Community_Relations', 0.4284264147281647)","('Business_Model_Resilience', 0.2583894729614258)","('Ecological_Impacts', 0.04666522517800331)","('NON-ESG', 0.4284264147281647)","('NON-ESG', 0.2583894729614258)","('NON-ESG', 0.04666522517800331)"
Line 518,"As a company dedicated to helping patients lead healthier lives, we recognize our responsibility to provide long-term benefits to society through our ESG priorities.","('Access_And_Affordability', 0.7773224115371704)","('Human_Rights_And_Community_Relations', 0.04123679921030998)","('Employee_Health_And_Safety', 0.023143382743000984)","(['Access to Healthcare'], 0.7773224115371704)","('NON-ESG', 0.04123679921030998)","('NON-ESG', 0.023143382743000984)"
Line 519,"Accordingly, we are committed to operating in an environmentally responsible manner by reducing our emissions and waste and embracing sustainable science and business practices.","('Waste_And_Hazardous_Materials_Management', 0.7879446744918823)","('Product_Design_And_Lifecycle_Management', 0.05843907967209816)","('Energy_Management', 0.022764848545193672)","([], 0.7879446744918823)","('NON-ESG', 0.05843907967209816)","('NON-ESG', 0.022764848545193672)"
Line 520,"Our business is growing, and we must continue to act across our global operations to reduce our environmental impact.","('Business_Model_Resilience', 0.52806556224823)","('Product_Design_And_Lifecycle_Management', 0.1653124839067459)","('Supply_Chain_Management', 0.10403938591480255)","(['Human Capital Development', 'Innovation Management'], 0.52806556224823)","('NON-ESG', 0.1653124839067459)","('NON-ESG', 0.10403938591480255)"
Line 521,"As we manage our environmental footprint, we consider every facet of our value chain and incorporate a science-first approach to identify opportunities through which we can make the most meaningful global impact.","('Business_Model_Resilience', 0.6507278084754944)","('Supply_Chain_Management', 0.13166359066963196)","('Systemic_Risk_Management', 0.06352800875902176)","(['Human Capital Development', 'Innovation Management'], 0.6507278084754944)","('NON-ESG', 0.13166359066963196)","('NON-ESG', 0.06352800875902176)"
Line 522,"Our efforts encompass our entire product life cycle, from how we design and produce our products to how we deliver them to patients and communities.","('Product_Design_And_Lifecycle_Management', 0.961280882358551)","('Selling_Practices_And_Product_Labeling', 0.004902328364551067)","('Product_Quality_And_Safety', 0.004619340877979994)","([], 0.961280882358551)","('NON-ESG', 0.004902328364551067)","('NON-ESG', 0.004619340877979994)"
Line 523,We have also established transition goals to continue driving environmental performance across our global operations while we simultaneously develop robust road maps to achieve our 2030 and 2040 commitments.,"('Business_Model_Resilience', 0.45436784625053406)","('Human_Rights_And_Community_Relations', 0.0910872370004654)","('Supply_Chain_Management', 0.07336390763521194)","('NON-ESG', 0.45436784625053406)","('NON-ESG', 0.0910872370004654)","('NON-ESG', 0.07336390763521194)"
Line 524,"These goals include achieving a 10% reduction in our energy use and GHG emissions intensity, a 25% reduction in waste to landfill and a 5% reduction in water intensity.","('GHG_Emissions', 0.9130459427833557)","('Energy_Management', 0.018349308520555496)","('Air_Quality', 0.011973164044320583)","(['Operational Eco-Efficiency'], 0.9130459427833557)","('NON-ESG', 0.018349308520555496)","('NON-ESG', 0.011973164044320583)"
Line 525,Setting transition goals also ensures that our expanded enterprise network is fully integrated with our comprehensive sustainability initiatives and reporting protocols.,"('Management_Of_Legal_And_Regulatory_Framework', 0.2960250675678253)","('Business_Model_Resilience', 0.23341156542301178)","('Human_Rights_And_Community_Relations', 0.04967406392097473)","('NON-ESG', 0.2960250675678253)","('NON-ESG', 0.23341156542301178)","('NON-ESG', 0.04967406392097473)"
Line 526,"As we build out our science-based targets (SBTs) and begin incorporating the Task Force on Climate-related Financial Disclosures (TCFD) scenarios into our disclosures, we will continue to evolve our efforts as part of our transition and contribution to a low-carbon economy.","('Physical_Impacts_Of_Climate_Change', 0.8673495650291443)","('Business_Model_Resilience', 0.04364035651087761)","('GHG_Emissions', 0.021530048921704292)","([], 0.8673495650291443)","('NON-ESG', 0.04364035651087761)","('NON-ESG', 0.021530048921704292)"
Line 527,In 2020 we set bold environmental goals to guide and hold us accountable.,"('Human_Rights_And_Community_Relations', 0.5913938879966736)","('Management_Of_Legal_And_Regulatory_Framework', 0.08587723225355148)","('Physical_Impacts_Of_Climate_Change', 0.06075745075941086)","([], 0.5913938879966736)","('NON-ESG', 0.08587723225355148)","('NON-ESG', 0.06075745075941086)"
Line 528,"By 2030 100% of purchased electricity will be procured from renewable sources By 2040 100% zero-emission vehicles in our commercial fleetNetneutral emissionsZero waste to landfillEquitable water use 2021 ESG REPORT | 39Energy and Emissions With climate change and its many impacts expected to exacerbate harmful diseases, we stand firmly committed to using our scientific expertise to drive innovation, decrease our energy use and emissions and build a more resilient planet.","('Physical_Impacts_Of_Climate_Change', 0.8651694059371948)","('GHG_Emissions', 0.03490626811981201)","('Business_Model_Resilience', 0.019338663667440414)","([], 0.8651694059371948)","('NON-ESG', 0.03490626811981201)","('NON-ESG', 0.019338663667440414)"
Line 529,"The work required to achieve our energy and GHG emissions goals is currently underway across our facilities, R&D labs, production sites and offices around the world.","('GHG_Emissions', 0.9616966843605042)","('Air_Quality', 0.007130702957510948)","('Energy_Management', 0.003718121675774455)","(['Operational Eco-Efficiency'], 0.9616966843605042)","('NON-ESG', 0.007130702957510948)","('NON-ESG', 0.003718121675774455)"
Line 530,"Our point of view on climate risk Our climate change strategy is based on understanding our contributions as citizens of the planet and as a responsible, healthcare-based, multinational company.","('Physical_Impacts_Of_Climate_Change', 0.9553680419921875)","('Business_Model_Resilience', 0.008050902746617794)","('GHG_Emissions', 0.004869742784649134)","([], 0.9553680419921875)","('NON-ESG', 0.008050902746617794)","('NON-ESG', 0.004869742784649134)"
Line 531,"Our aim is to follow the science and creatively apply technology and our know-how to solve tough business problems of diminishing resources, carbon emissions, energy consumption and waste generation.","('Energy_Management', 0.8716080784797668)","('Waste_And_Hazardous_Materials_Management', 0.018150562420487404)","('GHG_Emissions', 0.01244665402919054)","(['Operational Eco-Efficiency'], 0.8716080784797668)","('NON-ESG', 0.018150562420487404)","('NON-ESG', 0.01244665402919054)"
Line 532,"As a science-based company, it is important that we learn from scientific experts and databoth of which suggest that climate change can impact the severity and frequency of health problems and can contribute to the creation of unanticipated health problems in new locales.","('Physical_Impacts_Of_Climate_Change', 0.9372890591621399)","('Critical_Incident_Risk_Management', 0.013212700374424458)","('Business_Model_Resilience', 0.007736739236861467)","([], 0.9372890591621399)","('NON-ESG', 0.013212700374424458)","('NON-ESG', 0.007736739236861467)"
Line 533,We align our approaches to the intent of the UN Paris Climate Accord and seek to instill learnings from the EPAs Greenhouse Gas Reporting program.,"('GHG_Emissions', 0.9651771187782288)","('Ecological_Impacts', 0.003906747791916132)","('Physical_Impacts_Of_Climate_Change', 0.003733332734555006)","(['Operational Eco-Efficiency'], 0.9651771187782288)","('NON-ESG', 0.003906747791916132)","('NON-ESG', 0.003733332734555006)"
Line 534,"We disclose our results at least annually using frameworks such as CDP (formerly known as the Carbon Disclosure Project), GRI, the UN SDGs and SASB.","('Management_Of_Legal_And_Regulatory_Framework', 0.8626899123191833)","('GHG_Emissions', 0.026466937735676765)","('Ecological_Impacts', 0.013812552206218243)","([], 0.8626899123191833)","('NON-ESG', 0.026466937735676765)","('NON-ESG', 0.013812552206218243)"
Line 535,Committing to short-term emissions reduction targets and roadmaps along with a long-term transition plan enables us to focus on immediate impacts while maintaining alignment to our overarching climate strategy.,"('Physical_Impacts_Of_Climate_Change', 0.45314550399780273)","('GHG_Emissions', 0.23405437171459198)","('Business_Model_Resilience', 0.12156922370195389)","('NON-ESG', 0.45314550399780273)","('NON-ESG', 0.23405437171459198)","('NON-ESG', 0.12156922370195389)"
Line 536,"In the last quarter of 2021, we initiated a comprehensive climate-related risk and opportunity assessment which will aid our efforts to develop emissions reduction targets in line with SBTis criteria.","('Physical_Impacts_Of_Climate_Change', 0.7546020150184631)","('GHG_Emissions', 0.10390395671129227)","('Business_Model_Resilience', 0.0320124626159668)","([], 0.7546020150184631)","('NON-ESG', 0.10390395671129227)","('NON-ESG', 0.0320124626159668)"
Line 537,"Our 2021 Scope 1, 2 and 3 data underwent external assurance and will be used to drive part of our enterprise risk management process, which directly informs our business enterprise risk assessment process.","('Systemic_Risk_Management', 0.8319693207740784)","('Business_Model_Resilience', 0.040004804730415344)","('Business_Ethics', 0.02370506338775158)","([], 0.8319693207740784)","('NON-ESG', 0.040004804730415344)","('NON-ESG', 0.02370506338775158)"
Line 538,"This process includes ongoing regulatory and legislative assessments, monthly regulatory tracking meetings and analysis, and reporting potential financial, legal and operational risks to senior management.","('Management_Of_Legal_And_Regulatory_Framework', 0.9708634614944458)","('GHG_Emissions', 0.00219501880928874)","('Ecological_Impacts', 0.0020808465778827667)","([], 0.9708634614944458)","('NON-ESG', 0.00219501880928874)","('NON-ESG', 0.0020808465778827667)"
Line 539,"In 2021, the BMS Executive Leadership Team and Board of Directors authorized our first large-scale renewable energy supply contract (closed in April 2022).","('Energy_Management', 0.813219428062439)","('Supply_Chain_Management', 0.07331923395395279)","('Management_Of_Legal_And_Regulatory_Framework', 0.015478378161787987)","(['Operational Eco-Efficiency'], 0.813219428062439)","('NON-ESG', 0.07331923395395279)","('NON-ESG', 0.015478378161787987)"
Line 540,"This is a first, and a key step toward our goal of 100% of purchased electricity from renewable sources by 2030.","('Energy_Management', 0.9735089540481567)","('Management_Of_Legal_And_Regulatory_Framework', 0.004152647219598293)","('GHG_Emissions', 0.0021073631942272186)","(['Operational Eco-Efficiency'], 0.9735089540481567)","('NON-ESG', 0.004152647219598293)","('NON-ESG', 0.0021073631942272186)"
Line 541,"In addition, more than $2.3 million in funding was approved to support site-based projects across the BMS enterprise to drive increase in energy efficiency and reduction of GHG emissions.","('GHG_Emissions', 0.9511395692825317)","('Energy_Management', 0.008671385236084461)","('Air_Quality', 0.005847948603332043)","(['Operational Eco-Efficiency'], 0.9511395692825317)","('NON-ESG', 0.008671385236084461)","('NON-ESG', 0.005847948603332043)"
Line 542,"In 2021, we completed the implementation of 27 capital projects.","('Management_Of_Legal_And_Regulatory_Framework', 0.49368444085121155)","('Business_Model_Resilience', 0.10239839553833008)","('Energy_Management', 0.07576113194227219)","('NON-ESG', 0.49368444085121155)","('NON-ESG', 0.10239839553833008)","('NON-ESG', 0.07576113194227219)"
Line 543,"Most notably, 12 HVAC projects have been implemented across the network for which we are anticipating a reduction of over 1,154.4 mtons CO 2e annually.","('Energy_Management', 0.9002187848091125)","('Water_And_Wastewater_Management', 0.010580077767372131)","('Air_Quality', 0.008814126253128052)","(['Operational Eco-Efficiency'], 0.9002187848091125)","('NON-ESG', 0.010580077767372131)","('NON-ESG', 0.008814126253128052)"
Line 544,"We have made a series of process improvements by optimizing pump staging, replacing a boiler, improving a transformer, replacing low-efficiency motors, etc.","('Energy_Management', 0.9485368728637695)","('Product_Design_And_Lifecycle_Management', 0.010519430041313171)","('Water_And_Wastewater_Management', 0.005142783280462027)","(['Operational Eco-Efficiency'], 0.9485368728637695)","('NON-ESG', 0.010519430041313171)","('NON-ESG', 0.005142783280462027)"
Line 545,"These efforts are voluntary, apply primarily to Scope 1 and 2 energy use and emissions, and are estimated to save approximately $520,000 annually, for which the related investment was approximately $1.5 million.","('Energy_Management', 0.9659650921821594)","('Management_Of_Legal_And_Regulatory_Framework', 0.005696821957826614)","('Air_Quality', 0.00395245710387826)","(['Operational Eco-Efficiency'], 0.9659650921821594)","('NON-ESG', 0.005696821957826614)","('NON-ESG', 0.00395245710387826)"
Line 546,2021 ESG REPORT | 40Measuring and addressing our emissions Building out our SBTs will provide a data-driven set of milestones through which we will advance our journey to net-neutral carbon.,"('GHG_Emissions', 0.7767824530601501)","('Energy_Management', 0.05802833288908005)","('Air_Quality', 0.05453624203801155)","(['Operational Eco-Efficiency'], 0.7767824530601501)","('NON-ESG', 0.05802833288908005)","('NON-ESG', 0.05453624203801155)"
Line 547,This work will be the cornerstone of our efforts to drive environmental responsibility across our internal and external supply chains.,"('Supply_Chain_Management', 0.9471642971038818)","('Labor_Practices', 0.005312430672347546)","('Product_Design_And_Lifecycle_Management', 0.004531448241323233)","([], 0.9471642971038818)","('NON-ESG', 0.005312430672347546)","('NON-ESG', 0.004531448241323233)"
Line 548,"We recognize the importance of managing Scope 3 emissions, as they represent our biggest GHG outputs.","('GHG_Emissions', 0.9699638485908508)","('Ecological_Impacts', 0.0037133165169507265)","('Air_Quality', 0.0029014090541750193)","(['Operational Eco-Efficiency'], 0.9699638485908508)","('NON-ESG', 0.0037133165169507265)","('NON-ESG', 0.0029014090541750193)"
Line 549,"Doing so presents opportunities to expand our overall positive impact, as our Scope 3 emissions can be a partnering companys Scope 1 or Scope 2 emissions.","('GHG_Emissions', 0.8689974546432495)","('Air_Quality', 0.06788643449544907)","('Management_Of_Legal_And_Regulatory_Framework', 0.007717411033809185)","(['Operational Eco-Efficiency'], 0.8689974546432495)","('NON-ESG', 0.06788643449544907)","('NON-ESG', 0.007717411033809185)"
Line 550,"We have expanded our current tracking and management of Scope 3 emissions beyond employee travel, enabling us to optimize our internal and external value chains and identify areas of previously unseen climate risk.","('Physical_Impacts_Of_Climate_Change', 0.9224976897239685)","('Business_Model_Resilience', 0.016517773270606995)","('GHG_Emissions', 0.012208771891891956)","([], 0.9224976897239685)","('NON-ESG', 0.016517773270606995)","('NON-ESG', 0.012208771891891956)"
Line 551,"In 2021, we followed the GHG Protocol to measure GHG emissions for the seven Scope 3 categories of greatest impact to our emissions profile.","('GHG_Emissions', 0.9688488245010376)","('Air_Quality', 0.003948069177567959)","('Ecological_Impacts', 0.0031951861456036568)","(['Operational Eco-Efficiency'], 0.9688488245010376)","('NON-ESG', 0.003948069177567959)","('NON-ESG', 0.0031951861456036568)"
Line 552,This work will help us identify the indirect emissions that occur in our upstream and downstream value chains.,"('GHG_Emissions', 0.8105323910713196)","('Energy_Management', 0.04573974385857582)","('Management_Of_Legal_And_Regulatory_Framework', 0.026560591533780098)","(['Operational Eco-Efficiency'], 0.8105323910713196)","('NON-ESG', 0.04573974385857582)","('NON-ESG', 0.026560591533780098)"
Line 553,"Our Scope 3 data, along with our Scope 1 and Scope 2 GHG emissions data, has been externally verified with limited assurance.","('GHG_Emissions', 0.9644785523414612)","('Air_Quality', 0.005792411509901285)","('Water_And_Wastewater_Management', 0.00306691019795835)","(['Operational Eco-Efficiency'], 0.9644785523414612)","('NON-ESG', 0.005792411509901285)","('NON-ESG', 0.00306691019795835)"
Line 554,Additional information on our GHG emissions calculation methodologies and assurance certificates can be found in the Appendix .,"('GHG_Emissions', 0.9636978507041931)","('Air_Quality', 0.0063431658782064915)","('Management_Of_Legal_And_Regulatory_Framework', 0.002921039704233408)","(['Operational Eco-Efficiency'], 0.9636978507041931)","('NON-ESG', 0.0063431658782064915)","('NON-ESG', 0.002921039704233408)"
Line 555,"In 2021, we measured GHG emissions for our Scope 1, Scope 2 and seven categories of Scope3 and had this data externally verified with limitedassurance.","('GHG_Emissions', 0.9681372046470642)","('Air_Quality', 0.004216644447296858)","('Ecological_Impacts', 0.0028632711619138718)","(['Operational Eco-Efficiency'], 0.9681372046470642)","('NON-ESG', 0.004216644447296858)","('NON-ESG', 0.0028632711619138718)"
Line 556,"2019-PRESENT, SUSTAINABILITY METRICS ENERGY/GHG 2019 (BASELINE) 2021 19-21 % Change Revenue (million USD) 26,145146,385 77% Employees 30,000132,200 7% ENERGY USE (million gigajoules, unless otherwise noted) Scope 1 Direct Energy 4.1 3.9 (7%) Scope 2 Indirect Energy 1.8 1.6 (9%) Total Energy Use Scope 1 & 2 5.925.4 (7%) GREENHOUSE GAS (GHG) EMISSIONS (metric tons of CO 2 equivalent, unless otherwise noted) Scope 1 Direct GHG from Operations 218,186 204,271 (6%) Scope 2 Indirect GHG from Operations (Market-Based) 118,574 166,250 40%3 Scope 3 Indirect GHG from Value Chain 1,889,555 Category 1 Purchased Goods & Services 1,641,931 Category 2 Capital Goods 18,050 Category 3 Fuel & Energy Related Activities 82,560 Category 4 Upstream Transportation & Distribution 76,969 Category 5 Waste Generated in Operations 4,442 Category 6 Business Travel 103,300 10,862 (89%) Category 7 Employee Commuting 54,740 Biogenic Carbon 782 711 (9%)4 Total GHG from Operations Scope 1 & 2 336,7592370,521 10%3 Total GHG Scope 1, 2 & 3 2,260,075 1 Includes Celgene results from November 20, 2019 through December 31, 2019.","('GHG_Emissions', 0.9670701026916504)","('Air_Quality', 0.004731961991637945)","('Ecological_Impacts', 0.0035930341109633446)","(['Operational Eco-Efficiency'], 0.9670701026916504)","('NON-ESG', 0.004731961991637945)","('NON-ESG', 0.0035930341109633446)"
Line 557,"2019-PRESENT, SUSTAINABILITY METRICS ENERGY/GHG 2019 (BASELINE) 2021 19-21 % Change Revenue (million USD) 26,145146,385 77% Employees 30,000132,200 7% ENERGY USE (million gigajoules, unless otherwise noted) Scope 1 Direct Energy 4.1 3.9 (7%) Scope 2 Indirect Energy 1.8 1.6 (9%) Total Energy Use Scope 1 & 2 5.925.4 (7%) GREENHOUSE GAS (GHG) EMISSIONS (metric tons of CO 2 equivalent, unless otherwise noted) Scope 1 Direct GHG from Operations 218,186 204,271 (6%) Scope 2 Indirect GHG from Operations (Market-Based) 118,574 166,250 40%3 Scope 3 Indirect GHG from Value Chain 1,889,555 Category 1 Purchased Goods & Services 1,641,931 Category 2 Capital Goods 18,050 Category 3 Fuel & Energy Related Activities 82,560 Category 4 Upstream Transportation & Distribution 76,969 Category 5 Waste Generated in Operations 4,442 Category 6 Business Travel 103,300 10,862 (89%) Category 7 Employee Commuting 54,740 Biogenic Carbon 782 711 (9%)4 Total GHG from Operations Scope 1 & 2 336,7592370,521 10%3 Total GHG Scope 1, 2 & 3 2,260,075 1 Includes Celgene results from November 20, 2019 through December 31, 2019.","('GHG_Emissions', 0.9629033803939819)","('Air_Quality', 0.006525655742734671)","('Ecological_Impacts', 0.004025165922939777)","(['Operational Eco-Efficiency'], 0.9629033803939819)","('NON-ESG', 0.006525655742734671)","('NON-ESG', 0.004025165922939777)"
Line 558,"2019-PRESENT, SUSTAINABILITY METRICS ENERGY/GHG 2019 (BASELINE) 2021 19-21 % Change Revenue (million USD) 26,145146,385 77% Employees 30,000132,200 7% ENERGY USE (million gigajoules, unless otherwise noted) Scope 1 Direct Energy 4.1 3.9 (7%) Scope 2 Indirect Energy 1.8 1.6 (9%) Total Energy Use Scope 1 & 2 5.925.4 (7%) GREENHOUSE GAS (GHG) EMISSIONS (metric tons of CO 2 equivalent, unless otherwise noted) Scope 1 Direct GHG from Operations 218,186 204,271 (6%) Scope 2 Indirect GHG from Operations (Market-Based) 118,574 166,250 40%3 Scope 3 Indirect GHG from Value Chain 1,889,555 Category 1 Purchased Goods & Services 1,641,931 Category 2 Capital Goods 18,050 Category 3 Fuel & Energy Related Activities 82,560 Category 4 Upstream Transportation & Distribution 76,969 Category 5 Waste Generated in Operations 4,442 Category 6 Business Travel 103,300 10,862 (89%) Category 7 Employee Commuting 54,740 Biogenic Carbon 782 711 (9%)4 Total GHG from Operations Scope 1 & 2 336,7592370,521 10%3 Total GHG Scope 1, 2 & 3 2,260,075 1 Includes Celgene results from November 20, 2019 through December 31, 2019.","('Competitive_Behavior', 0.3301967680454254)","('Management_Of_Legal_And_Regulatory_Framework', 0.08366560935974121)","('Systemic_Risk_Management', 0.07296305149793625)","('NON-ESG', 0.3301967680454254)","('NON-ESG', 0.08366560935974121)","('NON-ESG', 0.07296305149793625)"
Line 559,2 2019 baseline and subsequent data reset to account for 2019 integration of Celgene.,"('Data_Security', 0.27663689851760864)","('Systemic_Risk_Management', 0.14776726067066193)","('Business_Model_Resilience', 0.1341172456741333)","('NON-ESG', 0.27663689851760864)","('NON-ESG', 0.14776726067066193)","('NON-ESG', 0.1341172456741333)"
Line 560,2020 and 2021 operational data significantly impacted by the COVID-19 pandemic.,"('Physical_Impacts_Of_Climate_Change', 0.44864773750305176)","('Systemic_Risk_Management', 0.24428264796733856)","('Business_Model_Resilience', 0.05707363039255142)","('NON-ESG', 0.44864773750305176)","('NON-ESG', 0.24428264796733856)","('NON-ESG', 0.05707363039255142)"
Line 561,2021 Scope 3 waste data third-party verified.,"('Waste_And_Hazardous_Materials_Management', 0.980500340461731)","('Water_And_Wastewater_Management', 0.0021288206335157156)","('Air_Quality', 0.0018135978607460856)","([], 0.980500340461731)","('NON-ESG', 0.0021288206335157156)","('NON-ESG', 0.0018135978607460856)"
Line 562,3 Increase attributed to expiration of a renewable electricity supply contract.,"('Energy_Management', 0.604682981967926)","('Management_Of_Legal_And_Regulatory_Framework', 0.11779697984457016)","('Supply_Chain_Management', 0.10840706527233124)","(['Operational Eco-Efficiency'], 0.604682981967926)","('NON-ESG', 0.11779697984457016)","('NON-ESG', 0.10840706527233124)"
Line 563,"4 Direct CO 2 emissions from biologically sequestered carbon, reported separately from the scopes; per GHG Protocol Corporate Accounting and Reporting Standard.","('GHG_Emissions', 0.968758761882782)","('Air_Quality', 0.00357533129863441)","('Ecological_Impacts', 0.0031835748814046383)","(['Operational Eco-Efficiency'], 0.968758761882782)","('NON-ESG', 0.00357533129863441)","('NON-ESG', 0.0031835748814046383)"
Line 564,"2021 ESG REPORT | 41 Energy and EmissionsWaste and Recycling We continuously monitor and manage both hazardous and nonhazardous waste, while identifying ways to further reduce, recover, reuse and recycle operationalmaterials.","('Waste_And_Hazardous_Materials_Management', 0.9825044274330139)","('Product_Design_And_Lifecycle_Management', 0.0013788614887744188)","('Employee_Health_And_Safety', 0.001328838407061994)","([], 0.9825044274330139)","('NON-ESG', 0.0013788614887744188)","('NON-ESG', 0.001328838407061994)"
Line 565,One of our environmental responsibility commitments is to achieve zero waste to landfill by 2040.,"('Waste_And_Hazardous_Materials_Management', 0.9786871075630188)","('Air_Quality', 0.0023667621426284313)","('Water_And_Wastewater_Management', 0.002346463268622756)","([], 0.9786871075630188)","('NON-ESG', 0.0023667621426284313)","('NON-ESG', 0.002346463268622756)"
Line 566,Our pollution prevention and waste minimization programs continue to drive improved management of BMS various waste streams.,"('Waste_And_Hazardous_Materials_Management', 0.9839441776275635)","('Water_And_Wastewater_Management', 0.0015238533960655332)","('Air_Quality', 0.001284047495573759)","([], 0.9839441776275635)","('NON-ESG', 0.0015238533960655332)","('NON-ESG', 0.001284047495573759)"
Line 567,"The revised and improved programs incorporate how we purchase, use, recycle and dispose of materials from the very beginning of the product life cycle.","('Product_Design_And_Lifecycle_Management', 0.9664517641067505)","('Product_Quality_And_Safety', 0.0031096271704882383)","('Selling_Practices_And_Product_Labeling', 0.0028550622519105673)","([], 0.9664517641067505)","('NON-ESG', 0.0031096271704882383)","('NON-ESG', 0.0028550622519105673)"
Line 568,"Our initiatives so far have led us to increase waste-to-energy facilities and composting options, as well as recycling of single-use technology bio-bags and other forward-thinking material management technologies.","('Waste_And_Hazardous_Materials_Management', 0.9769684672355652)","('Product_Design_And_Lifecycle_Management', 0.002731579588726163)","('Water_And_Wastewater_Management', 0.002110047498717904)","([], 0.9769684672355652)","('NON-ESG', 0.002731579588726163)","('NON-ESG', 0.002110047498717904)"
Line 569,"Reducing e-waste For decades, BMS has diligently managed and tracked our waste, including e-waste from office and laboratory equipment.","('Waste_And_Hazardous_Materials_Management', 0.9847608804702759)","('Data_Security', 0.0012501705205067992)","('Water_And_Wastewater_Management', 0.0011902091791853309)","([], 0.9847608804702759)","('NON-ESG', 0.0012501705205067992)","('NON-ESG', 0.0011902091791853309)"
Line 570,"As part of these efforts, for more than 10 years we have partnered with the Hewlett Packard Enterprise Circular Economy program to retire obsolete office equipment.","('Energy_Management', 0.4034183621406555)","('Product_Design_And_Lifecycle_Management', 0.12975473701953888)","('Data_Security', 0.06478958576917648)","('NON-ESG', 0.4034183621406555)","('NON-ESG', 0.12975473701953888)","('NON-ESG', 0.06478958576917648)"
Line 571,"In 2021, 100% of our office computing equipment returned to the programmore than 40,000 itemsto either be refurbished or recycled.","('Product_Design_And_Lifecycle_Management', 0.41745126247406006)","('Energy_Management', 0.3299427628517151)","('Waste_And_Hazardous_Materials_Management', 0.034540146589279175)","('NON-ESG', 0.41745126247406006)","('NON-ESG', 0.3299427628517151)","('NON-ESG', 0.034540146589279175)"
Line 572,The resulting savings of CO 2e emissions is equal to taking about 357 cars off the road for one year.,"('GHG_Emissions', 0.5582382678985596)","('Air_Quality', 0.24181948602199554)","('Energy_Management', 0.0902348980307579)","(['Operational Eco-Efficiency'], 0.5582382678985596)","('NON-ESG', 0.24181948602199554)","('NON-ESG', 0.0902348980307579)"
Line 573,"The BMS Asset Disposition program, which removes all equipment that is no longer needed in our labs and manufacturing areas, plays an active role in ensuring that used equipment stays out of the landfill as much as possible.","('Waste_And_Hazardous_Materials_Management', 0.48991912603378296)","('Energy_Management', 0.10387787222862244)","('Product_Design_And_Lifecycle_Management', 0.09445072710514069)","('NON-ESG', 0.48991912603378296)","('NON-ESG', 0.10387787222862244)","('NON-ESG', 0.09445072710514069)"
Line 574,"In 2021, we prevented approximately 95% of lab and manufacturing equipment from going into waste.","('Waste_And_Hazardous_Materials_Management', 0.9839488863945007)","('Water_And_Wastewater_Management', 0.0015112465480342507)","('Air_Quality', 0.0012203947408124804)","([], 0.9839488863945007)","('NON-ESG', 0.0015112465480342507)","('NON-ESG', 0.0012203947408124804)"
Line 575,"In 2021, our efforts resulted in: 10.9% reduced overall waste generated 2019-PRESENT, SUSTAINABILITY METRICS WASTE 2019 (baseline) 2021 19-21 % Change Revenue (million USD) 26,145146,385 77% Employees 30,000132,200 7% WASTE (kilograms) Hazardous 703,470 1,853,472 163.48% Nonhazardous 4,352,469 4,335,172 (0.40%) Recycled/Reused 8,112,919 5,545,413 (31.65%) Total Waste Generated 13,168,858211,734,057 (10.90%)3 1 Includes Celgene results from November 20, 2019 through December 31, 2019.","('Waste_And_Hazardous_Materials_Management', 0.9839473962783813)","('Water_And_Wastewater_Management', 0.0014746371889486909)","('Data_Security', 0.0012361883418634534)","([], 0.9839473962783813)","('NON-ESG', 0.0014746371889486909)","('NON-ESG', 0.0012361883418634534)"
Line 576,2 2019 baseline and subsequent data reset to account for 2019 integration of Celgene.,"('Data_Security', 0.27663689851760864)","('Systemic_Risk_Management', 0.14776726067066193)","('Business_Model_Resilience', 0.1341172456741333)","('NON-ESG', 0.27663689851760864)","('NON-ESG', 0.14776726067066193)","('NON-ESG', 0.1341172456741333)"
Line 577,3 2020 and 2021 operational data significantly impacted by the COVID-19 pandemic.,"('Physical_Impacts_Of_Climate_Change', 0.354971319437027)","('Systemic_Risk_Management', 0.2690420150756836)","('Business_Model_Resilience', 0.07177158445119858)","('NON-ESG', 0.354971319437027)","('NON-ESG', 0.2690420150756836)","('NON-ESG', 0.07177158445119858)"
Line 578,2021 Scope 3 waste data third-party verified.,"('Waste_And_Hazardous_Materials_Management', 0.980500340461731)","('Water_And_Wastewater_Management', 0.0021288206335157156)","('Air_Quality', 0.0018135978607460856)","([], 0.980500340461731)","('NON-ESG', 0.0021288206335157156)","('NON-ESG', 0.0018135978607460856)"
Line 579,2021 ESG REPORT | 42Water and Wastewater Water is a precious resource that is necessary to produce effective and safe medicines for our patients.,"('Water_And_Wastewater_Management', 0.975459098815918)","('Waste_And_Hazardous_Materials_Management', 0.00265944330021739)","('GHG_Emissions', 0.002054890152066946)","([], 0.975459098815918)","('NON-ESG', 0.00265944330021739)","('NON-ESG', 0.002054890152066946)"
Line 580,"To this end, we look for ways to reduce our water consumption and find better mechanisms of watertreatment.","('Water_And_Wastewater_Management', 0.9755402207374573)","('Energy_Management', 0.0028217907529324293)","('GHG_Emissions', 0.0022553056478500366)","([], 0.9755402207374573)","('NON-ESG', 0.0028217907529324293)","('NON-ESG', 0.0022553056478500366)"
Line 581,"Water conservation In 2021, BMS mobilized its sites to continue driving water efficiency to help achieve its water reduction goals.","('Water_And_Wastewater_Management', 0.9768542647361755)","('GHG_Emissions', 0.0026149777695536613)","('Ecological_Impacts', 0.0023155182134360075)","([], 0.9768542647361755)","('NON-ESG', 0.0026149777695536613)","('NON-ESG', 0.0023155182134360075)"
Line 582,"We focused on optimizing operational efficiency, deploying more efficient sequences of operation and implementing key capital upgrades.","('Energy_Management', 0.829389750957489)","('Product_Design_And_Lifecycle_Management', 0.02652161940932274)","('Management_Of_Legal_And_Regulatory_Framework', 0.016983550041913986)","(['Operational Eco-Efficiency'], 0.829389750957489)","('NON-ESG', 0.02652161940932274)","('NON-ESG', 0.016983550041913986)"
Line 583,"Despite the impacts of COVID-19, in 2021, we continued to find ways to drive efficiency through internally run virtual treasure hunt eventsefforts that led us to implement 24 energy and water reduction measures across the portfolio.","('Energy_Management', 0.9693053364753723)","('Water_And_Wastewater_Management', 0.005676796659827232)","('Air_Quality', 0.00275497417896986)","(['Operational Eco-Efficiency'], 0.9693053364753723)","('NON-ESG', 0.005676796659827232)","('NON-ESG', 0.00275497417896986)"
Line 584,This included six key water-use optimization projects at five critical sites.,"('Water_And_Wastewater_Management', 0.9683544039726257)","('GHG_Emissions', 0.00491977296769619)","('Energy_Management', 0.004619859158992767)","([], 0.9683544039726257)","('NON-ESG', 0.00491977296769619)","('NON-ESG', 0.004619859158992767)"
Line 585,"Wastewater treatment To safeguard water, we follow stringent corporate standards and guidelines that meet or exceed local requirements regarding the treatment and management of wastewater effluents.","('Water_And_Wastewater_Management', 0.9707284569740295)","('Waste_And_Hazardous_Materials_Management', 0.003232743125408888)","('Energy_Management', 0.003222525352612138)","([], 0.9707284569740295)","('NON-ESG', 0.003232743125408888)","('NON-ESG', 0.003222525352612138)"
Line 586,We design clean and efficient pharmaceutical manufacturing processes that do not have an adverse impact on the environment.,"('Product_Design_And_Lifecycle_Management', 0.4289794862270355)","('Energy_Management', 0.30230239033699036)","('Supply_Chain_Management', 0.05758684128522873)","('NON-ESG', 0.4289794862270355)","('NON-ESG', 0.30230239033699036)","('NON-ESG', 0.05758684128522873)"
Line 587,"Additionally, the wastewater from Bristol Myers Squibbs manufacturing facilities undergoes a high degree of treatment before being discharged to the environment.","('Water_And_Wastewater_Management', 0.9539939165115356)","('Waste_And_Hazardous_Materials_Management', 0.014085326343774796)","('GHG_Emissions', 0.0037924516946077347)","([], 0.9539939165115356)","('NON-ESG', 0.014085326343774796)","('NON-ESG', 0.0037924516946077347)"
Line 588,"This treatment is provided by company-owned and operated on-site infrastructure or off-site municipal wastewater treatment systems, or a combination of both.","('Water_And_Wastewater_Management', 0.9681466221809387)","('Waste_And_Hazardous_Materials_Management', 0.00448348093777895)","('Energy_Management', 0.003329332685098052)","([], 0.9681466221809387)","('NON-ESG', 0.00448348093777895)","('NON-ESG', 0.003329332685098052)"
Line 589,"Pharmaceuticals in the Environment(PiE) Pharmaceuticals have been found in the environment for decades, and with advancements in environmental detection techniques/ sensitivity and an increased frequency of monitoring campaigns, the number of pharmaceuticals identified has increased.","('Selling_Practices_And_Product_Labeling', 0.5160697102546692)","('Customer_Welfare', 0.19697728753089905)","('Product_Quality_And_Safety', 0.06850366294384003)","(['Business Ethics'], 0.5160697102546692)","('NON-ESG', 0.19697728753089905)","('NON-ESG', 0.06850366294384003)"
Line 590,"While the primary source of pharmaceuticals reaching the environment is through human use and subsequent excretion into wastewater systems, the improper disposal of unused medicines and manufacturing effluent discharge can also serve as secondarysources.","('Water_And_Wastewater_Management', 0.9510338306427002)","('Waste_And_Hazardous_Materials_Management', 0.012990440241992474)","('GHG_Emissions', 0.0037276381626725197)","([], 0.9510338306427002)","('NON-ESG', 0.012990440241992474)","('NON-ESG', 0.0037276381626725197)"
Line 591,"To help address this issue, BMS is involved with the Innovative Medicines Initiative (IMI) in Europe, a public-private research partnership between the European Union and the European pharmaceutical industry.","('Access_And_Affordability', 0.1855444312095642)","('Customer_Welfare', 0.14346209168434143)","('Selling_Practices_And_Product_Labeling', 0.09393062442541122)","('NON-ESG', 0.1855444312095642)","('NON-ESG', 0.14346209168434143)","('NON-ESG', 0.09393062442541122)"
Line 592,"BMS is currently participating in the Prioritization and Risk Evaluation of Medicines in the EnviRonment(PREMIER) initiative, which seeks to foster greener pharmaceutical design processes in addition to improving the availability of environmental data for all stakeholders.","('Access_And_Affordability', 0.46031397581100464)","('Customer_Welfare', 0.0684015303850174)","('Management_Of_Legal_And_Regulatory_Framework', 0.0574675016105175)","('NON-ESG', 0.46031397581100464)","('NON-ESG', 0.0684015303850174)","('NON-ESG', 0.0574675016105175)"
Line 593,"At BMS, we strive to ensure that operations at our facilities are both environmentally responsible and protective of personal and public health and safety, starting by designing clean and efficient manufacturing processes, and routinely assessing existing facility operations.","('Employee_Health_And_Safety', 0.9750708937644958)","('Product_Design_And_Lifecycle_Management', 0.003117102198302746)","('Product_Quality_And_Safety', 0.002904436318203807)","(['Health Outcome Contribution'], 0.9750708937644958)","('NON-ESG', 0.003117102198302746)","('NON-ESG', 0.002904436318203807)"
Line 594,"We establish safe discharge concentrations for our internal/external manufacturing processes that assess potential environmental impacts, and identify ways to minimize any potential environmental or human health impacts from discharge.","('Employee_Health_And_Safety', 0.5666218996047974)","('Water_And_Wastewater_Management', 0.10585656017065048)","('Waste_And_Hazardous_Materials_Management', 0.09379381686449051)","(['Health Outcome Contribution'], 0.5666218996047974)","('NON-ESG', 0.10585656017065048)","('NON-ESG', 0.09379381686449051)"
Line 595,"BMS works with numerous suppliers and third-party manufacturers who share our commitment to responsible practices, including compliance with all applicable legal and regulatory requirements, as well as our Standards of Business Conduct and Ethics for Third Parties (3PStandards).","('Business_Ethics', 0.7214650511741638)","('Management_Of_Legal_And_Regulatory_Framework', 0.17582450807094574)","('Product_Quality_And_Safety', 0.01551620289683342)","(['Business Ethics'], 0.7214650511741638)","('NON-ESG', 0.17582450807094574)","('NON-ESG', 0.01551620289683342)"
Line 596,"Environmental fate/effects studies and Environmental Risk Assessments (ERAs) are conducted for all new medicines when applying for approval, in accordance with local regulations.","('Management_Of_Legal_And_Regulatory_Framework', 0.21127350628376007)","('Selling_Practices_And_Product_Labeling', 0.1910405158996582)","('Access_And_Affordability', 0.1292750984430313)","('NON-ESG', 0.21127350628376007)","('NON-ESG', 0.1910405158996582)","('NON-ESG', 0.1292750984430313)"
Line 597,"We are committed to transparency in reporting the environmental data we collect, and have made information related to APIs available to the public through various partnership initiatives (e.g., iPiE*SUM, FASS database) and on our product Safety Data Sheets .","('Product_Quality_And_Safety', 0.8181052803993225)","('Selling_Practices_And_Product_Labeling', 0.037475310266017914)","('Customer_Privacy', 0.02548266388475895)","(['Product Quality & Recall Management'], 0.8181052803993225)","('NON-ESG', 0.037475310266017914)","('NON-ESG', 0.02548266388475895)"
Line 598,"Additionally, shifts in our portfolio to certain biologics (e.g., monoclonal antibodies) have produced new medicines that more readily biodegrade in the environment, further reducing impacts related to PiE.","('Customer_Welfare', 0.4708501696586609)","('Selling_Practices_And_Product_Labeling', 0.1656508892774582)","('Product_Design_And_Lifecycle_Management', 0.04994271323084831)","('NON-ESG', 0.4708501696586609)","('NON-ESG', 0.1656508892774582)","('NON-ESG', 0.04994271323084831)"
Line 599,BMS is committed to continuous improvement in this space.,"('Access_And_Affordability', 0.30789169669151306)","('Management_Of_Legal_And_Regulatory_Framework', 0.16114354133605957)","('Human_Rights_And_Community_Relations', 0.08642210066318512)","('NON-ESG', 0.30789169669151306)","('NON-ESG', 0.16114354133605957)","('NON-ESG', 0.08642210066318512)"
Line 600,"In 2022, BMS plans to commence its ecopharmacovigilance program to monitor our products post-launch for environmental risks by tracking the scientific literature for emerging data on exposure and effects.2019-PRESENT, SUSTAINABILITY METRICS WATER 2019 (baseline)202119-21 % Change Revenue (million USD) 26,145146,385 77% Employees 30,000132,200 7% WATER USE (million liters) Total WaterUse Municipal, Groundwater, Surface3,054.0113,168.25 4%2 1 Includes Celgene results from November 20, 2019 through December 31, 2019.","('Water_And_Wastewater_Management', 0.975439727306366)","('GHG_Emissions', 0.0023884454276412725)","('Waste_And_Hazardous_Materials_Management', 0.002071503782644868)","([], 0.975439727306366)","('NON-ESG', 0.0023884454276412725)","('NON-ESG', 0.002071503782644868)"
Line 601,"In 2022, BMS plans to commence its ecopharmacovigilance program to monitor our products post-launch for environmental risks by tracking the scientific literature for emerging data on exposure and effects.2019-PRESENT, SUSTAINABILITY METRICS WATER 2019 (baseline)202119-21 % Change Revenue (million USD) 26,145146,385 77% Employees 30,000132,200 7% WATER USE (million liters) Total WaterUse Municipal, Groundwater, Surface3,054.0113,168.25 4%2 1 Includes Celgene results from November 20, 2019 through December 31, 2019.","('Management_Of_Legal_And_Regulatory_Framework', 0.12465449422597885)","('Competitive_Behavior', 0.12235627323389053)","('Ecological_Impacts', 0.08450976014137268)","('NON-ESG', 0.12465449422597885)","('NON-ESG', 0.12235627323389053)","('NON-ESG', 0.08450976014137268)"
Line 602,"2 Due to multiple BMS site expansion projects, increased qualification work across our global operations, and the growing BMS CAR-T product line, the company saw a water use increase of 4% during this period.","('Water_And_Wastewater_Management', 0.9566339254379272)","('Energy_Management', 0.005740257445722818)","('Waste_And_Hazardous_Materials_Management', 0.005576266907155514)","([], 0.9566339254379272)","('NON-ESG', 0.005740257445722818)","('NON-ESG', 0.005576266907155514)"
Line 603,"2021 ESG REPORT | 43Green and Sustainable Science At the heart of our work to develop innovative, cutting -edge medicines is our expertise and commitment to green and sustainable science.","('Product_Design_And_Lifecycle_Management', 0.6926644444465637)","('Supply_Chain_Management', 0.050721894949674606)","('Business_Model_Resilience', 0.03574135899543762)","([], 0.6926644444465637)","('NON-ESG', 0.050721894949674606)","('NON-ESG', 0.03574135899543762)"
Line 604,"Aswe continue our journey to integrate green and sustainability principles into our product life cycle, we use predictive analytics to inform our design and development process and drive continuous innovationsand improvements.","('Product_Design_And_Lifecycle_Management', 0.9636927247047424)","('Product_Quality_And_Safety', 0.004206241108477116)","('Business_Model_Resilience', 0.003958307206630707)","([], 0.9636927247047424)","('NON-ESG', 0.004206241108477116)","('NON-ESG', 0.003958307206630707)"
Line 605,"Taking a data-driven approach, we rigorously track and communicate key metrics and their impact.","('Systemic_Risk_Management', 0.40918198227882385)","('Business_Model_Resilience', 0.11601664870977402)","('Management_Of_Legal_And_Regulatory_Framework', 0.09228397160768509)","('NON-ESG', 0.40918198227882385)","('NON-ESG', 0.11601664870977402)","('NON-ESG', 0.09228397160768509)"
Line 606,"This Green by Design approach offers a strategic pathway to building a sustainable future, as shown by broad overall YOY waste reductions achieved across BMS small molecule portfolio from 2020 to 2021.1 Eliminating waste with green chemistry Innovation and collaboration are at the core of our mission to create safe, economical and sustainable processes to supply high-quality active ingredients for the medicines we deliver to patients.","('Waste_And_Hazardous_Materials_Management', 0.9694979190826416)","('Product_Design_And_Lifecycle_Management', 0.0034560980275273323)","('Water_And_Wastewater_Management', 0.002988177817314863)","([], 0.9694979190826416)","('NON-ESG', 0.0034560980275273323)","('NON-ESG', 0.002988177817314863)"
Line 607,"We partner with external companies and academic institutions to invent and develop new capabilities, which both accelerate our development of new solutions and improve our sustainability footprint.","('Business_Model_Resilience', 0.2294943779706955)","('Product_Design_And_Lifecycle_Management', 0.18686501681804657)","('Management_Of_Legal_And_Regulatory_Framework', 0.10023804008960724)","('NON-ESG', 0.2294943779706955)","('NON-ESG', 0.18686501681804657)","('NON-ESG', 0.10023804008960724)"
Line 608,"Most notably, we recently teamed up with the Scripps Research Institute to introduce disruptive innovation in the field of stereoselective thiophosphate synthesis.","('Customer_Welfare', 0.32769516110420227)","('Competitive_Behavior', 0.1434330940246582)","('GHG_Emissions', 0.09483695775270462)","('NON-ESG', 0.32769516110420227)","('NON-ESG', 0.1434330940246582)","('NON-ESG', 0.09483695775270462)"
Line 609,Our partnership led to remarkable sustainability improvements on the STING-Interferon program.,"('Management_Of_Legal_And_Regulatory_Framework', 0.22855044901371002)","('Business_Model_Resilience', 0.19496986269950867)","('Product_Design_And_Lifecycle_Management', 0.077701635658741)","('NON-ESG', 0.22855044901371002)","('NON-ESG', 0.19496986269950867)","('NON-ESG', 0.077701635658741)"
Line 610,It also has broad implications for oligonucleotide drug discovery and was recognized by the 2021 EPA Green Chemistry Challenge Award.,"('Customer_Welfare', 0.20708055794239044)","('GHG_Emissions', 0.1373216062784195)","('Competitive_Behavior', 0.09848091751337051)","('NON-ESG', 0.20708055794239044)","('NON-ESG', 0.1373216062784195)","('NON-ESG', 0.09848091751337051)"
Line 611,"Through our ""Green by Design"" approach we have achieved broad reductions in waste across the small molecule portfolio, including a 49% average cPMI reduction across 9 projects in 2020 and 2021, eliminating >900 MT waste Eliminating waste with green chemistry BMS-986301O MeRSS SOP OO OO O O OOO N NN NNN NH2N NHSH SHP P Limonene oxide Inexpensive SustainableDISRUPTIVE INNOVATION 90% in waste 73% $/kg API 1 Learn more about the 2021 EPA Green Chemistry Challenge Award in our Annual Report and from the U.","('Waste_And_Hazardous_Materials_Management', 0.9832159876823425)","('Water_And_Wastewater_Management', 0.0015200530178844929)","('Data_Security', 0.001310420804657042)","([], 0.9832159876823425)","('NON-ESG', 0.0015200530178844929)","('NON-ESG', 0.001310420804657042)"
Line 612,S. EPA .,"('GHG_Emissions', 0.22405412793159485)","('Ecological_Impacts', 0.1629989594221115)","('Management_Of_Legal_And_Regulatory_Framework', 0.13480377197265625)","('NON-ESG', 0.22405412793159485)","('NON-ESG', 0.1629989594221115)","('NON-ESG', 0.13480377197265625)"
Line 613,2021 ESG REPORT | 44Packaging and Transportation Our commitment to sustainability does not end when our life-saving medicines have been developed and manufactured it continues throughout the distribution process to destinations around the world.,"('Access_And_Affordability', 0.3751871883869171)","('Product_Design_And_Lifecycle_Management', 0.19304980337619781)","('Customer_Welfare', 0.09361669421195984)","('NON-ESG', 0.3751871883869171)","('NON-ESG', 0.19304980337619781)","('NON-ESG', 0.09361669421195984)"
Line 614,"BMS Distribution and Logistics teams, which are responsible for storing and distributing the companys products, continually seek opportunities to reduce waste, conserve energy and reduce carbonemissions.","('Waste_And_Hazardous_Materials_Management', 0.8863798975944519)","('Product_Design_And_Lifecycle_Management', 0.04803428053855896)","('Supply_Chain_Management', 0.00624268501996994)","([], 0.8863798975944519)","('NON-ESG', 0.04803428053855896)","('NON-ESG', 0.00624268501996994)"
Line 615,BMS has fully outsourced our logistics operation and uses service providers for warehousing and transportation.,"('Product_Design_And_Lifecycle_Management', 0.2702829837799072)","('Supply_Chain_Management', 0.25583186745643616)","('Energy_Management', 0.1651890128850937)","('NON-ESG', 0.2702829837799072)","('NON-ESG', 0.25583186745643616)","('NON-ESG', 0.1651890128850937)"
Line 616,"As sustainability is embedded into our approach to supplier management, we actively review scoring of environmental responsibility criteria during the vendor selection process.","('Supply_Chain_Management', 0.9147241115570068)","('Product_Design_And_Lifecycle_Management', 0.0212482251226902)","('Business_Model_Resilience', 0.007922938093543053)","([], 0.9147241115570068)","('NON-ESG', 0.0212482251226902)","('NON-ESG', 0.007922938093543053)"
Line 617,"Once selected, we work proactively with our partners to incorporate actions that improve the environmental footprint for transportation of our products.","('Product_Design_And_Lifecycle_Management', 0.9666944146156311)","('Product_Quality_And_Safety', 0.004192540422081947)","('Selling_Practices_And_Product_Labeling', 0.0030892561189830303)","([], 0.9666944146156311)","('NON-ESG', 0.004192540422081947)","('NON-ESG', 0.0030892561189830303)"
Line 618,"Whether ground, air or ocean, the mode of transport of our products plays a meaningful role in developing our transportation plans.","('Product_Design_And_Lifecycle_Management', 0.961226224899292)","('Energy_Management', 0.005679480265825987)","('Selling_Practices_And_Product_Labeling', 0.0027775061316788197)","([], 0.961226224899292)","('NON-ESG', 0.005679480265825987)","('NON-ESG', 0.0027775061316788197)"
Line 619,"Wherever it is feasible and makes sense, we move from air to ocean transport, which significantly cuts carbon emissions, and utilize vendors who provide more efficient ground transportation.","('Air_Quality', 0.9757959246635437)","('GHG_Emissions', 0.0031520756892859936)","('Energy_Management', 0.002165410900488496)","([], 0.9757959246635437)","('NON-ESG', 0.0031520756892859936)","('NON-ESG', 0.002165410900488496)"
Line 620,"Some are even beginning to offer electric fleet vehicles, like in Brazil where we have reduced by 93kg the CO 2 emissions during the first month ofimplementation.","('Air_Quality', 0.4890625476837158)","('GHG_Emissions', 0.2573392689228058)","('Energy_Management', 0.13872675597667694)","('NON-ESG', 0.4890625476837158)","('NON-ESG', 0.2573392689228058)","('NON-ESG', 0.13872675597667694)"
Line 621,All of our products are shipped in temperature-controlled containers.,"('Product_Design_And_Lifecycle_Management', 0.6668049693107605)","('Waste_And_Hazardous_Materials_Management', 0.08386398106813431)","('Selling_Practices_And_Product_Labeling', 0.04285435006022453)","([], 0.6668049693107605)","('NON-ESG', 0.08386398106813431)","('NON-ESG', 0.04285435006022453)"
Line 622,Our biology-based therapies require cold-chain transport and must remain at a constant temperature (2-8 degrees C) from the time they leave the manufacturing facility to when they reach the patient.,"('Energy_Management', 0.5098485946655273)","('Water_And_Wastewater_Management', 0.08403429388999939)","('Supply_Chain_Management', 0.05660215765237808)","(['Operational Eco-Efficiency'], 0.5098485946655273)","('NON-ESG', 0.08403429388999939)","('NON-ESG', 0.05660215765237808)"
Line 623,Thats why we ship these almost exclusively in battery-operated refrigerated pallet-sized containers that are completely reusable.,"('Product_Design_And_Lifecycle_Management', 0.7457382678985596)","('Energy_Management', 0.06316790729761124)","('Waste_And_Hazardous_Materials_Management', 0.06165115907788277)","([], 0.7457382678985596)","('NON-ESG', 0.06316790729761124)","('NON-ESG', 0.06165115907788277)"
Line 624,"When we have smaller, parcel-sized shipments, we use passive refrigeration in insulated shipper boxes with gel-pack inserts.","('Energy_Management', 0.7234223484992981)","('Product_Design_And_Lifecycle_Management', 0.1110045462846756)","('Waste_And_Hazardous_Materials_Management', 0.02144896611571312)","(['Operational Eco-Efficiency'], 0.7234223484992981)","('NON-ESG', 0.1110045462846756)","('NON-ESG', 0.02144896611571312)"
Line 625,"Currently, we use reusable parcel containers in Puerto Rico, Mexico and Canada and plan to expand their use in other markets where possible in coming months.","('Product_Design_And_Lifecycle_Management', 0.7932102680206299)","('Waste_And_Hazardous_Materials_Management', 0.05786626413464546)","('Energy_Management', 0.0393819622695446)","([], 0.7932102680206299)","('NON-ESG', 0.05786626413464546)","('NON-ESG', 0.0393819622695446)"
Line 626,"Ultimately, bolstering our supply chains reliability, agility and sustainability is a priority for us, and we will continue to work with vendors who share our commitment to continuing to reduce our transportation-related environmental impacts.","('Supply_Chain_Management', 0.9513051509857178)","('Product_Design_And_Lifecycle_Management', 0.0058079673908650875)","('Physical_Impacts_Of_Climate_Change', 0.0037595112808048725)","([], 0.9513051509857178)","('NON-ESG', 0.0058079673908650875)","('NON-ESG', 0.0037595112808048725)"
Line 627,"In 2022, we expect to continue our commitment to sustainability with further reductions in carbon dioxide emissions, such as with the transition from RKN active shipping containers to thermal blankets, potentially saving up to 25kg of CO 2e per insulated pallet, as well as landfill waste reductions.2021 Highlights Reduced CO 2 emissions by 33% with the implementation of new shipping containers in two key shipping lanes 100% reduction in Sulphur Oxide, 91% reduction in Nitrogen Oxide, and 29% reduction in Carbon Dioxide through the conversion of barges to ocean vessels powered by Liquified Natural Gas (LNG) between the U.","('Waste_And_Hazardous_Materials_Management', 0.7098628878593445)","('Air_Quality', 0.07702095806598663)","('GHG_Emissions', 0.055568624287843704)","([], 0.7098628878593445)","('NON-ESG', 0.07702095806598663)","('NON-ESG', 0.055568624287843704)"
Line 628,"In 2022, we expect to continue our commitment to sustainability with further reductions in carbon dioxide emissions, such as with the transition from RKN active shipping containers to thermal blankets, potentially saving up to 25kg of CO 2e per insulated pallet, as well as landfill waste reductions.2021 Highlights Reduced CO 2 emissions by 33% with the implementation of new shipping containers in two key shipping lanes 100% reduction in Sulphur Oxide, 91% reduction in Nitrogen Oxide, and 29% reduction in Carbon Dioxide through the conversion of barges to ocean vessels powered by Liquified Natural Gas (LNG) between the U.","('GHG_Emissions', 0.9326125383377075)","('Water_And_Wastewater_Management', 0.012767576612532139)","('Energy_Management', 0.00874932762235403)","(['Operational Eco-Efficiency'], 0.9326125383377075)","('NON-ESG', 0.012767576612532139)","('NON-ESG', 0.00874932762235403)"
Line 629,"S. & Puerto Rico Reduced CO 2 emissions by ~70% converting from air to ocean mode for vendor shipments to Puerto Rico 3 Ton carbon emissions reduction in Argentina due to alignment of product order size and shipping container capacity 2021 ESG REPORT | 45Responsible sourcing In support of our efforts to address Scope 3 emissions, our Strategic Sourcing and Procurement organization is committed to driving reductions in negative environmental impacts across our external value chain.","('Air_Quality', 0.8521868586540222)","('GHG_Emissions', 0.04307522624731064)","('Energy_Management', 0.03492562845349312)","([], 0.8521868586540222)","('NON-ESG', 0.04307522624731064)","('NON-ESG', 0.03492562845349312)"
Line 630,"This commitment is being led through our sustainable procurement strategy, in which sustainability is embedded as a value driver in supplier partnership and innovation.","('Supply_Chain_Management', 0.8417285084724426)","('Product_Design_And_Lifecycle_Management', 0.06688113510608673)","('Business_Model_Resilience', 0.009528032504022121)","([], 0.8417285084724426)","('NON-ESG', 0.06688113510608673)","('NON-ESG', 0.009528032504022121)"
Line 631,One component of this strategy that we are developing is our Responsible Sourcing program.,"('Supply_Chain_Management', 0.3268716633319855)","('Product_Design_And_Lifecycle_Management', 0.1890961080789566)","('Business_Model_Resilience', 0.10642635077238083)","('NON-ESG', 0.3268716633319855)","('NON-ESG', 0.1890961080789566)","('NON-ESG', 0.10642635077238083)"
Line 632,"Through the program, we plan to work with supply chain partners to assess their current state of environmental responsibility, set goals and targets to drive progress toward continuous sustainable improvement, and mitigate risks across our supply chain while contributing to our global commitments to environmental responsibility.","('Supply_Chain_Management', 0.9530565142631531)","('Product_Design_And_Lifecycle_Management', 0.0043800268322229385)","('Labor_Practices', 0.003604757133871317)","([], 0.9530565142631531)","('NON-ESG', 0.0043800268322229385)","('NON-ESG', 0.003604757133871317)"
Line 633,"The Responsible Sourcing program is key to realizing BMS sustainability procurement strategy, which includes: Monitoring the supply chain sustainability risks and performance Addressing sustainability as a core area of performance in the SS&P/supplier partnership Implementing a core set of requirements to move suppliers through a journey of continuous improvement Increasing supplier due diligence to ensure that our suppliers are aligned with BMS in their values and ESG commitments Aligning to directly support BMS Third-Party Risk Management program, which identifies and reduces risks relating to the use of third parties BMS partners with EcoVadis to support the realization of the Responsible Sourcing program, which endeavors to realize the following benefits, outcomes and goals: Benefits Active engagement with suppliers to support their efforts to improve legal and regulatory compliance, brand reputation and stakeholder relations Support of our suppliers on their sustainability journey Building relationships with suppliers that have made ESG within their own operations a priorityExpected outcomes Increased awareness of supplier sustainability profiles Development of robust ESG capabilities and ways of working Increased transparency anddisclosure Drive performance improvementsProgram goals Embed ESG principles into and across BMS global sourcing and procurement strategy Implement requirements to level-set supplier performance and ensure strategic, values-based partnership 2021 ESG REPORT | 46 Packaging and TransportationSustainable Facility Design Managing our global facilities responsibly enables us to further reduce our environmental impact and ensure our buildings are inclusive for all.","('Supply_Chain_Management', 0.9532715082168579)","('Labor_Practices', 0.003942464012652636)","('Product_Design_And_Lifecycle_Management', 0.003805262502282858)","([], 0.9532715082168579)","('NON-ESG', 0.003942464012652636)","('NON-ESG', 0.003805262502282858)"
Line 634,"The Responsible Sourcing program is key to realizing BMS sustainability procurement strategy, which includes: Monitoring the supply chain sustainability risks and performance Addressing sustainability as a core area of performance in the SS&P/supplier partnership Implementing a core set of requirements to move suppliers through a journey of continuous improvement Increasing supplier due diligence to ensure that our suppliers are aligned with BMS in their values and ESG commitments Aligning to directly support BMS Third-Party Risk Management program, which identifies and reduces risks relating to the use of third parties BMS partners with EcoVadis to support the realization of the Responsible Sourcing program, which endeavors to realize the following benefits, outcomes and goals: Benefits Active engagement with suppliers to support their efforts to improve legal and regulatory compliance, brand reputation and stakeholder relations Support of our suppliers on their sustainability journey Building relationships with suppliers that have made ESG within their own operations a priorityExpected outcomes Increased awareness of supplier sustainability profiles Development of robust ESG capabilities and ways of working Increased transparency anddisclosure Drive performance improvementsProgram goals Embed ESG principles into and across BMS global sourcing and procurement strategy Implement requirements to level-set supplier performance and ensure strategic, values-based partnership 2021 ESG REPORT | 46 Packaging and TransportationSustainable Facility Design Managing our global facilities responsibly enables us to further reduce our environmental impact and ensure our buildings are inclusive for all.","('Supply_Chain_Management', 0.9242926239967346)","('Systemic_Risk_Management', 0.010816684924066067)","('Business_Model_Resilience', 0.0053310454823076725)","([], 0.9242926239967346)","('NON-ESG', 0.010816684924066067)","('NON-ESG', 0.0053310454823076725)"
Line 635,"The Responsible Sourcing program is key to realizing BMS sustainability procurement strategy, which includes: Monitoring the supply chain sustainability risks and performance Addressing sustainability as a core area of performance in the SS&P/supplier partnership Implementing a core set of requirements to move suppliers through a journey of continuous improvement Increasing supplier due diligence to ensure that our suppliers are aligned with BMS in their values and ESG commitments Aligning to directly support BMS Third-Party Risk Management program, which identifies and reduces risks relating to the use of third parties BMS partners with EcoVadis to support the realization of the Responsible Sourcing program, which endeavors to realize the following benefits, outcomes and goals: Benefits Active engagement with suppliers to support their efforts to improve legal and regulatory compliance, brand reputation and stakeholder relations Support of our suppliers on their sustainability journey Building relationships with suppliers that have made ESG within their own operations a priorityExpected outcomes Increased awareness of supplier sustainability profiles Development of robust ESG capabilities and ways of working Increased transparency anddisclosure Drive performance improvementsProgram goals Embed ESG principles into and across BMS global sourcing and procurement strategy Implement requirements to level-set supplier performance and ensure strategic, values-based partnership 2021 ESG REPORT | 46 Packaging and TransportationSustainable Facility Design Managing our global facilities responsibly enables us to further reduce our environmental impact and ensure our buildings are inclusive for all.","('Supply_Chain_Management', 0.9534943699836731)","('Systemic_Risk_Management', 0.005063926801085472)","('Labor_Practices', 0.0035664597526192665)","([], 0.9534943699836731)","('NON-ESG', 0.005063926801085472)","('NON-ESG', 0.0035664597526192665)"
Line 636,"The Responsible Sourcing program is key to realizing BMS sustainability procurement strategy, which includes: Monitoring the supply chain sustainability risks and performance Addressing sustainability as a core area of performance in the SS&P/supplier partnership Implementing a core set of requirements to move suppliers through a journey of continuous improvement Increasing supplier due diligence to ensure that our suppliers are aligned with BMS in their values and ESG commitments Aligning to directly support BMS Third-Party Risk Management program, which identifies and reduces risks relating to the use of third parties BMS partners with EcoVadis to support the realization of the Responsible Sourcing program, which endeavors to realize the following benefits, outcomes and goals: Benefits Active engagement with suppliers to support their efforts to improve legal and regulatory compliance, brand reputation and stakeholder relations Support of our suppliers on their sustainability journey Building relationships with suppliers that have made ESG within their own operations a priorityExpected outcomes Increased awareness of supplier sustainability profiles Development of robust ESG capabilities and ways of working Increased transparency anddisclosure Drive performance improvementsProgram goals Embed ESG principles into and across BMS global sourcing and procurement strategy Implement requirements to level-set supplier performance and ensure strategic, values-based partnership 2021 ESG REPORT | 46 Packaging and TransportationSustainable Facility Design Managing our global facilities responsibly enables us to further reduce our environmental impact and ensure our buildings are inclusive for all.","('Product_Design_And_Lifecycle_Management', 0.525861918926239)","('Business_Model_Resilience', 0.08334337919950485)","('Energy_Management', 0.06961680203676224)","([], 0.525861918926239)","('NON-ESG', 0.08334337919950485)","('NON-ESG', 0.06961680203676224)"
Line 637,"Accordingly, when we construct new facilities or retrofit old ones, we do so with a long-term view utilizing sustainable construction practices, incorporating state-of-the-art efficiencies and applying universal design principles.","('Product_Design_And_Lifecycle_Management', 0.5858203172683716)","('Energy_Management', 0.1649162322282791)","('Business_Model_Resilience', 0.04042888432741165)","([], 0.5858203172683716)","('NON-ESG', 0.1649162322282791)","('NON-ESG', 0.04042888432741165)"
Line 638,"In 2021, BMS revised our design criteria for sustainable facilities.","('Product_Design_And_Lifecycle_Management', 0.7095627784729004)","('Business_Model_Resilience', 0.05478258430957794)","('Energy_Management', 0.02716056816279888)","([], 0.7095627784729004)","('NON-ESG', 0.05478258430957794)","('NON-ESG', 0.02716056816279888)"
Line 639,"Moving forward, all facility designs are required to meet or exceed LEED Silver standardsand may also consider BREEAM qualificationsboth of which enable us to maintain our commitment to healthy, efficient, carbon- and cost-saving green buildings.","('Management_Of_Legal_And_Regulatory_Framework', 0.20731604099273682)","('Product_Quality_And_Safety', 0.19348925352096558)","('Energy_Management', 0.16395102441310883)","('NON-ESG', 0.20731604099273682)","('NON-ESG', 0.19348925352096558)","('NON-ESG', 0.16395102441310883)"
Line 640,"To meet these standards, our buildings must adhere to stringent criteria, which drive us to: Optimize energy efficiency, including participation in energy life cycle assessments and identifying opportunities to use alternate fuel sources Minimize water use, including creating use-modeling and water balance maps, and by identifying opportunities to reuse, repurpose and recycle water Minimize waste and eliminate waste to landfill, including rerouting maintenance, demolition and construction waste; adding waste management expectations to supplier contracts; and auditing packing to drive the transition to reusable, recoverable and/or recyclable materials Support the transition to zero-emission vehicles through our EV charging station programframework The success of our efforts is reflected in our ongoing recognition by the EPA as an ENERGY STAR Partner of the YearSustained Excellence, and in the number of LEED-certified or BREEAM-qualified facilities in the BMS network.","('Waste_And_Hazardous_Materials_Management', 0.980471134185791)","('Water_And_Wastewater_Management', 0.002337081590667367)","('Product_Design_And_Lifecycle_Management', 0.001625508302822709)","([], 0.980471134185791)","('NON-ESG', 0.002337081590667367)","('NON-ESG', 0.001625508302822709)"
Line 641,"To meet these standards, our buildings must adhere to stringent criteria, which drive us to: Optimize energy efficiency, including participation in energy life cycle assessments and identifying opportunities to use alternate fuel sources Minimize water use, including creating use-modeling and water balance maps, and by identifying opportunities to reuse, repurpose and recycle water Minimize waste and eliminate waste to landfill, including rerouting maintenance, demolition and construction waste; adding waste management expectations to supplier contracts; and auditing packing to drive the transition to reusable, recoverable and/or recyclable materials Support the transition to zero-emission vehicles through our EV charging station programframework The success of our efforts is reflected in our ongoing recognition by the EPA as an ENERGY STAR Partner of the YearSustained Excellence, and in the number of LEED-certified or BREEAM-qualified facilities in the BMS network.","('Product_Design_And_Lifecycle_Management', 0.4205722510814667)","('Supply_Chain_Management', 0.24503551423549652)","('Energy_Management', 0.11344753205776215)","('NON-ESG', 0.4205722510814667)","('NON-ESG', 0.24503551423549652)","('NON-ESG', 0.11344753205776215)"
Line 642,"Integrating universal design In alignment with our commitment to employee health, safety and wellness, BMS has committed to the adoption of universal design to help ensure our buildings are accessible.","('Employee_Health_And_Safety', 0.9730868339538574)","('Employee_Engagement_Inclusion_And_Diversity', 0.004348522052168846)","('Product_Quality_And_Safety', 0.0026571627240628004)","(['Health Outcome Contribution'], 0.9730868339538574)","('NON-ESG', 0.004348522052168846)","('NON-ESG', 0.0026571627240628004)"
Line 643,"This includes designing with flexibility in mind to account for the vast diversity of peoples skills, knowledge and needs.","('Employee_Engagement_Inclusion_And_Diversity', 0.9691998362541199)","('Human_Rights_And_Community_Relations', 0.0025891347322613)","('Business_Model_Resilience', 0.0023528700694441795)","(['Talent Attraction & Retention'], 0.9691998362541199)","('NON-ESG', 0.0025891347322613)","('NON-ESG', 0.0023528700694441795)"
Line 644,"Principles of universal design1 Equitable use to provide same means of use for all users regardless ofabilities2 Flexibility in use to accommodate a wide range of individual preferences and abilities 3 Simple and intuitive useto accommodate users experience, knowledge, language skills, or current concentration level 4 Perceptible informationto ensure effective communication ofnecessary information totheuser, regardless of ambient conditions or theuserssensory abilities5 Tolerance for error to minimize hazards andthe adverse consequencesof accidental or unintended actions6 Low physical effort to allow design to be used efficiently and comfortably and with a minimum of fatigue7 Size and space for approach and use to enable approach, reach, manipulation, and use regardless of users body size, posture, ormobility Enabling electric vehicle use As our employees returned to their offices in 2021, we experienced increased participation and utilization in our charging station program for electric vehicles (EVs) and hybrid plug-in cars.","('Employee_Engagement_Inclusion_And_Diversity', 0.28992536664009094)","('Customer_Privacy', 0.12126611918210983)","('Data_Security', 0.1002330407500267)","('NON-ESG', 0.28992536664009094)","('NON-ESG', 0.12126611918210983)","('NON-ESG', 0.1002330407500267)"
Line 645,"Principles of universal design1 Equitable use to provide same means of use for all users regardless ofabilities2 Flexibility in use to accommodate a wide range of individual preferences and abilities 3 Simple and intuitive useto accommodate users experience, knowledge, language skills, or current concentration level 4 Perceptible informationto ensure effective communication ofnecessary information totheuser, regardless of ambient conditions or theuserssensory abilities5 Tolerance for error to minimize hazards andthe adverse consequencesof accidental or unintended actions6 Low physical effort to allow design to be used efficiently and comfortably and with a minimum of fatigue7 Size and space for approach and use to enable approach, reach, manipulation, and use regardless of users body size, posture, ormobility Enabling electric vehicle use As our employees returned to their offices in 2021, we experienced increased participation and utilization in our charging station program for electric vehicles (EVs) and hybrid plug-in cars.","('Employee_Health_And_Safety', 0.5377992391586304)","('Product_Design_And_Lifecycle_Management', 0.1362544149160385)","('Energy_Management', 0.07073094695806503)","(['Health Outcome Contribution'], 0.5377992391586304)","('NON-ESG', 0.1362544149160385)","('NON-ESG', 0.07073094695806503)"
Line 646,"Principles of universal design1 Equitable use to provide same means of use for all users regardless ofabilities2 Flexibility in use to accommodate a wide range of individual preferences and abilities 3 Simple and intuitive useto accommodate users experience, knowledge, language skills, or current concentration level 4 Perceptible informationto ensure effective communication ofnecessary information totheuser, regardless of ambient conditions or theuserssensory abilities5 Tolerance for error to minimize hazards andthe adverse consequencesof accidental or unintended actions6 Low physical effort to allow design to be used efficiently and comfortably and with a minimum of fatigue7 Size and space for approach and use to enable approach, reach, manipulation, and use regardless of users body size, posture, ormobility Enabling electric vehicle use As our employees returned to their offices in 2021, we experienced increased participation and utilization in our charging station program for electric vehicles (EVs) and hybrid plug-in cars.","('Product_Design_And_Lifecycle_Management', 0.37082624435424805)","('Energy_Management', 0.26960277557373047)","('Competitive_Behavior', 0.04573187977075577)","('NON-ESG', 0.37082624435424805)","('NON-ESG', 0.26960277557373047)","('NON-ESG', 0.04573187977075577)"
Line 647,In the U.,"('Management_Of_Legal_And_Regulatory_Framework', 0.3326531648635864)","('Product_Design_And_Lifecycle_Management', 0.08272774517536163)","('Competitive_Behavior', 0.05485570803284645)","('NON-ESG', 0.3326531648635864)","('NON-ESG', 0.08272774517536163)","('NON-ESG', 0.05485570803284645)"
Line 648,"S., 10 facilities currently utilize these stations, with more than 500 participants using them more than 12,000 times each year.","('Energy_Management', 0.2855619192123413)","('Customer_Welfare', 0.1363595575094223)","('Supply_Chain_Management', 0.09863153100013733)","('NON-ESG', 0.2855619192123413)","('NON-ESG', 0.1363595575094223)","('NON-ESG', 0.09863153100013733)"
Line 649,We also have plans to expand the program to BMS locations that are undergoing major renovations and new construction.,"('Access_And_Affordability', 0.21187636256217957)","('Employee_Engagement_Inclusion_And_Diversity', 0.11926823854446411)","('Product_Design_And_Lifecycle_Management', 0.07846689969301224)","('NON-ESG', 0.21187636256217957)","('NON-ESG', 0.11926823854446411)","('NON-ESG', 0.07846689969301224)"
Line 650,"In Europe, our Boudry, Switzerland, facility has 25 participants, and the newest programat our Cruiserath, Ireland, facilityalready has 30 participants.","('Access_And_Affordability', 0.14136508107185364)","('Management_Of_Legal_And_Regulatory_Framework', 0.10388294607400894)","('Competitive_Behavior', 0.07752149552106857)","('NON-ESG', 0.14136508107185364)","('NON-ESG', 0.10388294607400894)","('NON-ESG', 0.07752149552106857)"
Line 651,We will continue to promote and engage employees in this program as part of our ongoing sustainability journey.,"('Employee_Engagement_Inclusion_And_Diversity', 0.60112065076828)","('Labor_Practices', 0.10578000545501709)","('Employee_Health_And_Safety', 0.06380219012498856)","(['Talent Attraction & Retention'], 0.60112065076828)","('NON-ESG', 0.10578000545501709)","('NON-ESG', 0.06380219012498856)"
Line 652,2021 ESG REPORT | 47Embracing clean and renewable energy BMS currently manages an on-site EV charging network consisting of 155 EV charging points and more than 500 subscribers across 10 U.,"('Energy_Management', 0.926015317440033)","('Product_Design_And_Lifecycle_Management', 0.008780892007052898)","('Management_Of_Legal_And_Regulatory_Framework', 0.006007527466863394)","(['Operational Eco-Efficiency'], 0.926015317440033)","('NON-ESG', 0.008780892007052898)","('NON-ESG', 0.006007527466863394)"
Line 653,S. sites.,"('Customer_Privacy', 0.28644683957099915)","('Data_Security', 0.21430550515651703)","('Business_Model_Resilience', 0.06165143847465515)","('NON-ESG', 0.28644683957099915)","('NON-ESG', 0.21430550515651703)","('NON-ESG', 0.06165143847465515)"
Line 654,"Our 2021 solar photovoltaic (PV) footprint includes PV arrays installed at three New Jersey locations, as well as locations in China and the U.","('Energy_Management', 0.9544766545295715)","('Management_Of_Legal_And_Regulatory_Framework', 0.009779849089682102)","('Product_Design_And_Lifecycle_Management', 0.003929421305656433)","(['Operational Eco-Efficiency'], 0.9544766545295715)","('NON-ESG', 0.009779849089682102)","('NON-ESG', 0.003929421305656433)"
Line 655,K.,"('Competitive_Behavior', 0.10340268164873123)","('Business_Ethics', 0.09743013978004456)","('Waste_And_Hazardous_Materials_Management', 0.06572005152702332)","('NON-ESG', 0.10340268164873123)","('NON-ESG', 0.09743013978004456)","('NON-ESG', 0.06572005152702332)"
Line 656,"The PV arrays carry a maximum output of nearly 3.4 MW, which is equivalent to the energy needed to power more than 300 homes.","('Energy_Management', 0.9761784672737122)","('Management_Of_Legal_And_Regulatory_Framework', 0.002755808411166072)","('Critical_Incident_Risk_Management', 0.002022333675995469)","(['Operational Eco-Efficiency'], 0.9761784672737122)","('NON-ESG', 0.002755808411166072)","('NON-ESG', 0.002022333675995469)"
Line 657,"We procure green electricity via electric supply contracts in local markets in Ireland, Germany and California in the U.","('Energy_Management', 0.9001554250717163)","('Supply_Chain_Management', 0.027204103767871857)","('Management_Of_Legal_And_Regulatory_Framework', 0.010902886278927326)","(['Operational Eco-Efficiency'], 0.9001554250717163)","('NON-ESG', 0.027204103767871857)","('NON-ESG', 0.010902886278927326)"
Line 658,"S. Today, nearly 7% of our total imported electricity originates from renewable sources.","('Energy_Management', 0.9657981395721436)","('Management_Of_Legal_And_Regulatory_Framework', 0.0071916175074875355)","('Water_And_Wastewater_Management', 0.0024028534535318613)","(['Operational Eco-Efficiency'], 0.9657981395721436)","('NON-ESG', 0.0071916175074875355)","('NON-ESG', 0.0024028534535318613)"
Line 659,"We expanded our partnership with CarbonFund.org, once again enabling a carbon-neutral Global Leadership Team meeting and offsetting more than 25% of the emissions from our 2021 global employee travel.","('GHG_Emissions', 0.5823503136634827)","('Air_Quality', 0.20859386026859283)","('Energy_Management', 0.042644254863262177)","(['Operational Eco-Efficiency'], 0.5823503136634827)","('NON-ESG', 0.20859386026859283)","('NON-ESG', 0.042644254863262177)"
Line 660,Designing energy-efficient facilities Twenty BMS sites (100% of those that are eligible) are participating in the ENERGY STAR Challenge for Industry.,"('Energy_Management', 0.9801464676856995)","('Air_Quality', 0.002130434149876237)","('Management_Of_Legal_And_Regulatory_Framework', 0.0017406827537342906)","(['Operational Eco-Efficiency'], 0.9801464676856995)","('NON-ESG', 0.002130434149876237)","('NON-ESG', 0.0017406827537342906)"
Line 661,The challenge is a global call to action for industrial sites to reduce their energy intensity by 10% within five years.,"('Energy_Management', 0.9782455563545227)","('Management_Of_Legal_And_Regulatory_Framework', 0.0022712007630616426)","('Air_Quality', 0.002255660016089678)","(['Operational Eco-Efficiency'], 0.9782455563545227)","('NON-ESG', 0.0022712007630616426)","('NON-ESG', 0.002255660016089678)"
Line 662,The Princeton Pike site earned ENERGY STAR Certification in 2021 for the fourth year in a row.,"('Energy_Management', 0.49222034215927124)","('Product_Design_And_Lifecycle_Management', 0.1950732320547104)","('Product_Quality_And_Safety', 0.07427487522363663)","('NON-ESG', 0.49222034215927124)","('NON-ESG', 0.1950732320547104)","('NON-ESG', 0.07427487522363663)"
Line 663,Nassau Park also showed continued improvement during the year and is on track to earn ENERGY STAR certification soon.,"('Product_Quality_And_Safety', 0.26235559582710266)","('Management_Of_Legal_And_Regulatory_Framework', 0.23586302995681763)","('Product_Design_And_Lifecycle_Management', 0.0793442502617836)","('NON-ESG', 0.26235559582710266)","('NON-ESG', 0.23586302995681763)","('NON-ESG', 0.0793442502617836)"
Line 664,"Additionally, BMS is the sole tenant of an ENERGY STAR-certified facility located in Tampa,Florida.","('Energy_Management', 0.5218876600265503)","('Management_Of_Legal_And_Regulatory_Framework', 0.06553810089826584)","('Product_Design_And_Lifecycle_Management', 0.052681874483823776)","(['Operational Eco-Efficiency'], 0.5218876600265503)","('NON-ESG', 0.06553810089826584)","('NON-ESG', 0.052681874483823776)"
Line 665,"At the annual ENERGY STAR Industrial Partners Meeting in November 2021, BMS received Top Project recognition for our Lawrenceville, New Jersey, Cogeneration Project.","('Energy_Management', 0.812695324420929)","('Product_Design_And_Lifecycle_Management', 0.0644202008843422)","('Supply_Chain_Management', 0.024944303557276726)","(['Operational Eco-Efficiency'], 0.812695324420929)","('NON-ESG', 0.0644202008843422)","('NON-ESG', 0.024944303557276726)"
Line 666,"In 2021, our major U.","('Competitive_Behavior', 0.20693770051002502)","('Business_Model_Resilience', 0.1400907337665558)","('Systemic_Risk_Management', 0.1047859936952591)","('NON-ESG', 0.20693770051002502)","('NON-ESG', 0.1400907337665558)","('NON-ESG', 0.1047859936952591)"
Line 667,"S. sites in Massachusetts, New York and New Jersey held virtual lighting fairs.","('Competitive_Behavior', 0.33841949701309204)","('Management_Of_Legal_And_Regulatory_Framework', 0.2760401666164398)","('Systemic_Risk_Management', 0.04717722907662392)","('NON-ESG', 0.33841949701309204)","('NON-ESG', 0.2760401666164398)","('NON-ESG', 0.04717722907662392)"
Line 668,These events reached thousands of employees with the opportunity to learn about ENERGY STAR-certified LED light bulbs and purchase them at a discounted price.,"('Energy_Management', 0.609317421913147)","('Product_Design_And_Lifecycle_Management', 0.24365957081317902)","('Product_Quality_And_Safety', 0.021175941452383995)","(['Operational Eco-Efficiency'], 0.609317421913147)","('NON-ESG', 0.24365957081317902)","('NON-ESG', 0.021175941452383995)"
Line 669,"For the seventh year in a row, the EPA has recognized BMS as an ENERGY STAR Partner of the Year.","('Management_Of_Legal_And_Regulatory_Framework', 0.7904587388038635)","('GHG_Emissions', 0.03269222006201744)","('Ecological_Impacts', 0.031670019030570984)","([], 0.7904587388038635)","('NON-ESG', 0.03269222006201744)","('NON-ESG', 0.031670019030570984)"
Line 670,"Furthermore, the company has once again earned the title of ENERGY STAR Partner of the YearSustained Excellence.","('Business_Model_Resilience', 0.24169765412807465)","('Systemic_Risk_Management', 0.15594825148582458)","('Competitive_Behavior', 0.15123844146728516)","('NON-ESG', 0.24169765412807465)","('NON-ESG', 0.15594825148582458)","('NON-ESG', 0.15123844146728516)"
Line 671,"2021 ESG REPORT | 48 Sustainable Facility DesignEmployee Engagement inSustainability BMS employees are passionate about creating healthier communities, which drives them to take action to protect the planet.","('Human_Rights_And_Community_Relations', 0.3131738007068634)","('Ecological_Impacts', 0.13830173015594482)","('Access_And_Affordability', 0.11931725591421127)","('NON-ESG', 0.3131738007068634)","('NON-ESG', 0.13830173015594482)","('NON-ESG', 0.11931725591421127)"
Line 672,We offer opportunities and programs for all employees to get involved in building momentum to enhance sustainability across our global operations.,"('Employee_Engagement_Inclusion_And_Diversity', 0.7841153740882874)","('Employee_Health_And_Safety', 0.030893076211214066)","('Labor_Practices', 0.02075539156794548)","(['Talent Attraction & Retention'], 0.7841153740882874)","('NON-ESG', 0.030893076211214066)","('NON-ESG', 0.02075539156794548)"
Line 673,"Go Green is a global, employee-led BMS initiative, which drives sustainability engagement across our company.","('Product_Design_And_Lifecycle_Management', 0.4419543445110321)","('Employee_Health_And_Safety', 0.06887725740671158)","('Human_Rights_And_Community_Relations', 0.06513196229934692)","('NON-ESG', 0.4419543445110321)","('NON-ESG', 0.06887725740671158)","('NON-ESG', 0.06513196229934692)"
Line 674,"In 2021, Go Green held virtual global celebrations themed around Earth Day, Earth Hour, energy conservation and recycling.","('Energy_Management', 0.7591767907142639)","('Product_Design_And_Lifecycle_Management', 0.064947709441185)","('Management_Of_Legal_And_Regulatory_Framework', 0.017955981194972992)","(['Operational Eco-Efficiency'], 0.7591767907142639)","('NON-ESG', 0.064947709441185)","('NON-ESG', 0.017955981194972992)"
Line 675,The events aimed to empower employees and support their efforts to protect the environment at work and at home.,"('Human_Rights_And_Community_Relations', 0.6954491138458252)","('Employee_Health_And_Safety', 0.10901614278554916)","('Access_And_Affordability', 0.03430255874991417)","([], 0.6954491138458252)","('NON-ESG', 0.10901614278554916)","('NON-ESG', 0.03430255874991417)"
Line 676,"Employees around the world further demonstrated their commitment by participating in a range of sustainability-focused activities, including establishing on-site organic gardens and beehives, planting trees, recycling, cleaning greenways and watershed areas, and working to build awareness about energy and water conservation.","('Ecological_Impacts', 0.9285275936126709)","('Water_And_Wastewater_Management', 0.02314811758697033)","('Product_Design_And_Lifecycle_Management', 0.004978496115654707)","([], 0.9285275936126709)","('NON-ESG', 0.02314811758697033)","('NON-ESG', 0.004978496115654707)"
Line 677,"In addition, Go Green facilitated the new ride-share and alternative transportation functions to reduce the environmental impact of employee commuting.","('Energy_Management', 0.2920006811618805)","('Employee_Health_And_Safety', 0.11810585111379623)","('Air_Quality', 0.07158228009939194)","('NON-ESG', 0.2920006811618805)","('NON-ESG', 0.11810585111379623)","('NON-ESG', 0.07158228009939194)"
Line 678,"During the year, we also developed the framework for both our zero waste to landfill site program and our Green Office certification program, with input from employees across our global enterprise.","('Waste_And_Hazardous_Materials_Management', 0.9809476137161255)","('Water_And_Wastewater_Management', 0.002384853083640337)","('Air_Quality', 0.0019426281796768308)","([], 0.9809476137161255)","('NON-ESG', 0.002384853083640337)","('NON-ESG', 0.0019426281796768308)"
Line 679,"In 2022, we plan to launch be launching these programs at select sites across the network, in support of our Green Return to Work initiative.","('Human_Rights_And_Community_Relations', 0.3194393813610077)","('Access_And_Affordability', 0.16286511719226837)","('Management_Of_Legal_And_Regulatory_Framework', 0.11820286512374878)","('NON-ESG', 0.3194393813610077)","('NON-ESG', 0.16286511719226837)","('NON-ESG', 0.11820286512374878)"
Line 680,"Our Green Labs certification program encourages employees to reduce their environmental impact by minimizing their work-based energy usage, water usage and waste.","('Energy_Management', 0.9444212317466736)","('Product_Design_And_Lifecycle_Management', 0.009094453416764736)","('Water_And_Wastewater_Management', 0.007658461574465036)","(['Operational Eco-Efficiency'], 0.9444212317466736)","('NON-ESG', 0.009094453416764736)","('NON-ESG', 0.007658461574465036)"
Line 681,"As we maintained laboratory operations during the pandemic, the certification program continued to grow, with nearly 600 labs certified and participation by 92% of all labs within the BMS facilities.","('Access_And_Affordability', 0.28166723251342773)","('Employee_Engagement_Inclusion_And_Diversity', 0.18510548770427704)","('Product_Quality_And_Safety', 0.09690701961517334)","('NON-ESG', 0.28166723251342773)","('NON-ESG', 0.18510548770427704)","('NON-ESG', 0.09690701961517334)"
Line 682,"Employee-led action Many BMS employees are passionate about reducing their environmental impact, including participants in our CLIMB (Cultivating Leadership and Innovation for Millennials and Beyond) PBRG.","('Employee_Engagement_Inclusion_And_Diversity', 0.3861871063709259)","('Human_Rights_And_Community_Relations', 0.17963869869709015)","('Employee_Health_And_Safety', 0.08738627284765244)","('NON-ESG', 0.3861871063709259)","('NON-ESG', 0.17963869869709015)","('NON-ESG', 0.08738627284765244)"
Line 683,"In 2021, CLIMB partnered with the Corporate Sustainability Team to launch a Sustainability Calendar Challenge, which encouraged employees to prioritize wellbeing and environmental stewardship.","('Human_Rights_And_Community_Relations', 0.24346095323562622)","('Employee_Health_And_Safety', 0.17191758751869202)","('Product_Design_And_Lifecycle_Management', 0.10168959200382233)","('NON-ESG', 0.24346095323562622)","('NON-ESG', 0.17191758751869202)","('NON-ESG', 0.10168959200382233)"
Line 684,"During the 12-month challenge, employees tracked progress toward specific goals through a mobile app.","('Human_Rights_And_Community_Relations', 0.21781563758850098)","('Employee_Engagement_Inclusion_And_Diversity', 0.12803588807582855)","('Labor_Practices', 0.07227089256048203)","('NON-ESG', 0.21781563758850098)","('NON-ESG', 0.12803588807582855)","('NON-ESG', 0.07227089256048203)"
Line 685,"CLIMB also partnered with Grow-a-Row, an organization that provides fresh produce to food deserts in the U.","('Customer_Welfare', 0.5010770559310913)","('Selling_Practices_And_Product_Labeling', 0.09473484754562378)","('Access_And_Affordability', 0.05372563749551773)","([], 0.5010770559310913)","('NON-ESG', 0.09473484754562378)","('NON-ESG', 0.05372563749551773)"
Line 686,"S., and in 2021, CLIMB members, along with other local volunteers, handpicked 9,600 pounds of corn (38,000 servings) and 2,650 pounds of tomatoes (10,600 servings) at the Grow-a-Row farm in New Jersey.","('Customer_Welfare', 0.36433374881744385)","('Selling_Practices_And_Product_Labeling', 0.17982088029384613)","('Access_And_Affordability', 0.05563678592443466)","('NON-ESG', 0.36433374881744385)","('NON-ESG', 0.17982088029384613)","('NON-ESG', 0.05563678592443466)"
Line 687,Their work facilitated access to fresh and healthy food to support communities where BMS operates.,"('Access_And_Affordability', 0.5759537816047668)","('Customer_Welfare', 0.13758233189582825)","('Product_Design_And_Lifecycle_Management', 0.04059908911585808)","(['Access to Healthcare'], 0.5759537816047668)","('NON-ESG', 0.13758233189582825)","('NON-ESG', 0.04059908911585808)"
Line 688,"Here are a few of the other ways employees across the globe made an impact in 2021: Guaynabo, Puerto Rico Implemented reduction of waste generation in facilitys dining areas, including: Implementation of no plastics policy Robust recycling program for cardboard, paper, newspaper, aluminum and key plasticsRome, Italy Partnered with Treedom, a company that stands out for directly financing small agro-forestry projects and providing environmental and social benefits.","('Waste_And_Hazardous_Materials_Management', 0.9735416173934937)","('Product_Design_And_Lifecycle_Management', 0.0029621736612170935)","('Water_And_Wastewater_Management', 0.002363749546930194)","([], 0.9735416173934937)","('NON-ESG', 0.0029621736612170935)","('NON-ESG', 0.002363749546930194)"
Line 689,"The five-year project involves planting 2,500 trees in Africa, Asia, Europe and Latin America by 2025.","('Ecological_Impacts', 0.6426514983177185)","('Access_And_Affordability', 0.06346362084150314)","('Product_Design_And_Lifecycle_Management', 0.039203543215990067)","([], 0.6426514983177185)","('NON-ESG', 0.06346362084150314)","('NON-ESG', 0.039203543215990067)"
Line 690,"Projected environmental and social benefits: CO 2 absorption globally Reforestation Protection and restoration of local biodiversity Fight against desertification and soil erosion Economic support for local farmersSteinhausen, Switzerland Implementation of waste management efforts, including: Held an employee engagement workshop with Zero Waste Switzerland and introduced employee education to drive increased awareness of actions each individual can take to minimize consumption of natural resources Led an EV Ride & Drive event with test drives Organized exclusive e-bike discounts from local stores to promote sustainable commuting 2021 ESG REPORT | 49Appendix 51 Development Portfolio by Therapeutic Area 54 BMS 2021 ESG Data 61 SASB 63 GRI 72 NBIM 75 Forward-Looking Information and Non-GAAP Financial Information 2021 ESG REPORT | 50Development Portfolio by Therapeutic Area Oncology Phase I Additional Indications OPDIVO Solid Tumors OPDIVO + YERVOY Solid Tumors Investigational Compounds motolimod SCCHN relatlimab^ Solid Tumors Anti-TIM-3^ Solid Tumors STING Agonist Solid Tumors AHR Antagonist Solid Tumors Anti-CTLA-4 NF-Probody Solid Tumors BET Inhibitor (CC-95775)^ Solid Tumors Anti-SIRP Solid Tumors CD3xPSCA Solid Tumors Anti-IL8^ Solid Tumors AR-LDD Solid Tumors Anti-NKG2A Solid Tumors TGF Inhibitor Solid Tumors IL-12 Fc Solid Tumors Anti-CCR8 Solid Tumors TIGIT Bispecific Solid Tumors farletuzumab-eribulin ADC Solid Tumors MAGE A4/8 TCE-Bispecific Solid TumorsPhase II Additional Indications OPDIVO Solid Tumors 1L CRC Pan Tumor TMB High Pediatric OPDIVO + YERVOY Solid Tumors Metastatic Castration- Resistant Prostate OPDIVO + CDK4/6 Inhibitor Neoadjuvant ER+/HER2- Breast OPDIVO + relatlimab Solid Tumors OPDIVO + linrodostat Solid Tumors OPDIVO + bempegaldesleukin 1L Bladder# POMALYST/IMNOVID Pediatric Glioblastoma Investigational Compounds Anti-CTLA-4 NF^ Solid Tumors Anti-CTLA-4 Probody^ Solid Tumors Anti-TIGIT^ Solid Tumors Anti-Fucosyl GM1 Solid Tumors LSD1 Inhibitor Extensive Stage SCLC BET Inhibitor (CC-90010)^ Solid Tumors farletuzumab-eribulin ADC Solid Tumors subcutaneous nivolumab + rHuPH20 Solid TumorsPhase III Additional Indications OPDIVO 1L Glioblastoma 1L HCC 1L Head & Neck 1L Head & Neck Locally Advanced 1L Esophageal High-Risk Non-Muscle Invasive Bladder Cancer Adjuvant Gastric Adjuvant HCC Adjuvant Melanoma Adjuvant RCC Metastatic Castration- Resistant Prostate Neoadjuvant ER+/HER2- Breast Neoadjuvant NSCLC Peri-adjuvant NSCLC Unresectable NSCLC OPDIVO + YERVOY 1L Bladder 1L Esophageal 1L Gastric 1L HCC Intermediate HCC 1L CRC (MSI-High) Adjuvant Melanoma Adjuvant RCC NSCLC EGFR Mutant Unresectable NSCLC OPDIVO + relatlimab 1L Melanoma OPDIVO + linrodostat Neoadjuvant Muscle Invasive Bladder Cancer OPDIVO + bempegaldesleukin 1L Melanoma Adjuvant Melanoma# Muscle Invasive Bladder Cancer 1L RCC# OPDIVO + YERVOY + cabozantinib Metastatic RCC Investigational Compounds subcutaneous nivolumab + rHuPH20 Advanced RCCApproved Indications OPDIVO 1L Metastatic Melanoma 1L Gastric Adjuvant Melanoma Adjuvant Bladder Adjuvant Esophageal/ Gastroesophageal Mesothelioma Previously treated advanced RCC Previously treated Gastric Cancer (Japan, China) Previously treated Metastatic Head & Neck Previously treated Metastatic Melanoma Previously treated Metastatic MSI-High CRC Previously treated Metastatic Non-squamous NSCLC Previously treated Metastatic Squamous NSCLC Previously treated Metastatic Urothelial Previously treated Esophageal OPDIVO + YERVOY 1L Metastatic Melanoma 1L Mesothelioma 1L NSCLC 1L RCC Previously treated Metastatic MSI-High CRC Previously treated HCC OPDIVO + cabozantinib Metastatic RCC YERVOY Adjuvant Melanoma Metastatic Melanoma ABRAXANE Breast Gastric Locally Advanced or Metastatic NSCLC Metastatic Breast Cancer NSCLC Pancreatic Unresectable Pancreatic Listed in this section are our clinical studies and approved indications for our marketed products in the related therapeutic area as of February 4, 2022.","('Ecological_Impacts', 0.8138822913169861)","('Waste_And_Hazardous_Materials_Management', 0.1000288724899292)","('Water_And_Wastewater_Management', 0.020842384546995163)","([], 0.8138822913169861)","('NON-ESG', 0.1000288724899292)","('NON-ESG', 0.020842384546995163)"
Line 691,"Projected environmental and social benefits: CO 2 absorption globally Reforestation Protection and restoration of local biodiversity Fight against desertification and soil erosion Economic support for local farmersSteinhausen, Switzerland Implementation of waste management efforts, including: Held an employee engagement workshop with Zero Waste Switzerland and introduced employee education to drive increased awareness of actions each individual can take to minimize consumption of natural resources Led an EV Ride & Drive event with test drives Organized exclusive e-bike discounts from local stores to promote sustainable commuting 2021 ESG REPORT | 49Appendix 51 Development Portfolio by Therapeutic Area 54 BMS 2021 ESG Data 61 SASB 63 GRI 72 NBIM 75 Forward-Looking Information and Non-GAAP Financial Information 2021 ESG REPORT | 50Development Portfolio by Therapeutic Area Oncology Phase I Additional Indications OPDIVO Solid Tumors OPDIVO + YERVOY Solid Tumors Investigational Compounds motolimod SCCHN relatlimab^ Solid Tumors Anti-TIM-3^ Solid Tumors STING Agonist Solid Tumors AHR Antagonist Solid Tumors Anti-CTLA-4 NF-Probody Solid Tumors BET Inhibitor (CC-95775)^ Solid Tumors Anti-SIRP Solid Tumors CD3xPSCA Solid Tumors Anti-IL8^ Solid Tumors AR-LDD Solid Tumors Anti-NKG2A Solid Tumors TGF Inhibitor Solid Tumors IL-12 Fc Solid Tumors Anti-CCR8 Solid Tumors TIGIT Bispecific Solid Tumors farletuzumab-eribulin ADC Solid Tumors MAGE A4/8 TCE-Bispecific Solid TumorsPhase II Additional Indications OPDIVO Solid Tumors 1L CRC Pan Tumor TMB High Pediatric OPDIVO + YERVOY Solid Tumors Metastatic Castration- Resistant Prostate OPDIVO + CDK4/6 Inhibitor Neoadjuvant ER+/HER2- Breast OPDIVO + relatlimab Solid Tumors OPDIVO + linrodostat Solid Tumors OPDIVO + bempegaldesleukin 1L Bladder# POMALYST/IMNOVID Pediatric Glioblastoma Investigational Compounds Anti-CTLA-4 NF^ Solid Tumors Anti-CTLA-4 Probody^ Solid Tumors Anti-TIGIT^ Solid Tumors Anti-Fucosyl GM1 Solid Tumors LSD1 Inhibitor Extensive Stage SCLC BET Inhibitor (CC-90010)^ Solid Tumors farletuzumab-eribulin ADC Solid Tumors subcutaneous nivolumab + rHuPH20 Solid TumorsPhase III Additional Indications OPDIVO 1L Glioblastoma 1L HCC 1L Head & Neck 1L Head & Neck Locally Advanced 1L Esophageal High-Risk Non-Muscle Invasive Bladder Cancer Adjuvant Gastric Adjuvant HCC Adjuvant Melanoma Adjuvant RCC Metastatic Castration- Resistant Prostate Neoadjuvant ER+/HER2- Breast Neoadjuvant NSCLC Peri-adjuvant NSCLC Unresectable NSCLC OPDIVO + YERVOY 1L Bladder 1L Esophageal 1L Gastric 1L HCC Intermediate HCC 1L CRC (MSI-High) Adjuvant Melanoma Adjuvant RCC NSCLC EGFR Mutant Unresectable NSCLC OPDIVO + relatlimab 1L Melanoma OPDIVO + linrodostat Neoadjuvant Muscle Invasive Bladder Cancer OPDIVO + bempegaldesleukin 1L Melanoma Adjuvant Melanoma# Muscle Invasive Bladder Cancer 1L RCC# OPDIVO + YERVOY + cabozantinib Metastatic RCC Investigational Compounds subcutaneous nivolumab + rHuPH20 Advanced RCCApproved Indications OPDIVO 1L Metastatic Melanoma 1L Gastric Adjuvant Melanoma Adjuvant Bladder Adjuvant Esophageal/ Gastroesophageal Mesothelioma Previously treated advanced RCC Previously treated Gastric Cancer (Japan, China) Previously treated Metastatic Head & Neck Previously treated Metastatic Melanoma Previously treated Metastatic MSI-High CRC Previously treated Metastatic Non-squamous NSCLC Previously treated Metastatic Squamous NSCLC Previously treated Metastatic Urothelial Previously treated Esophageal OPDIVO + YERVOY 1L Metastatic Melanoma 1L Mesothelioma 1L NSCLC 1L RCC Previously treated Metastatic MSI-High CRC Previously treated HCC OPDIVO + cabozantinib Metastatic RCC YERVOY Adjuvant Melanoma Metastatic Melanoma ABRAXANE Breast Gastric Locally Advanced or Metastatic NSCLC Metastatic Breast Cancer NSCLC Pancreatic Unresectable Pancreatic Listed in this section are our clinical studies and approved indications for our marketed products in the related therapeutic area as of February 4, 2022.","('Customer_Welfare', 0.41468122601509094)","('Competitive_Behavior', 0.16247166693210602)","('Systemic_Risk_Management', 0.05637309327721596)","('NON-ESG', 0.41468122601509094)","('NON-ESG', 0.16247166693210602)","('NON-ESG', 0.05637309327721596)"
Line 692,"Projected environmental and social benefits: CO 2 absorption globally Reforestation Protection and restoration of local biodiversity Fight against desertification and soil erosion Economic support for local farmersSteinhausen, Switzerland Implementation of waste management efforts, including: Held an employee engagement workshop with Zero Waste Switzerland and introduced employee education to drive increased awareness of actions each individual can take to minimize consumption of natural resources Led an EV Ride & Drive event with test drives Organized exclusive e-bike discounts from local stores to promote sustainable commuting 2021 ESG REPORT | 49Appendix 51 Development Portfolio by Therapeutic Area 54 BMS 2021 ESG Data 61 SASB 63 GRI 72 NBIM 75 Forward-Looking Information and Non-GAAP Financial Information 2021 ESG REPORT | 50Development Portfolio by Therapeutic Area Oncology Phase I Additional Indications OPDIVO Solid Tumors OPDIVO + YERVOY Solid Tumors Investigational Compounds motolimod SCCHN relatlimab^ Solid Tumors Anti-TIM-3^ Solid Tumors STING Agonist Solid Tumors AHR Antagonist Solid Tumors Anti-CTLA-4 NF-Probody Solid Tumors BET Inhibitor (CC-95775)^ Solid Tumors Anti-SIRP Solid Tumors CD3xPSCA Solid Tumors Anti-IL8^ Solid Tumors AR-LDD Solid Tumors Anti-NKG2A Solid Tumors TGF Inhibitor Solid Tumors IL-12 Fc Solid Tumors Anti-CCR8 Solid Tumors TIGIT Bispecific Solid Tumors farletuzumab-eribulin ADC Solid Tumors MAGE A4/8 TCE-Bispecific Solid TumorsPhase II Additional Indications OPDIVO Solid Tumors 1L CRC Pan Tumor TMB High Pediatric OPDIVO + YERVOY Solid Tumors Metastatic Castration- Resistant Prostate OPDIVO + CDK4/6 Inhibitor Neoadjuvant ER+/HER2- Breast OPDIVO + relatlimab Solid Tumors OPDIVO + linrodostat Solid Tumors OPDIVO + bempegaldesleukin 1L Bladder# POMALYST/IMNOVID Pediatric Glioblastoma Investigational Compounds Anti-CTLA-4 NF^ Solid Tumors Anti-CTLA-4 Probody^ Solid Tumors Anti-TIGIT^ Solid Tumors Anti-Fucosyl GM1 Solid Tumors LSD1 Inhibitor Extensive Stage SCLC BET Inhibitor (CC-90010)^ Solid Tumors farletuzumab-eribulin ADC Solid Tumors subcutaneous nivolumab + rHuPH20 Solid TumorsPhase III Additional Indications OPDIVO 1L Glioblastoma 1L HCC 1L Head & Neck 1L Head & Neck Locally Advanced 1L Esophageal High-Risk Non-Muscle Invasive Bladder Cancer Adjuvant Gastric Adjuvant HCC Adjuvant Melanoma Adjuvant RCC Metastatic Castration- Resistant Prostate Neoadjuvant ER+/HER2- Breast Neoadjuvant NSCLC Peri-adjuvant NSCLC Unresectable NSCLC OPDIVO + YERVOY 1L Bladder 1L Esophageal 1L Gastric 1L HCC Intermediate HCC 1L CRC (MSI-High) Adjuvant Melanoma Adjuvant RCC NSCLC EGFR Mutant Unresectable NSCLC OPDIVO + relatlimab 1L Melanoma OPDIVO + linrodostat Neoadjuvant Muscle Invasive Bladder Cancer OPDIVO + bempegaldesleukin 1L Melanoma Adjuvant Melanoma# Muscle Invasive Bladder Cancer 1L RCC# OPDIVO + YERVOY + cabozantinib Metastatic RCC Investigational Compounds subcutaneous nivolumab + rHuPH20 Advanced RCCApproved Indications OPDIVO 1L Metastatic Melanoma 1L Gastric Adjuvant Melanoma Adjuvant Bladder Adjuvant Esophageal/ Gastroesophageal Mesothelioma Previously treated advanced RCC Previously treated Gastric Cancer (Japan, China) Previously treated Metastatic Head & Neck Previously treated Metastatic Melanoma Previously treated Metastatic MSI-High CRC Previously treated Metastatic Non-squamous NSCLC Previously treated Metastatic Squamous NSCLC Previously treated Metastatic Urothelial Previously treated Esophageal OPDIVO + YERVOY 1L Metastatic Melanoma 1L Mesothelioma 1L NSCLC 1L RCC Previously treated Metastatic MSI-High CRC Previously treated HCC OPDIVO + cabozantinib Metastatic RCC YERVOY Adjuvant Melanoma Metastatic Melanoma ABRAXANE Breast Gastric Locally Advanced or Metastatic NSCLC Metastatic Breast Cancer NSCLC Pancreatic Unresectable Pancreatic Listed in this section are our clinical studies and approved indications for our marketed products in the related therapeutic area as of February 4, 2022.","('Ecological_Impacts', 0.11840386688709259)","('Competitive_Behavior', 0.10050124675035477)","('GHG_Emissions', 0.10042142868041992)","('NON-ESG', 0.11840386688709259)","('NON-ESG', 0.10050124675035477)","('NON-ESG', 0.10042142868041992)"
Line 693,"Projected environmental and social benefits: CO 2 absorption globally Reforestation Protection and restoration of local biodiversity Fight against desertification and soil erosion Economic support for local farmersSteinhausen, Switzerland Implementation of waste management efforts, including: Held an employee engagement workshop with Zero Waste Switzerland and introduced employee education to drive increased awareness of actions each individual can take to minimize consumption of natural resources Led an EV Ride & Drive event with test drives Organized exclusive e-bike discounts from local stores to promote sustainable commuting 2021 ESG REPORT | 49Appendix 51 Development Portfolio by Therapeutic Area 54 BMS 2021 ESG Data 61 SASB 63 GRI 72 NBIM 75 Forward-Looking Information and Non-GAAP Financial Information 2021 ESG REPORT | 50Development Portfolio by Therapeutic Area Oncology Phase I Additional Indications OPDIVO Solid Tumors OPDIVO + YERVOY Solid Tumors Investigational Compounds motolimod SCCHN relatlimab^ Solid Tumors Anti-TIM-3^ Solid Tumors STING Agonist Solid Tumors AHR Antagonist Solid Tumors Anti-CTLA-4 NF-Probody Solid Tumors BET Inhibitor (CC-95775)^ Solid Tumors Anti-SIRP Solid Tumors CD3xPSCA Solid Tumors Anti-IL8^ Solid Tumors AR-LDD Solid Tumors Anti-NKG2A Solid Tumors TGF Inhibitor Solid Tumors IL-12 Fc Solid Tumors Anti-CCR8 Solid Tumors TIGIT Bispecific Solid Tumors farletuzumab-eribulin ADC Solid Tumors MAGE A4/8 TCE-Bispecific Solid TumorsPhase II Additional Indications OPDIVO Solid Tumors 1L CRC Pan Tumor TMB High Pediatric OPDIVO + YERVOY Solid Tumors Metastatic Castration- Resistant Prostate OPDIVO + CDK4/6 Inhibitor Neoadjuvant ER+/HER2- Breast OPDIVO + relatlimab Solid Tumors OPDIVO + linrodostat Solid Tumors OPDIVO + bempegaldesleukin 1L Bladder# POMALYST/IMNOVID Pediatric Glioblastoma Investigational Compounds Anti-CTLA-4 NF^ Solid Tumors Anti-CTLA-4 Probody^ Solid Tumors Anti-TIGIT^ Solid Tumors Anti-Fucosyl GM1 Solid Tumors LSD1 Inhibitor Extensive Stage SCLC BET Inhibitor (CC-90010)^ Solid Tumors farletuzumab-eribulin ADC Solid Tumors subcutaneous nivolumab + rHuPH20 Solid TumorsPhase III Additional Indications OPDIVO 1L Glioblastoma 1L HCC 1L Head & Neck 1L Head & Neck Locally Advanced 1L Esophageal High-Risk Non-Muscle Invasive Bladder Cancer Adjuvant Gastric Adjuvant HCC Adjuvant Melanoma Adjuvant RCC Metastatic Castration- Resistant Prostate Neoadjuvant ER+/HER2- Breast Neoadjuvant NSCLC Peri-adjuvant NSCLC Unresectable NSCLC OPDIVO + YERVOY 1L Bladder 1L Esophageal 1L Gastric 1L HCC Intermediate HCC 1L CRC (MSI-High) Adjuvant Melanoma Adjuvant RCC NSCLC EGFR Mutant Unresectable NSCLC OPDIVO + relatlimab 1L Melanoma OPDIVO + linrodostat Neoadjuvant Muscle Invasive Bladder Cancer OPDIVO + bempegaldesleukin 1L Melanoma Adjuvant Melanoma# Muscle Invasive Bladder Cancer 1L RCC# OPDIVO + YERVOY + cabozantinib Metastatic RCC Investigational Compounds subcutaneous nivolumab + rHuPH20 Advanced RCCApproved Indications OPDIVO 1L Metastatic Melanoma 1L Gastric Adjuvant Melanoma Adjuvant Bladder Adjuvant Esophageal/ Gastroesophageal Mesothelioma Previously treated advanced RCC Previously treated Gastric Cancer (Japan, China) Previously treated Metastatic Head & Neck Previously treated Metastatic Melanoma Previously treated Metastatic MSI-High CRC Previously treated Metastatic Non-squamous NSCLC Previously treated Metastatic Squamous NSCLC Previously treated Metastatic Urothelial Previously treated Esophageal OPDIVO + YERVOY 1L Metastatic Melanoma 1L Mesothelioma 1L NSCLC 1L RCC Previously treated Metastatic MSI-High CRC Previously treated HCC OPDIVO + cabozantinib Metastatic RCC YERVOY Adjuvant Melanoma Metastatic Melanoma ABRAXANE Breast Gastric Locally Advanced or Metastatic NSCLC Metastatic Breast Cancer NSCLC Pancreatic Unresectable Pancreatic Listed in this section are our clinical studies and approved indications for our marketed products in the related therapeutic area as of February 4, 2022.","('Customer_Welfare', 0.18923042714595795)","('Competitive_Behavior', 0.1615782082080841)","('Access_And_Affordability', 0.08566317707300186)","('NON-ESG', 0.18923042714595795)","('NON-ESG', 0.1615782082080841)","('NON-ESG', 0.08566317707300186)"
Line 694,"Projected environmental and social benefits: CO 2 absorption globally Reforestation Protection and restoration of local biodiversity Fight against desertification and soil erosion Economic support for local farmersSteinhausen, Switzerland Implementation of waste management efforts, including: Held an employee engagement workshop with Zero Waste Switzerland and introduced employee education to drive increased awareness of actions each individual can take to minimize consumption of natural resources Led an EV Ride & Drive event with test drives Organized exclusive e-bike discounts from local stores to promote sustainable commuting 2021 ESG REPORT | 49Appendix 51 Development Portfolio by Therapeutic Area 54 BMS 2021 ESG Data 61 SASB 63 GRI 72 NBIM 75 Forward-Looking Information and Non-GAAP Financial Information 2021 ESG REPORT | 50Development Portfolio by Therapeutic Area Oncology Phase I Additional Indications OPDIVO Solid Tumors OPDIVO + YERVOY Solid Tumors Investigational Compounds motolimod SCCHN relatlimab^ Solid Tumors Anti-TIM-3^ Solid Tumors STING Agonist Solid Tumors AHR Antagonist Solid Tumors Anti-CTLA-4 NF-Probody Solid Tumors BET Inhibitor (CC-95775)^ Solid Tumors Anti-SIRP Solid Tumors CD3xPSCA Solid Tumors Anti-IL8^ Solid Tumors AR-LDD Solid Tumors Anti-NKG2A Solid Tumors TGF Inhibitor Solid Tumors IL-12 Fc Solid Tumors Anti-CCR8 Solid Tumors TIGIT Bispecific Solid Tumors farletuzumab-eribulin ADC Solid Tumors MAGE A4/8 TCE-Bispecific Solid TumorsPhase II Additional Indications OPDIVO Solid Tumors 1L CRC Pan Tumor TMB High Pediatric OPDIVO + YERVOY Solid Tumors Metastatic Castration- Resistant Prostate OPDIVO + CDK4/6 Inhibitor Neoadjuvant ER+/HER2- Breast OPDIVO + relatlimab Solid Tumors OPDIVO + linrodostat Solid Tumors OPDIVO + bempegaldesleukin 1L Bladder# POMALYST/IMNOVID Pediatric Glioblastoma Investigational Compounds Anti-CTLA-4 NF^ Solid Tumors Anti-CTLA-4 Probody^ Solid Tumors Anti-TIGIT^ Solid Tumors Anti-Fucosyl GM1 Solid Tumors LSD1 Inhibitor Extensive Stage SCLC BET Inhibitor (CC-90010)^ Solid Tumors farletuzumab-eribulin ADC Solid Tumors subcutaneous nivolumab + rHuPH20 Solid TumorsPhase III Additional Indications OPDIVO 1L Glioblastoma 1L HCC 1L Head & Neck 1L Head & Neck Locally Advanced 1L Esophageal High-Risk Non-Muscle Invasive Bladder Cancer Adjuvant Gastric Adjuvant HCC Adjuvant Melanoma Adjuvant RCC Metastatic Castration- Resistant Prostate Neoadjuvant ER+/HER2- Breast Neoadjuvant NSCLC Peri-adjuvant NSCLC Unresectable NSCLC OPDIVO + YERVOY 1L Bladder 1L Esophageal 1L Gastric 1L HCC Intermediate HCC 1L CRC (MSI-High) Adjuvant Melanoma Adjuvant RCC NSCLC EGFR Mutant Unresectable NSCLC OPDIVO + relatlimab 1L Melanoma OPDIVO + linrodostat Neoadjuvant Muscle Invasive Bladder Cancer OPDIVO + bempegaldesleukin 1L Melanoma Adjuvant Melanoma# Muscle Invasive Bladder Cancer 1L RCC# OPDIVO + YERVOY + cabozantinib Metastatic RCC Investigational Compounds subcutaneous nivolumab + rHuPH20 Advanced RCCApproved Indications OPDIVO 1L Metastatic Melanoma 1L Gastric Adjuvant Melanoma Adjuvant Bladder Adjuvant Esophageal/ Gastroesophageal Mesothelioma Previously treated advanced RCC Previously treated Gastric Cancer (Japan, China) Previously treated Metastatic Head & Neck Previously treated Metastatic Melanoma Previously treated Metastatic MSI-High CRC Previously treated Metastatic Non-squamous NSCLC Previously treated Metastatic Squamous NSCLC Previously treated Metastatic Urothelial Previously treated Esophageal OPDIVO + YERVOY 1L Metastatic Melanoma 1L Mesothelioma 1L NSCLC 1L RCC Previously treated Metastatic MSI-High CRC Previously treated HCC OPDIVO + cabozantinib Metastatic RCC YERVOY Adjuvant Melanoma Metastatic Melanoma ABRAXANE Breast Gastric Locally Advanced or Metastatic NSCLC Metastatic Breast Cancer NSCLC Pancreatic Unresectable Pancreatic Listed in this section are our clinical studies and approved indications for our marketed products in the related therapeutic area as of February 4, 2022.","('Access_And_Affordability', 0.18250772356987)","('Employee_Health_And_Safety', 0.10719740390777588)","('Customer_Welfare', 0.10163169354200363)","('NON-ESG', 0.18250772356987)","('NON-ESG', 0.10719740390777588)","('NON-ESG', 0.10163169354200363)"
Line 695,"Projected environmental and social benefits: CO 2 absorption globally Reforestation Protection and restoration of local biodiversity Fight against desertification and soil erosion Economic support for local farmersSteinhausen, Switzerland Implementation of waste management efforts, including: Held an employee engagement workshop with Zero Waste Switzerland and introduced employee education to drive increased awareness of actions each individual can take to minimize consumption of natural resources Led an EV Ride & Drive event with test drives Organized exclusive e-bike discounts from local stores to promote sustainable commuting 2021 ESG REPORT | 49Appendix 51 Development Portfolio by Therapeutic Area 54 BMS 2021 ESG Data 61 SASB 63 GRI 72 NBIM 75 Forward-Looking Information and Non-GAAP Financial Information 2021 ESG REPORT | 50Development Portfolio by Therapeutic Area Oncology Phase I Additional Indications OPDIVO Solid Tumors OPDIVO + YERVOY Solid Tumors Investigational Compounds motolimod SCCHN relatlimab^ Solid Tumors Anti-TIM-3^ Solid Tumors STING Agonist Solid Tumors AHR Antagonist Solid Tumors Anti-CTLA-4 NF-Probody Solid Tumors BET Inhibitor (CC-95775)^ Solid Tumors Anti-SIRP Solid Tumors CD3xPSCA Solid Tumors Anti-IL8^ Solid Tumors AR-LDD Solid Tumors Anti-NKG2A Solid Tumors TGF Inhibitor Solid Tumors IL-12 Fc Solid Tumors Anti-CCR8 Solid Tumors TIGIT Bispecific Solid Tumors farletuzumab-eribulin ADC Solid Tumors MAGE A4/8 TCE-Bispecific Solid TumorsPhase II Additional Indications OPDIVO Solid Tumors 1L CRC Pan Tumor TMB High Pediatric OPDIVO + YERVOY Solid Tumors Metastatic Castration- Resistant Prostate OPDIVO + CDK4/6 Inhibitor Neoadjuvant ER+/HER2- Breast OPDIVO + relatlimab Solid Tumors OPDIVO + linrodostat Solid Tumors OPDIVO + bempegaldesleukin 1L Bladder# POMALYST/IMNOVID Pediatric Glioblastoma Investigational Compounds Anti-CTLA-4 NF^ Solid Tumors Anti-CTLA-4 Probody^ Solid Tumors Anti-TIGIT^ Solid Tumors Anti-Fucosyl GM1 Solid Tumors LSD1 Inhibitor Extensive Stage SCLC BET Inhibitor (CC-90010)^ Solid Tumors farletuzumab-eribulin ADC Solid Tumors subcutaneous nivolumab + rHuPH20 Solid TumorsPhase III Additional Indications OPDIVO 1L Glioblastoma 1L HCC 1L Head & Neck 1L Head & Neck Locally Advanced 1L Esophageal High-Risk Non-Muscle Invasive Bladder Cancer Adjuvant Gastric Adjuvant HCC Adjuvant Melanoma Adjuvant RCC Metastatic Castration- Resistant Prostate Neoadjuvant ER+/HER2- Breast Neoadjuvant NSCLC Peri-adjuvant NSCLC Unresectable NSCLC OPDIVO + YERVOY 1L Bladder 1L Esophageal 1L Gastric 1L HCC Intermediate HCC 1L CRC (MSI-High) Adjuvant Melanoma Adjuvant RCC NSCLC EGFR Mutant Unresectable NSCLC OPDIVO + relatlimab 1L Melanoma OPDIVO + linrodostat Neoadjuvant Muscle Invasive Bladder Cancer OPDIVO + bempegaldesleukin 1L Melanoma Adjuvant Melanoma# Muscle Invasive Bladder Cancer 1L RCC# OPDIVO + YERVOY + cabozantinib Metastatic RCC Investigational Compounds subcutaneous nivolumab + rHuPH20 Advanced RCCApproved Indications OPDIVO 1L Metastatic Melanoma 1L Gastric Adjuvant Melanoma Adjuvant Bladder Adjuvant Esophageal/ Gastroesophageal Mesothelioma Previously treated advanced RCC Previously treated Gastric Cancer (Japan, China) Previously treated Metastatic Head & Neck Previously treated Metastatic Melanoma Previously treated Metastatic MSI-High CRC Previously treated Metastatic Non-squamous NSCLC Previously treated Metastatic Squamous NSCLC Previously treated Metastatic Urothelial Previously treated Esophageal OPDIVO + YERVOY 1L Metastatic Melanoma 1L Mesothelioma 1L NSCLC 1L RCC Previously treated Metastatic MSI-High CRC Previously treated HCC OPDIVO + cabozantinib Metastatic RCC YERVOY Adjuvant Melanoma Metastatic Melanoma ABRAXANE Breast Gastric Locally Advanced or Metastatic NSCLC Metastatic Breast Cancer NSCLC Pancreatic Unresectable Pancreatic Listed in this section are our clinical studies and approved indications for our marketed products in the related therapeutic area as of February 4, 2022.","('Employee_Health_And_Safety', 0.11455148458480835)","('Access_And_Affordability', 0.10797753930091858)","('Ecological_Impacts', 0.10337641835212708)","('NON-ESG', 0.11455148458480835)","('NON-ESG', 0.10797753930091858)","('NON-ESG', 0.10337641835212708)"
Line 696,"Projected environmental and social benefits: CO 2 absorption globally Reforestation Protection and restoration of local biodiversity Fight against desertification and soil erosion Economic support for local farmersSteinhausen, Switzerland Implementation of waste management efforts, including: Held an employee engagement workshop with Zero Waste Switzerland and introduced employee education to drive increased awareness of actions each individual can take to minimize consumption of natural resources Led an EV Ride & Drive event with test drives Organized exclusive e-bike discounts from local stores to promote sustainable commuting 2021 ESG REPORT | 49Appendix 51 Development Portfolio by Therapeutic Area 54 BMS 2021 ESG Data 61 SASB 63 GRI 72 NBIM 75 Forward-Looking Information and Non-GAAP Financial Information 2021 ESG REPORT | 50Development Portfolio by Therapeutic Area Oncology Phase I Additional Indications OPDIVO Solid Tumors OPDIVO + YERVOY Solid Tumors Investigational Compounds motolimod SCCHN relatlimab^ Solid Tumors Anti-TIM-3^ Solid Tumors STING Agonist Solid Tumors AHR Antagonist Solid Tumors Anti-CTLA-4 NF-Probody Solid Tumors BET Inhibitor (CC-95775)^ Solid Tumors Anti-SIRP Solid Tumors CD3xPSCA Solid Tumors Anti-IL8^ Solid Tumors AR-LDD Solid Tumors Anti-NKG2A Solid Tumors TGF Inhibitor Solid Tumors IL-12 Fc Solid Tumors Anti-CCR8 Solid Tumors TIGIT Bispecific Solid Tumors farletuzumab-eribulin ADC Solid Tumors MAGE A4/8 TCE-Bispecific Solid TumorsPhase II Additional Indications OPDIVO Solid Tumors 1L CRC Pan Tumor TMB High Pediatric OPDIVO + YERVOY Solid Tumors Metastatic Castration- Resistant Prostate OPDIVO + CDK4/6 Inhibitor Neoadjuvant ER+/HER2- Breast OPDIVO + relatlimab Solid Tumors OPDIVO + linrodostat Solid Tumors OPDIVO + bempegaldesleukin 1L Bladder# POMALYST/IMNOVID Pediatric Glioblastoma Investigational Compounds Anti-CTLA-4 NF^ Solid Tumors Anti-CTLA-4 Probody^ Solid Tumors Anti-TIGIT^ Solid Tumors Anti-Fucosyl GM1 Solid Tumors LSD1 Inhibitor Extensive Stage SCLC BET Inhibitor (CC-90010)^ Solid Tumors farletuzumab-eribulin ADC Solid Tumors subcutaneous nivolumab + rHuPH20 Solid TumorsPhase III Additional Indications OPDIVO 1L Glioblastoma 1L HCC 1L Head & Neck 1L Head & Neck Locally Advanced 1L Esophageal High-Risk Non-Muscle Invasive Bladder Cancer Adjuvant Gastric Adjuvant HCC Adjuvant Melanoma Adjuvant RCC Metastatic Castration- Resistant Prostate Neoadjuvant ER+/HER2- Breast Neoadjuvant NSCLC Peri-adjuvant NSCLC Unresectable NSCLC OPDIVO + YERVOY 1L Bladder 1L Esophageal 1L Gastric 1L HCC Intermediate HCC 1L CRC (MSI-High) Adjuvant Melanoma Adjuvant RCC NSCLC EGFR Mutant Unresectable NSCLC OPDIVO + relatlimab 1L Melanoma OPDIVO + linrodostat Neoadjuvant Muscle Invasive Bladder Cancer OPDIVO + bempegaldesleukin 1L Melanoma Adjuvant Melanoma# Muscle Invasive Bladder Cancer 1L RCC# OPDIVO + YERVOY + cabozantinib Metastatic RCC Investigational Compounds subcutaneous nivolumab + rHuPH20 Advanced RCCApproved Indications OPDIVO 1L Metastatic Melanoma 1L Gastric Adjuvant Melanoma Adjuvant Bladder Adjuvant Esophageal/ Gastroesophageal Mesothelioma Previously treated advanced RCC Previously treated Gastric Cancer (Japan, China) Previously treated Metastatic Head & Neck Previously treated Metastatic Melanoma Previously treated Metastatic MSI-High CRC Previously treated Metastatic Non-squamous NSCLC Previously treated Metastatic Squamous NSCLC Previously treated Metastatic Urothelial Previously treated Esophageal OPDIVO + YERVOY 1L Metastatic Melanoma 1L Mesothelioma 1L NSCLC 1L RCC Previously treated Metastatic MSI-High CRC Previously treated HCC OPDIVO + cabozantinib Metastatic RCC YERVOY Adjuvant Melanoma Metastatic Melanoma ABRAXANE Breast Gastric Locally Advanced or Metastatic NSCLC Metastatic Breast Cancer NSCLC Pancreatic Unresectable Pancreatic Listed in this section are our clinical studies and approved indications for our marketed products in the related therapeutic area as of February 4, 2022.","('Access_And_Affordability', 0.1312481015920639)","('Employee_Health_And_Safety', 0.1305159479379654)","('Ecological_Impacts', 0.09451067447662354)","('NON-ESG', 0.1312481015920639)","('NON-ESG', 0.1305159479379654)","('NON-ESG', 0.09451067447662354)"
Line 697,"Projected environmental and social benefits: CO 2 absorption globally Reforestation Protection and restoration of local biodiversity Fight against desertification and soil erosion Economic support for local farmersSteinhausen, Switzerland Implementation of waste management efforts, including: Held an employee engagement workshop with Zero Waste Switzerland and introduced employee education to drive increased awareness of actions each individual can take to minimize consumption of natural resources Led an EV Ride & Drive event with test drives Organized exclusive e-bike discounts from local stores to promote sustainable commuting 2021 ESG REPORT | 49Appendix 51 Development Portfolio by Therapeutic Area 54 BMS 2021 ESG Data 61 SASB 63 GRI 72 NBIM 75 Forward-Looking Information and Non-GAAP Financial Information 2021 ESG REPORT | 50Development Portfolio by Therapeutic Area Oncology Phase I Additional Indications OPDIVO Solid Tumors OPDIVO + YERVOY Solid Tumors Investigational Compounds motolimod SCCHN relatlimab^ Solid Tumors Anti-TIM-3^ Solid Tumors STING Agonist Solid Tumors AHR Antagonist Solid Tumors Anti-CTLA-4 NF-Probody Solid Tumors BET Inhibitor (CC-95775)^ Solid Tumors Anti-SIRP Solid Tumors CD3xPSCA Solid Tumors Anti-IL8^ Solid Tumors AR-LDD Solid Tumors Anti-NKG2A Solid Tumors TGF Inhibitor Solid Tumors IL-12 Fc Solid Tumors Anti-CCR8 Solid Tumors TIGIT Bispecific Solid Tumors farletuzumab-eribulin ADC Solid Tumors MAGE A4/8 TCE-Bispecific Solid TumorsPhase II Additional Indications OPDIVO Solid Tumors 1L CRC Pan Tumor TMB High Pediatric OPDIVO + YERVOY Solid Tumors Metastatic Castration- Resistant Prostate OPDIVO + CDK4/6 Inhibitor Neoadjuvant ER+/HER2- Breast OPDIVO + relatlimab Solid Tumors OPDIVO + linrodostat Solid Tumors OPDIVO + bempegaldesleukin 1L Bladder# POMALYST/IMNOVID Pediatric Glioblastoma Investigational Compounds Anti-CTLA-4 NF^ Solid Tumors Anti-CTLA-4 Probody^ Solid Tumors Anti-TIGIT^ Solid Tumors Anti-Fucosyl GM1 Solid Tumors LSD1 Inhibitor Extensive Stage SCLC BET Inhibitor (CC-90010)^ Solid Tumors farletuzumab-eribulin ADC Solid Tumors subcutaneous nivolumab + rHuPH20 Solid TumorsPhase III Additional Indications OPDIVO 1L Glioblastoma 1L HCC 1L Head & Neck 1L Head & Neck Locally Advanced 1L Esophageal High-Risk Non-Muscle Invasive Bladder Cancer Adjuvant Gastric Adjuvant HCC Adjuvant Melanoma Adjuvant RCC Metastatic Castration- Resistant Prostate Neoadjuvant ER+/HER2- Breast Neoadjuvant NSCLC Peri-adjuvant NSCLC Unresectable NSCLC OPDIVO + YERVOY 1L Bladder 1L Esophageal 1L Gastric 1L HCC Intermediate HCC 1L CRC (MSI-High) Adjuvant Melanoma Adjuvant RCC NSCLC EGFR Mutant Unresectable NSCLC OPDIVO + relatlimab 1L Melanoma OPDIVO + linrodostat Neoadjuvant Muscle Invasive Bladder Cancer OPDIVO + bempegaldesleukin 1L Melanoma Adjuvant Melanoma# Muscle Invasive Bladder Cancer 1L RCC# OPDIVO + YERVOY + cabozantinib Metastatic RCC Investigational Compounds subcutaneous nivolumab + rHuPH20 Advanced RCCApproved Indications OPDIVO 1L Metastatic Melanoma 1L Gastric Adjuvant Melanoma Adjuvant Bladder Adjuvant Esophageal/ Gastroesophageal Mesothelioma Previously treated advanced RCC Previously treated Gastric Cancer (Japan, China) Previously treated Metastatic Head & Neck Previously treated Metastatic Melanoma Previously treated Metastatic MSI-High CRC Previously treated Metastatic Non-squamous NSCLC Previously treated Metastatic Squamous NSCLC Previously treated Metastatic Urothelial Previously treated Esophageal OPDIVO + YERVOY 1L Metastatic Melanoma 1L Mesothelioma 1L NSCLC 1L RCC Previously treated Metastatic MSI-High CRC Previously treated HCC OPDIVO + cabozantinib Metastatic RCC YERVOY Adjuvant Melanoma Metastatic Melanoma ABRAXANE Breast Gastric Locally Advanced or Metastatic NSCLC Metastatic Breast Cancer NSCLC Pancreatic Unresectable Pancreatic Listed in this section are our clinical studies and approved indications for our marketed products in the related therapeutic area as of February 4, 2022.","('Customer_Welfare', 0.3368493914604187)","('Selling_Practices_And_Product_Labeling', 0.1715533435344696)","('Product_Quality_And_Safety', 0.08067655563354492)","('NON-ESG', 0.3368493914604187)","('NON-ESG', 0.1715533435344696)","('NON-ESG', 0.08067655563354492)"
Line 698,"Whether any of the listed compounds ultimately becomes a marketed product depends on the results of clinical studies, the competitive landscape of the potential products market, reimbursement decisions by payers and the manufacturing processes necessary to produce the potential product on a commercial scale, among other factors.","('Product_Design_And_Lifecycle_Management', 0.36436840891838074)","('Customer_Welfare', 0.2454926073551178)","('Selling_Practices_And_Product_Labeling', 0.1301676332950592)","('NON-ESG', 0.36436840891838074)","('NON-ESG', 0.2454926073551178)","('NON-ESG', 0.1301676332950592)"
Line 699,"There can be no assurance that we will seek regulatory approval of any of these compounds or that, if such approval is sought, it will be obtained.","('Management_Of_Legal_And_Regulatory_Framework', 0.7222027778625488)","('Competitive_Behavior', 0.05362560600042343)","('Selling_Practices_And_Product_Labeling', 0.03917940333485603)","([], 0.7222027778625488)","('NON-ESG', 0.05362560600042343)","('NON-ESG', 0.03917940333485603)"
Line 700,There is also no assurance that a compound which gets approved will be commercially successful.,"('Selling_Practices_And_Product_Labeling', 0.2941547930240631)","('Customer_Welfare', 0.20389920473098755)","('Product_Quality_And_Safety', 0.15643256902694702)","('NON-ESG', 0.2941547930240631)","('NON-ESG', 0.20389920473098755)","('NON-ESG', 0.15643256902694702)"
Line 701,"At this stage of development, we cannot determine all intellectual property issues or all the patent protection that may, or may not, be available for these investigational compounds.","('Competitive_Behavior', 0.910686731338501)","('Management_Of_Legal_And_Regulatory_Framework', 0.02263294719159603)","('Business_Ethics', 0.007932922802865505)","([], 0.910686731338501)","('NON-ESG', 0.02263294719159603)","('NON-ESG', 0.007932922802865505)"
Line 702,"2021 ESG REPORT | 51Hematology Phase I Additional Indications OPDIVO Hematologic Malignancies BREYANZI (liso-cel) 3L+ Mantle Cell Lymphoma ABECMA (idecel) High-Risk Newly Diagnosed Multiple Myeloma Investigational Compounds relatlimab^ Hematologic Malignancies BET Inhibitor (CC-95775) Non-Hodgkin Lymphoma BET Inhibitor (CC-90010) Hematologic Malignancies BCMA ADC Relapsed/Refractory Multiple Myeloma BCMA TCE Relapsed/Refractory Multiple Myeloma BCMA NEX T Relapsed/Refractory Multiple Myeloma GPRC5D CAR T Relapsed/Refractory Multiple Myeloma GSPT1 CELMoD (CC-90009) Relapsed/Refractory Acute Myeloid Leukemia Anti-SIRP Non-Hodgkin Lymphoma LSD1 Inhibitor Relapsed/Refractory Non- Hodgkin Lymphoma CD19 NEX T Relapsed/Refractory Non- Hodgkin Lymphoma iberdomide Non-Hodgkin Lymphoma CD33 NKE Relapsed/Refractory Multiple Myeloma CD47xCD20 Non-Hodgkin Lymphoma CK1a CELMoD Hematologic Malignancies ROR1 CAR T Hematologic Malignancies BCMA NKE Relapsed/Refractory Multiple MyelomaPhase II Additional Indications OPDIVO Non-Hodgkin Lymphoma (Diffuse Large B-cell Lymphoma) Non-Hodgkin Lymphoma (Follicular Lymphoma) Pediatric Hodgkin Lymphoma Primary Testicular Lymphoma OPDIVO + EMPLICITI Relapsed/Refractory Multiple Myeloma REBLOZYL Non-Transfusion- Dependent Beta- Thalassemia ONUREG Post HMA Failure MDS BREYANZI 2L Diffuse Large B-cell Lymphoma Transplant Non-Eligible 3L+Chronic Lymphocytic Leukemia 3L+ Follicular Lymphoma / Marginal Zone Lymphoma 2L+ Pediatric B-cell Acute Lymphoblastic Leukemia 2L+ Primary CNS Lymphoma 1L High Grade B-cell Lymphoma ABECMA (ide-cel) High-Risk Newly Diagnosed Multiple Myeloma 2L Relapsed/Refractory Multiple Myeloma 4L+ Relapsed/Refractory Multiple Myeloma Investigational Compounds iberdomide Relapsed/Refractory Multiple Myeloma A/I CELMoD (CC-92480) Relapsed/Refractory Multiple Myeloma BET Inhibitor (BMS- 986158) Hematologic MalignanciesPhase III Additional Indications OPDIVO Refractory Hodgkin Lymphoma EMPLICITI + REVLIMID 1L Multiple Myeloma REBLOZYL ESA Naive MDS MF Anemia INREBIC MF Previously treated with Ruxolitinib ONUREG Angioimmunoblastic T-cell Lymphoma Lower Risk MDS ABECMA (ide-cel) 3L Relapsed/Refractory Multiple Myeloma BREYANZI 2L Diffuse Large B-cell Lymphoma Transplant EligibleApproved Indications REVLIMID 1L Multiple Myeloma Mantle Cell Lymphoma MDS Multiple Myeloma Previously treated Follicular Lymphoma Relapsed/Refractory Adult T-cell Leukemia/Lymphoma OPDIVO Advanced Hodgkin Lymphoma POMALYST/IMNOVID Multiple Myeloma Relapsed/Refractory Multiple Myeloma AIDS-related Kaposi Sarcoma HIV-negative Kaposi Sarcoma EMPLICITI + POMALYST/ IMNOVID Relapsed/Refractory Multiple Myeloma EMPLICITI + REVLIMID Relapsed/Refractory Multiple Myeloma SPRYCEL 1L CML Pediatric ALL Refractory CML REBLOZYL Transfusion-Dependent Beta- Thalassemia MDS Previously treated with ESA INREBIC MF ONUREG Post-Induction Acute Myeloid Leukemia Maintenance BREYANZI 3L+ Diffuse Large B-cell Lymphoma ABECMA (ide-cel) 5L+ Relapsed/Refractory Multiple Myeloma 2021 ESG REPORT | 52 Development Portfolio by Therapeutic AreaImmunology Phase I Investigational Compounds TYK2 Inhibitor Autoimmune Disease TLR 7/8 Inhibitor Autoimmune Disease MK2 Inhibitor Autoimmune Disease IL2-CD25 Autoimmune Disease Anti-CD40 Autoimmune Disease afimetoran Cutaneous Lupus ErythematosusPhase II Investigational Compounds branebrutinib Rheumatoid Arthritis Sjogrens Disease Systemic Lupus Erythematosus Atopic Dermatitis deucravacitinib Crohns Disease Lupus Nephritis Systemic Lupus Erythematosus Ulcerative Colitis Discoid Lupus Erythematosus iberdomide Systemic Lupus Erythematosus cendakimab Atopic Dermatitis afimetoran Systemic Lupus Erythematosus S1PR1 Modulator Atopic Dermatitis MK2 Inhibitor Ankylosing SpondylitisPhase III Additional Indications ZEPOSIA Crohns Disease Investigational Compounds deucravacitinib Psoriasis Psoriatic Arthritis cendakimab Eosinophilic EsophagitisApproved Indications ORENCIA Active Polyarticular JIA Early Rheumatoid Arthritis JIA Intravenous JIA Subcutaneous Psoriatic Arthritis RA Auto injector RA Intravenous RA Subcutaneous Acute Graft versus Host Disease ZEPOSIA Relapsing Multiple Sclerosis Ulcerative Colitis Cardiovascular Phase I Investigational Compounds Factor XIa Inhibitor Thrombotic Disorders Cardiac Myosin Inhibitor Hypertrophic Cardiomyopathy ROMK Inhibitor Heart FailurePhase II Additional Indications ELIQUIS Pediatric Heart Disease Investigational Compounds mavacamten Non-Obstructive Hypertrophic Cardiomyopathy Heart Failure with Preserved Ejection Fraction danicamtiv Genetic Dilated Cardiomyopathy milvexian Thrombotic Disorders FA-Relaxin Heart FailurePhase III Additional Indications ELIQUIS VTE prevention in pediatrics with ALL Investigational Compounds mavacamten Obstructive Hypertrophic Cardiomyopathy Obstructive Hypertrophic Cardiomyopathy Septal Reduction Therapy EligibleApproved Indications ELIQUIS Stroke Prevention in Atrial Fibrillation Venous Thromboembolism Prevention Orthopedic Surgery Venous Thromboembolism Treatment Fibrotic Diseases Phase I Investigational Compounds NME 1 FibrosisPhase II Investigational Compounds HSP47 Non-Alcoholic Steatohepatitis LPA 1 Antagonist Pulmonary FibrosisNeuroscience Phase I Investigational Compounds FAAH/MGLL Dual Inhibitor Neuroscience Anti-Tau Neuroscience BTK Inhibitor Neuroscience eIF2b Activator NeuroscienceCOVID-19 Phase II Additional Indications ORENCIA COVID-19 treatment Investigational Compounds SARS-CoV-2 mAb Duo COVID-19 Therapy or Prevention# Note: Above pipeline excludes clinical collaborations Development Partnership: OPDIVO, YERVOY, Relatlimab: Ono (our collaboration with Ono also includes other early-stage compounds); EMPLICITI: AbbVie; bempegaldesleukin: Nektar; cabozantinib: Exelixis, Inc.; ELIQUIS: Pfizer; Factor XIa Inhibitor: Janssen Pharmaceuticals, Inc.; HSP47: Nitto Denko Corporation; CD3xPSCA: GeMoaB Monoclonals GmbH; ABECMA (ide-cel): 2seventy bio; REBLOZYL: Merck; AHR: Ikena Oncology; CD22 ADC: T riPhase Accelerator; Immune T olerance: Anokion SA; SARS-CoV-2 mAb Duo: Rockefeller University; TIGIT Bispecific: Agenus; farletuzumab-eribulin ADC: Eisai; rHuPH20: Halozyme; Anti-T au: Prothena Corporation PLC; eIF2b Activator: Evotec SE; MAGE A4/8 TCE Bispecific: Immatics.","('Access_And_Affordability', 0.2376852184534073)","('Employee_Health_And_Safety', 0.1210852563381195)","('Product_Quality_And_Safety', 0.07404538244009018)","('NON-ESG', 0.2376852184534073)","('NON-ESG', 0.1210852563381195)","('NON-ESG', 0.07404538244009018)"
Line 703,"2021 ESG REPORT | 51Hematology Phase I Additional Indications OPDIVO Hematologic Malignancies BREYANZI (liso-cel) 3L+ Mantle Cell Lymphoma ABECMA (idecel) High-Risk Newly Diagnosed Multiple Myeloma Investigational Compounds relatlimab^ Hematologic Malignancies BET Inhibitor (CC-95775) Non-Hodgkin Lymphoma BET Inhibitor (CC-90010) Hematologic Malignancies BCMA ADC Relapsed/Refractory Multiple Myeloma BCMA TCE Relapsed/Refractory Multiple Myeloma BCMA NEX T Relapsed/Refractory Multiple Myeloma GPRC5D CAR T Relapsed/Refractory Multiple Myeloma GSPT1 CELMoD (CC-90009) Relapsed/Refractory Acute Myeloid Leukemia Anti-SIRP Non-Hodgkin Lymphoma LSD1 Inhibitor Relapsed/Refractory Non- Hodgkin Lymphoma CD19 NEX T Relapsed/Refractory Non- Hodgkin Lymphoma iberdomide Non-Hodgkin Lymphoma CD33 NKE Relapsed/Refractory Multiple Myeloma CD47xCD20 Non-Hodgkin Lymphoma CK1a CELMoD Hematologic Malignancies ROR1 CAR T Hematologic Malignancies BCMA NKE Relapsed/Refractory Multiple MyelomaPhase II Additional Indications OPDIVO Non-Hodgkin Lymphoma (Diffuse Large B-cell Lymphoma) Non-Hodgkin Lymphoma (Follicular Lymphoma) Pediatric Hodgkin Lymphoma Primary Testicular Lymphoma OPDIVO + EMPLICITI Relapsed/Refractory Multiple Myeloma REBLOZYL Non-Transfusion- Dependent Beta- Thalassemia ONUREG Post HMA Failure MDS BREYANZI 2L Diffuse Large B-cell Lymphoma Transplant Non-Eligible 3L+Chronic Lymphocytic Leukemia 3L+ Follicular Lymphoma / Marginal Zone Lymphoma 2L+ Pediatric B-cell Acute Lymphoblastic Leukemia 2L+ Primary CNS Lymphoma 1L High Grade B-cell Lymphoma ABECMA (ide-cel) High-Risk Newly Diagnosed Multiple Myeloma 2L Relapsed/Refractory Multiple Myeloma 4L+ Relapsed/Refractory Multiple Myeloma Investigational Compounds iberdomide Relapsed/Refractory Multiple Myeloma A/I CELMoD (CC-92480) Relapsed/Refractory Multiple Myeloma BET Inhibitor (BMS- 986158) Hematologic MalignanciesPhase III Additional Indications OPDIVO Refractory Hodgkin Lymphoma EMPLICITI + REVLIMID 1L Multiple Myeloma REBLOZYL ESA Naive MDS MF Anemia INREBIC MF Previously treated with Ruxolitinib ONUREG Angioimmunoblastic T-cell Lymphoma Lower Risk MDS ABECMA (ide-cel) 3L Relapsed/Refractory Multiple Myeloma BREYANZI 2L Diffuse Large B-cell Lymphoma Transplant EligibleApproved Indications REVLIMID 1L Multiple Myeloma Mantle Cell Lymphoma MDS Multiple Myeloma Previously treated Follicular Lymphoma Relapsed/Refractory Adult T-cell Leukemia/Lymphoma OPDIVO Advanced Hodgkin Lymphoma POMALYST/IMNOVID Multiple Myeloma Relapsed/Refractory Multiple Myeloma AIDS-related Kaposi Sarcoma HIV-negative Kaposi Sarcoma EMPLICITI + POMALYST/ IMNOVID Relapsed/Refractory Multiple Myeloma EMPLICITI + REVLIMID Relapsed/Refractory Multiple Myeloma SPRYCEL 1L CML Pediatric ALL Refractory CML REBLOZYL Transfusion-Dependent Beta- Thalassemia MDS Previously treated with ESA INREBIC MF ONUREG Post-Induction Acute Myeloid Leukemia Maintenance BREYANZI 3L+ Diffuse Large B-cell Lymphoma ABECMA (ide-cel) 5L+ Relapsed/Refractory Multiple Myeloma 2021 ESG REPORT | 52 Development Portfolio by Therapeutic AreaImmunology Phase I Investigational Compounds TYK2 Inhibitor Autoimmune Disease TLR 7/8 Inhibitor Autoimmune Disease MK2 Inhibitor Autoimmune Disease IL2-CD25 Autoimmune Disease Anti-CD40 Autoimmune Disease afimetoran Cutaneous Lupus ErythematosusPhase II Investigational Compounds branebrutinib Rheumatoid Arthritis Sjogrens Disease Systemic Lupus Erythematosus Atopic Dermatitis deucravacitinib Crohns Disease Lupus Nephritis Systemic Lupus Erythematosus Ulcerative Colitis Discoid Lupus Erythematosus iberdomide Systemic Lupus Erythematosus cendakimab Atopic Dermatitis afimetoran Systemic Lupus Erythematosus S1PR1 Modulator Atopic Dermatitis MK2 Inhibitor Ankylosing SpondylitisPhase III Additional Indications ZEPOSIA Crohns Disease Investigational Compounds deucravacitinib Psoriasis Psoriatic Arthritis cendakimab Eosinophilic EsophagitisApproved Indications ORENCIA Active Polyarticular JIA Early Rheumatoid Arthritis JIA Intravenous JIA Subcutaneous Psoriatic Arthritis RA Auto injector RA Intravenous RA Subcutaneous Acute Graft versus Host Disease ZEPOSIA Relapsing Multiple Sclerosis Ulcerative Colitis Cardiovascular Phase I Investigational Compounds Factor XIa Inhibitor Thrombotic Disorders Cardiac Myosin Inhibitor Hypertrophic Cardiomyopathy ROMK Inhibitor Heart FailurePhase II Additional Indications ELIQUIS Pediatric Heart Disease Investigational Compounds mavacamten Non-Obstructive Hypertrophic Cardiomyopathy Heart Failure with Preserved Ejection Fraction danicamtiv Genetic Dilated Cardiomyopathy milvexian Thrombotic Disorders FA-Relaxin Heart FailurePhase III Additional Indications ELIQUIS VTE prevention in pediatrics with ALL Investigational Compounds mavacamten Obstructive Hypertrophic Cardiomyopathy Obstructive Hypertrophic Cardiomyopathy Septal Reduction Therapy EligibleApproved Indications ELIQUIS Stroke Prevention in Atrial Fibrillation Venous Thromboembolism Prevention Orthopedic Surgery Venous Thromboembolism Treatment Fibrotic Diseases Phase I Investigational Compounds NME 1 FibrosisPhase II Investigational Compounds HSP47 Non-Alcoholic Steatohepatitis LPA 1 Antagonist Pulmonary FibrosisNeuroscience Phase I Investigational Compounds FAAH/MGLL Dual Inhibitor Neuroscience Anti-Tau Neuroscience BTK Inhibitor Neuroscience eIF2b Activator NeuroscienceCOVID-19 Phase II Additional Indications ORENCIA COVID-19 treatment Investigational Compounds SARS-CoV-2 mAb Duo COVID-19 Therapy or Prevention# Note: Above pipeline excludes clinical collaborations Development Partnership: OPDIVO, YERVOY, Relatlimab: Ono (our collaboration with Ono also includes other early-stage compounds); EMPLICITI: AbbVie; bempegaldesleukin: Nektar; cabozantinib: Exelixis, Inc.; ELIQUIS: Pfizer; Factor XIa Inhibitor: Janssen Pharmaceuticals, Inc.; HSP47: Nitto Denko Corporation; CD3xPSCA: GeMoaB Monoclonals GmbH; ABECMA (ide-cel): 2seventy bio; REBLOZYL: Merck; AHR: Ikena Oncology; CD22 ADC: T riPhase Accelerator; Immune T olerance: Anokion SA; SARS-CoV-2 mAb Duo: Rockefeller University; TIGIT Bispecific: Agenus; farletuzumab-eribulin ADC: Eisai; rHuPH20: Halozyme; Anti-T au: Prothena Corporation PLC; eIF2b Activator: Evotec SE; MAGE A4/8 TCE Bispecific: Immatics.","('Access_And_Affordability', 0.2766738831996918)","('Employee_Engagement_Inclusion_And_Diversity', 0.07023070752620697)","('Ecological_Impacts', 0.06877371668815613)","('NON-ESG', 0.2766738831996918)","('NON-ESG', 0.07023070752620697)","('NON-ESG', 0.06877371668815613)"
Line 704,"2021 ESG REPORT | 51Hematology Phase I Additional Indications OPDIVO Hematologic Malignancies BREYANZI (liso-cel) 3L+ Mantle Cell Lymphoma ABECMA (idecel) High-Risk Newly Diagnosed Multiple Myeloma Investigational Compounds relatlimab^ Hematologic Malignancies BET Inhibitor (CC-95775) Non-Hodgkin Lymphoma BET Inhibitor (CC-90010) Hematologic Malignancies BCMA ADC Relapsed/Refractory Multiple Myeloma BCMA TCE Relapsed/Refractory Multiple Myeloma BCMA NEX T Relapsed/Refractory Multiple Myeloma GPRC5D CAR T Relapsed/Refractory Multiple Myeloma GSPT1 CELMoD (CC-90009) Relapsed/Refractory Acute Myeloid Leukemia Anti-SIRP Non-Hodgkin Lymphoma LSD1 Inhibitor Relapsed/Refractory Non- Hodgkin Lymphoma CD19 NEX T Relapsed/Refractory Non- Hodgkin Lymphoma iberdomide Non-Hodgkin Lymphoma CD33 NKE Relapsed/Refractory Multiple Myeloma CD47xCD20 Non-Hodgkin Lymphoma CK1a CELMoD Hematologic Malignancies ROR1 CAR T Hematologic Malignancies BCMA NKE Relapsed/Refractory Multiple MyelomaPhase II Additional Indications OPDIVO Non-Hodgkin Lymphoma (Diffuse Large B-cell Lymphoma) Non-Hodgkin Lymphoma (Follicular Lymphoma) Pediatric Hodgkin Lymphoma Primary Testicular Lymphoma OPDIVO + EMPLICITI Relapsed/Refractory Multiple Myeloma REBLOZYL Non-Transfusion- Dependent Beta- Thalassemia ONUREG Post HMA Failure MDS BREYANZI 2L Diffuse Large B-cell Lymphoma Transplant Non-Eligible 3L+Chronic Lymphocytic Leukemia 3L+ Follicular Lymphoma / Marginal Zone Lymphoma 2L+ Pediatric B-cell Acute Lymphoblastic Leukemia 2L+ Primary CNS Lymphoma 1L High Grade B-cell Lymphoma ABECMA (ide-cel) High-Risk Newly Diagnosed Multiple Myeloma 2L Relapsed/Refractory Multiple Myeloma 4L+ Relapsed/Refractory Multiple Myeloma Investigational Compounds iberdomide Relapsed/Refractory Multiple Myeloma A/I CELMoD (CC-92480) Relapsed/Refractory Multiple Myeloma BET Inhibitor (BMS- 986158) Hematologic MalignanciesPhase III Additional Indications OPDIVO Refractory Hodgkin Lymphoma EMPLICITI + REVLIMID 1L Multiple Myeloma REBLOZYL ESA Naive MDS MF Anemia INREBIC MF Previously treated with Ruxolitinib ONUREG Angioimmunoblastic T-cell Lymphoma Lower Risk MDS ABECMA (ide-cel) 3L Relapsed/Refractory Multiple Myeloma BREYANZI 2L Diffuse Large B-cell Lymphoma Transplant EligibleApproved Indications REVLIMID 1L Multiple Myeloma Mantle Cell Lymphoma MDS Multiple Myeloma Previously treated Follicular Lymphoma Relapsed/Refractory Adult T-cell Leukemia/Lymphoma OPDIVO Advanced Hodgkin Lymphoma POMALYST/IMNOVID Multiple Myeloma Relapsed/Refractory Multiple Myeloma AIDS-related Kaposi Sarcoma HIV-negative Kaposi Sarcoma EMPLICITI + POMALYST/ IMNOVID Relapsed/Refractory Multiple Myeloma EMPLICITI + REVLIMID Relapsed/Refractory Multiple Myeloma SPRYCEL 1L CML Pediatric ALL Refractory CML REBLOZYL Transfusion-Dependent Beta- Thalassemia MDS Previously treated with ESA INREBIC MF ONUREG Post-Induction Acute Myeloid Leukemia Maintenance BREYANZI 3L+ Diffuse Large B-cell Lymphoma ABECMA (ide-cel) 5L+ Relapsed/Refractory Multiple Myeloma 2021 ESG REPORT | 52 Development Portfolio by Therapeutic AreaImmunology Phase I Investigational Compounds TYK2 Inhibitor Autoimmune Disease TLR 7/8 Inhibitor Autoimmune Disease MK2 Inhibitor Autoimmune Disease IL2-CD25 Autoimmune Disease Anti-CD40 Autoimmune Disease afimetoran Cutaneous Lupus ErythematosusPhase II Investigational Compounds branebrutinib Rheumatoid Arthritis Sjogrens Disease Systemic Lupus Erythematosus Atopic Dermatitis deucravacitinib Crohns Disease Lupus Nephritis Systemic Lupus Erythematosus Ulcerative Colitis Discoid Lupus Erythematosus iberdomide Systemic Lupus Erythematosus cendakimab Atopic Dermatitis afimetoran Systemic Lupus Erythematosus S1PR1 Modulator Atopic Dermatitis MK2 Inhibitor Ankylosing SpondylitisPhase III Additional Indications ZEPOSIA Crohns Disease Investigational Compounds deucravacitinib Psoriasis Psoriatic Arthritis cendakimab Eosinophilic EsophagitisApproved Indications ORENCIA Active Polyarticular JIA Early Rheumatoid Arthritis JIA Intravenous JIA Subcutaneous Psoriatic Arthritis RA Auto injector RA Intravenous RA Subcutaneous Acute Graft versus Host Disease ZEPOSIA Relapsing Multiple Sclerosis Ulcerative Colitis Cardiovascular Phase I Investigational Compounds Factor XIa Inhibitor Thrombotic Disorders Cardiac Myosin Inhibitor Hypertrophic Cardiomyopathy ROMK Inhibitor Heart FailurePhase II Additional Indications ELIQUIS Pediatric Heart Disease Investigational Compounds mavacamten Non-Obstructive Hypertrophic Cardiomyopathy Heart Failure with Preserved Ejection Fraction danicamtiv Genetic Dilated Cardiomyopathy milvexian Thrombotic Disorders FA-Relaxin Heart FailurePhase III Additional Indications ELIQUIS VTE prevention in pediatrics with ALL Investigational Compounds mavacamten Obstructive Hypertrophic Cardiomyopathy Obstructive Hypertrophic Cardiomyopathy Septal Reduction Therapy EligibleApproved Indications ELIQUIS Stroke Prevention in Atrial Fibrillation Venous Thromboembolism Prevention Orthopedic Surgery Venous Thromboembolism Treatment Fibrotic Diseases Phase I Investigational Compounds NME 1 FibrosisPhase II Investigational Compounds HSP47 Non-Alcoholic Steatohepatitis LPA 1 Antagonist Pulmonary FibrosisNeuroscience Phase I Investigational Compounds FAAH/MGLL Dual Inhibitor Neuroscience Anti-Tau Neuroscience BTK Inhibitor Neuroscience eIF2b Activator NeuroscienceCOVID-19 Phase II Additional Indications ORENCIA COVID-19 treatment Investigational Compounds SARS-CoV-2 mAb Duo COVID-19 Therapy or Prevention# Note: Above pipeline excludes clinical collaborations Development Partnership: OPDIVO, YERVOY, Relatlimab: Ono (our collaboration with Ono also includes other early-stage compounds); EMPLICITI: AbbVie; bempegaldesleukin: Nektar; cabozantinib: Exelixis, Inc.; ELIQUIS: Pfizer; Factor XIa Inhibitor: Janssen Pharmaceuticals, Inc.; HSP47: Nitto Denko Corporation; CD3xPSCA: GeMoaB Monoclonals GmbH; ABECMA (ide-cel): 2seventy bio; REBLOZYL: Merck; AHR: Ikena Oncology; CD22 ADC: T riPhase Accelerator; Immune T olerance: Anokion SA; SARS-CoV-2 mAb Duo: Rockefeller University; TIGIT Bispecific: Agenus; farletuzumab-eribulin ADC: Eisai; rHuPH20: Halozyme; Anti-T au: Prothena Corporation PLC; eIF2b Activator: Evotec SE; MAGE A4/8 TCE Bispecific: Immatics.","('Access_And_Affordability', 0.2872544825077057)","('Employee_Engagement_Inclusion_And_Diversity', 0.10371620208024979)","('Ecological_Impacts', 0.06674220412969589)","('NON-ESG', 0.2872544825077057)","('NON-ESG', 0.10371620208024979)","('NON-ESG', 0.06674220412969589)"
Line 705,"2021 ESG REPORT | 51Hematology Phase I Additional Indications OPDIVO Hematologic Malignancies BREYANZI (liso-cel) 3L+ Mantle Cell Lymphoma ABECMA (idecel) High-Risk Newly Diagnosed Multiple Myeloma Investigational Compounds relatlimab^ Hematologic Malignancies BET Inhibitor (CC-95775) Non-Hodgkin Lymphoma BET Inhibitor (CC-90010) Hematologic Malignancies BCMA ADC Relapsed/Refractory Multiple Myeloma BCMA TCE Relapsed/Refractory Multiple Myeloma BCMA NEX T Relapsed/Refractory Multiple Myeloma GPRC5D CAR T Relapsed/Refractory Multiple Myeloma GSPT1 CELMoD (CC-90009) Relapsed/Refractory Acute Myeloid Leukemia Anti-SIRP Non-Hodgkin Lymphoma LSD1 Inhibitor Relapsed/Refractory Non- Hodgkin Lymphoma CD19 NEX T Relapsed/Refractory Non- Hodgkin Lymphoma iberdomide Non-Hodgkin Lymphoma CD33 NKE Relapsed/Refractory Multiple Myeloma CD47xCD20 Non-Hodgkin Lymphoma CK1a CELMoD Hematologic Malignancies ROR1 CAR T Hematologic Malignancies BCMA NKE Relapsed/Refractory Multiple MyelomaPhase II Additional Indications OPDIVO Non-Hodgkin Lymphoma (Diffuse Large B-cell Lymphoma) Non-Hodgkin Lymphoma (Follicular Lymphoma) Pediatric Hodgkin Lymphoma Primary Testicular Lymphoma OPDIVO + EMPLICITI Relapsed/Refractory Multiple Myeloma REBLOZYL Non-Transfusion- Dependent Beta- Thalassemia ONUREG Post HMA Failure MDS BREYANZI 2L Diffuse Large B-cell Lymphoma Transplant Non-Eligible 3L+Chronic Lymphocytic Leukemia 3L+ Follicular Lymphoma / Marginal Zone Lymphoma 2L+ Pediatric B-cell Acute Lymphoblastic Leukemia 2L+ Primary CNS Lymphoma 1L High Grade B-cell Lymphoma ABECMA (ide-cel) High-Risk Newly Diagnosed Multiple Myeloma 2L Relapsed/Refractory Multiple Myeloma 4L+ Relapsed/Refractory Multiple Myeloma Investigational Compounds iberdomide Relapsed/Refractory Multiple Myeloma A/I CELMoD (CC-92480) Relapsed/Refractory Multiple Myeloma BET Inhibitor (BMS- 986158) Hematologic MalignanciesPhase III Additional Indications OPDIVO Refractory Hodgkin Lymphoma EMPLICITI + REVLIMID 1L Multiple Myeloma REBLOZYL ESA Naive MDS MF Anemia INREBIC MF Previously treated with Ruxolitinib ONUREG Angioimmunoblastic T-cell Lymphoma Lower Risk MDS ABECMA (ide-cel) 3L Relapsed/Refractory Multiple Myeloma BREYANZI 2L Diffuse Large B-cell Lymphoma Transplant EligibleApproved Indications REVLIMID 1L Multiple Myeloma Mantle Cell Lymphoma MDS Multiple Myeloma Previously treated Follicular Lymphoma Relapsed/Refractory Adult T-cell Leukemia/Lymphoma OPDIVO Advanced Hodgkin Lymphoma POMALYST/IMNOVID Multiple Myeloma Relapsed/Refractory Multiple Myeloma AIDS-related Kaposi Sarcoma HIV-negative Kaposi Sarcoma EMPLICITI + POMALYST/ IMNOVID Relapsed/Refractory Multiple Myeloma EMPLICITI + REVLIMID Relapsed/Refractory Multiple Myeloma SPRYCEL 1L CML Pediatric ALL Refractory CML REBLOZYL Transfusion-Dependent Beta- Thalassemia MDS Previously treated with ESA INREBIC MF ONUREG Post-Induction Acute Myeloid Leukemia Maintenance BREYANZI 3L+ Diffuse Large B-cell Lymphoma ABECMA (ide-cel) 5L+ Relapsed/Refractory Multiple Myeloma 2021 ESG REPORT | 52 Development Portfolio by Therapeutic AreaImmunology Phase I Investigational Compounds TYK2 Inhibitor Autoimmune Disease TLR 7/8 Inhibitor Autoimmune Disease MK2 Inhibitor Autoimmune Disease IL2-CD25 Autoimmune Disease Anti-CD40 Autoimmune Disease afimetoran Cutaneous Lupus ErythematosusPhase II Investigational Compounds branebrutinib Rheumatoid Arthritis Sjogrens Disease Systemic Lupus Erythematosus Atopic Dermatitis deucravacitinib Crohns Disease Lupus Nephritis Systemic Lupus Erythematosus Ulcerative Colitis Discoid Lupus Erythematosus iberdomide Systemic Lupus Erythematosus cendakimab Atopic Dermatitis afimetoran Systemic Lupus Erythematosus S1PR1 Modulator Atopic Dermatitis MK2 Inhibitor Ankylosing SpondylitisPhase III Additional Indications ZEPOSIA Crohns Disease Investigational Compounds deucravacitinib Psoriasis Psoriatic Arthritis cendakimab Eosinophilic EsophagitisApproved Indications ORENCIA Active Polyarticular JIA Early Rheumatoid Arthritis JIA Intravenous JIA Subcutaneous Psoriatic Arthritis RA Auto injector RA Intravenous RA Subcutaneous Acute Graft versus Host Disease ZEPOSIA Relapsing Multiple Sclerosis Ulcerative Colitis Cardiovascular Phase I Investigational Compounds Factor XIa Inhibitor Thrombotic Disorders Cardiac Myosin Inhibitor Hypertrophic Cardiomyopathy ROMK Inhibitor Heart FailurePhase II Additional Indications ELIQUIS Pediatric Heart Disease Investigational Compounds mavacamten Non-Obstructive Hypertrophic Cardiomyopathy Heart Failure with Preserved Ejection Fraction danicamtiv Genetic Dilated Cardiomyopathy milvexian Thrombotic Disorders FA-Relaxin Heart FailurePhase III Additional Indications ELIQUIS VTE prevention in pediatrics with ALL Investigational Compounds mavacamten Obstructive Hypertrophic Cardiomyopathy Obstructive Hypertrophic Cardiomyopathy Septal Reduction Therapy EligibleApproved Indications ELIQUIS Stroke Prevention in Atrial Fibrillation Venous Thromboembolism Prevention Orthopedic Surgery Venous Thromboembolism Treatment Fibrotic Diseases Phase I Investigational Compounds NME 1 FibrosisPhase II Investigational Compounds HSP47 Non-Alcoholic Steatohepatitis LPA 1 Antagonist Pulmonary FibrosisNeuroscience Phase I Investigational Compounds FAAH/MGLL Dual Inhibitor Neuroscience Anti-Tau Neuroscience BTK Inhibitor Neuroscience eIF2b Activator NeuroscienceCOVID-19 Phase II Additional Indications ORENCIA COVID-19 treatment Investigational Compounds SARS-CoV-2 mAb Duo COVID-19 Therapy or Prevention# Note: Above pipeline excludes clinical collaborations Development Partnership: OPDIVO, YERVOY, Relatlimab: Ono (our collaboration with Ono also includes other early-stage compounds); EMPLICITI: AbbVie; bempegaldesleukin: Nektar; cabozantinib: Exelixis, Inc.; ELIQUIS: Pfizer; Factor XIa Inhibitor: Janssen Pharmaceuticals, Inc.; HSP47: Nitto Denko Corporation; CD3xPSCA: GeMoaB Monoclonals GmbH; ABECMA (ide-cel): 2seventy bio; REBLOZYL: Merck; AHR: Ikena Oncology; CD22 ADC: T riPhase Accelerator; Immune T olerance: Anokion SA; SARS-CoV-2 mAb Duo: Rockefeller University; TIGIT Bispecific: Agenus; farletuzumab-eribulin ADC: Eisai; rHuPH20: Halozyme; Anti-T au: Prothena Corporation PLC; eIF2b Activator: Evotec SE; MAGE A4/8 TCE Bispecific: Immatics.","('Access_And_Affordability', 0.24884861707687378)","('Product_Quality_And_Safety', 0.06709574908018112)","('Ecological_Impacts', 0.06590939313173294)","('NON-ESG', 0.24884861707687378)","('NON-ESG', 0.06709574908018112)","('NON-ESG', 0.06590939313173294)"
Line 706,"2021 ESG REPORT | 51Hematology Phase I Additional Indications OPDIVO Hematologic Malignancies BREYANZI (liso-cel) 3L+ Mantle Cell Lymphoma ABECMA (idecel) High-Risk Newly Diagnosed Multiple Myeloma Investigational Compounds relatlimab^ Hematologic Malignancies BET Inhibitor (CC-95775) Non-Hodgkin Lymphoma BET Inhibitor (CC-90010) Hematologic Malignancies BCMA ADC Relapsed/Refractory Multiple Myeloma BCMA TCE Relapsed/Refractory Multiple Myeloma BCMA NEX T Relapsed/Refractory Multiple Myeloma GPRC5D CAR T Relapsed/Refractory Multiple Myeloma GSPT1 CELMoD (CC-90009) Relapsed/Refractory Acute Myeloid Leukemia Anti-SIRP Non-Hodgkin Lymphoma LSD1 Inhibitor Relapsed/Refractory Non- Hodgkin Lymphoma CD19 NEX T Relapsed/Refractory Non- Hodgkin Lymphoma iberdomide Non-Hodgkin Lymphoma CD33 NKE Relapsed/Refractory Multiple Myeloma CD47xCD20 Non-Hodgkin Lymphoma CK1a CELMoD Hematologic Malignancies ROR1 CAR T Hematologic Malignancies BCMA NKE Relapsed/Refractory Multiple MyelomaPhase II Additional Indications OPDIVO Non-Hodgkin Lymphoma (Diffuse Large B-cell Lymphoma) Non-Hodgkin Lymphoma (Follicular Lymphoma) Pediatric Hodgkin Lymphoma Primary Testicular Lymphoma OPDIVO + EMPLICITI Relapsed/Refractory Multiple Myeloma REBLOZYL Non-Transfusion- Dependent Beta- Thalassemia ONUREG Post HMA Failure MDS BREYANZI 2L Diffuse Large B-cell Lymphoma Transplant Non-Eligible 3L+Chronic Lymphocytic Leukemia 3L+ Follicular Lymphoma / Marginal Zone Lymphoma 2L+ Pediatric B-cell Acute Lymphoblastic Leukemia 2L+ Primary CNS Lymphoma 1L High Grade B-cell Lymphoma ABECMA (ide-cel) High-Risk Newly Diagnosed Multiple Myeloma 2L Relapsed/Refractory Multiple Myeloma 4L+ Relapsed/Refractory Multiple Myeloma Investigational Compounds iberdomide Relapsed/Refractory Multiple Myeloma A/I CELMoD (CC-92480) Relapsed/Refractory Multiple Myeloma BET Inhibitor (BMS- 986158) Hematologic MalignanciesPhase III Additional Indications OPDIVO Refractory Hodgkin Lymphoma EMPLICITI + REVLIMID 1L Multiple Myeloma REBLOZYL ESA Naive MDS MF Anemia INREBIC MF Previously treated with Ruxolitinib ONUREG Angioimmunoblastic T-cell Lymphoma Lower Risk MDS ABECMA (ide-cel) 3L Relapsed/Refractory Multiple Myeloma BREYANZI 2L Diffuse Large B-cell Lymphoma Transplant EligibleApproved Indications REVLIMID 1L Multiple Myeloma Mantle Cell Lymphoma MDS Multiple Myeloma Previously treated Follicular Lymphoma Relapsed/Refractory Adult T-cell Leukemia/Lymphoma OPDIVO Advanced Hodgkin Lymphoma POMALYST/IMNOVID Multiple Myeloma Relapsed/Refractory Multiple Myeloma AIDS-related Kaposi Sarcoma HIV-negative Kaposi Sarcoma EMPLICITI + POMALYST/ IMNOVID Relapsed/Refractory Multiple Myeloma EMPLICITI + REVLIMID Relapsed/Refractory Multiple Myeloma SPRYCEL 1L CML Pediatric ALL Refractory CML REBLOZYL Transfusion-Dependent Beta- Thalassemia MDS Previously treated with ESA INREBIC MF ONUREG Post-Induction Acute Myeloid Leukemia Maintenance BREYANZI 3L+ Diffuse Large B-cell Lymphoma ABECMA (ide-cel) 5L+ Relapsed/Refractory Multiple Myeloma 2021 ESG REPORT | 52 Development Portfolio by Therapeutic AreaImmunology Phase I Investigational Compounds TYK2 Inhibitor Autoimmune Disease TLR 7/8 Inhibitor Autoimmune Disease MK2 Inhibitor Autoimmune Disease IL2-CD25 Autoimmune Disease Anti-CD40 Autoimmune Disease afimetoran Cutaneous Lupus ErythematosusPhase II Investigational Compounds branebrutinib Rheumatoid Arthritis Sjogrens Disease Systemic Lupus Erythematosus Atopic Dermatitis deucravacitinib Crohns Disease Lupus Nephritis Systemic Lupus Erythematosus Ulcerative Colitis Discoid Lupus Erythematosus iberdomide Systemic Lupus Erythematosus cendakimab Atopic Dermatitis afimetoran Systemic Lupus Erythematosus S1PR1 Modulator Atopic Dermatitis MK2 Inhibitor Ankylosing SpondylitisPhase III Additional Indications ZEPOSIA Crohns Disease Investigational Compounds deucravacitinib Psoriasis Psoriatic Arthritis cendakimab Eosinophilic EsophagitisApproved Indications ORENCIA Active Polyarticular JIA Early Rheumatoid Arthritis JIA Intravenous JIA Subcutaneous Psoriatic Arthritis RA Auto injector RA Intravenous RA Subcutaneous Acute Graft versus Host Disease ZEPOSIA Relapsing Multiple Sclerosis Ulcerative Colitis Cardiovascular Phase I Investigational Compounds Factor XIa Inhibitor Thrombotic Disorders Cardiac Myosin Inhibitor Hypertrophic Cardiomyopathy ROMK Inhibitor Heart FailurePhase II Additional Indications ELIQUIS Pediatric Heart Disease Investigational Compounds mavacamten Non-Obstructive Hypertrophic Cardiomyopathy Heart Failure with Preserved Ejection Fraction danicamtiv Genetic Dilated Cardiomyopathy milvexian Thrombotic Disorders FA-Relaxin Heart FailurePhase III Additional Indications ELIQUIS VTE prevention in pediatrics with ALL Investigational Compounds mavacamten Obstructive Hypertrophic Cardiomyopathy Obstructive Hypertrophic Cardiomyopathy Septal Reduction Therapy EligibleApproved Indications ELIQUIS Stroke Prevention in Atrial Fibrillation Venous Thromboembolism Prevention Orthopedic Surgery Venous Thromboembolism Treatment Fibrotic Diseases Phase I Investigational Compounds NME 1 FibrosisPhase II Investigational Compounds HSP47 Non-Alcoholic Steatohepatitis LPA 1 Antagonist Pulmonary FibrosisNeuroscience Phase I Investigational Compounds FAAH/MGLL Dual Inhibitor Neuroscience Anti-Tau Neuroscience BTK Inhibitor Neuroscience eIF2b Activator NeuroscienceCOVID-19 Phase II Additional Indications ORENCIA COVID-19 treatment Investigational Compounds SARS-CoV-2 mAb Duo COVID-19 Therapy or Prevention# Note: Above pipeline excludes clinical collaborations Development Partnership: OPDIVO, YERVOY, Relatlimab: Ono (our collaboration with Ono also includes other early-stage compounds); EMPLICITI: AbbVie; bempegaldesleukin: Nektar; cabozantinib: Exelixis, Inc.; ELIQUIS: Pfizer; Factor XIa Inhibitor: Janssen Pharmaceuticals, Inc.; HSP47: Nitto Denko Corporation; CD3xPSCA: GeMoaB Monoclonals GmbH; ABECMA (ide-cel): 2seventy bio; REBLOZYL: Merck; AHR: Ikena Oncology; CD22 ADC: T riPhase Accelerator; Immune T olerance: Anokion SA; SARS-CoV-2 mAb Duo: Rockefeller University; TIGIT Bispecific: Agenus; farletuzumab-eribulin ADC: Eisai; rHuPH20: Halozyme; Anti-T au: Prothena Corporation PLC; eIF2b Activator: Evotec SE; MAGE A4/8 TCE Bispecific: Immatics.","('Access_And_Affordability', 0.31086617708206177)","('Ecological_Impacts', 0.08324740827083588)","('Employee_Engagement_Inclusion_And_Diversity', 0.06441006809473038)","('NON-ESG', 0.31086617708206177)","('NON-ESG', 0.08324740827083588)","('NON-ESG', 0.06441006809473038)"
Line 707,"2021 ESG REPORT | 51Hematology Phase I Additional Indications OPDIVO Hematologic Malignancies BREYANZI (liso-cel) 3L+ Mantle Cell Lymphoma ABECMA (idecel) High-Risk Newly Diagnosed Multiple Myeloma Investigational Compounds relatlimab^ Hematologic Malignancies BET Inhibitor (CC-95775) Non-Hodgkin Lymphoma BET Inhibitor (CC-90010) Hematologic Malignancies BCMA ADC Relapsed/Refractory Multiple Myeloma BCMA TCE Relapsed/Refractory Multiple Myeloma BCMA NEX T Relapsed/Refractory Multiple Myeloma GPRC5D CAR T Relapsed/Refractory Multiple Myeloma GSPT1 CELMoD (CC-90009) Relapsed/Refractory Acute Myeloid Leukemia Anti-SIRP Non-Hodgkin Lymphoma LSD1 Inhibitor Relapsed/Refractory Non- Hodgkin Lymphoma CD19 NEX T Relapsed/Refractory Non- Hodgkin Lymphoma iberdomide Non-Hodgkin Lymphoma CD33 NKE Relapsed/Refractory Multiple Myeloma CD47xCD20 Non-Hodgkin Lymphoma CK1a CELMoD Hematologic Malignancies ROR1 CAR T Hematologic Malignancies BCMA NKE Relapsed/Refractory Multiple MyelomaPhase II Additional Indications OPDIVO Non-Hodgkin Lymphoma (Diffuse Large B-cell Lymphoma) Non-Hodgkin Lymphoma (Follicular Lymphoma) Pediatric Hodgkin Lymphoma Primary Testicular Lymphoma OPDIVO + EMPLICITI Relapsed/Refractory Multiple Myeloma REBLOZYL Non-Transfusion- Dependent Beta- Thalassemia ONUREG Post HMA Failure MDS BREYANZI 2L Diffuse Large B-cell Lymphoma Transplant Non-Eligible 3L+Chronic Lymphocytic Leukemia 3L+ Follicular Lymphoma / Marginal Zone Lymphoma 2L+ Pediatric B-cell Acute Lymphoblastic Leukemia 2L+ Primary CNS Lymphoma 1L High Grade B-cell Lymphoma ABECMA (ide-cel) High-Risk Newly Diagnosed Multiple Myeloma 2L Relapsed/Refractory Multiple Myeloma 4L+ Relapsed/Refractory Multiple Myeloma Investigational Compounds iberdomide Relapsed/Refractory Multiple Myeloma A/I CELMoD (CC-92480) Relapsed/Refractory Multiple Myeloma BET Inhibitor (BMS- 986158) Hematologic MalignanciesPhase III Additional Indications OPDIVO Refractory Hodgkin Lymphoma EMPLICITI + REVLIMID 1L Multiple Myeloma REBLOZYL ESA Naive MDS MF Anemia INREBIC MF Previously treated with Ruxolitinib ONUREG Angioimmunoblastic T-cell Lymphoma Lower Risk MDS ABECMA (ide-cel) 3L Relapsed/Refractory Multiple Myeloma BREYANZI 2L Diffuse Large B-cell Lymphoma Transplant EligibleApproved Indications REVLIMID 1L Multiple Myeloma Mantle Cell Lymphoma MDS Multiple Myeloma Previously treated Follicular Lymphoma Relapsed/Refractory Adult T-cell Leukemia/Lymphoma OPDIVO Advanced Hodgkin Lymphoma POMALYST/IMNOVID Multiple Myeloma Relapsed/Refractory Multiple Myeloma AIDS-related Kaposi Sarcoma HIV-negative Kaposi Sarcoma EMPLICITI + POMALYST/ IMNOVID Relapsed/Refractory Multiple Myeloma EMPLICITI + REVLIMID Relapsed/Refractory Multiple Myeloma SPRYCEL 1L CML Pediatric ALL Refractory CML REBLOZYL Transfusion-Dependent Beta- Thalassemia MDS Previously treated with ESA INREBIC MF ONUREG Post-Induction Acute Myeloid Leukemia Maintenance BREYANZI 3L+ Diffuse Large B-cell Lymphoma ABECMA (ide-cel) 5L+ Relapsed/Refractory Multiple Myeloma 2021 ESG REPORT | 52 Development Portfolio by Therapeutic AreaImmunology Phase I Investigational Compounds TYK2 Inhibitor Autoimmune Disease TLR 7/8 Inhibitor Autoimmune Disease MK2 Inhibitor Autoimmune Disease IL2-CD25 Autoimmune Disease Anti-CD40 Autoimmune Disease afimetoran Cutaneous Lupus ErythematosusPhase II Investigational Compounds branebrutinib Rheumatoid Arthritis Sjogrens Disease Systemic Lupus Erythematosus Atopic Dermatitis deucravacitinib Crohns Disease Lupus Nephritis Systemic Lupus Erythematosus Ulcerative Colitis Discoid Lupus Erythematosus iberdomide Systemic Lupus Erythematosus cendakimab Atopic Dermatitis afimetoran Systemic Lupus Erythematosus S1PR1 Modulator Atopic Dermatitis MK2 Inhibitor Ankylosing SpondylitisPhase III Additional Indications ZEPOSIA Crohns Disease Investigational Compounds deucravacitinib Psoriasis Psoriatic Arthritis cendakimab Eosinophilic EsophagitisApproved Indications ORENCIA Active Polyarticular JIA Early Rheumatoid Arthritis JIA Intravenous JIA Subcutaneous Psoriatic Arthritis RA Auto injector RA Intravenous RA Subcutaneous Acute Graft versus Host Disease ZEPOSIA Relapsing Multiple Sclerosis Ulcerative Colitis Cardiovascular Phase I Investigational Compounds Factor XIa Inhibitor Thrombotic Disorders Cardiac Myosin Inhibitor Hypertrophic Cardiomyopathy ROMK Inhibitor Heart FailurePhase II Additional Indications ELIQUIS Pediatric Heart Disease Investigational Compounds mavacamten Non-Obstructive Hypertrophic Cardiomyopathy Heart Failure with Preserved Ejection Fraction danicamtiv Genetic Dilated Cardiomyopathy milvexian Thrombotic Disorders FA-Relaxin Heart FailurePhase III Additional Indications ELIQUIS VTE prevention in pediatrics with ALL Investigational Compounds mavacamten Obstructive Hypertrophic Cardiomyopathy Obstructive Hypertrophic Cardiomyopathy Septal Reduction Therapy EligibleApproved Indications ELIQUIS Stroke Prevention in Atrial Fibrillation Venous Thromboembolism Prevention Orthopedic Surgery Venous Thromboembolism Treatment Fibrotic Diseases Phase I Investigational Compounds NME 1 FibrosisPhase II Investigational Compounds HSP47 Non-Alcoholic Steatohepatitis LPA 1 Antagonist Pulmonary FibrosisNeuroscience Phase I Investigational Compounds FAAH/MGLL Dual Inhibitor Neuroscience Anti-Tau Neuroscience BTK Inhibitor Neuroscience eIF2b Activator NeuroscienceCOVID-19 Phase II Additional Indications ORENCIA COVID-19 treatment Investigational Compounds SARS-CoV-2 mAb Duo COVID-19 Therapy or Prevention# Note: Above pipeline excludes clinical collaborations Development Partnership: OPDIVO, YERVOY, Relatlimab: Ono (our collaboration with Ono also includes other early-stage compounds); EMPLICITI: AbbVie; bempegaldesleukin: Nektar; cabozantinib: Exelixis, Inc.; ELIQUIS: Pfizer; Factor XIa Inhibitor: Janssen Pharmaceuticals, Inc.; HSP47: Nitto Denko Corporation; CD3xPSCA: GeMoaB Monoclonals GmbH; ABECMA (ide-cel): 2seventy bio; REBLOZYL: Merck; AHR: Ikena Oncology; CD22 ADC: T riPhase Accelerator; Immune T olerance: Anokion SA; SARS-CoV-2 mAb Duo: Rockefeller University; TIGIT Bispecific: Agenus; farletuzumab-eribulin ADC: Eisai; rHuPH20: Halozyme; Anti-T au: Prothena Corporation PLC; eIF2b Activator: Evotec SE; MAGE A4/8 TCE Bispecific: Immatics.","('Access_And_Affordability', 0.3003506362438202)","('Employee_Health_And_Safety', 0.10835496336221695)","('Employee_Engagement_Inclusion_And_Diversity', 0.0966867133975029)","('NON-ESG', 0.3003506362438202)","('NON-ESG', 0.10835496336221695)","('NON-ESG', 0.0966867133975029)"
Line 708,"2021 ESG REPORT | 51Hematology Phase I Additional Indications OPDIVO Hematologic Malignancies BREYANZI (liso-cel) 3L+ Mantle Cell Lymphoma ABECMA (idecel) High-Risk Newly Diagnosed Multiple Myeloma Investigational Compounds relatlimab^ Hematologic Malignancies BET Inhibitor (CC-95775) Non-Hodgkin Lymphoma BET Inhibitor (CC-90010) Hematologic Malignancies BCMA ADC Relapsed/Refractory Multiple Myeloma BCMA TCE Relapsed/Refractory Multiple Myeloma BCMA NEX T Relapsed/Refractory Multiple Myeloma GPRC5D CAR T Relapsed/Refractory Multiple Myeloma GSPT1 CELMoD (CC-90009) Relapsed/Refractory Acute Myeloid Leukemia Anti-SIRP Non-Hodgkin Lymphoma LSD1 Inhibitor Relapsed/Refractory Non- Hodgkin Lymphoma CD19 NEX T Relapsed/Refractory Non- Hodgkin Lymphoma iberdomide Non-Hodgkin Lymphoma CD33 NKE Relapsed/Refractory Multiple Myeloma CD47xCD20 Non-Hodgkin Lymphoma CK1a CELMoD Hematologic Malignancies ROR1 CAR T Hematologic Malignancies BCMA NKE Relapsed/Refractory Multiple MyelomaPhase II Additional Indications OPDIVO Non-Hodgkin Lymphoma (Diffuse Large B-cell Lymphoma) Non-Hodgkin Lymphoma (Follicular Lymphoma) Pediatric Hodgkin Lymphoma Primary Testicular Lymphoma OPDIVO + EMPLICITI Relapsed/Refractory Multiple Myeloma REBLOZYL Non-Transfusion- Dependent Beta- Thalassemia ONUREG Post HMA Failure MDS BREYANZI 2L Diffuse Large B-cell Lymphoma Transplant Non-Eligible 3L+Chronic Lymphocytic Leukemia 3L+ Follicular Lymphoma / Marginal Zone Lymphoma 2L+ Pediatric B-cell Acute Lymphoblastic Leukemia 2L+ Primary CNS Lymphoma 1L High Grade B-cell Lymphoma ABECMA (ide-cel) High-Risk Newly Diagnosed Multiple Myeloma 2L Relapsed/Refractory Multiple Myeloma 4L+ Relapsed/Refractory Multiple Myeloma Investigational Compounds iberdomide Relapsed/Refractory Multiple Myeloma A/I CELMoD (CC-92480) Relapsed/Refractory Multiple Myeloma BET Inhibitor (BMS- 986158) Hematologic MalignanciesPhase III Additional Indications OPDIVO Refractory Hodgkin Lymphoma EMPLICITI + REVLIMID 1L Multiple Myeloma REBLOZYL ESA Naive MDS MF Anemia INREBIC MF Previously treated with Ruxolitinib ONUREG Angioimmunoblastic T-cell Lymphoma Lower Risk MDS ABECMA (ide-cel) 3L Relapsed/Refractory Multiple Myeloma BREYANZI 2L Diffuse Large B-cell Lymphoma Transplant EligibleApproved Indications REVLIMID 1L Multiple Myeloma Mantle Cell Lymphoma MDS Multiple Myeloma Previously treated Follicular Lymphoma Relapsed/Refractory Adult T-cell Leukemia/Lymphoma OPDIVO Advanced Hodgkin Lymphoma POMALYST/IMNOVID Multiple Myeloma Relapsed/Refractory Multiple Myeloma AIDS-related Kaposi Sarcoma HIV-negative Kaposi Sarcoma EMPLICITI + POMALYST/ IMNOVID Relapsed/Refractory Multiple Myeloma EMPLICITI + REVLIMID Relapsed/Refractory Multiple Myeloma SPRYCEL 1L CML Pediatric ALL Refractory CML REBLOZYL Transfusion-Dependent Beta- Thalassemia MDS Previously treated with ESA INREBIC MF ONUREG Post-Induction Acute Myeloid Leukemia Maintenance BREYANZI 3L+ Diffuse Large B-cell Lymphoma ABECMA (ide-cel) 5L+ Relapsed/Refractory Multiple Myeloma 2021 ESG REPORT | 52 Development Portfolio by Therapeutic AreaImmunology Phase I Investigational Compounds TYK2 Inhibitor Autoimmune Disease TLR 7/8 Inhibitor Autoimmune Disease MK2 Inhibitor Autoimmune Disease IL2-CD25 Autoimmune Disease Anti-CD40 Autoimmune Disease afimetoran Cutaneous Lupus ErythematosusPhase II Investigational Compounds branebrutinib Rheumatoid Arthritis Sjogrens Disease Systemic Lupus Erythematosus Atopic Dermatitis deucravacitinib Crohns Disease Lupus Nephritis Systemic Lupus Erythematosus Ulcerative Colitis Discoid Lupus Erythematosus iberdomide Systemic Lupus Erythematosus cendakimab Atopic Dermatitis afimetoran Systemic Lupus Erythematosus S1PR1 Modulator Atopic Dermatitis MK2 Inhibitor Ankylosing SpondylitisPhase III Additional Indications ZEPOSIA Crohns Disease Investigational Compounds deucravacitinib Psoriasis Psoriatic Arthritis cendakimab Eosinophilic EsophagitisApproved Indications ORENCIA Active Polyarticular JIA Early Rheumatoid Arthritis JIA Intravenous JIA Subcutaneous Psoriatic Arthritis RA Auto injector RA Intravenous RA Subcutaneous Acute Graft versus Host Disease ZEPOSIA Relapsing Multiple Sclerosis Ulcerative Colitis Cardiovascular Phase I Investigational Compounds Factor XIa Inhibitor Thrombotic Disorders Cardiac Myosin Inhibitor Hypertrophic Cardiomyopathy ROMK Inhibitor Heart FailurePhase II Additional Indications ELIQUIS Pediatric Heart Disease Investigational Compounds mavacamten Non-Obstructive Hypertrophic Cardiomyopathy Heart Failure with Preserved Ejection Fraction danicamtiv Genetic Dilated Cardiomyopathy milvexian Thrombotic Disorders FA-Relaxin Heart FailurePhase III Additional Indications ELIQUIS VTE prevention in pediatrics with ALL Investigational Compounds mavacamten Obstructive Hypertrophic Cardiomyopathy Obstructive Hypertrophic Cardiomyopathy Septal Reduction Therapy EligibleApproved Indications ELIQUIS Stroke Prevention in Atrial Fibrillation Venous Thromboembolism Prevention Orthopedic Surgery Venous Thromboembolism Treatment Fibrotic Diseases Phase I Investigational Compounds NME 1 FibrosisPhase II Investigational Compounds HSP47 Non-Alcoholic Steatohepatitis LPA 1 Antagonist Pulmonary FibrosisNeuroscience Phase I Investigational Compounds FAAH/MGLL Dual Inhibitor Neuroscience Anti-Tau Neuroscience BTK Inhibitor Neuroscience eIF2b Activator NeuroscienceCOVID-19 Phase II Additional Indications ORENCIA COVID-19 treatment Investigational Compounds SARS-CoV-2 mAb Duo COVID-19 Therapy or Prevention# Note: Above pipeline excludes clinical collaborations Development Partnership: OPDIVO, YERVOY, Relatlimab: Ono (our collaboration with Ono also includes other early-stage compounds); EMPLICITI: AbbVie; bempegaldesleukin: Nektar; cabozantinib: Exelixis, Inc.; ELIQUIS: Pfizer; Factor XIa Inhibitor: Janssen Pharmaceuticals, Inc.; HSP47: Nitto Denko Corporation; CD3xPSCA: GeMoaB Monoclonals GmbH; ABECMA (ide-cel): 2seventy bio; REBLOZYL: Merck; AHR: Ikena Oncology; CD22 ADC: T riPhase Accelerator; Immune T olerance: Anokion SA; SARS-CoV-2 mAb Duo: Rockefeller University; TIGIT Bispecific: Agenus; farletuzumab-eribulin ADC: Eisai; rHuPH20: Halozyme; Anti-T au: Prothena Corporation PLC; eIF2b Activator: Evotec SE; MAGE A4/8 TCE Bispecific: Immatics.","('Employee_Health_And_Safety', 0.268703818321228)","('Systemic_Risk_Management', 0.11358218640089035)","('Business_Ethics', 0.07979589700698853)","('NON-ESG', 0.268703818321228)","('NON-ESG', 0.11358218640089035)","('NON-ESG', 0.07979589700698853)"
Line 709,"2021 ESG REPORT | 51Hematology Phase I Additional Indications OPDIVO Hematologic Malignancies BREYANZI (liso-cel) 3L+ Mantle Cell Lymphoma ABECMA (idecel) High-Risk Newly Diagnosed Multiple Myeloma Investigational Compounds relatlimab^ Hematologic Malignancies BET Inhibitor (CC-95775) Non-Hodgkin Lymphoma BET Inhibitor (CC-90010) Hematologic Malignancies BCMA ADC Relapsed/Refractory Multiple Myeloma BCMA TCE Relapsed/Refractory Multiple Myeloma BCMA NEX T Relapsed/Refractory Multiple Myeloma GPRC5D CAR T Relapsed/Refractory Multiple Myeloma GSPT1 CELMoD (CC-90009) Relapsed/Refractory Acute Myeloid Leukemia Anti-SIRP Non-Hodgkin Lymphoma LSD1 Inhibitor Relapsed/Refractory Non- Hodgkin Lymphoma CD19 NEX T Relapsed/Refractory Non- Hodgkin Lymphoma iberdomide Non-Hodgkin Lymphoma CD33 NKE Relapsed/Refractory Multiple Myeloma CD47xCD20 Non-Hodgkin Lymphoma CK1a CELMoD Hematologic Malignancies ROR1 CAR T Hematologic Malignancies BCMA NKE Relapsed/Refractory Multiple MyelomaPhase II Additional Indications OPDIVO Non-Hodgkin Lymphoma (Diffuse Large B-cell Lymphoma) Non-Hodgkin Lymphoma (Follicular Lymphoma) Pediatric Hodgkin Lymphoma Primary Testicular Lymphoma OPDIVO + EMPLICITI Relapsed/Refractory Multiple Myeloma REBLOZYL Non-Transfusion- Dependent Beta- Thalassemia ONUREG Post HMA Failure MDS BREYANZI 2L Diffuse Large B-cell Lymphoma Transplant Non-Eligible 3L+Chronic Lymphocytic Leukemia 3L+ Follicular Lymphoma / Marginal Zone Lymphoma 2L+ Pediatric B-cell Acute Lymphoblastic Leukemia 2L+ Primary CNS Lymphoma 1L High Grade B-cell Lymphoma ABECMA (ide-cel) High-Risk Newly Diagnosed Multiple Myeloma 2L Relapsed/Refractory Multiple Myeloma 4L+ Relapsed/Refractory Multiple Myeloma Investigational Compounds iberdomide Relapsed/Refractory Multiple Myeloma A/I CELMoD (CC-92480) Relapsed/Refractory Multiple Myeloma BET Inhibitor (BMS- 986158) Hematologic MalignanciesPhase III Additional Indications OPDIVO Refractory Hodgkin Lymphoma EMPLICITI + REVLIMID 1L Multiple Myeloma REBLOZYL ESA Naive MDS MF Anemia INREBIC MF Previously treated with Ruxolitinib ONUREG Angioimmunoblastic T-cell Lymphoma Lower Risk MDS ABECMA (ide-cel) 3L Relapsed/Refractory Multiple Myeloma BREYANZI 2L Diffuse Large B-cell Lymphoma Transplant EligibleApproved Indications REVLIMID 1L Multiple Myeloma Mantle Cell Lymphoma MDS Multiple Myeloma Previously treated Follicular Lymphoma Relapsed/Refractory Adult T-cell Leukemia/Lymphoma OPDIVO Advanced Hodgkin Lymphoma POMALYST/IMNOVID Multiple Myeloma Relapsed/Refractory Multiple Myeloma AIDS-related Kaposi Sarcoma HIV-negative Kaposi Sarcoma EMPLICITI + POMALYST/ IMNOVID Relapsed/Refractory Multiple Myeloma EMPLICITI + REVLIMID Relapsed/Refractory Multiple Myeloma SPRYCEL 1L CML Pediatric ALL Refractory CML REBLOZYL Transfusion-Dependent Beta- Thalassemia MDS Previously treated with ESA INREBIC MF ONUREG Post-Induction Acute Myeloid Leukemia Maintenance BREYANZI 3L+ Diffuse Large B-cell Lymphoma ABECMA (ide-cel) 5L+ Relapsed/Refractory Multiple Myeloma 2021 ESG REPORT | 52 Development Portfolio by Therapeutic AreaImmunology Phase I Investigational Compounds TYK2 Inhibitor Autoimmune Disease TLR 7/8 Inhibitor Autoimmune Disease MK2 Inhibitor Autoimmune Disease IL2-CD25 Autoimmune Disease Anti-CD40 Autoimmune Disease afimetoran Cutaneous Lupus ErythematosusPhase II Investigational Compounds branebrutinib Rheumatoid Arthritis Sjogrens Disease Systemic Lupus Erythematosus Atopic Dermatitis deucravacitinib Crohns Disease Lupus Nephritis Systemic Lupus Erythematosus Ulcerative Colitis Discoid Lupus Erythematosus iberdomide Systemic Lupus Erythematosus cendakimab Atopic Dermatitis afimetoran Systemic Lupus Erythematosus S1PR1 Modulator Atopic Dermatitis MK2 Inhibitor Ankylosing SpondylitisPhase III Additional Indications ZEPOSIA Crohns Disease Investigational Compounds deucravacitinib Psoriasis Psoriatic Arthritis cendakimab Eosinophilic EsophagitisApproved Indications ORENCIA Active Polyarticular JIA Early Rheumatoid Arthritis JIA Intravenous JIA Subcutaneous Psoriatic Arthritis RA Auto injector RA Intravenous RA Subcutaneous Acute Graft versus Host Disease ZEPOSIA Relapsing Multiple Sclerosis Ulcerative Colitis Cardiovascular Phase I Investigational Compounds Factor XIa Inhibitor Thrombotic Disorders Cardiac Myosin Inhibitor Hypertrophic Cardiomyopathy ROMK Inhibitor Heart FailurePhase II Additional Indications ELIQUIS Pediatric Heart Disease Investigational Compounds mavacamten Non-Obstructive Hypertrophic Cardiomyopathy Heart Failure with Preserved Ejection Fraction danicamtiv Genetic Dilated Cardiomyopathy milvexian Thrombotic Disorders FA-Relaxin Heart FailurePhase III Additional Indications ELIQUIS VTE prevention in pediatrics with ALL Investigational Compounds mavacamten Obstructive Hypertrophic Cardiomyopathy Obstructive Hypertrophic Cardiomyopathy Septal Reduction Therapy EligibleApproved Indications ELIQUIS Stroke Prevention in Atrial Fibrillation Venous Thromboembolism Prevention Orthopedic Surgery Venous Thromboembolism Treatment Fibrotic Diseases Phase I Investigational Compounds NME 1 FibrosisPhase II Investigational Compounds HSP47 Non-Alcoholic Steatohepatitis LPA 1 Antagonist Pulmonary FibrosisNeuroscience Phase I Investigational Compounds FAAH/MGLL Dual Inhibitor Neuroscience Anti-Tau Neuroscience BTK Inhibitor Neuroscience eIF2b Activator NeuroscienceCOVID-19 Phase II Additional Indications ORENCIA COVID-19 treatment Investigational Compounds SARS-CoV-2 mAb Duo COVID-19 Therapy or Prevention# Note: Above pipeline excludes clinical collaborations Development Partnership: OPDIVO, YERVOY, Relatlimab: Ono (our collaboration with Ono also includes other early-stage compounds); EMPLICITI: AbbVie; bempegaldesleukin: Nektar; cabozantinib: Exelixis, Inc.; ELIQUIS: Pfizer; Factor XIa Inhibitor: Janssen Pharmaceuticals, Inc.; HSP47: Nitto Denko Corporation; CD3xPSCA: GeMoaB Monoclonals GmbH; ABECMA (ide-cel): 2seventy bio; REBLOZYL: Merck; AHR: Ikena Oncology; CD22 ADC: T riPhase Accelerator; Immune T olerance: Anokion SA; SARS-CoV-2 mAb Duo: Rockefeller University; TIGIT Bispecific: Agenus; farletuzumab-eribulin ADC: Eisai; rHuPH20: Halozyme; Anti-T au: Prothena Corporation PLC; eIF2b Activator: Evotec SE; MAGE A4/8 TCE Bispecific: Immatics.","('Employee_Health_And_Safety', 0.2048051953315735)","('Product_Quality_And_Safety', 0.10712195932865143)","('Access_And_Affordability', 0.10247533768415451)","('NON-ESG', 0.2048051953315735)","('NON-ESG', 0.10712195932865143)","('NON-ESG', 0.10247533768415451)"
Line 710,"2021 ESG REPORT | 51Hematology Phase I Additional Indications OPDIVO Hematologic Malignancies BREYANZI (liso-cel) 3L+ Mantle Cell Lymphoma ABECMA (idecel) High-Risk Newly Diagnosed Multiple Myeloma Investigational Compounds relatlimab^ Hematologic Malignancies BET Inhibitor (CC-95775) Non-Hodgkin Lymphoma BET Inhibitor (CC-90010) Hematologic Malignancies BCMA ADC Relapsed/Refractory Multiple Myeloma BCMA TCE Relapsed/Refractory Multiple Myeloma BCMA NEX T Relapsed/Refractory Multiple Myeloma GPRC5D CAR T Relapsed/Refractory Multiple Myeloma GSPT1 CELMoD (CC-90009) Relapsed/Refractory Acute Myeloid Leukemia Anti-SIRP Non-Hodgkin Lymphoma LSD1 Inhibitor Relapsed/Refractory Non- Hodgkin Lymphoma CD19 NEX T Relapsed/Refractory Non- Hodgkin Lymphoma iberdomide Non-Hodgkin Lymphoma CD33 NKE Relapsed/Refractory Multiple Myeloma CD47xCD20 Non-Hodgkin Lymphoma CK1a CELMoD Hematologic Malignancies ROR1 CAR T Hematologic Malignancies BCMA NKE Relapsed/Refractory Multiple MyelomaPhase II Additional Indications OPDIVO Non-Hodgkin Lymphoma (Diffuse Large B-cell Lymphoma) Non-Hodgkin Lymphoma (Follicular Lymphoma) Pediatric Hodgkin Lymphoma Primary Testicular Lymphoma OPDIVO + EMPLICITI Relapsed/Refractory Multiple Myeloma REBLOZYL Non-Transfusion- Dependent Beta- Thalassemia ONUREG Post HMA Failure MDS BREYANZI 2L Diffuse Large B-cell Lymphoma Transplant Non-Eligible 3L+Chronic Lymphocytic Leukemia 3L+ Follicular Lymphoma / Marginal Zone Lymphoma 2L+ Pediatric B-cell Acute Lymphoblastic Leukemia 2L+ Primary CNS Lymphoma 1L High Grade B-cell Lymphoma ABECMA (ide-cel) High-Risk Newly Diagnosed Multiple Myeloma 2L Relapsed/Refractory Multiple Myeloma 4L+ Relapsed/Refractory Multiple Myeloma Investigational Compounds iberdomide Relapsed/Refractory Multiple Myeloma A/I CELMoD (CC-92480) Relapsed/Refractory Multiple Myeloma BET Inhibitor (BMS- 986158) Hematologic MalignanciesPhase III Additional Indications OPDIVO Refractory Hodgkin Lymphoma EMPLICITI + REVLIMID 1L Multiple Myeloma REBLOZYL ESA Naive MDS MF Anemia INREBIC MF Previously treated with Ruxolitinib ONUREG Angioimmunoblastic T-cell Lymphoma Lower Risk MDS ABECMA (ide-cel) 3L Relapsed/Refractory Multiple Myeloma BREYANZI 2L Diffuse Large B-cell Lymphoma Transplant EligibleApproved Indications REVLIMID 1L Multiple Myeloma Mantle Cell Lymphoma MDS Multiple Myeloma Previously treated Follicular Lymphoma Relapsed/Refractory Adult T-cell Leukemia/Lymphoma OPDIVO Advanced Hodgkin Lymphoma POMALYST/IMNOVID Multiple Myeloma Relapsed/Refractory Multiple Myeloma AIDS-related Kaposi Sarcoma HIV-negative Kaposi Sarcoma EMPLICITI + POMALYST/ IMNOVID Relapsed/Refractory Multiple Myeloma EMPLICITI + REVLIMID Relapsed/Refractory Multiple Myeloma SPRYCEL 1L CML Pediatric ALL Refractory CML REBLOZYL Transfusion-Dependent Beta- Thalassemia MDS Previously treated with ESA INREBIC MF ONUREG Post-Induction Acute Myeloid Leukemia Maintenance BREYANZI 3L+ Diffuse Large B-cell Lymphoma ABECMA (ide-cel) 5L+ Relapsed/Refractory Multiple Myeloma 2021 ESG REPORT | 52 Development Portfolio by Therapeutic AreaImmunology Phase I Investigational Compounds TYK2 Inhibitor Autoimmune Disease TLR 7/8 Inhibitor Autoimmune Disease MK2 Inhibitor Autoimmune Disease IL2-CD25 Autoimmune Disease Anti-CD40 Autoimmune Disease afimetoran Cutaneous Lupus ErythematosusPhase II Investigational Compounds branebrutinib Rheumatoid Arthritis Sjogrens Disease Systemic Lupus Erythematosus Atopic Dermatitis deucravacitinib Crohns Disease Lupus Nephritis Systemic Lupus Erythematosus Ulcerative Colitis Discoid Lupus Erythematosus iberdomide Systemic Lupus Erythematosus cendakimab Atopic Dermatitis afimetoran Systemic Lupus Erythematosus S1PR1 Modulator Atopic Dermatitis MK2 Inhibitor Ankylosing SpondylitisPhase III Additional Indications ZEPOSIA Crohns Disease Investigational Compounds deucravacitinib Psoriasis Psoriatic Arthritis cendakimab Eosinophilic EsophagitisApproved Indications ORENCIA Active Polyarticular JIA Early Rheumatoid Arthritis JIA Intravenous JIA Subcutaneous Psoriatic Arthritis RA Auto injector RA Intravenous RA Subcutaneous Acute Graft versus Host Disease ZEPOSIA Relapsing Multiple Sclerosis Ulcerative Colitis Cardiovascular Phase I Investigational Compounds Factor XIa Inhibitor Thrombotic Disorders Cardiac Myosin Inhibitor Hypertrophic Cardiomyopathy ROMK Inhibitor Heart FailurePhase II Additional Indications ELIQUIS Pediatric Heart Disease Investigational Compounds mavacamten Non-Obstructive Hypertrophic Cardiomyopathy Heart Failure with Preserved Ejection Fraction danicamtiv Genetic Dilated Cardiomyopathy milvexian Thrombotic Disorders FA-Relaxin Heart FailurePhase III Additional Indications ELIQUIS VTE prevention in pediatrics with ALL Investigational Compounds mavacamten Obstructive Hypertrophic Cardiomyopathy Obstructive Hypertrophic Cardiomyopathy Septal Reduction Therapy EligibleApproved Indications ELIQUIS Stroke Prevention in Atrial Fibrillation Venous Thromboembolism Prevention Orthopedic Surgery Venous Thromboembolism Treatment Fibrotic Diseases Phase I Investigational Compounds NME 1 FibrosisPhase II Investigational Compounds HSP47 Non-Alcoholic Steatohepatitis LPA 1 Antagonist Pulmonary FibrosisNeuroscience Phase I Investigational Compounds FAAH/MGLL Dual Inhibitor Neuroscience Anti-Tau Neuroscience BTK Inhibitor Neuroscience eIF2b Activator NeuroscienceCOVID-19 Phase II Additional Indications ORENCIA COVID-19 treatment Investigational Compounds SARS-CoV-2 mAb Duo COVID-19 Therapy or Prevention# Note: Above pipeline excludes clinical collaborations Development Partnership: OPDIVO, YERVOY, Relatlimab: Ono (our collaboration with Ono also includes other early-stage compounds); EMPLICITI: AbbVie; bempegaldesleukin: Nektar; cabozantinib: Exelixis, Inc.; ELIQUIS: Pfizer; Factor XIa Inhibitor: Janssen Pharmaceuticals, Inc.; HSP47: Nitto Denko Corporation; CD3xPSCA: GeMoaB Monoclonals GmbH; ABECMA (ide-cel): 2seventy bio; REBLOZYL: Merck; AHR: Ikena Oncology; CD22 ADC: T riPhase Accelerator; Immune T olerance: Anokion SA; SARS-CoV-2 mAb Duo: Rockefeller University; TIGIT Bispecific: Agenus; farletuzumab-eribulin ADC: Eisai; rHuPH20: Halozyme; Anti-T au: Prothena Corporation PLC; eIF2b Activator: Evotec SE; MAGE A4/8 TCE Bispecific: Immatics.","('Employee_Health_And_Safety', 0.22805258631706238)","('Access_And_Affordability', 0.10670150816440582)","('Systemic_Risk_Management', 0.09619379788637161)","('NON-ESG', 0.22805258631706238)","('NON-ESG', 0.10670150816440582)","('NON-ESG', 0.09619379788637161)"
Line 711,"2021 ESG REPORT | 51Hematology Phase I Additional Indications OPDIVO Hematologic Malignancies BREYANZI (liso-cel) 3L+ Mantle Cell Lymphoma ABECMA (idecel) High-Risk Newly Diagnosed Multiple Myeloma Investigational Compounds relatlimab^ Hematologic Malignancies BET Inhibitor (CC-95775) Non-Hodgkin Lymphoma BET Inhibitor (CC-90010) Hematologic Malignancies BCMA ADC Relapsed/Refractory Multiple Myeloma BCMA TCE Relapsed/Refractory Multiple Myeloma BCMA NEX T Relapsed/Refractory Multiple Myeloma GPRC5D CAR T Relapsed/Refractory Multiple Myeloma GSPT1 CELMoD (CC-90009) Relapsed/Refractory Acute Myeloid Leukemia Anti-SIRP Non-Hodgkin Lymphoma LSD1 Inhibitor Relapsed/Refractory Non- Hodgkin Lymphoma CD19 NEX T Relapsed/Refractory Non- Hodgkin Lymphoma iberdomide Non-Hodgkin Lymphoma CD33 NKE Relapsed/Refractory Multiple Myeloma CD47xCD20 Non-Hodgkin Lymphoma CK1a CELMoD Hematologic Malignancies ROR1 CAR T Hematologic Malignancies BCMA NKE Relapsed/Refractory Multiple MyelomaPhase II Additional Indications OPDIVO Non-Hodgkin Lymphoma (Diffuse Large B-cell Lymphoma) Non-Hodgkin Lymphoma (Follicular Lymphoma) Pediatric Hodgkin Lymphoma Primary Testicular Lymphoma OPDIVO + EMPLICITI Relapsed/Refractory Multiple Myeloma REBLOZYL Non-Transfusion- Dependent Beta- Thalassemia ONUREG Post HMA Failure MDS BREYANZI 2L Diffuse Large B-cell Lymphoma Transplant Non-Eligible 3L+Chronic Lymphocytic Leukemia 3L+ Follicular Lymphoma / Marginal Zone Lymphoma 2L+ Pediatric B-cell Acute Lymphoblastic Leukemia 2L+ Primary CNS Lymphoma 1L High Grade B-cell Lymphoma ABECMA (ide-cel) High-Risk Newly Diagnosed Multiple Myeloma 2L Relapsed/Refractory Multiple Myeloma 4L+ Relapsed/Refractory Multiple Myeloma Investigational Compounds iberdomide Relapsed/Refractory Multiple Myeloma A/I CELMoD (CC-92480) Relapsed/Refractory Multiple Myeloma BET Inhibitor (BMS- 986158) Hematologic MalignanciesPhase III Additional Indications OPDIVO Refractory Hodgkin Lymphoma EMPLICITI + REVLIMID 1L Multiple Myeloma REBLOZYL ESA Naive MDS MF Anemia INREBIC MF Previously treated with Ruxolitinib ONUREG Angioimmunoblastic T-cell Lymphoma Lower Risk MDS ABECMA (ide-cel) 3L Relapsed/Refractory Multiple Myeloma BREYANZI 2L Diffuse Large B-cell Lymphoma Transplant EligibleApproved Indications REVLIMID 1L Multiple Myeloma Mantle Cell Lymphoma MDS Multiple Myeloma Previously treated Follicular Lymphoma Relapsed/Refractory Adult T-cell Leukemia/Lymphoma OPDIVO Advanced Hodgkin Lymphoma POMALYST/IMNOVID Multiple Myeloma Relapsed/Refractory Multiple Myeloma AIDS-related Kaposi Sarcoma HIV-negative Kaposi Sarcoma EMPLICITI + POMALYST/ IMNOVID Relapsed/Refractory Multiple Myeloma EMPLICITI + REVLIMID Relapsed/Refractory Multiple Myeloma SPRYCEL 1L CML Pediatric ALL Refractory CML REBLOZYL Transfusion-Dependent Beta- Thalassemia MDS Previously treated with ESA INREBIC MF ONUREG Post-Induction Acute Myeloid Leukemia Maintenance BREYANZI 3L+ Diffuse Large B-cell Lymphoma ABECMA (ide-cel) 5L+ Relapsed/Refractory Multiple Myeloma 2021 ESG REPORT | 52 Development Portfolio by Therapeutic AreaImmunology Phase I Investigational Compounds TYK2 Inhibitor Autoimmune Disease TLR 7/8 Inhibitor Autoimmune Disease MK2 Inhibitor Autoimmune Disease IL2-CD25 Autoimmune Disease Anti-CD40 Autoimmune Disease afimetoran Cutaneous Lupus ErythematosusPhase II Investigational Compounds branebrutinib Rheumatoid Arthritis Sjogrens Disease Systemic Lupus Erythematosus Atopic Dermatitis deucravacitinib Crohns Disease Lupus Nephritis Systemic Lupus Erythematosus Ulcerative Colitis Discoid Lupus Erythematosus iberdomide Systemic Lupus Erythematosus cendakimab Atopic Dermatitis afimetoran Systemic Lupus Erythematosus S1PR1 Modulator Atopic Dermatitis MK2 Inhibitor Ankylosing SpondylitisPhase III Additional Indications ZEPOSIA Crohns Disease Investigational Compounds deucravacitinib Psoriasis Psoriatic Arthritis cendakimab Eosinophilic EsophagitisApproved Indications ORENCIA Active Polyarticular JIA Early Rheumatoid Arthritis JIA Intravenous JIA Subcutaneous Psoriatic Arthritis RA Auto injector RA Intravenous RA Subcutaneous Acute Graft versus Host Disease ZEPOSIA Relapsing Multiple Sclerosis Ulcerative Colitis Cardiovascular Phase I Investigational Compounds Factor XIa Inhibitor Thrombotic Disorders Cardiac Myosin Inhibitor Hypertrophic Cardiomyopathy ROMK Inhibitor Heart FailurePhase II Additional Indications ELIQUIS Pediatric Heart Disease Investigational Compounds mavacamten Non-Obstructive Hypertrophic Cardiomyopathy Heart Failure with Preserved Ejection Fraction danicamtiv Genetic Dilated Cardiomyopathy milvexian Thrombotic Disorders FA-Relaxin Heart FailurePhase III Additional Indications ELIQUIS VTE prevention in pediatrics with ALL Investigational Compounds mavacamten Obstructive Hypertrophic Cardiomyopathy Obstructive Hypertrophic Cardiomyopathy Septal Reduction Therapy EligibleApproved Indications ELIQUIS Stroke Prevention in Atrial Fibrillation Venous Thromboembolism Prevention Orthopedic Surgery Venous Thromboembolism Treatment Fibrotic Diseases Phase I Investigational Compounds NME 1 FibrosisPhase II Investigational Compounds HSP47 Non-Alcoholic Steatohepatitis LPA 1 Antagonist Pulmonary FibrosisNeuroscience Phase I Investigational Compounds FAAH/MGLL Dual Inhibitor Neuroscience Anti-Tau Neuroscience BTK Inhibitor Neuroscience eIF2b Activator NeuroscienceCOVID-19 Phase II Additional Indications ORENCIA COVID-19 treatment Investigational Compounds SARS-CoV-2 mAb Duo COVID-19 Therapy or Prevention# Note: Above pipeline excludes clinical collaborations Development Partnership: OPDIVO, YERVOY, Relatlimab: Ono (our collaboration with Ono also includes other early-stage compounds); EMPLICITI: AbbVie; bempegaldesleukin: Nektar; cabozantinib: Exelixis, Inc.; ELIQUIS: Pfizer; Factor XIa Inhibitor: Janssen Pharmaceuticals, Inc.; HSP47: Nitto Denko Corporation; CD3xPSCA: GeMoaB Monoclonals GmbH; ABECMA (ide-cel): 2seventy bio; REBLOZYL: Merck; AHR: Ikena Oncology; CD22 ADC: T riPhase Accelerator; Immune T olerance: Anokion SA; SARS-CoV-2 mAb Duo: Rockefeller University; TIGIT Bispecific: Agenus; farletuzumab-eribulin ADC: Eisai; rHuPH20: Halozyme; Anti-T au: Prothena Corporation PLC; eIF2b Activator: Evotec SE; MAGE A4/8 TCE Bispecific: Immatics.","('Employee_Health_And_Safety', 0.2201017141342163)","('Access_And_Affordability', 0.1360611617565155)","('Systemic_Risk_Management', 0.08629083633422852)","('NON-ESG', 0.2201017141342163)","('NON-ESG', 0.1360611617565155)","('NON-ESG', 0.08629083633422852)"
Line 712,"2021 ESG REPORT | 51Hematology Phase I Additional Indications OPDIVO Hematologic Malignancies BREYANZI (liso-cel) 3L+ Mantle Cell Lymphoma ABECMA (idecel) High-Risk Newly Diagnosed Multiple Myeloma Investigational Compounds relatlimab^ Hematologic Malignancies BET Inhibitor (CC-95775) Non-Hodgkin Lymphoma BET Inhibitor (CC-90010) Hematologic Malignancies BCMA ADC Relapsed/Refractory Multiple Myeloma BCMA TCE Relapsed/Refractory Multiple Myeloma BCMA NEX T Relapsed/Refractory Multiple Myeloma GPRC5D CAR T Relapsed/Refractory Multiple Myeloma GSPT1 CELMoD (CC-90009) Relapsed/Refractory Acute Myeloid Leukemia Anti-SIRP Non-Hodgkin Lymphoma LSD1 Inhibitor Relapsed/Refractory Non- Hodgkin Lymphoma CD19 NEX T Relapsed/Refractory Non- Hodgkin Lymphoma iberdomide Non-Hodgkin Lymphoma CD33 NKE Relapsed/Refractory Multiple Myeloma CD47xCD20 Non-Hodgkin Lymphoma CK1a CELMoD Hematologic Malignancies ROR1 CAR T Hematologic Malignancies BCMA NKE Relapsed/Refractory Multiple MyelomaPhase II Additional Indications OPDIVO Non-Hodgkin Lymphoma (Diffuse Large B-cell Lymphoma) Non-Hodgkin Lymphoma (Follicular Lymphoma) Pediatric Hodgkin Lymphoma Primary Testicular Lymphoma OPDIVO + EMPLICITI Relapsed/Refractory Multiple Myeloma REBLOZYL Non-Transfusion- Dependent Beta- Thalassemia ONUREG Post HMA Failure MDS BREYANZI 2L Diffuse Large B-cell Lymphoma Transplant Non-Eligible 3L+Chronic Lymphocytic Leukemia 3L+ Follicular Lymphoma / Marginal Zone Lymphoma 2L+ Pediatric B-cell Acute Lymphoblastic Leukemia 2L+ Primary CNS Lymphoma 1L High Grade B-cell Lymphoma ABECMA (ide-cel) High-Risk Newly Diagnosed Multiple Myeloma 2L Relapsed/Refractory Multiple Myeloma 4L+ Relapsed/Refractory Multiple Myeloma Investigational Compounds iberdomide Relapsed/Refractory Multiple Myeloma A/I CELMoD (CC-92480) Relapsed/Refractory Multiple Myeloma BET Inhibitor (BMS- 986158) Hematologic MalignanciesPhase III Additional Indications OPDIVO Refractory Hodgkin Lymphoma EMPLICITI + REVLIMID 1L Multiple Myeloma REBLOZYL ESA Naive MDS MF Anemia INREBIC MF Previously treated with Ruxolitinib ONUREG Angioimmunoblastic T-cell Lymphoma Lower Risk MDS ABECMA (ide-cel) 3L Relapsed/Refractory Multiple Myeloma BREYANZI 2L Diffuse Large B-cell Lymphoma Transplant EligibleApproved Indications REVLIMID 1L Multiple Myeloma Mantle Cell Lymphoma MDS Multiple Myeloma Previously treated Follicular Lymphoma Relapsed/Refractory Adult T-cell Leukemia/Lymphoma OPDIVO Advanced Hodgkin Lymphoma POMALYST/IMNOVID Multiple Myeloma Relapsed/Refractory Multiple Myeloma AIDS-related Kaposi Sarcoma HIV-negative Kaposi Sarcoma EMPLICITI + POMALYST/ IMNOVID Relapsed/Refractory Multiple Myeloma EMPLICITI + REVLIMID Relapsed/Refractory Multiple Myeloma SPRYCEL 1L CML Pediatric ALL Refractory CML REBLOZYL Transfusion-Dependent Beta- Thalassemia MDS Previously treated with ESA INREBIC MF ONUREG Post-Induction Acute Myeloid Leukemia Maintenance BREYANZI 3L+ Diffuse Large B-cell Lymphoma ABECMA (ide-cel) 5L+ Relapsed/Refractory Multiple Myeloma 2021 ESG REPORT | 52 Development Portfolio by Therapeutic AreaImmunology Phase I Investigational Compounds TYK2 Inhibitor Autoimmune Disease TLR 7/8 Inhibitor Autoimmune Disease MK2 Inhibitor Autoimmune Disease IL2-CD25 Autoimmune Disease Anti-CD40 Autoimmune Disease afimetoran Cutaneous Lupus ErythematosusPhase II Investigational Compounds branebrutinib Rheumatoid Arthritis Sjogrens Disease Systemic Lupus Erythematosus Atopic Dermatitis deucravacitinib Crohns Disease Lupus Nephritis Systemic Lupus Erythematosus Ulcerative Colitis Discoid Lupus Erythematosus iberdomide Systemic Lupus Erythematosus cendakimab Atopic Dermatitis afimetoran Systemic Lupus Erythematosus S1PR1 Modulator Atopic Dermatitis MK2 Inhibitor Ankylosing SpondylitisPhase III Additional Indications ZEPOSIA Crohns Disease Investigational Compounds deucravacitinib Psoriasis Psoriatic Arthritis cendakimab Eosinophilic EsophagitisApproved Indications ORENCIA Active Polyarticular JIA Early Rheumatoid Arthritis JIA Intravenous JIA Subcutaneous Psoriatic Arthritis RA Auto injector RA Intravenous RA Subcutaneous Acute Graft versus Host Disease ZEPOSIA Relapsing Multiple Sclerosis Ulcerative Colitis Cardiovascular Phase I Investigational Compounds Factor XIa Inhibitor Thrombotic Disorders Cardiac Myosin Inhibitor Hypertrophic Cardiomyopathy ROMK Inhibitor Heart FailurePhase II Additional Indications ELIQUIS Pediatric Heart Disease Investigational Compounds mavacamten Non-Obstructive Hypertrophic Cardiomyopathy Heart Failure with Preserved Ejection Fraction danicamtiv Genetic Dilated Cardiomyopathy milvexian Thrombotic Disorders FA-Relaxin Heart FailurePhase III Additional Indications ELIQUIS VTE prevention in pediatrics with ALL Investigational Compounds mavacamten Obstructive Hypertrophic Cardiomyopathy Obstructive Hypertrophic Cardiomyopathy Septal Reduction Therapy EligibleApproved Indications ELIQUIS Stroke Prevention in Atrial Fibrillation Venous Thromboembolism Prevention Orthopedic Surgery Venous Thromboembolism Treatment Fibrotic Diseases Phase I Investigational Compounds NME 1 FibrosisPhase II Investigational Compounds HSP47 Non-Alcoholic Steatohepatitis LPA 1 Antagonist Pulmonary FibrosisNeuroscience Phase I Investigational Compounds FAAH/MGLL Dual Inhibitor Neuroscience Anti-Tau Neuroscience BTK Inhibitor Neuroscience eIF2b Activator NeuroscienceCOVID-19 Phase II Additional Indications ORENCIA COVID-19 treatment Investigational Compounds SARS-CoV-2 mAb Duo COVID-19 Therapy or Prevention# Note: Above pipeline excludes clinical collaborations Development Partnership: OPDIVO, YERVOY, Relatlimab: Ono (our collaboration with Ono also includes other early-stage compounds); EMPLICITI: AbbVie; bempegaldesleukin: Nektar; cabozantinib: Exelixis, Inc.; ELIQUIS: Pfizer; Factor XIa Inhibitor: Janssen Pharmaceuticals, Inc.; HSP47: Nitto Denko Corporation; CD3xPSCA: GeMoaB Monoclonals GmbH; ABECMA (ide-cel): 2seventy bio; REBLOZYL: Merck; AHR: Ikena Oncology; CD22 ADC: T riPhase Accelerator; Immune T olerance: Anokion SA; SARS-CoV-2 mAb Duo: Rockefeller University; TIGIT Bispecific: Agenus; farletuzumab-eribulin ADC: Eisai; rHuPH20: Halozyme; Anti-T au: Prothena Corporation PLC; eIF2b Activator: Evotec SE; MAGE A4/8 TCE Bispecific: Immatics.","('Customer_Welfare', 0.22749589383602142)","('Competitive_Behavior', 0.21289679408073425)","('GHG_Emissions', 0.07587365061044693)","('NON-ESG', 0.22749589383602142)","('NON-ESG', 0.21289679408073425)","('NON-ESG', 0.07587365061044693)"
Line 713,"2021 ESG REPORT | 51Hematology Phase I Additional Indications OPDIVO Hematologic Malignancies BREYANZI (liso-cel) 3L+ Mantle Cell Lymphoma ABECMA (idecel) High-Risk Newly Diagnosed Multiple Myeloma Investigational Compounds relatlimab^ Hematologic Malignancies BET Inhibitor (CC-95775) Non-Hodgkin Lymphoma BET Inhibitor (CC-90010) Hematologic Malignancies BCMA ADC Relapsed/Refractory Multiple Myeloma BCMA TCE Relapsed/Refractory Multiple Myeloma BCMA NEX T Relapsed/Refractory Multiple Myeloma GPRC5D CAR T Relapsed/Refractory Multiple Myeloma GSPT1 CELMoD (CC-90009) Relapsed/Refractory Acute Myeloid Leukemia Anti-SIRP Non-Hodgkin Lymphoma LSD1 Inhibitor Relapsed/Refractory Non- Hodgkin Lymphoma CD19 NEX T Relapsed/Refractory Non- Hodgkin Lymphoma iberdomide Non-Hodgkin Lymphoma CD33 NKE Relapsed/Refractory Multiple Myeloma CD47xCD20 Non-Hodgkin Lymphoma CK1a CELMoD Hematologic Malignancies ROR1 CAR T Hematologic Malignancies BCMA NKE Relapsed/Refractory Multiple MyelomaPhase II Additional Indications OPDIVO Non-Hodgkin Lymphoma (Diffuse Large B-cell Lymphoma) Non-Hodgkin Lymphoma (Follicular Lymphoma) Pediatric Hodgkin Lymphoma Primary Testicular Lymphoma OPDIVO + EMPLICITI Relapsed/Refractory Multiple Myeloma REBLOZYL Non-Transfusion- Dependent Beta- Thalassemia ONUREG Post HMA Failure MDS BREYANZI 2L Diffuse Large B-cell Lymphoma Transplant Non-Eligible 3L+Chronic Lymphocytic Leukemia 3L+ Follicular Lymphoma / Marginal Zone Lymphoma 2L+ Pediatric B-cell Acute Lymphoblastic Leukemia 2L+ Primary CNS Lymphoma 1L High Grade B-cell Lymphoma ABECMA (ide-cel) High-Risk Newly Diagnosed Multiple Myeloma 2L Relapsed/Refractory Multiple Myeloma 4L+ Relapsed/Refractory Multiple Myeloma Investigational Compounds iberdomide Relapsed/Refractory Multiple Myeloma A/I CELMoD (CC-92480) Relapsed/Refractory Multiple Myeloma BET Inhibitor (BMS- 986158) Hematologic MalignanciesPhase III Additional Indications OPDIVO Refractory Hodgkin Lymphoma EMPLICITI + REVLIMID 1L Multiple Myeloma REBLOZYL ESA Naive MDS MF Anemia INREBIC MF Previously treated with Ruxolitinib ONUREG Angioimmunoblastic T-cell Lymphoma Lower Risk MDS ABECMA (ide-cel) 3L Relapsed/Refractory Multiple Myeloma BREYANZI 2L Diffuse Large B-cell Lymphoma Transplant EligibleApproved Indications REVLIMID 1L Multiple Myeloma Mantle Cell Lymphoma MDS Multiple Myeloma Previously treated Follicular Lymphoma Relapsed/Refractory Adult T-cell Leukemia/Lymphoma OPDIVO Advanced Hodgkin Lymphoma POMALYST/IMNOVID Multiple Myeloma Relapsed/Refractory Multiple Myeloma AIDS-related Kaposi Sarcoma HIV-negative Kaposi Sarcoma EMPLICITI + POMALYST/ IMNOVID Relapsed/Refractory Multiple Myeloma EMPLICITI + REVLIMID Relapsed/Refractory Multiple Myeloma SPRYCEL 1L CML Pediatric ALL Refractory CML REBLOZYL Transfusion-Dependent Beta- Thalassemia MDS Previously treated with ESA INREBIC MF ONUREG Post-Induction Acute Myeloid Leukemia Maintenance BREYANZI 3L+ Diffuse Large B-cell Lymphoma ABECMA (ide-cel) 5L+ Relapsed/Refractory Multiple Myeloma 2021 ESG REPORT | 52 Development Portfolio by Therapeutic AreaImmunology Phase I Investigational Compounds TYK2 Inhibitor Autoimmune Disease TLR 7/8 Inhibitor Autoimmune Disease MK2 Inhibitor Autoimmune Disease IL2-CD25 Autoimmune Disease Anti-CD40 Autoimmune Disease afimetoran Cutaneous Lupus ErythematosusPhase II Investigational Compounds branebrutinib Rheumatoid Arthritis Sjogrens Disease Systemic Lupus Erythematosus Atopic Dermatitis deucravacitinib Crohns Disease Lupus Nephritis Systemic Lupus Erythematosus Ulcerative Colitis Discoid Lupus Erythematosus iberdomide Systemic Lupus Erythematosus cendakimab Atopic Dermatitis afimetoran Systemic Lupus Erythematosus S1PR1 Modulator Atopic Dermatitis MK2 Inhibitor Ankylosing SpondylitisPhase III Additional Indications ZEPOSIA Crohns Disease Investigational Compounds deucravacitinib Psoriasis Psoriatic Arthritis cendakimab Eosinophilic EsophagitisApproved Indications ORENCIA Active Polyarticular JIA Early Rheumatoid Arthritis JIA Intravenous JIA Subcutaneous Psoriatic Arthritis RA Auto injector RA Intravenous RA Subcutaneous Acute Graft versus Host Disease ZEPOSIA Relapsing Multiple Sclerosis Ulcerative Colitis Cardiovascular Phase I Investigational Compounds Factor XIa Inhibitor Thrombotic Disorders Cardiac Myosin Inhibitor Hypertrophic Cardiomyopathy ROMK Inhibitor Heart FailurePhase II Additional Indications ELIQUIS Pediatric Heart Disease Investigational Compounds mavacamten Non-Obstructive Hypertrophic Cardiomyopathy Heart Failure with Preserved Ejection Fraction danicamtiv Genetic Dilated Cardiomyopathy milvexian Thrombotic Disorders FA-Relaxin Heart FailurePhase III Additional Indications ELIQUIS VTE prevention in pediatrics with ALL Investigational Compounds mavacamten Obstructive Hypertrophic Cardiomyopathy Obstructive Hypertrophic Cardiomyopathy Septal Reduction Therapy EligibleApproved Indications ELIQUIS Stroke Prevention in Atrial Fibrillation Venous Thromboembolism Prevention Orthopedic Surgery Venous Thromboembolism Treatment Fibrotic Diseases Phase I Investigational Compounds NME 1 FibrosisPhase II Investigational Compounds HSP47 Non-Alcoholic Steatohepatitis LPA 1 Antagonist Pulmonary FibrosisNeuroscience Phase I Investigational Compounds FAAH/MGLL Dual Inhibitor Neuroscience Anti-Tau Neuroscience BTK Inhibitor Neuroscience eIF2b Activator NeuroscienceCOVID-19 Phase II Additional Indications ORENCIA COVID-19 treatment Investigational Compounds SARS-CoV-2 mAb Duo COVID-19 Therapy or Prevention# Note: Above pipeline excludes clinical collaborations Development Partnership: OPDIVO, YERVOY, Relatlimab: Ono (our collaboration with Ono also includes other early-stage compounds); EMPLICITI: AbbVie; bempegaldesleukin: Nektar; cabozantinib: Exelixis, Inc.; ELIQUIS: Pfizer; Factor XIa Inhibitor: Janssen Pharmaceuticals, Inc.; HSP47: Nitto Denko Corporation; CD3xPSCA: GeMoaB Monoclonals GmbH; ABECMA (ide-cel): 2seventy bio; REBLOZYL: Merck; AHR: Ikena Oncology; CD22 ADC: T riPhase Accelerator; Immune T olerance: Anokion SA; SARS-CoV-2 mAb Duo: Rockefeller University; TIGIT Bispecific: Agenus; farletuzumab-eribulin ADC: Eisai; rHuPH20: Halozyme; Anti-T au: Prothena Corporation PLC; eIF2b Activator: Evotec SE; MAGE A4/8 TCE Bispecific: Immatics.","('Customer_Welfare', 0.3004920780658722)","('Competitive_Behavior', 0.09417680650949478)","('GHG_Emissions', 0.07168909907341003)","('NON-ESG', 0.3004920780658722)","('NON-ESG', 0.09417680650949478)","('NON-ESG', 0.07168909907341003)"
Line 714,"2021 ESG REPORT | 51Hematology Phase I Additional Indications OPDIVO Hematologic Malignancies BREYANZI (liso-cel) 3L+ Mantle Cell Lymphoma ABECMA (idecel) High-Risk Newly Diagnosed Multiple Myeloma Investigational Compounds relatlimab^ Hematologic Malignancies BET Inhibitor (CC-95775) Non-Hodgkin Lymphoma BET Inhibitor (CC-90010) Hematologic Malignancies BCMA ADC Relapsed/Refractory Multiple Myeloma BCMA TCE Relapsed/Refractory Multiple Myeloma BCMA NEX T Relapsed/Refractory Multiple Myeloma GPRC5D CAR T Relapsed/Refractory Multiple Myeloma GSPT1 CELMoD (CC-90009) Relapsed/Refractory Acute Myeloid Leukemia Anti-SIRP Non-Hodgkin Lymphoma LSD1 Inhibitor Relapsed/Refractory Non- Hodgkin Lymphoma CD19 NEX T Relapsed/Refractory Non- Hodgkin Lymphoma iberdomide Non-Hodgkin Lymphoma CD33 NKE Relapsed/Refractory Multiple Myeloma CD47xCD20 Non-Hodgkin Lymphoma CK1a CELMoD Hematologic Malignancies ROR1 CAR T Hematologic Malignancies BCMA NKE Relapsed/Refractory Multiple MyelomaPhase II Additional Indications OPDIVO Non-Hodgkin Lymphoma (Diffuse Large B-cell Lymphoma) Non-Hodgkin Lymphoma (Follicular Lymphoma) Pediatric Hodgkin Lymphoma Primary Testicular Lymphoma OPDIVO + EMPLICITI Relapsed/Refractory Multiple Myeloma REBLOZYL Non-Transfusion- Dependent Beta- Thalassemia ONUREG Post HMA Failure MDS BREYANZI 2L Diffuse Large B-cell Lymphoma Transplant Non-Eligible 3L+Chronic Lymphocytic Leukemia 3L+ Follicular Lymphoma / Marginal Zone Lymphoma 2L+ Pediatric B-cell Acute Lymphoblastic Leukemia 2L+ Primary CNS Lymphoma 1L High Grade B-cell Lymphoma ABECMA (ide-cel) High-Risk Newly Diagnosed Multiple Myeloma 2L Relapsed/Refractory Multiple Myeloma 4L+ Relapsed/Refractory Multiple Myeloma Investigational Compounds iberdomide Relapsed/Refractory Multiple Myeloma A/I CELMoD (CC-92480) Relapsed/Refractory Multiple Myeloma BET Inhibitor (BMS- 986158) Hematologic MalignanciesPhase III Additional Indications OPDIVO Refractory Hodgkin Lymphoma EMPLICITI + REVLIMID 1L Multiple Myeloma REBLOZYL ESA Naive MDS MF Anemia INREBIC MF Previously treated with Ruxolitinib ONUREG Angioimmunoblastic T-cell Lymphoma Lower Risk MDS ABECMA (ide-cel) 3L Relapsed/Refractory Multiple Myeloma BREYANZI 2L Diffuse Large B-cell Lymphoma Transplant EligibleApproved Indications REVLIMID 1L Multiple Myeloma Mantle Cell Lymphoma MDS Multiple Myeloma Previously treated Follicular Lymphoma Relapsed/Refractory Adult T-cell Leukemia/Lymphoma OPDIVO Advanced Hodgkin Lymphoma POMALYST/IMNOVID Multiple Myeloma Relapsed/Refractory Multiple Myeloma AIDS-related Kaposi Sarcoma HIV-negative Kaposi Sarcoma EMPLICITI + POMALYST/ IMNOVID Relapsed/Refractory Multiple Myeloma EMPLICITI + REVLIMID Relapsed/Refractory Multiple Myeloma SPRYCEL 1L CML Pediatric ALL Refractory CML REBLOZYL Transfusion-Dependent Beta- Thalassemia MDS Previously treated with ESA INREBIC MF ONUREG Post-Induction Acute Myeloid Leukemia Maintenance BREYANZI 3L+ Diffuse Large B-cell Lymphoma ABECMA (ide-cel) 5L+ Relapsed/Refractory Multiple Myeloma 2021 ESG REPORT | 52 Development Portfolio by Therapeutic AreaImmunology Phase I Investigational Compounds TYK2 Inhibitor Autoimmune Disease TLR 7/8 Inhibitor Autoimmune Disease MK2 Inhibitor Autoimmune Disease IL2-CD25 Autoimmune Disease Anti-CD40 Autoimmune Disease afimetoran Cutaneous Lupus ErythematosusPhase II Investigational Compounds branebrutinib Rheumatoid Arthritis Sjogrens Disease Systemic Lupus Erythematosus Atopic Dermatitis deucravacitinib Crohns Disease Lupus Nephritis Systemic Lupus Erythematosus Ulcerative Colitis Discoid Lupus Erythematosus iberdomide Systemic Lupus Erythematosus cendakimab Atopic Dermatitis afimetoran Systemic Lupus Erythematosus S1PR1 Modulator Atopic Dermatitis MK2 Inhibitor Ankylosing SpondylitisPhase III Additional Indications ZEPOSIA Crohns Disease Investigational Compounds deucravacitinib Psoriasis Psoriatic Arthritis cendakimab Eosinophilic EsophagitisApproved Indications ORENCIA Active Polyarticular JIA Early Rheumatoid Arthritis JIA Intravenous JIA Subcutaneous Psoriatic Arthritis RA Auto injector RA Intravenous RA Subcutaneous Acute Graft versus Host Disease ZEPOSIA Relapsing Multiple Sclerosis Ulcerative Colitis Cardiovascular Phase I Investigational Compounds Factor XIa Inhibitor Thrombotic Disorders Cardiac Myosin Inhibitor Hypertrophic Cardiomyopathy ROMK Inhibitor Heart FailurePhase II Additional Indications ELIQUIS Pediatric Heart Disease Investigational Compounds mavacamten Non-Obstructive Hypertrophic Cardiomyopathy Heart Failure with Preserved Ejection Fraction danicamtiv Genetic Dilated Cardiomyopathy milvexian Thrombotic Disorders FA-Relaxin Heart FailurePhase III Additional Indications ELIQUIS VTE prevention in pediatrics with ALL Investigational Compounds mavacamten Obstructive Hypertrophic Cardiomyopathy Obstructive Hypertrophic Cardiomyopathy Septal Reduction Therapy EligibleApproved Indications ELIQUIS Stroke Prevention in Atrial Fibrillation Venous Thromboembolism Prevention Orthopedic Surgery Venous Thromboembolism Treatment Fibrotic Diseases Phase I Investigational Compounds NME 1 FibrosisPhase II Investigational Compounds HSP47 Non-Alcoholic Steatohepatitis LPA 1 Antagonist Pulmonary FibrosisNeuroscience Phase I Investigational Compounds FAAH/MGLL Dual Inhibitor Neuroscience Anti-Tau Neuroscience BTK Inhibitor Neuroscience eIF2b Activator NeuroscienceCOVID-19 Phase II Additional Indications ORENCIA COVID-19 treatment Investigational Compounds SARS-CoV-2 mAb Duo COVID-19 Therapy or Prevention# Note: Above pipeline excludes clinical collaborations Development Partnership: OPDIVO, YERVOY, Relatlimab: Ono (our collaboration with Ono also includes other early-stage compounds); EMPLICITI: AbbVie; bempegaldesleukin: Nektar; cabozantinib: Exelixis, Inc.; ELIQUIS: Pfizer; Factor XIa Inhibitor: Janssen Pharmaceuticals, Inc.; HSP47: Nitto Denko Corporation; CD3xPSCA: GeMoaB Monoclonals GmbH; ABECMA (ide-cel): 2seventy bio; REBLOZYL: Merck; AHR: Ikena Oncology; CD22 ADC: T riPhase Accelerator; Immune T olerance: Anokion SA; SARS-CoV-2 mAb Duo: Rockefeller University; TIGIT Bispecific: Agenus; farletuzumab-eribulin ADC: Eisai; rHuPH20: Halozyme; Anti-T au: Prothena Corporation PLC; eIF2b Activator: Evotec SE; MAGE A4/8 TCE Bispecific: Immatics.","('Customer_Welfare', 0.2527226209640503)","('Competitive_Behavior', 0.14510737359523773)","('GHG_Emissions', 0.0901184156537056)","('NON-ESG', 0.2527226209640503)","('NON-ESG', 0.14510737359523773)","('NON-ESG', 0.0901184156537056)"
Line 715,"^ T rial(s) exploring various combinations # Partner-run study 2021 ESG REPORT | 53 Development Portfolio by Therapeutic AreaBMS 2021 ESG Data Topic 2020 2021 Corporate Director tenure 0-4 years 9 6 5-10 years 4 4 >10 years 1 0 Director diversity Women 5 4 Black/African American 2 2 Asian American 2 0 Latino/Hispanic 1 Women and underrepresented racial and ethnic groups 50% 60% Highlights Worldwide revenues ($ Billions) 42.5 46.4 Employees 30,250 32,200 R&D investment including Acquired IPRD ($ Billions) 11.1 11.4 Key corporate measures R&D investment including Acquired IPRD ($ Billions) 11.1 11.4 Total revenues ($ Millions) 42,518 46,358 People Workplace Global executive representation by gender 42.8% 45.2% Global management level by gender: Executive: Female 42.8% 45.5% Executive: Male 57.2% 54.5% Manager: Female 50.7% 51.8% Manager: Male 49.3% 48.2% Professional: Female 56.9% 57.4% Professional: Male 43.1% 42.6% Gender parity: Reach parity at the executive level for women globally 42.1% 45.2% Black/African American employees: Double executive representation in the U.","('Employee_Engagement_Inclusion_And_Diversity', 0.9753656387329102)","('Business_Model_Resilience', 0.0016320914728567004)","('Human_Rights_And_Community_Relations', 0.0015504328766837716)","(['Talent Attraction & Retention'], 0.9753656387329102)","('NON-ESG', 0.0016320914728567004)","('NON-ESG', 0.0015504328766837716)"
Line 716,"^ T rial(s) exploring various combinations # Partner-run study 2021 ESG REPORT | 53 Development Portfolio by Therapeutic AreaBMS 2021 ESG Data Topic 2020 2021 Corporate Director tenure 0-4 years 9 6 5-10 years 4 4 >10 years 1 0 Director diversity Women 5 4 Black/African American 2 2 Asian American 2 0 Latino/Hispanic 1 Women and underrepresented racial and ethnic groups 50% 60% Highlights Worldwide revenues ($ Billions) 42.5 46.4 Employees 30,250 32,200 R&D investment including Acquired IPRD ($ Billions) 11.1 11.4 Key corporate measures R&D investment including Acquired IPRD ($ Billions) 11.1 11.4 Total revenues ($ Millions) 42,518 46,358 People Workplace Global executive representation by gender 42.8% 45.2% Global management level by gender: Executive: Female 42.8% 45.5% Executive: Male 57.2% 54.5% Manager: Female 50.7% 51.8% Manager: Male 49.3% 48.2% Professional: Female 56.9% 57.4% Professional: Male 43.1% 42.6% Gender parity: Reach parity at the executive level for women globally 42.1% 45.2% Black/African American employees: Double executive representation in the U.","('Employee_Engagement_Inclusion_And_Diversity', 0.9552512764930725)","('Labor_Practices', 0.004033740144222975)","('Human_Rights_And_Community_Relations', 0.003311188891530037)","(['Talent Attraction & Retention'], 0.9552512764930725)","('NON-ESG', 0.004033740144222975)","('NON-ESG', 0.003311188891530037)"
Line 717,"^ T rial(s) exploring various combinations # Partner-run study 2021 ESG REPORT | 53 Development Portfolio by Therapeutic AreaBMS 2021 ESG Data Topic 2020 2021 Corporate Director tenure 0-4 years 9 6 5-10 years 4 4 >10 years 1 0 Director diversity Women 5 4 Black/African American 2 2 Asian American 2 0 Latino/Hispanic 1 Women and underrepresented racial and ethnic groups 50% 60% Highlights Worldwide revenues ($ Billions) 42.5 46.4 Employees 30,250 32,200 R&D investment including Acquired IPRD ($ Billions) 11.1 11.4 Key corporate measures R&D investment including Acquired IPRD ($ Billions) 11.1 11.4 Total revenues ($ Millions) 42,518 46,358 People Workplace Global executive representation by gender 42.8% 45.2% Global management level by gender: Executive: Female 42.8% 45.5% Executive: Male 57.2% 54.5% Manager: Female 50.7% 51.8% Manager: Male 49.3% 48.2% Professional: Female 56.9% 57.4% Professional: Male 43.1% 42.6% Gender parity: Reach parity at the executive level for women globally 42.1% 45.2% Black/African American employees: Double executive representation in the U.","('Labor_Practices', 0.5597051978111267)","('Employee_Engagement_Inclusion_And_Diversity', 0.2972792387008667)","('Director_Removal', 0.02214868925511837)","([], 0.5597051978111267)","('NON-ESG', 0.2972792387008667)","('NON-ESG', 0.02214868925511837)"
Line 718,S. 3.0% 4.5% Latino/Hispanic employees: Double executive representation in the U.,"('Employee_Engagement_Inclusion_And_Diversity', 0.9662691950798035)","('Labor_Practices', 0.003526803571730852)","('Customer_Welfare', 0.0020748882088810205)","(['Talent Attraction & Retention'], 0.9662691950798035)","('NON-ESG', 0.003526803571730852)","('NON-ESG', 0.0020748882088810205)"
Line 719,"S. 3.7% 7.2% 2021 ESG REPORT | 542021 employee safety performance Business EHS inspectionsCAPA completed &closedFull investigations closedNear miss/unsafe condition reports/ 100 employees Commercial 5 7 15 Enabling functions 17 17 GPS 7,071 2,094 975 59 R&ED 2,793 52 88 35 Service provider 301 128 Total 9,864 2,469 1,215 109 SIF incident SIF near miss Motor vehicle accident 7 Pressure 7 Hazardous materials 14 Working from heights 19 Machine guarding Overhead hazards 2 Control of hazardous energy 1 5 Electrical 3 Process safety Other 16 Total 1 73 2021 ESG REPORT | 55 2021 ESG DataTopic 2020 2021 Suppliers Diverse spend: Diverse Business Enterprise (DBE) $695,336,854 $899,277,462 Diverse spend: Minority Business Enterprise (MBE) $450,241,075 $550,931,958 Diverse spend: Women Business Enterprise (WBE) $299,861,314 $429,985,082 Diverse spend: Veterans Business Enterprise (VBE) $53,226,133 $56,494,195 Diverse spend: Disability-Owned Business Enterprise (DOBE) $17,942,401 $8,248,492 Diverse spend: LGBT Business Enterprise (LGBTBE) $10,917,260 $15,309,109 Actual percent: Diverse Business Enterprise (DBE) 13.6% 15.3% Actual percent: Minority Business Enterprise (MBE) 8.8% 9.4% Actual percent: Women Business Enterprise (WBE) 5.9% 7.3% Actual percent: Veterans Business Enterprise (VBE) 1.0% 1.0% Actual percent: Disability-Owned Business Enterprise (DOBE) 0.4% 0.5% Actual percent: LGBT Business Enterprise (LGBTBE) 0.2% 0.3% Actual percent: Diverse Business Enterprise (DBE) 13.6% 15.3% Internal SS&P area goal Diverse Business Enterprise (DBE) 12.0% 12.7% Internal SS&P area goal Minority Business Enterprise (MBE) 8.2% 6.3% Internal SS&P area goal Women Business Enterprise (WBE) 3.9% 4.8% Internal SS&P area goal Veterans Business Enterprise (VBE) 0.7% 0.7% Internal SS&P area goal Disability-Owned Business Enterprise (DOBE) 0.2% 0.1% Product Compounds in development across platforms 50+ 50+ Disease areas being studied 40+ 60+ Marketed product families 46 43 External contract manufacturing sites 100+ 140+ Active development programs 54 100 No observable impact from COVID-19 including no drug shortages impacting patients 0 0 Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP) by type 0 0 Products listed in the FDA MedWatch Safety Alerts for Human Medical Products database 0 0 Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System 0 0 Number of recalls issued; total units recalled 0 0 Partnering to speed transformational medicines to patients: Development pipeline is externally sourced 60% 60% Active alliances, collaborations and partnerships 300+ 300+ 2021 ESG REPORT | 56 2021 ESG DataTopic 2019 2020 2021 Environment* T otal greenhouse gas emissions (CO 2e); thousands of metric tons Scope 1 (Direct) 218.2 202.4 204.3 Scope 2 (Indirect market-based) 118.6 122.6 166.3 Total (Scope 1+2) from operations 336.8 325.0 370.5 Scope 3 (Category 1 Purchased goods & services) 1,641.9 Scope 3 (Category 2 Capital goods) 18.1 Scope 3 (Category 3 Fuel- & energy-related activities) 82.6 Scope 3 (Category 4 Upstream transportation & distribution) 77.0 Scope 3 (Category 5 Waste generated in operations) 4.4 Scope 3 (Category 6 Business travel) 103.3 17.7 10.9 Scope 3 (Category 7 Employee commuting) 54.7 Scope 3 total 1,889.6 Total (Scope 1+2+3) 2,260.1 T otal energy use Total energy use; millions of gigajoules Scope 1 (Direct) 4.1 3.8 3.9 Scope 2 (Indirect) 1.8 1.7 1.6 Total (Scope 1+2) 5.9 5.5 5.5 Waste generated; millions of kilograms Hazardous 0.7 0.2 1.9 Nonhazardous 4.4 1.3 4.3 Recycled/reused 8.1 3.4 5.6 Total 13.2 4.8 11.7 Water use Water use; billion liters 3.1 3.1 3.2 2021 ESG REPORT | 57 2021 ESG Data*Explanation of Scope 3 emissions calculations Sources of Scope 3 emissionsEvaluation statusEmissions in reporting year (metric tons CO 2e)Emissions calculation methodologyPercentage of emissions calculated using data obtained from suppliers or value chain partnersExplanation Purchased goods and servicesRelevant, calculated1,641,931 Hybrid approach 22% Bristol Myers Squibb uses a hybrid approach to calculate Purchased Goods and Services emissions by collecting supplier-specific data via the CDP Supply Chain program as well as spend data for suppliers outside of that program.","('Employee_Health_And_Safety', 0.9768105745315552)","('Critical_Incident_Risk_Management', 0.0031232114415615797)","('Waste_And_Hazardous_Materials_Management', 0.002675015013664961)","(['Health Outcome Contribution'], 0.9768105745315552)","('NON-ESG', 0.0031232114415615797)","('NON-ESG', 0.002675015013664961)"
Line 720,"S. 3.7% 7.2% 2021 ESG REPORT | 542021 employee safety performance Business EHS inspectionsCAPA completed &closedFull investigations closedNear miss/unsafe condition reports/ 100 employees Commercial 5 7 15 Enabling functions 17 17 GPS 7,071 2,094 975 59 R&ED 2,793 52 88 35 Service provider 301 128 Total 9,864 2,469 1,215 109 SIF incident SIF near miss Motor vehicle accident 7 Pressure 7 Hazardous materials 14 Working from heights 19 Machine guarding Overhead hazards 2 Control of hazardous energy 1 5 Electrical 3 Process safety Other 16 Total 1 73 2021 ESG REPORT | 55 2021 ESG DataTopic 2020 2021 Suppliers Diverse spend: Diverse Business Enterprise (DBE) $695,336,854 $899,277,462 Diverse spend: Minority Business Enterprise (MBE) $450,241,075 $550,931,958 Diverse spend: Women Business Enterprise (WBE) $299,861,314 $429,985,082 Diverse spend: Veterans Business Enterprise (VBE) $53,226,133 $56,494,195 Diverse spend: Disability-Owned Business Enterprise (DOBE) $17,942,401 $8,248,492 Diverse spend: LGBT Business Enterprise (LGBTBE) $10,917,260 $15,309,109 Actual percent: Diverse Business Enterprise (DBE) 13.6% 15.3% Actual percent: Minority Business Enterprise (MBE) 8.8% 9.4% Actual percent: Women Business Enterprise (WBE) 5.9% 7.3% Actual percent: Veterans Business Enterprise (VBE) 1.0% 1.0% Actual percent: Disability-Owned Business Enterprise (DOBE) 0.4% 0.5% Actual percent: LGBT Business Enterprise (LGBTBE) 0.2% 0.3% Actual percent: Diverse Business Enterprise (DBE) 13.6% 15.3% Internal SS&P area goal Diverse Business Enterprise (DBE) 12.0% 12.7% Internal SS&P area goal Minority Business Enterprise (MBE) 8.2% 6.3% Internal SS&P area goal Women Business Enterprise (WBE) 3.9% 4.8% Internal SS&P area goal Veterans Business Enterprise (VBE) 0.7% 0.7% Internal SS&P area goal Disability-Owned Business Enterprise (DOBE) 0.2% 0.1% Product Compounds in development across platforms 50+ 50+ Disease areas being studied 40+ 60+ Marketed product families 46 43 External contract manufacturing sites 100+ 140+ Active development programs 54 100 No observable impact from COVID-19 including no drug shortages impacting patients 0 0 Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP) by type 0 0 Products listed in the FDA MedWatch Safety Alerts for Human Medical Products database 0 0 Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System 0 0 Number of recalls issued; total units recalled 0 0 Partnering to speed transformational medicines to patients: Development pipeline is externally sourced 60% 60% Active alliances, collaborations and partnerships 300+ 300+ 2021 ESG REPORT | 56 2021 ESG DataTopic 2019 2020 2021 Environment* T otal greenhouse gas emissions (CO 2e); thousands of metric tons Scope 1 (Direct) 218.2 202.4 204.3 Scope 2 (Indirect market-based) 118.6 122.6 166.3 Total (Scope 1+2) from operations 336.8 325.0 370.5 Scope 3 (Category 1 Purchased goods & services) 1,641.9 Scope 3 (Category 2 Capital goods) 18.1 Scope 3 (Category 3 Fuel- & energy-related activities) 82.6 Scope 3 (Category 4 Upstream transportation & distribution) 77.0 Scope 3 (Category 5 Waste generated in operations) 4.4 Scope 3 (Category 6 Business travel) 103.3 17.7 10.9 Scope 3 (Category 7 Employee commuting) 54.7 Scope 3 total 1,889.6 Total (Scope 1+2+3) 2,260.1 T otal energy use Total energy use; millions of gigajoules Scope 1 (Direct) 4.1 3.8 3.9 Scope 2 (Indirect) 1.8 1.7 1.6 Total (Scope 1+2) 5.9 5.5 5.5 Waste generated; millions of kilograms Hazardous 0.7 0.2 1.9 Nonhazardous 4.4 1.3 4.3 Recycled/reused 8.1 3.4 5.6 Total 13.2 4.8 11.7 Water use Water use; billion liters 3.1 3.1 3.2 2021 ESG REPORT | 57 2021 ESG Data*Explanation of Scope 3 emissions calculations Sources of Scope 3 emissionsEvaluation statusEmissions in reporting year (metric tons CO 2e)Emissions calculation methodologyPercentage of emissions calculated using data obtained from suppliers or value chain partnersExplanation Purchased goods and servicesRelevant, calculated1,641,931 Hybrid approach 22% Bristol Myers Squibb uses a hybrid approach to calculate Purchased Goods and Services emissions by collecting supplier-specific data via the CDP Supply Chain program as well as spend data for suppliers outside of that program.","('Employee_Engagement_Inclusion_And_Diversity', 0.9498474597930908)","('Business_Model_Resilience', 0.0037809638306498528)","('Access_And_Affordability', 0.0035029801074415445)","(['Talent Attraction & Retention'], 0.9498474597930908)","('NON-ESG', 0.0037809638306498528)","('NON-ESG', 0.0035029801074415445)"
Line 721,"S. 3.7% 7.2% 2021 ESG REPORT | 542021 employee safety performance Business EHS inspectionsCAPA completed &closedFull investigations closedNear miss/unsafe condition reports/ 100 employees Commercial 5 7 15 Enabling functions 17 17 GPS 7,071 2,094 975 59 R&ED 2,793 52 88 35 Service provider 301 128 Total 9,864 2,469 1,215 109 SIF incident SIF near miss Motor vehicle accident 7 Pressure 7 Hazardous materials 14 Working from heights 19 Machine guarding Overhead hazards 2 Control of hazardous energy 1 5 Electrical 3 Process safety Other 16 Total 1 73 2021 ESG REPORT | 55 2021 ESG DataTopic 2020 2021 Suppliers Diverse spend: Diverse Business Enterprise (DBE) $695,336,854 $899,277,462 Diverse spend: Minority Business Enterprise (MBE) $450,241,075 $550,931,958 Diverse spend: Women Business Enterprise (WBE) $299,861,314 $429,985,082 Diverse spend: Veterans Business Enterprise (VBE) $53,226,133 $56,494,195 Diverse spend: Disability-Owned Business Enterprise (DOBE) $17,942,401 $8,248,492 Diverse spend: LGBT Business Enterprise (LGBTBE) $10,917,260 $15,309,109 Actual percent: Diverse Business Enterprise (DBE) 13.6% 15.3% Actual percent: Minority Business Enterprise (MBE) 8.8% 9.4% Actual percent: Women Business Enterprise (WBE) 5.9% 7.3% Actual percent: Veterans Business Enterprise (VBE) 1.0% 1.0% Actual percent: Disability-Owned Business Enterprise (DOBE) 0.4% 0.5% Actual percent: LGBT Business Enterprise (LGBTBE) 0.2% 0.3% Actual percent: Diverse Business Enterprise (DBE) 13.6% 15.3% Internal SS&P area goal Diverse Business Enterprise (DBE) 12.0% 12.7% Internal SS&P area goal Minority Business Enterprise (MBE) 8.2% 6.3% Internal SS&P area goal Women Business Enterprise (WBE) 3.9% 4.8% Internal SS&P area goal Veterans Business Enterprise (VBE) 0.7% 0.7% Internal SS&P area goal Disability-Owned Business Enterprise (DOBE) 0.2% 0.1% Product Compounds in development across platforms 50+ 50+ Disease areas being studied 40+ 60+ Marketed product families 46 43 External contract manufacturing sites 100+ 140+ Active development programs 54 100 No observable impact from COVID-19 including no drug shortages impacting patients 0 0 Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP) by type 0 0 Products listed in the FDA MedWatch Safety Alerts for Human Medical Products database 0 0 Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System 0 0 Number of recalls issued; total units recalled 0 0 Partnering to speed transformational medicines to patients: Development pipeline is externally sourced 60% 60% Active alliances, collaborations and partnerships 300+ 300+ 2021 ESG REPORT | 56 2021 ESG DataTopic 2019 2020 2021 Environment* T otal greenhouse gas emissions (CO 2e); thousands of metric tons Scope 1 (Direct) 218.2 202.4 204.3 Scope 2 (Indirect market-based) 118.6 122.6 166.3 Total (Scope 1+2) from operations 336.8 325.0 370.5 Scope 3 (Category 1 Purchased goods & services) 1,641.9 Scope 3 (Category 2 Capital goods) 18.1 Scope 3 (Category 3 Fuel- & energy-related activities) 82.6 Scope 3 (Category 4 Upstream transportation & distribution) 77.0 Scope 3 (Category 5 Waste generated in operations) 4.4 Scope 3 (Category 6 Business travel) 103.3 17.7 10.9 Scope 3 (Category 7 Employee commuting) 54.7 Scope 3 total 1,889.6 Total (Scope 1+2+3) 2,260.1 T otal energy use Total energy use; millions of gigajoules Scope 1 (Direct) 4.1 3.8 3.9 Scope 2 (Indirect) 1.8 1.7 1.6 Total (Scope 1+2) 5.9 5.5 5.5 Waste generated; millions of kilograms Hazardous 0.7 0.2 1.9 Nonhazardous 4.4 1.3 4.3 Recycled/reused 8.1 3.4 5.6 Total 13.2 4.8 11.7 Water use Water use; billion liters 3.1 3.1 3.2 2021 ESG REPORT | 57 2021 ESG Data*Explanation of Scope 3 emissions calculations Sources of Scope 3 emissionsEvaluation statusEmissions in reporting year (metric tons CO 2e)Emissions calculation methodologyPercentage of emissions calculated using data obtained from suppliers or value chain partnersExplanation Purchased goods and servicesRelevant, calculated1,641,931 Hybrid approach 22% Bristol Myers Squibb uses a hybrid approach to calculate Purchased Goods and Services emissions by collecting supplier-specific data via the CDP Supply Chain program as well as spend data for suppliers outside of that program.","('Employee_Engagement_Inclusion_And_Diversity', 0.9639249444007874)","('Business_Model_Resilience', 0.002814750885590911)","('Human_Rights_And_Community_Relations', 0.0024189141113311052)","(['Talent Attraction & Retention'], 0.9639249444007874)","('NON-ESG', 0.002814750885590911)","('NON-ESG', 0.0024189141113311052)"
Line 722,"S. 3.7% 7.2% 2021 ESG REPORT | 542021 employee safety performance Business EHS inspectionsCAPA completed &closedFull investigations closedNear miss/unsafe condition reports/ 100 employees Commercial 5 7 15 Enabling functions 17 17 GPS 7,071 2,094 975 59 R&ED 2,793 52 88 35 Service provider 301 128 Total 9,864 2,469 1,215 109 SIF incident SIF near miss Motor vehicle accident 7 Pressure 7 Hazardous materials 14 Working from heights 19 Machine guarding Overhead hazards 2 Control of hazardous energy 1 5 Electrical 3 Process safety Other 16 Total 1 73 2021 ESG REPORT | 55 2021 ESG DataTopic 2020 2021 Suppliers Diverse spend: Diverse Business Enterprise (DBE) $695,336,854 $899,277,462 Diverse spend: Minority Business Enterprise (MBE) $450,241,075 $550,931,958 Diverse spend: Women Business Enterprise (WBE) $299,861,314 $429,985,082 Diverse spend: Veterans Business Enterprise (VBE) $53,226,133 $56,494,195 Diverse spend: Disability-Owned Business Enterprise (DOBE) $17,942,401 $8,248,492 Diverse spend: LGBT Business Enterprise (LGBTBE) $10,917,260 $15,309,109 Actual percent: Diverse Business Enterprise (DBE) 13.6% 15.3% Actual percent: Minority Business Enterprise (MBE) 8.8% 9.4% Actual percent: Women Business Enterprise (WBE) 5.9% 7.3% Actual percent: Veterans Business Enterprise (VBE) 1.0% 1.0% Actual percent: Disability-Owned Business Enterprise (DOBE) 0.4% 0.5% Actual percent: LGBT Business Enterprise (LGBTBE) 0.2% 0.3% Actual percent: Diverse Business Enterprise (DBE) 13.6% 15.3% Internal SS&P area goal Diverse Business Enterprise (DBE) 12.0% 12.7% Internal SS&P area goal Minority Business Enterprise (MBE) 8.2% 6.3% Internal SS&P area goal Women Business Enterprise (WBE) 3.9% 4.8% Internal SS&P area goal Veterans Business Enterprise (VBE) 0.7% 0.7% Internal SS&P area goal Disability-Owned Business Enterprise (DOBE) 0.2% 0.1% Product Compounds in development across platforms 50+ 50+ Disease areas being studied 40+ 60+ Marketed product families 46 43 External contract manufacturing sites 100+ 140+ Active development programs 54 100 No observable impact from COVID-19 including no drug shortages impacting patients 0 0 Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP) by type 0 0 Products listed in the FDA MedWatch Safety Alerts for Human Medical Products database 0 0 Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System 0 0 Number of recalls issued; total units recalled 0 0 Partnering to speed transformational medicines to patients: Development pipeline is externally sourced 60% 60% Active alliances, collaborations and partnerships 300+ 300+ 2021 ESG REPORT | 56 2021 ESG DataTopic 2019 2020 2021 Environment* T otal greenhouse gas emissions (CO 2e); thousands of metric tons Scope 1 (Direct) 218.2 202.4 204.3 Scope 2 (Indirect market-based) 118.6 122.6 166.3 Total (Scope 1+2) from operations 336.8 325.0 370.5 Scope 3 (Category 1 Purchased goods & services) 1,641.9 Scope 3 (Category 2 Capital goods) 18.1 Scope 3 (Category 3 Fuel- & energy-related activities) 82.6 Scope 3 (Category 4 Upstream transportation & distribution) 77.0 Scope 3 (Category 5 Waste generated in operations) 4.4 Scope 3 (Category 6 Business travel) 103.3 17.7 10.9 Scope 3 (Category 7 Employee commuting) 54.7 Scope 3 total 1,889.6 Total (Scope 1+2+3) 2,260.1 T otal energy use Total energy use; millions of gigajoules Scope 1 (Direct) 4.1 3.8 3.9 Scope 2 (Indirect) 1.8 1.7 1.6 Total (Scope 1+2) 5.9 5.5 5.5 Waste generated; millions of kilograms Hazardous 0.7 0.2 1.9 Nonhazardous 4.4 1.3 4.3 Recycled/reused 8.1 3.4 5.6 Total 13.2 4.8 11.7 Water use Water use; billion liters 3.1 3.1 3.2 2021 ESG REPORT | 57 2021 ESG Data*Explanation of Scope 3 emissions calculations Sources of Scope 3 emissionsEvaluation statusEmissions in reporting year (metric tons CO 2e)Emissions calculation methodologyPercentage of emissions calculated using data obtained from suppliers or value chain partnersExplanation Purchased goods and servicesRelevant, calculated1,641,931 Hybrid approach 22% Bristol Myers Squibb uses a hybrid approach to calculate Purchased Goods and Services emissions by collecting supplier-specific data via the CDP Supply Chain program as well as spend data for suppliers outside of that program.","('Product_Design_And_Lifecycle_Management', 0.8137949109077454)","('Customer_Welfare', 0.04089444875717163)","('Product_Quality_And_Safety', 0.027590829879045486)","([], 0.8137949109077454)","('NON-ESG', 0.04089444875717163)","('NON-ESG', 0.027590829879045486)"
Line 723,"S. 3.7% 7.2% 2021 ESG REPORT | 542021 employee safety performance Business EHS inspectionsCAPA completed &closedFull investigations closedNear miss/unsafe condition reports/ 100 employees Commercial 5 7 15 Enabling functions 17 17 GPS 7,071 2,094 975 59 R&ED 2,793 52 88 35 Service provider 301 128 Total 9,864 2,469 1,215 109 SIF incident SIF near miss Motor vehicle accident 7 Pressure 7 Hazardous materials 14 Working from heights 19 Machine guarding Overhead hazards 2 Control of hazardous energy 1 5 Electrical 3 Process safety Other 16 Total 1 73 2021 ESG REPORT | 55 2021 ESG DataTopic 2020 2021 Suppliers Diverse spend: Diverse Business Enterprise (DBE) $695,336,854 $899,277,462 Diverse spend: Minority Business Enterprise (MBE) $450,241,075 $550,931,958 Diverse spend: Women Business Enterprise (WBE) $299,861,314 $429,985,082 Diverse spend: Veterans Business Enterprise (VBE) $53,226,133 $56,494,195 Diverse spend: Disability-Owned Business Enterprise (DOBE) $17,942,401 $8,248,492 Diverse spend: LGBT Business Enterprise (LGBTBE) $10,917,260 $15,309,109 Actual percent: Diverse Business Enterprise (DBE) 13.6% 15.3% Actual percent: Minority Business Enterprise (MBE) 8.8% 9.4% Actual percent: Women Business Enterprise (WBE) 5.9% 7.3% Actual percent: Veterans Business Enterprise (VBE) 1.0% 1.0% Actual percent: Disability-Owned Business Enterprise (DOBE) 0.4% 0.5% Actual percent: LGBT Business Enterprise (LGBTBE) 0.2% 0.3% Actual percent: Diverse Business Enterprise (DBE) 13.6% 15.3% Internal SS&P area goal Diverse Business Enterprise (DBE) 12.0% 12.7% Internal SS&P area goal Minority Business Enterprise (MBE) 8.2% 6.3% Internal SS&P area goal Women Business Enterprise (WBE) 3.9% 4.8% Internal SS&P area goal Veterans Business Enterprise (VBE) 0.7% 0.7% Internal SS&P area goal Disability-Owned Business Enterprise (DOBE) 0.2% 0.1% Product Compounds in development across platforms 50+ 50+ Disease areas being studied 40+ 60+ Marketed product families 46 43 External contract manufacturing sites 100+ 140+ Active development programs 54 100 No observable impact from COVID-19 including no drug shortages impacting patients 0 0 Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP) by type 0 0 Products listed in the FDA MedWatch Safety Alerts for Human Medical Products database 0 0 Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System 0 0 Number of recalls issued; total units recalled 0 0 Partnering to speed transformational medicines to patients: Development pipeline is externally sourced 60% 60% Active alliances, collaborations and partnerships 300+ 300+ 2021 ESG REPORT | 56 2021 ESG DataTopic 2019 2020 2021 Environment* T otal greenhouse gas emissions (CO 2e); thousands of metric tons Scope 1 (Direct) 218.2 202.4 204.3 Scope 2 (Indirect market-based) 118.6 122.6 166.3 Total (Scope 1+2) from operations 336.8 325.0 370.5 Scope 3 (Category 1 Purchased goods & services) 1,641.9 Scope 3 (Category 2 Capital goods) 18.1 Scope 3 (Category 3 Fuel- & energy-related activities) 82.6 Scope 3 (Category 4 Upstream transportation & distribution) 77.0 Scope 3 (Category 5 Waste generated in operations) 4.4 Scope 3 (Category 6 Business travel) 103.3 17.7 10.9 Scope 3 (Category 7 Employee commuting) 54.7 Scope 3 total 1,889.6 Total (Scope 1+2+3) 2,260.1 T otal energy use Total energy use; millions of gigajoules Scope 1 (Direct) 4.1 3.8 3.9 Scope 2 (Indirect) 1.8 1.7 1.6 Total (Scope 1+2) 5.9 5.5 5.5 Waste generated; millions of kilograms Hazardous 0.7 0.2 1.9 Nonhazardous 4.4 1.3 4.3 Recycled/reused 8.1 3.4 5.6 Total 13.2 4.8 11.7 Water use Water use; billion liters 3.1 3.1 3.2 2021 ESG REPORT | 57 2021 ESG Data*Explanation of Scope 3 emissions calculations Sources of Scope 3 emissionsEvaluation statusEmissions in reporting year (metric tons CO 2e)Emissions calculation methodologyPercentage of emissions calculated using data obtained from suppliers or value chain partnersExplanation Purchased goods and servicesRelevant, calculated1,641,931 Hybrid approach 22% Bristol Myers Squibb uses a hybrid approach to calculate Purchased Goods and Services emissions by collecting supplier-specific data via the CDP Supply Chain program as well as spend data for suppliers outside of that program.","('Product_Quality_And_Safety', 0.8847911953926086)","('Selling_Practices_And_Product_Labeling', 0.026722915470600128)","('Product_Design_And_Lifecycle_Management', 0.011856689117848873)","(['Product Quality & Recall Management'], 0.8847911953926086)","('NON-ESG', 0.026722915470600128)","('NON-ESG', 0.011856689117848873)"
Line 724,"S. 3.7% 7.2% 2021 ESG REPORT | 542021 employee safety performance Business EHS inspectionsCAPA completed &closedFull investigations closedNear miss/unsafe condition reports/ 100 employees Commercial 5 7 15 Enabling functions 17 17 GPS 7,071 2,094 975 59 R&ED 2,793 52 88 35 Service provider 301 128 Total 9,864 2,469 1,215 109 SIF incident SIF near miss Motor vehicle accident 7 Pressure 7 Hazardous materials 14 Working from heights 19 Machine guarding Overhead hazards 2 Control of hazardous energy 1 5 Electrical 3 Process safety Other 16 Total 1 73 2021 ESG REPORT | 55 2021 ESG DataTopic 2020 2021 Suppliers Diverse spend: Diverse Business Enterprise (DBE) $695,336,854 $899,277,462 Diverse spend: Minority Business Enterprise (MBE) $450,241,075 $550,931,958 Diverse spend: Women Business Enterprise (WBE) $299,861,314 $429,985,082 Diverse spend: Veterans Business Enterprise (VBE) $53,226,133 $56,494,195 Diverse spend: Disability-Owned Business Enterprise (DOBE) $17,942,401 $8,248,492 Diverse spend: LGBT Business Enterprise (LGBTBE) $10,917,260 $15,309,109 Actual percent: Diverse Business Enterprise (DBE) 13.6% 15.3% Actual percent: Minority Business Enterprise (MBE) 8.8% 9.4% Actual percent: Women Business Enterprise (WBE) 5.9% 7.3% Actual percent: Veterans Business Enterprise (VBE) 1.0% 1.0% Actual percent: Disability-Owned Business Enterprise (DOBE) 0.4% 0.5% Actual percent: LGBT Business Enterprise (LGBTBE) 0.2% 0.3% Actual percent: Diverse Business Enterprise (DBE) 13.6% 15.3% Internal SS&P area goal Diverse Business Enterprise (DBE) 12.0% 12.7% Internal SS&P area goal Minority Business Enterprise (MBE) 8.2% 6.3% Internal SS&P area goal Women Business Enterprise (WBE) 3.9% 4.8% Internal SS&P area goal Veterans Business Enterprise (VBE) 0.7% 0.7% Internal SS&P area goal Disability-Owned Business Enterprise (DOBE) 0.2% 0.1% Product Compounds in development across platforms 50+ 50+ Disease areas being studied 40+ 60+ Marketed product families 46 43 External contract manufacturing sites 100+ 140+ Active development programs 54 100 No observable impact from COVID-19 including no drug shortages impacting patients 0 0 Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP) by type 0 0 Products listed in the FDA MedWatch Safety Alerts for Human Medical Products database 0 0 Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System 0 0 Number of recalls issued; total units recalled 0 0 Partnering to speed transformational medicines to patients: Development pipeline is externally sourced 60% 60% Active alliances, collaborations and partnerships 300+ 300+ 2021 ESG REPORT | 56 2021 ESG DataTopic 2019 2020 2021 Environment* T otal greenhouse gas emissions (CO 2e); thousands of metric tons Scope 1 (Direct) 218.2 202.4 204.3 Scope 2 (Indirect market-based) 118.6 122.6 166.3 Total (Scope 1+2) from operations 336.8 325.0 370.5 Scope 3 (Category 1 Purchased goods & services) 1,641.9 Scope 3 (Category 2 Capital goods) 18.1 Scope 3 (Category 3 Fuel- & energy-related activities) 82.6 Scope 3 (Category 4 Upstream transportation & distribution) 77.0 Scope 3 (Category 5 Waste generated in operations) 4.4 Scope 3 (Category 6 Business travel) 103.3 17.7 10.9 Scope 3 (Category 7 Employee commuting) 54.7 Scope 3 total 1,889.6 Total (Scope 1+2+3) 2,260.1 T otal energy use Total energy use; millions of gigajoules Scope 1 (Direct) 4.1 3.8 3.9 Scope 2 (Indirect) 1.8 1.7 1.6 Total (Scope 1+2) 5.9 5.5 5.5 Waste generated; millions of kilograms Hazardous 0.7 0.2 1.9 Nonhazardous 4.4 1.3 4.3 Recycled/reused 8.1 3.4 5.6 Total 13.2 4.8 11.7 Water use Water use; billion liters 3.1 3.1 3.2 2021 ESG REPORT | 57 2021 ESG Data*Explanation of Scope 3 emissions calculations Sources of Scope 3 emissionsEvaluation statusEmissions in reporting year (metric tons CO 2e)Emissions calculation methodologyPercentage of emissions calculated using data obtained from suppliers or value chain partnersExplanation Purchased goods and servicesRelevant, calculated1,641,931 Hybrid approach 22% Bristol Myers Squibb uses a hybrid approach to calculate Purchased Goods and Services emissions by collecting supplier-specific data via the CDP Supply Chain program as well as spend data for suppliers outside of that program.","('GHG_Emissions', 0.956902027130127)","('Management_Of_Legal_And_Regulatory_Framework', 0.00471954420208931)","('Ecological_Impacts', 0.0041476949118077755)","(['Operational Eco-Efficiency'], 0.956902027130127)","('NON-ESG', 0.00471954420208931)","('NON-ESG', 0.0041476949118077755)"
Line 725,"S. 3.7% 7.2% 2021 ESG REPORT | 542021 employee safety performance Business EHS inspectionsCAPA completed &closedFull investigations closedNear miss/unsafe condition reports/ 100 employees Commercial 5 7 15 Enabling functions 17 17 GPS 7,071 2,094 975 59 R&ED 2,793 52 88 35 Service provider 301 128 Total 9,864 2,469 1,215 109 SIF incident SIF near miss Motor vehicle accident 7 Pressure 7 Hazardous materials 14 Working from heights 19 Machine guarding Overhead hazards 2 Control of hazardous energy 1 5 Electrical 3 Process safety Other 16 Total 1 73 2021 ESG REPORT | 55 2021 ESG DataTopic 2020 2021 Suppliers Diverse spend: Diverse Business Enterprise (DBE) $695,336,854 $899,277,462 Diverse spend: Minority Business Enterprise (MBE) $450,241,075 $550,931,958 Diverse spend: Women Business Enterprise (WBE) $299,861,314 $429,985,082 Diverse spend: Veterans Business Enterprise (VBE) $53,226,133 $56,494,195 Diverse spend: Disability-Owned Business Enterprise (DOBE) $17,942,401 $8,248,492 Diverse spend: LGBT Business Enterprise (LGBTBE) $10,917,260 $15,309,109 Actual percent: Diverse Business Enterprise (DBE) 13.6% 15.3% Actual percent: Minority Business Enterprise (MBE) 8.8% 9.4% Actual percent: Women Business Enterprise (WBE) 5.9% 7.3% Actual percent: Veterans Business Enterprise (VBE) 1.0% 1.0% Actual percent: Disability-Owned Business Enterprise (DOBE) 0.4% 0.5% Actual percent: LGBT Business Enterprise (LGBTBE) 0.2% 0.3% Actual percent: Diverse Business Enterprise (DBE) 13.6% 15.3% Internal SS&P area goal Diverse Business Enterprise (DBE) 12.0% 12.7% Internal SS&P area goal Minority Business Enterprise (MBE) 8.2% 6.3% Internal SS&P area goal Women Business Enterprise (WBE) 3.9% 4.8% Internal SS&P area goal Veterans Business Enterprise (VBE) 0.7% 0.7% Internal SS&P area goal Disability-Owned Business Enterprise (DOBE) 0.2% 0.1% Product Compounds in development across platforms 50+ 50+ Disease areas being studied 40+ 60+ Marketed product families 46 43 External contract manufacturing sites 100+ 140+ Active development programs 54 100 No observable impact from COVID-19 including no drug shortages impacting patients 0 0 Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP) by type 0 0 Products listed in the FDA MedWatch Safety Alerts for Human Medical Products database 0 0 Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System 0 0 Number of recalls issued; total units recalled 0 0 Partnering to speed transformational medicines to patients: Development pipeline is externally sourced 60% 60% Active alliances, collaborations and partnerships 300+ 300+ 2021 ESG REPORT | 56 2021 ESG DataTopic 2019 2020 2021 Environment* T otal greenhouse gas emissions (CO 2e); thousands of metric tons Scope 1 (Direct) 218.2 202.4 204.3 Scope 2 (Indirect market-based) 118.6 122.6 166.3 Total (Scope 1+2) from operations 336.8 325.0 370.5 Scope 3 (Category 1 Purchased goods & services) 1,641.9 Scope 3 (Category 2 Capital goods) 18.1 Scope 3 (Category 3 Fuel- & energy-related activities) 82.6 Scope 3 (Category 4 Upstream transportation & distribution) 77.0 Scope 3 (Category 5 Waste generated in operations) 4.4 Scope 3 (Category 6 Business travel) 103.3 17.7 10.9 Scope 3 (Category 7 Employee commuting) 54.7 Scope 3 total 1,889.6 Total (Scope 1+2+3) 2,260.1 T otal energy use Total energy use; millions of gigajoules Scope 1 (Direct) 4.1 3.8 3.9 Scope 2 (Indirect) 1.8 1.7 1.6 Total (Scope 1+2) 5.9 5.5 5.5 Waste generated; millions of kilograms Hazardous 0.7 0.2 1.9 Nonhazardous 4.4 1.3 4.3 Recycled/reused 8.1 3.4 5.6 Total 13.2 4.8 11.7 Water use Water use; billion liters 3.1 3.1 3.2 2021 ESG REPORT | 57 2021 ESG Data*Explanation of Scope 3 emissions calculations Sources of Scope 3 emissionsEvaluation statusEmissions in reporting year (metric tons CO 2e)Emissions calculation methodologyPercentage of emissions calculated using data obtained from suppliers or value chain partnersExplanation Purchased goods and servicesRelevant, calculated1,641,931 Hybrid approach 22% Bristol Myers Squibb uses a hybrid approach to calculate Purchased Goods and Services emissions by collecting supplier-specific data via the CDP Supply Chain program as well as spend data for suppliers outside of that program.","('Waste_And_Hazardous_Materials_Management', 0.9348439574241638)","('Energy_Management', 0.014294138178229332)","('Water_And_Wastewater_Management', 0.0062722149305045605)","([], 0.9348439574241638)","('NON-ESG', 0.014294138178229332)","('NON-ESG', 0.0062722149305045605)"
Line 726,"S. 3.7% 7.2% 2021 ESG REPORT | 542021 employee safety performance Business EHS inspectionsCAPA completed &closedFull investigations closedNear miss/unsafe condition reports/ 100 employees Commercial 5 7 15 Enabling functions 17 17 GPS 7,071 2,094 975 59 R&ED 2,793 52 88 35 Service provider 301 128 Total 9,864 2,469 1,215 109 SIF incident SIF near miss Motor vehicle accident 7 Pressure 7 Hazardous materials 14 Working from heights 19 Machine guarding Overhead hazards 2 Control of hazardous energy 1 5 Electrical 3 Process safety Other 16 Total 1 73 2021 ESG REPORT | 55 2021 ESG DataTopic 2020 2021 Suppliers Diverse spend: Diverse Business Enterprise (DBE) $695,336,854 $899,277,462 Diverse spend: Minority Business Enterprise (MBE) $450,241,075 $550,931,958 Diverse spend: Women Business Enterprise (WBE) $299,861,314 $429,985,082 Diverse spend: Veterans Business Enterprise (VBE) $53,226,133 $56,494,195 Diverse spend: Disability-Owned Business Enterprise (DOBE) $17,942,401 $8,248,492 Diverse spend: LGBT Business Enterprise (LGBTBE) $10,917,260 $15,309,109 Actual percent: Diverse Business Enterprise (DBE) 13.6% 15.3% Actual percent: Minority Business Enterprise (MBE) 8.8% 9.4% Actual percent: Women Business Enterprise (WBE) 5.9% 7.3% Actual percent: Veterans Business Enterprise (VBE) 1.0% 1.0% Actual percent: Disability-Owned Business Enterprise (DOBE) 0.4% 0.5% Actual percent: LGBT Business Enterprise (LGBTBE) 0.2% 0.3% Actual percent: Diverse Business Enterprise (DBE) 13.6% 15.3% Internal SS&P area goal Diverse Business Enterprise (DBE) 12.0% 12.7% Internal SS&P area goal Minority Business Enterprise (MBE) 8.2% 6.3% Internal SS&P area goal Women Business Enterprise (WBE) 3.9% 4.8% Internal SS&P area goal Veterans Business Enterprise (VBE) 0.7% 0.7% Internal SS&P area goal Disability-Owned Business Enterprise (DOBE) 0.2% 0.1% Product Compounds in development across platforms 50+ 50+ Disease areas being studied 40+ 60+ Marketed product families 46 43 External contract manufacturing sites 100+ 140+ Active development programs 54 100 No observable impact from COVID-19 including no drug shortages impacting patients 0 0 Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP) by type 0 0 Products listed in the FDA MedWatch Safety Alerts for Human Medical Products database 0 0 Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System 0 0 Number of recalls issued; total units recalled 0 0 Partnering to speed transformational medicines to patients: Development pipeline is externally sourced 60% 60% Active alliances, collaborations and partnerships 300+ 300+ 2021 ESG REPORT | 56 2021 ESG DataTopic 2019 2020 2021 Environment* T otal greenhouse gas emissions (CO 2e); thousands of metric tons Scope 1 (Direct) 218.2 202.4 204.3 Scope 2 (Indirect market-based) 118.6 122.6 166.3 Total (Scope 1+2) from operations 336.8 325.0 370.5 Scope 3 (Category 1 Purchased goods & services) 1,641.9 Scope 3 (Category 2 Capital goods) 18.1 Scope 3 (Category 3 Fuel- & energy-related activities) 82.6 Scope 3 (Category 4 Upstream transportation & distribution) 77.0 Scope 3 (Category 5 Waste generated in operations) 4.4 Scope 3 (Category 6 Business travel) 103.3 17.7 10.9 Scope 3 (Category 7 Employee commuting) 54.7 Scope 3 total 1,889.6 Total (Scope 1+2+3) 2,260.1 T otal energy use Total energy use; millions of gigajoules Scope 1 (Direct) 4.1 3.8 3.9 Scope 2 (Indirect) 1.8 1.7 1.6 Total (Scope 1+2) 5.9 5.5 5.5 Waste generated; millions of kilograms Hazardous 0.7 0.2 1.9 Nonhazardous 4.4 1.3 4.3 Recycled/reused 8.1 3.4 5.6 Total 13.2 4.8 11.7 Water use Water use; billion liters 3.1 3.1 3.2 2021 ESG REPORT | 57 2021 ESG Data*Explanation of Scope 3 emissions calculations Sources of Scope 3 emissionsEvaluation statusEmissions in reporting year (metric tons CO 2e)Emissions calculation methodologyPercentage of emissions calculated using data obtained from suppliers or value chain partnersExplanation Purchased goods and servicesRelevant, calculated1,641,931 Hybrid approach 22% Bristol Myers Squibb uses a hybrid approach to calculate Purchased Goods and Services emissions by collecting supplier-specific data via the CDP Supply Chain program as well as spend data for suppliers outside of that program.","('GHG_Emissions', 0.7098695635795593)","('Air_Quality', 0.055802494287490845)","('Energy_Management', 0.049794141203165054)","(['Operational Eco-Efficiency'], 0.7098695635795593)","('NON-ESG', 0.055802494287490845)","('NON-ESG', 0.049794141203165054)"
Line 727,"S. 3.7% 7.2% 2021 ESG REPORT | 542021 employee safety performance Business EHS inspectionsCAPA completed &closedFull investigations closedNear miss/unsafe condition reports/ 100 employees Commercial 5 7 15 Enabling functions 17 17 GPS 7,071 2,094 975 59 R&ED 2,793 52 88 35 Service provider 301 128 Total 9,864 2,469 1,215 109 SIF incident SIF near miss Motor vehicle accident 7 Pressure 7 Hazardous materials 14 Working from heights 19 Machine guarding Overhead hazards 2 Control of hazardous energy 1 5 Electrical 3 Process safety Other 16 Total 1 73 2021 ESG REPORT | 55 2021 ESG DataTopic 2020 2021 Suppliers Diverse spend: Diverse Business Enterprise (DBE) $695,336,854 $899,277,462 Diverse spend: Minority Business Enterprise (MBE) $450,241,075 $550,931,958 Diverse spend: Women Business Enterprise (WBE) $299,861,314 $429,985,082 Diverse spend: Veterans Business Enterprise (VBE) $53,226,133 $56,494,195 Diverse spend: Disability-Owned Business Enterprise (DOBE) $17,942,401 $8,248,492 Diverse spend: LGBT Business Enterprise (LGBTBE) $10,917,260 $15,309,109 Actual percent: Diverse Business Enterprise (DBE) 13.6% 15.3% Actual percent: Minority Business Enterprise (MBE) 8.8% 9.4% Actual percent: Women Business Enterprise (WBE) 5.9% 7.3% Actual percent: Veterans Business Enterprise (VBE) 1.0% 1.0% Actual percent: Disability-Owned Business Enterprise (DOBE) 0.4% 0.5% Actual percent: LGBT Business Enterprise (LGBTBE) 0.2% 0.3% Actual percent: Diverse Business Enterprise (DBE) 13.6% 15.3% Internal SS&P area goal Diverse Business Enterprise (DBE) 12.0% 12.7% Internal SS&P area goal Minority Business Enterprise (MBE) 8.2% 6.3% Internal SS&P area goal Women Business Enterprise (WBE) 3.9% 4.8% Internal SS&P area goal Veterans Business Enterprise (VBE) 0.7% 0.7% Internal SS&P area goal Disability-Owned Business Enterprise (DOBE) 0.2% 0.1% Product Compounds in development across platforms 50+ 50+ Disease areas being studied 40+ 60+ Marketed product families 46 43 External contract manufacturing sites 100+ 140+ Active development programs 54 100 No observable impact from COVID-19 including no drug shortages impacting patients 0 0 Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP) by type 0 0 Products listed in the FDA MedWatch Safety Alerts for Human Medical Products database 0 0 Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System 0 0 Number of recalls issued; total units recalled 0 0 Partnering to speed transformational medicines to patients: Development pipeline is externally sourced 60% 60% Active alliances, collaborations and partnerships 300+ 300+ 2021 ESG REPORT | 56 2021 ESG DataTopic 2019 2020 2021 Environment* T otal greenhouse gas emissions (CO 2e); thousands of metric tons Scope 1 (Direct) 218.2 202.4 204.3 Scope 2 (Indirect market-based) 118.6 122.6 166.3 Total (Scope 1+2) from operations 336.8 325.0 370.5 Scope 3 (Category 1 Purchased goods & services) 1,641.9 Scope 3 (Category 2 Capital goods) 18.1 Scope 3 (Category 3 Fuel- & energy-related activities) 82.6 Scope 3 (Category 4 Upstream transportation & distribution) 77.0 Scope 3 (Category 5 Waste generated in operations) 4.4 Scope 3 (Category 6 Business travel) 103.3 17.7 10.9 Scope 3 (Category 7 Employee commuting) 54.7 Scope 3 total 1,889.6 Total (Scope 1+2+3) 2,260.1 T otal energy use Total energy use; millions of gigajoules Scope 1 (Direct) 4.1 3.8 3.9 Scope 2 (Indirect) 1.8 1.7 1.6 Total (Scope 1+2) 5.9 5.5 5.5 Waste generated; millions of kilograms Hazardous 0.7 0.2 1.9 Nonhazardous 4.4 1.3 4.3 Recycled/reused 8.1 3.4 5.6 Total 13.2 4.8 11.7 Water use Water use; billion liters 3.1 3.1 3.2 2021 ESG REPORT | 57 2021 ESG Data*Explanation of Scope 3 emissions calculations Sources of Scope 3 emissionsEvaluation statusEmissions in reporting year (metric tons CO 2e)Emissions calculation methodologyPercentage of emissions calculated using data obtained from suppliers or value chain partnersExplanation Purchased goods and servicesRelevant, calculated1,641,931 Hybrid approach 22% Bristol Myers Squibb uses a hybrid approach to calculate Purchased Goods and Services emissions by collecting supplier-specific data via the CDP Supply Chain program as well as spend data for suppliers outside of that program.","('Supply_Chain_Management', 0.9369077086448669)","('Product_Design_And_Lifecycle_Management', 0.008326336741447449)","('Labor_Practices', 0.006053917575627565)","([], 0.9369077086448669)","('NON-ESG', 0.008326336741447449)","('NON-ESG', 0.006053917575627565)"
Line 728,Supplier-specific data for 95 of our key suppliers was collected through the CDP Supply Chain Module.,"('Supply_Chain_Management', 0.9390363693237305)","('Labor_Practices', 0.006691472604870796)","('Product_Design_And_Lifecycle_Management', 0.003983816131949425)","([], 0.9390363693237305)","('NON-ESG', 0.006691472604870796)","('NON-ESG', 0.003983816131949425)"
Line 729,The methodology used by individual suppliers was not requested.,"('Supply_Chain_Management', 0.8630326390266418)","('Labor_Practices', 0.013988756574690342)","('Product_Design_And_Lifecycle_Management', 0.011302880942821503)","([], 0.8630326390266418)","('NON-ESG', 0.013988756574690342)","('NON-ESG', 0.011302880942821503)"
Line 730,"Data were allocated to Bristol Myers Squibb using various methods including production volume, financials and business travel.","('Systemic_Risk_Management', 0.19759486615657806)","('Supply_Chain_Management', 0.15421704947948456)","('Energy_Management', 0.1477372646331787)","('NON-ESG', 0.19759486615657806)","('NON-ESG', 0.15421704947948456)","('NON-ESG', 0.1477372646331787)"
Line 731,"For the remaining suppliers, 100% of total spend data was collected.","('Supply_Chain_Management', 0.8566589951515198)","('Energy_Management', 0.014476497657597065)","('Labor_Practices', 0.012704460881650448)","([], 0.8566589951515198)","('NON-ESG', 0.014476497657597065)","('NON-ESG', 0.012704460881650448)"
Line 732,"For spend data, EEIO factors were used to calculate emissions.","('Air_Quality', 0.49077802896499634)","('GHG_Emissions', 0.3480655252933502)","('Energy_Management', 0.04453248903155327)","('NON-ESG', 0.49077802896499634)","('NON-ESG', 0.3480655252933502)","('NON-ESG', 0.04453248903155327)"
Line 733,100% of BMS PG&S emissions have been calculated using the hybrid approach.,"('GHG_Emissions', 0.7387582063674927)","('Air_Quality', 0.1531197726726532)","('Energy_Management', 0.027667801827192307)","(['Operational Eco-Efficiency'], 0.7387582063674927)","('NON-ESG', 0.1531197726726532)","('NON-ESG', 0.027667801827192307)"
Line 734,"Capital goods Relevant, calculated18,050 Spend-based method5% 100% of capital spend was collected.","('Management_Of_Legal_And_Regulatory_Framework', 0.7423607110977173)","('Systemic_Risk_Management', 0.04186619073152542)","('Competitive_Behavior', 0.03422977775335312)","([], 0.7423607110977173)","('NON-ESG', 0.04186619073152542)","('NON-ESG', 0.03422977775335312)"
Line 735,EEIO factors were utilized to calculate emissions for this category.,"('GHG_Emissions', 0.44713059067726135)","('Air_Quality', 0.41524845361709595)","('Energy_Management', 0.034563273191452026)","('NON-ESG', 0.44713059067726135)","('NON-ESG', 0.41524845361709595)","('NON-ESG', 0.034563273191452026)"
Line 736,"Fuel- and energy-related activitiesRelevant, calculated82,560 Average data method0% Data was obtained directly from fuel and electric power consumption data tracked from invoices or other actual activity data used in the Scope 1 and 2 emissions calculations.","('Energy_Management', 0.9355962872505188)","('Air_Quality', 0.021823346614837646)","('GHG_Emissions', 0.00842991191893816)","(['Operational Eco-Efficiency'], 0.9355962872505188)","('NON-ESG', 0.021823346614837646)","('NON-ESG', 0.00842991191893816)"
Line 737,DEFRA well- to-tank emission factors were applied to calculate upstream emissions associated with the fuels used in BMS operations.,"('Air_Quality', 0.9670668840408325)","('GHG_Emissions', 0.00560753745958209)","('Energy_Management', 0.004482159856706858)","([], 0.9670668840408325)","('NON-ESG', 0.00560753745958209)","('NON-ESG', 0.004482159856706858)"
Line 738,"Additionally, eGRID and IEA grid loss factors are applied to BMS Scope 2 electric power emissions to calculate the upstream transmission and distribution losses.","('Air_Quality', 0.48435500264167786)","('GHG_Emissions', 0.3638751208782196)","('Energy_Management', 0.055742617696523666)","('NON-ESG', 0.48435500264167786)","('NON-ESG', 0.3638751208782196)","('NON-ESG', 0.055742617696523666)"
Line 739,"2021 ESG REPORT | 58 2021 ESG Data*Explanation of Scope 3 emissions calculations Sources of Scope 3 emissionsEvaluation statusEmissions in reporting year (metric tons CO 2e)Emissions calculation methodologyPercentage of emissions calculated using data obtained from suppliers or value chain partnersExplanation Upstream transportation and distributionRelevant, calculated76,969 Hybrid approach 5% Data was obtained directly from our upstream logistics carriers.","('GHG_Emissions', 0.8426884412765503)","('Air_Quality', 0.0844964012503624)","('Energy_Management', 0.008753773756325245)","(['Operational Eco-Efficiency'], 0.8426884412765503)","('NON-ESG', 0.0844964012503624)","('NON-ESG', 0.008753773756325245)"
Line 740,"Emissions were calculated using the distance- based method with raw data provided by transporters (Distance, Mass, Mode) and emission factors.","('Air_Quality', 0.9527503848075867)","('GHG_Emissions', 0.014743607491254807)","('Energy_Management', 0.004636435769498348)","([], 0.9527503848075867)","('NON-ESG', 0.014743607491254807)","('NON-ESG', 0.004636435769498348)"
Line 741,"Additional data included supplier-specific data provided through CDP Supply Chain Module, and spend data.","('Supply_Chain_Management', 0.9436653256416321)","('Labor_Practices', 0.0059745716862380505)","('Physical_Impacts_Of_Climate_Change', 0.003923338372260332)","([], 0.9436653256416321)","('NON-ESG', 0.0059745716862380505)","('NON-ESG', 0.003923338372260332)"
Line 742,Emissions from spend data were calculated using EEIO factors.,"('GHG_Emissions', 0.435184508562088)","('Air_Quality', 0.4167029559612274)","('Management_Of_Legal_And_Regulatory_Framework', 0.030400140210986137)","('NON-ESG', 0.435184508562088)","('NON-ESG', 0.4167029559612274)","('NON-ESG', 0.030400140210986137)"
Line 743,"Waste generated in operationsRelevant, calculated 4,442 Waste-type- specific method0% Data was obtained from invoices or other actual activity data.","('Waste_And_Hazardous_Materials_Management', 0.9836100339889526)","('Water_And_Wastewater_Management', 0.0017506771255284548)","('Air_Quality', 0.0013763440074399114)","([], 0.9836100339889526)","('NON-ESG', 0.0017506771255284548)","('NON-ESG', 0.0013763440074399114)"
Line 744,Table 9 of the EPA GHG Emission Factors Hub for Scope 3: Waste Generated in Operations was used to determine appropriate emission factors for calculations.,"('GHG_Emissions', 0.8303136229515076)","('Air_Quality', 0.11180027574300766)","('Management_Of_Legal_And_Regulatory_Framework', 0.006728914566338062)","(['Operational Eco-Efficiency'], 0.8303136229515076)","('NON-ESG', 0.11180027574300766)","('NON-ESG', 0.006728914566338062)"
Line 745,"Business travel Relevant, calculated 10,862 Distance-based method5% Uses methodology as recommended by the Department for Environment, Food & Rural Affairs (DEFRA).","('Management_Of_Legal_And_Regulatory_Framework', 0.49276426434516907)","('Ecological_Impacts', 0.17734532058238983)","('Human_Rights_And_Community_Relations', 0.030383942648768425)","('NON-ESG', 0.49276426434516907)","('NON-ESG', 0.17734532058238983)","('NON-ESG', 0.030383942648768425)"
Line 746,"Applied DEFRA factors to short-, medium- and long-haul flights.","('Systemic_Risk_Management', 0.28585392236709595)","('Management_Of_Legal_And_Regulatory_Framework', 0.24499964714050293)","('Competitive_Behavior', 0.1670607030391693)","('NON-ESG', 0.28585392236709595)","('NON-ESG', 0.24499964714050293)","('NON-ESG', 0.1670607030391693)"
Line 747,We have a full accounting of CO 2 emissions from business air travel.,"('Air_Quality', 0.968268096446991)","('GHG_Emissions', 0.006534948945045471)","('Energy_Management', 0.002701226621866226)","([], 0.968268096446991)","('NON-ESG', 0.006534948945045471)","('NON-ESG', 0.002701226621866226)"
Line 748,"Employee commuting Relevant, calculated 54,740 Average data method0% Data was estimated using the GHG Protocol Quantis Scope 3 Evaluator for which the number of BMS employees was leveraged as an input.","('GHG_Emissions', 0.9562060236930847)","('Water_And_Wastewater_Management', 0.0057725198566913605)","('Air_Quality', 0.005074972752481699)","(['Operational Eco-Efficiency'], 0.9562060236930847)","('NON-ESG', 0.0057725198566913605)","('NON-ESG', 0.005074972752481699)"
Line 749,Multiplied total number of employees as stated in our 10-K by Quantis tools 1700 kg CO 2e number.,"('Labor_Practices', 0.6485158205032349)","('Director_Removal', 0.08216871321201324)","('Employee_Engagement_Inclusion_And_Diversity', 0.05467749759554863)","([], 0.6485158205032349)","('NON-ESG', 0.08216871321201324)","('NON-ESG', 0.05467749759554863)"
Line 750,"Upstream leased assets Not relevant, explanation provided Data for these leased assets is included in our Scope 1 and 2 emissions.","('GHG_Emissions', 0.6190259456634521)","('Management_Of_Legal_And_Regulatory_Framework', 0.1523635983467102)","('Energy_Management', 0.07463594526052475)","(['Operational Eco-Efficiency'], 0.6190259456634521)","('NON-ESG', 0.1523635983467102)","('NON-ESG', 0.07463594526052475)"
Line 751,"Downstream transportation and distributionNot relevant, explanation provided All Transportation & Distribution data had an associated spend, and therefore emissions from T&D have been allocated to Category 4 based on GHG Scope 3 Standard that says: ""Outbound transportation and distribution services that are purchased by the reporting company are excluded from Category 9 and included in Category 4 (Upstream transportation and distribution) because the reporting company purchases the service.","('GHG_Emissions', 0.9654049277305603)","('Water_And_Wastewater_Management', 0.003775025950744748)","('Air_Quality', 0.003421816974878311)","(['Operational Eco-Efficiency'], 0.9654049277305603)","('NON-ESG', 0.003775025950744748)","('NON-ESG', 0.003421816974878311)"
Line 752,"Category 9 includes only emissions from transportation and distribution of products after the point of sale.""","('Product_Design_And_Lifecycle_Management', 0.9460444450378418)","('Energy_Management', 0.00835643894970417)","('Product_Quality_And_Safety', 0.0076138111762702465)","([], 0.9460444450378418)","('NON-ESG', 0.00835643894970417)","('NON-ESG', 0.0076138111762702465)"
Line 753,"2021 ESG REPORT | 59 2021 ESG Data*Explanation of Scope 3 emissions calculations Sources of Scope 3 emissionsEvaluation statusEmissions in reporting year (metric tons CO 2e)Emissions calculation methodologyPercentage of emissions calculated using data obtained from suppliers or value chain partnersExplanation Processing of soldproductsNot relevant, explanation provided We do not believe the processing of sold products meets the relevancy criteria for size of contribution.","('GHG_Emissions', 0.5058891773223877)","('Air_Quality', 0.23877963423728943)","('Energy_Management', 0.07453830540180206)","(['Operational Eco-Efficiency'], 0.5058891773223877)","('NON-ESG', 0.23877963423728943)","('NON-ESG', 0.07453830540180206)"
Line 754,"Use of sold products Not relevant, explanation provided Pharmaceutical products sold by our company are consumed and do not meet the relevance criteria for size of contribution.","('Product_Design_And_Lifecycle_Management', 0.3973858952522278)","('Selling_Practices_And_Product_Labeling', 0.33321240544319153)","('Customer_Welfare', 0.12270015478134155)","('NON-ESG', 0.3973858952522278)","('NON-ESG', 0.33321240544319153)","('NON-ESG', 0.12270015478134155)"
Line 755,"End-of-life treatment of sold productsNot relevant, explanation provided We do not expect the size of the contribution of end-of-life treatment for sold products and associated packaging to be relevant.","('Product_Design_And_Lifecycle_Management', 0.9610019326210022)","('Selling_Practices_And_Product_Labeling', 0.0056015201844275)","('Product_Quality_And_Safety', 0.004374357871711254)","([], 0.9610019326210022)","('NON-ESG', 0.0056015201844275)","('NON-ESG', 0.004374357871711254)"
Line 756,"Downstream leased assetsNot relevant, explanation provided We lease small office spaces at several locations worldwide and do not believe the size of the contribution is significant under the relevancy criteria.","('Energy_Management', 0.3103727400302887)","('Competitive_Behavior', 0.11856534332036972)","('Business_Model_Resilience', 0.06713255494832993)","('NON-ESG', 0.3103727400302887)","('NON-ESG', 0.11856534332036972)","('NON-ESG', 0.06713255494832993)"
Line 757,"Franchises Not relevant, explanation provided We do not have a franchise business model; therefore, we do not meet the relevancy criteria of size, influence or risk.","('Business_Model_Resilience', 0.4532909095287323)","('Systemic_Risk_Management', 0.2341579645872116)","('Competitive_Behavior', 0.08749380707740784)","('NON-ESG', 0.4532909095287323)","('NON-ESG', 0.2341579645872116)","('NON-ESG', 0.08749380707740784)"
Line 758,"Investments Not relevant, explanation provided We are not a financial institution whose primary purpose is investing for profit; therefore, we do not meet the relevancy criteria of size, influence or risk.","('Systemic_Risk_Management', 0.5203495025634766)","('Business_Model_Resilience', 0.20585143566131592)","('Competitive_Behavior', 0.0874713808298111)","([], 0.5203495025634766)","('NON-ESG', 0.20585143566131592)","('NON-ESG', 0.0874713808298111)"
Line 759,2021 ESG REPORT | 60 2021 ESG DataSustainability Accounting Standards Board (SASB) 2021 Index Topic Code/Metric Response/Reference Activity MetricsNumber of patients treated: HC-BP-000.A Not reported Number of drugs (1) in portfolio and (2) in research and development (Phases I-III).,"('Access_And_Affordability', 0.3143424689769745)","('Customer_Welfare', 0.10591323673725128)","('Product_Quality_And_Safety', 0.09044479578733444)","('NON-ESG', 0.3143424689769745)","('NON-ESG', 0.10591323673725128)","('NON-ESG', 0.09044479578733444)"
Line 760,"HC-BP-000.B2021 ESG Report: Innovation, Equity and Access to Healthcare >> Innovation Safety of Clinical Trial ParticipantsDiscussion, by world region, of management process for ensuring quality and patient safety during clinical trials.","('Product_Quality_And_Safety', 0.8066751956939697)","('Employee_Health_And_Safety', 0.027920758351683617)","('Customer_Welfare', 0.021525505930185318)","(['Product Quality & Recall Management'], 0.8066751956939697)","('NON-ESG', 0.027920758351683617)","('NON-ESG', 0.021525505930185318)"
Line 761,"HC-BP-210a.12021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical and Safe Products 2021 ESG Report: Innovation, Equity and Access to Healthcare >> Clinical Trials Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI).","('Business_Ethics', 0.9342747330665588)","('Management_Of_Legal_And_Regulatory_Framework', 0.01076025702059269)","('Product_Quality_And_Safety', 0.009083271957933903)","(['Business Ethics'], 0.9342747330665588)","('NON-ESG', 0.01076025702059269)","('NON-ESG', 0.009083271957933903)"
Line 762,HC-BP-210a.2None Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries: HC-BP-210a.32021 10-K Access to MedicinesDescription of actions and initiatives to promote access to healthcare products for priority diseases and in priority countries as defined by the Access to Medicine Index.,"('Access_And_Affordability', 0.6346039175987244)","('Customer_Welfare', 0.054423738270998)","('Product_Quality_And_Safety', 0.05431261286139488)","(['Access to Healthcare'], 0.6346039175987244)","('NON-ESG', 0.054423738270998)","('NON-ESG', 0.05431261286139488)"
Line 763,"HC-BP-240a.12021 ESG Report: Innovation, Equity and Access to Healthcare List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP).","('Product_Design_And_Lifecycle_Management', 0.4847433567047119)","('Customer_Welfare', 0.16593730449676514)","('Product_Quality_And_Safety', 0.08907690644264221)","('NON-ESG', 0.4847433567047119)","('NON-ESG', 0.16593730449676514)","('NON-ESG', 0.08907690644264221)"
Line 764,HC-BP-240a.2Reyataz (atazanavir) Affordability and PricingNumber of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period.,"('Competitive_Behavior', 0.5837897062301636)","('Customer_Welfare', 0.1209334135055542)","('Selling_Practices_And_Product_Labeling', 0.07661610096693039)","([], 0.5837897062301636)","('NON-ESG', 0.1209334135055542)","('NON-ESG', 0.07661610096693039)"
Line 765,HC-BP-240.b.12021 10-K Percentage change in (1) average list price and (2) average net price across US product portfolio compared to previous year.,"('Product_Design_And_Lifecycle_Management', 0.6566759347915649)","('Customer_Welfare', 0.06358964741230011)","('Selling_Practices_And_Product_Labeling', 0.050771865993738174)","([], 0.6566759347915649)","('NON-ESG', 0.06358964741230011)","('NON-ESG', 0.050771865993738174)"
Line 766,"HC-BP-240b.22021 ESG Report: Innovation, Equity and Access to Healthcare >> Access to Healthcare Percentage change in (1) list price and (2) net price of product with largest increase compared to previous year.","('Product_Design_And_Lifecycle_Management', 0.6267343759536743)","('Customer_Welfare', 0.1063837856054306)","('Selling_Practices_And_Product_Labeling', 0.03969837725162506)","([], 0.6267343759536743)","('NON-ESG', 0.1063837856054306)","('NON-ESG', 0.03969837725162506)"
Line 767,"HC-BP-240b.22021 ESG Report: Innovation, Equity and Access to Healthcare >> Access to Healthcare Drug SafetyList of products listed in the Food and Drug Administration's (FDA) MedWatch Safety Alerts for Human Medical Products Database.","('Product_Quality_And_Safety', 0.9117438793182373)","('Selling_Practices_And_Product_Labeling', 0.011980977840721607)","('Product_Design_And_Lifecycle_Management', 0.009206200018525124)","(['Product Quality & Recall Management'], 0.9117438793182373)","('NON-ESG', 0.011980977840721607)","('NON-ESG', 0.009206200018525124)"
Line 768,"HC-BP-250a.12021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical and Safe Products Please visit the FAERS MedWatch page for more information.","('Business_Ethics', 0.9587557911872864)","('Product_Quality_And_Safety', 0.004516975022852421)","('Management_Of_Legal_And_Regulatory_Framework', 0.003751141484826803)","(['Business Ethics'], 0.9587557911872864)","('NON-ESG', 0.004516975022852421)","('NON-ESG', 0.003751141484826803)"
Line 769,Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System.,"('Product_Quality_And_Safety', 0.4773215353488922)","('Employee_Health_And_Safety', 0.28988468647003174)","('Selling_Practices_And_Product_Labeling', 0.03578931838274002)","('NON-ESG', 0.4773215353488922)","('NON-ESG', 0.28988468647003174)","('NON-ESG', 0.03578931838274002)"
Line 770,"HC-BP-250a.22021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical and Safe Products Please visit the FAERS MedWatch page for more information.","('Business_Ethics', 0.9596350193023682)","('Product_Quality_And_Safety', 0.004230336286127567)","('Competitive_Behavior', 0.0036932781804353)","(['Business Ethics'], 0.9596350193023682)","('NON-ESG', 0.004230336286127567)","('NON-ESG', 0.0036932781804353)"
Line 771,2021 ESG REPORT | 61Topic Code/Metric Response/Reference Drug Safety (cont.,"('Product_Quality_And_Safety', 0.8686254620552063)","('Customer_Welfare', 0.014735035598278046)","('Selling_Practices_And_Product_Labeling', 0.01231932919472456)","(['Product Quality & Recall Management'], 0.8686254620552063)","('NON-ESG', 0.014735035598278046)","('NON-ESG', 0.01231932919472456)"
Line 772,")Number of recalls issued, total units recalled.","('Critical_Incident_Risk_Management', 0.1984829306602478)","('Product_Quality_And_Safety', 0.1366448998451233)","('Employee_Health_And_Safety', 0.08164858818054199)","('NON-ESG', 0.1984829306602478)","('NON-ESG', 0.1366448998451233)","('NON-ESG', 0.08164858818054199)"
Line 773,"HC-BP-250a.32017: 1 2018: 0 2019: 0 2020: 0 2021: 0 Total amount of product accepted for takeback, reuse or disposal.","('Product_Design_And_Lifecycle_Management', 0.8881959319114685)","('Selling_Practices_And_Product_Labeling', 0.0333644300699234)","('Product_Quality_And_Safety', 0.016046717762947083)","([], 0.8881959319114685)","('NON-ESG', 0.0333644300699234)","('NON-ESG', 0.016046717762947083)"
Line 774,"HC-BP-250a.42021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical and Safe Products Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type.","('Business_Ethics', 0.963636040687561)","('Product_Quality_And_Safety', 0.003439008491113782)","('Management_Of_Legal_And_Regulatory_Framework', 0.003237335942685604)","(['Business Ethics'], 0.963636040687561)","('NON-ESG', 0.003439008491113782)","('NON-ESG', 0.003237335942685604)"
Line 775,"HC-BP-250a.52021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical and Safe Products Counterfeit DrugsDescription of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting.","('Business_Ethics', 0.8229033350944519)","('Data_Security', 0.04597719758749008)","('Product_Quality_And_Safety', 0.025060098618268967)","(['Business Ethics'], 0.8229033350944519)","('NON-ESG', 0.04597719758749008)","('NON-ESG', 0.025060098618268967)"
Line 776,"HC-BP-260a.12021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical and Safe Products Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products.","('Business_Ethics', 0.9005900621414185)","('Product_Quality_And_Safety', 0.018503325060009956)","('Data_Security', 0.015116546303033829)","(['Business Ethics'], 0.9005900621414185)","('NON-ESG', 0.018503325060009956)","('NON-ESG', 0.015116546303033829)"
Line 777,"HC-BP-260a.22021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical and Safe Products Number of actions that led to raids, seizure, arrests and/or filing of criminal charges related to counterfeit products.","('Business_Ethics', 0.8678394556045532)","('Product_Quality_And_Safety', 0.02963099628686905)","('Data_Security', 0.01281809527426958)","(['Business Ethics'], 0.8678394556045532)","('NON-ESG', 0.02963099628686905)","('NON-ESG', 0.01281809527426958)"
Line 778,"HC-BP-260a.32021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical and Safe Products Ethical MarketingTotal amount of monetary losses as a result of legal proceedings associated with false marketing claims.","('Business_Ethics', 0.9433256387710571)","('Product_Quality_And_Safety', 0.007784577552229166)","('Competitive_Behavior', 0.006951631046831608)","(['Business Ethics'], 0.9433256387710571)","('NON-ESG', 0.007784577552229166)","('NON-ESG', 0.006951631046831608)"
Line 779,HC-BP-270a.12021 10-K Description of code of ethics governing promotion of off-label use of products.,"('Selling_Practices_And_Product_Labeling', 0.7271637320518494)","('Product_Quality_And_Safety', 0.07156439870595932)","('Product_Design_And_Lifecycle_Management', 0.059001374989748)","(['Business Ethics'], 0.7271637320518494)","('NON-ESG', 0.07156439870595932)","('NON-ESG', 0.059001374989748)"
Line 780,"HC-BP-270a.22021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical Business Employee Recruitment, Development and RetentionDiscussion of talent recruitment and retention efforts for scientists and R&D personnel.","('Employee_Engagement_Inclusion_And_Diversity', 0.5952482223510742)","('Business_Ethics', 0.19759997725486755)","('Employee_Health_And_Safety', 0.03396163880825043)","(['Talent Attraction & Retention'], 0.5952482223510742)","('NON-ESG', 0.19759997725486755)","('NON-ESG', 0.03396163880825043)"
Line 781,"HC-BP-330a.1Not reported (1) Voluntary and (2) involuntary turnover rate for (a) executives/senior managers, (b) mid-level managers, (c) professionals, and (d) all others.","('Labor_Practices', 0.405961811542511)","('Employee_Engagement_Inclusion_And_Diversity', 0.2190043032169342)","('Director_Removal', 0.1146722063422203)","('NON-ESG', 0.405961811542511)","('NON-ESG', 0.2190043032169342)","('NON-ESG', 0.1146722063422203)"
Line 782,HC-BP-330a.2Not reported Supply Chain ManagementPercentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients.,"('Supply_Chain_Management', 0.9481754899024963)","('Product_Design_And_Lifecycle_Management', 0.004855101928114891)","('Labor_Practices', 0.0038670559879392385)","([], 0.9481754899024963)","('NON-ESG', 0.004855101928114891)","('NON-ESG', 0.0038670559879392385)"
Line 783,HC-BP-430a.1BMS adheres to the audit principles of the International Pharmaceutical Supply Chain Initiative (PSCI) for 100% or all audited third-party suppliers in our network.,"('Supply_Chain_Management', 0.9473061561584473)","('Labor_Practices', 0.005108071956783533)","('Product_Design_And_Lifecycle_Management', 0.003980861511081457)","([], 0.9473061561584473)","('NON-ESG', 0.005108071956783533)","('NON-ESG', 0.003980861511081457)"
Line 784,Business EthicsTotal amount of monetary losses as a result of legal proceedings associated with corruption and bribery.,"('Business_Ethics', 0.974062979221344)","('Management_Of_Legal_And_Regulatory_Framework', 0.002063307911157608)","('Competitive_Behavior', 0.0019627714063972235)","(['Business Ethics'], 0.974062979221344)","('NON-ESG', 0.002063307911157608)","('NON-ESG', 0.0019627714063972235)"
Line 785,HC-BP-510a.22021 10-K Description of code of ethics governing interactions with healthcare professionals.,"('Business_Ethics', 0.9653006196022034)","('Management_Of_Legal_And_Regulatory_Framework', 0.003679146058857441)","('Customer_Privacy', 0.0029961077962070704)","(['Business Ethics'], 0.9653006196022034)","('NON-ESG', 0.003679146058857441)","('NON-ESG', 0.0029961077962070704)"
Line 786,"HC-BP-510a.12021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical Business 2021 ESG Report: Appendix >> NBIM Index 2021 ESG REPORT | 62 2021 SASB IndexGlobal Reporting Initiative (GRI) 2021 Index This index aligns with the Global Reporting Initiatives 2018 Sustainability Reporting Standards.","('Business_Ethics', 0.9667304158210754)","('Management_Of_Legal_And_Regulatory_Framework', 0.0035040194634348154)","('Competitive_Behavior', 0.002829927019774914)","(['Business Ethics'], 0.9667304158210754)","('NON-ESG', 0.0035040194634348154)","('NON-ESG', 0.002829927019774914)"
Line 787,This report has been prepared in accordance with the GRI Standards: Core option.,"('Management_Of_Legal_And_Regulatory_Framework', 0.5812124013900757)","('Product_Quality_And_Safety', 0.16000381112098694)","('Human_Rights_And_Community_Relations', 0.03048824332654476)","([], 0.5812124013900757)","('NON-ESG', 0.16000381112098694)","('NON-ESG', 0.03048824332654476)"
Line 788,"Our index facilitates access to Core reporting elements as well as additional Comprehensive level elements, where available.","('Management_Of_Legal_And_Regulatory_Framework', 0.31422099471092224)","('Systemic_Risk_Management', 0.2494402378797531)","('Access_And_Affordability', 0.08745142817497253)","('NON-ESG', 0.31422099471092224)","('NON-ESG', 0.2494402378797531)","('NON-ESG', 0.08745142817497253)"
Line 789,"UN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-1 Name of the organization Bristol Myers Squibb GRI 102-2 Primary brands, products and services Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.","('Customer_Welfare', 0.39650800824165344)","('Selling_Practices_And_Product_Labeling', 0.1305803507566452)","('Product_Design_And_Lifecycle_Management', 0.10849867016077042)","('NON-ESG', 0.39650800824165344)","('NON-ESG', 0.1305803507566452)","('NON-ESG', 0.10849867016077042)"
Line 790,Learn more on our company webpage and in our 2021 10-K .,"('Business_Model_Resilience', 0.15105441212654114)","('Access_And_Affordability', 0.13553018867969513)","('Employee_Engagement_Inclusion_And_Diversity', 0.1285264790058136)","('NON-ESG', 0.15105441212654114)","('NON-ESG', 0.13553018867969513)","('NON-ESG', 0.1285264790058136)"
Line 791,"GRI 102-3 Location of organizations headquarters New York, New York, USA GRI 102-4 Number and name of countries where the organization operatesOur products are sold worldwide, primarily to wholesalers, distributors, specialty pharmacies and, to a lesser extent, directly to retailers, hospitals, clinics and government agencies.","('Product_Design_And_Lifecycle_Management', 0.4492701590061188)","('Selling_Practices_And_Product_Labeling', 0.2229813039302826)","('Customer_Welfare', 0.17003540694713593)","('NON-ESG', 0.4492701590061188)","('NON-ESG', 0.2229813039302826)","('NON-ESG', 0.17003540694713593)"
Line 792,We manufacture products in the U.,"('Product_Design_And_Lifecycle_Management', 0.9330953359603882)","('Product_Quality_And_Safety', 0.009242802858352661)","('Selling_Practices_And_Product_Labeling', 0.007998003624379635)","([], 0.9330953359603882)","('NON-ESG', 0.009242802858352661)","('NON-ESG', 0.007998003624379635)"
Line 793,S. and Puerto Rico and have significant manufacturing operations in two foreign countries.,"('Product_Design_And_Lifecycle_Management', 0.5960392355918884)","('Supply_Chain_Management', 0.11432018876075745)","('Customer_Welfare', 0.0374135822057724)","([], 0.5960392355918884)","('NON-ESG', 0.11432018876075745)","('NON-ESG', 0.0374135822057724)"
Line 794,We have facilities in numerous countries .,"('Product_Design_And_Lifecycle_Management', 0.14890965819358826)","('Supply_Chain_Management', 0.11540082097053528)","('Employee_Engagement_Inclusion_And_Diversity', 0.08429981768131256)","('NON-ESG', 0.14890965819358826)","('NON-ESG', 0.11540082097053528)","('NON-ESG', 0.08429981768131256)"
Line 795,"GRI 102-5 Nature of ownership and legal form Bristol Myers Squibb Company was incorporated under the laws of the State of Delaware in August 1933 under the name Bristol Myers Company, as successor to a New York business started in 1887.","('Management_Of_Legal_And_Regulatory_Framework', 0.20788857340812683)","('Customer_Welfare', 0.10453279316425323)","('Competitive_Behavior', 0.09965604543685913)","('NON-ESG', 0.20788857340812683)","('NON-ESG', 0.10453279316425323)","('NON-ESG', 0.09965604543685913)"
Line 796,"In 1989, Bristol Myers Company changed its name to Bristol Myers Squibb Company as a result of a merger.","('Systemic_Risk_Management', 0.17176350951194763)","('Customer_Welfare', 0.1531432718038559)","('Competitive_Behavior', 0.1414492279291153)","('NON-ESG', 0.17176350951194763)","('NON-ESG', 0.1531432718038559)","('NON-ESG', 0.1414492279291153)"
Line 797,"We completed the Celgene transaction on November 20, 2019.","('Business_Model_Resilience', 0.309577077627182)","('Competitive_Behavior', 0.0958774983882904)","('Systemic_Risk_Management', 0.0878034308552742)","('NON-ESG', 0.309577077627182)","('NON-ESG', 0.0958774983882904)","('NON-ESG', 0.0878034308552742)"
Line 798,"On November 17, 2020, we completed our acquisition of MyoKardia for approximately $13.1 billion in cash.","('Business_Model_Resilience', 0.2583750784397125)","('Systemic_Risk_Management', 0.22965851426124573)","('Business_Ethics', 0.06515582650899887)","('NON-ESG', 0.2583750784397125)","('NON-ESG', 0.22965851426124573)","('NON-ESG', 0.06515582650899887)"
Line 799,We continue to operate in one segment Biopharmaceuticals.,"('Product_Design_And_Lifecycle_Management', 0.31715717911720276)","('Supply_Chain_Management', 0.19761423766613007)","('Customer_Welfare', 0.14479440450668335)","('NON-ESG', 0.31715717911720276)","('NON-ESG', 0.19761423766613007)","('NON-ESG', 0.14479440450668335)"
Line 800,Learn more in our 2021 10-K .,"('Access_And_Affordability', 0.7045430541038513)","('Employee_Engagement_Inclusion_And_Diversity', 0.08984088152647018)","('Human_Rights_And_Community_Relations', 0.02185164950788021)","(['Access to Healthcare'], 0.7045430541038513)","('NON-ESG', 0.08984088152647018)","('NON-ESG', 0.02185164950788021)"
Line 801,"GRI 102-6 Nature of markets served (including geographic breakdown, sectors served, and types of customers and beneficiaries)2021 10-K , pages 3-8, 13-15 GRI 102-7 Scale of the reporting organization (employees, operations, net sales, capitalization, quantity of products/services)Operations, net sales and products: 2021 10-K , pages 1, 19-31 As of December 31, 2020, we had approximately 30,250 employees in 47 countries.","('Product_Design_And_Lifecycle_Management', 0.6972671747207642)","('Business_Model_Resilience', 0.06668512523174286)","('Customer_Welfare', 0.05422665551304817)","([], 0.6972671747207642)","('NON-ESG', 0.06668512523174286)","('NON-ESG', 0.05422665551304817)"
Line 802,Approximately 57% of our employees are located in the U.,"('Employee_Engagement_Inclusion_And_Diversity', 0.49209022521972656)","('Labor_Practices', 0.1321416199207306)","('Director_Removal', 0.05321956425905228)","('NON-ESG', 0.49209022521972656)","('NON-ESG', 0.1321416199207306)","('NON-ESG', 0.05321956425905228)"
Line 803,S. (excluding Puerto Rico) and 43% are located outside of the U.,"('Management_Of_Legal_And_Regulatory_Framework', 0.4132874608039856)","('Competitive_Behavior', 0.11440851539373398)","('Ecological_Impacts', 0.050330113619565964)","('NON-ESG', 0.4132874608039856)","('NON-ESG', 0.11440851539373398)","('NON-ESG', 0.050330113619565964)"
Line 804,"S. We supplement our employee population with independent contractors, contingent workers and temporary workforce support as needed.","('Labor_Practices', 0.9486787915229797)","('Employee_Health_And_Safety', 0.010021612048149109)","('Employee_Engagement_Inclusion_And_Diversity', 0.00796074140816927)","([], 0.9486787915229797)","('NON-ESG', 0.010021612048149109)","('NON-ESG', 0.00796074140816927)"
Line 805,The average tenure of our employees is approximately eight years.,"('Labor_Practices', 0.5989112854003906)","('Employee_Engagement_Inclusion_And_Diversity', 0.19479535520076752)","('Director_Removal', 0.06454552710056305)","([], 0.5989112854003906)","('NON-ESG', 0.19479535520076752)","('NON-ESG', 0.06454552710056305)"
Line 806,"GRI 102-8 Total workforce by employment type, employment contract, and region, broken down by gender, report significant variations in employment numbersSee Global Inclusion & Diversity Report , pages 5, 23-25 GRI 102-9 Describe supply chain 2021 ESG Report: Our People >> Supply Chain CDP Our Suppliers 2021 ESG REPORT | 63UN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-10 Significant changes from previous report regarding size, structure, ownership, or its supply chainWe completed the Celgene transaction on November 20, 2019.","('Supply_Chain_Management', 0.5426476001739502)","('Employee_Engagement_Inclusion_And_Diversity', 0.1738375574350357)","('Labor_Practices', 0.0789312869310379)","([], 0.5426476001739502)","('NON-ESG', 0.1738375574350357)","('NON-ESG', 0.0789312869310379)"
Line 807,"GRI 102-8 Total workforce by employment type, employment contract, and region, broken down by gender, report significant variations in employment numbersSee Global Inclusion & Diversity Report , pages 5, 23-25 GRI 102-9 Describe supply chain 2021 ESG Report: Our People >> Supply Chain CDP Our Suppliers 2021 ESG REPORT | 63UN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-10 Significant changes from previous report regarding size, structure, ownership, or its supply chainWe completed the Celgene transaction on November 20, 2019.","('Business_Model_Resilience', 0.20661146938800812)","('Competitive_Behavior', 0.09704424440860748)","('Customer_Privacy', 0.0963084027171135)","('NON-ESG', 0.20661146938800812)","('NON-ESG', 0.09704424440860748)","('NON-ESG', 0.0963084027171135)"
Line 808,"On November 17, 2020, we completed our acquisition of MyoKardia for approximately $13.1 billion in cash.","('Business_Model_Resilience', 0.2583750784397125)","('Systemic_Risk_Management', 0.22965851426124573)","('Business_Ethics', 0.06515582650899887)","('NON-ESG', 0.2583750784397125)","('NON-ESG', 0.22965851426124573)","('NON-ESG', 0.06515582650899887)"
Line 809,We continue to operate in one segmentBiopharmaceuticals.,"('Customer_Welfare', 0.27537333965301514)","('Product_Design_And_Lifecycle_Management', 0.26622313261032104)","('Supply_Chain_Management', 0.06268512457609177)","('NON-ESG', 0.27537333965301514)","('NON-ESG', 0.26622313261032104)","('NON-ESG', 0.06268512457609177)"
Line 810,Learn more in our 2021 10-K .,"('Access_And_Affordability', 0.7045430541038513)","('Employee_Engagement_Inclusion_And_Diversity', 0.08984088152647018)","('Human_Rights_And_Community_Relations', 0.02185164950788021)","(['Access to Healthcare'], 0.7045430541038513)","('NON-ESG', 0.08984088152647018)","('NON-ESG', 0.02185164950788021)"
Line 811,"GRI 102-11 Explanation of whether and how the precautionary approach or principle is addressed by the organization2021 ESG Report: Introduction >> UN Sustainable Development Goals >> Standing Up for Human Rights; Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Ethical and Safe Products GRI 102-12 External charters, principles, initiatives Overarching Policies Voluntary standards GRI 102-13 Memberships in associations Stakeholder Engagement Business association memberships GRI 102-14 Statement from senior management 2021 ESG Report: CEO Letter GRI 102-15 (Comprehensive)Description of key impacts, risks, and opportunities 2021 10-K 2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management GRI 102-16 Internally developed statements of mission or values, codes of conduct, codes of ethics, and principles relevant to sustainable developmentBMS Codes of Conduct GRI 102-17 (Comprehensive)Internal and external mechanisms for reporting concerns about unethical or unlawful behavior, and matters related to organizational integrity, such as escalation through line management, whistleblowing mechanisms or hotlinesBMS Codes of Conduct 2021 ESG Report: Ethics, Integrity, Quality and Governance >> EthicalBusiness GRI 102-18 Governance structure of the organization, including committees under the highest governance body; identify any committees responsible for decision-making on economic, environmental and social impacts2021 ESG Report: Introduction >> Our Approach to ESG Governance Board of Directors Board Committee & Charters GRI 102-19 (Comprehensive)Process for delegating authority for economic, environmental and social topics from highest governance body to senior executives and other employees2021 ESG Report: Introduction >> Our Approach to ESG; Ethics, Integrity, Quality and Governance >> Governance and Risk Management BMS Codes of Conduct GRI 102-20 (Comprehensive)Identify executive-level position with responsibility for economic, environmental and social topics and reporting to highest governance body2021 ESG Report: Introduction >> Our Approach to ESG Leadership Team GRI 102-21 (Comprehensive)Mechanisms for consultation between stakeholders and highest governance body on economic, environmental and social topicsBMS Codes of Conduct GRI 102-22 (Comprehensive)Composition of the highest governance body and its committees2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines Board of Directors GRI 102-23 (Comprehensive)Indicate whether the Chair of the highest governance body is also an executive officer, and if so, reason for this arrangementGovernance Board of Directors GRI 102-24 (Comprehensive)Report the nomination and selection processes for the highest governance body and its committees, and the criteria used for nominating and selecting highest governance body membersCorporate Governance Guidelines Composition and structure of the Board Committee on Directors and Corporate Governance 2021 ESG REPORT | 64 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-25 (Comprehensive)Processes in place for the highest governance body to ensure conflicts of interest are avoided and managedCorporate Governance Guidelines Board ResponsibilitiesItem 4 Compliance, Ethics and Conflicts of Interest GRI 102-26 (Comprehensive)Role of highest governance body and senior executives in developing, approving, and updating the purpose, value, or mission statements, strategies, policies and goals related to economic, environmental and social impacts2021 ESG Report: Introduction >> Our Approach to ESG; Environmental Responsibility >> Our Approach Environmental, Health and Safety Policy GRI 102-27 (Comprehensive)Measures taken to develop and enhance the highest governance body's collective knowledge of economic, environmental and social topics2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines GRI 102-28 (Comprehensive)Process for evaluating the highest governance body's own performance with respect to economic, environmental and social and if evaluation is independent or self-assessment2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines Evaluating the Boards Performance GRI 102-29 (Comprehensive)Process of the highest governance body's role for overseeing the organization's identification and management of economic, environmental, and social performance and if stakeholder consultation is used2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Environmental Responsibility >> Our Approach Governance Committee on Directors and Corporate Governance Charter GRI 102-30 (Comprehensive)Role of the highest governance body in reviewing the effectiveness of the organization's risk management processes for EES topics2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Board Committee & Charters Audit Committee Charter Responsibilities and DutiesItem 10 GRI 102-31 (Comprehensive)Frequency of the highest governance body's review of EES impacts, risks, and opportunities2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Environmental Responsibility >> Our Approach Board Committee & Charters Committee on Directors and Corporate Governance CharterResponsibilities and Duties Items 15 and 17 GRI 102-32 (Comprehensive)Highest committee or position that formally reviews and approves the organization's sustainability report and ensures all material Aspects are coveredBMS Leadership Team GRI 102-33 (Comprehensive)Process for communicating critical concerns to the highest governance body2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Ethical Business Board Committee & Charters Systems for Managing Risks GRI 102-34 (Comprehensive)Nature and total number of critical concerns that were communicated to the highest governance body and the mechanism(s) used to address and resolve them2021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical Business GRI 102-35 (Comprehensive)Remuneration policies for highest governance body and senior executives; linkage between compensation for members of the highest governance body, senior managers, and executives, and the organization's performance2021 10-K Corporate Governance Guidelines Governance & Executive Compensation Policies Corporate Governance Guidelines Annual Evaluation of the Chief Executive Officer Compensation and Management Development Committee Charter 2021 ESG REPORT | 65 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-36 (Comprehensive)Process for determining remuneration Corporate Governance Guidelines Governance & Executive Compensation Policies Corporate Governance Guidelines Annual Evaluation of the Chief Executive Officer Compensation and Management Development Committee Charter GRI 102-40 List of stakeholder groups engaged by the organizationCorporate engagement: World Health Organization UN Global Compact UN Global Compact Communication on Progress 2021 Pharmaceutical Supply Chain Initiative By issue: Access to Medicines Corporate Giving Drug Donations and Philanthropic Efforts Disaster Relief and Product Donations Community Support For more on our engagement, visit our company website .","('Business_Ethics', 0.935860812664032)","('Human_Rights_And_Community_Relations', 0.010117441415786743)","('Management_Of_Legal_And_Regulatory_Framework', 0.008411472663283348)","(['Business Ethics'], 0.935860812664032)","('NON-ESG', 0.010117441415786743)","('NON-ESG', 0.008411472663283348)"
Line 812,"GRI 102-11 Explanation of whether and how the precautionary approach or principle is addressed by the organization2021 ESG Report: Introduction >> UN Sustainable Development Goals >> Standing Up for Human Rights; Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Ethical and Safe Products GRI 102-12 External charters, principles, initiatives Overarching Policies Voluntary standards GRI 102-13 Memberships in associations Stakeholder Engagement Business association memberships GRI 102-14 Statement from senior management 2021 ESG Report: CEO Letter GRI 102-15 (Comprehensive)Description of key impacts, risks, and opportunities 2021 10-K 2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management GRI 102-16 Internally developed statements of mission or values, codes of conduct, codes of ethics, and principles relevant to sustainable developmentBMS Codes of Conduct GRI 102-17 (Comprehensive)Internal and external mechanisms for reporting concerns about unethical or unlawful behavior, and matters related to organizational integrity, such as escalation through line management, whistleblowing mechanisms or hotlinesBMS Codes of Conduct 2021 ESG Report: Ethics, Integrity, Quality and Governance >> EthicalBusiness GRI 102-18 Governance structure of the organization, including committees under the highest governance body; identify any committees responsible for decision-making on economic, environmental and social impacts2021 ESG Report: Introduction >> Our Approach to ESG Governance Board of Directors Board Committee & Charters GRI 102-19 (Comprehensive)Process for delegating authority for economic, environmental and social topics from highest governance body to senior executives and other employees2021 ESG Report: Introduction >> Our Approach to ESG; Ethics, Integrity, Quality and Governance >> Governance and Risk Management BMS Codes of Conduct GRI 102-20 (Comprehensive)Identify executive-level position with responsibility for economic, environmental and social topics and reporting to highest governance body2021 ESG Report: Introduction >> Our Approach to ESG Leadership Team GRI 102-21 (Comprehensive)Mechanisms for consultation between stakeholders and highest governance body on economic, environmental and social topicsBMS Codes of Conduct GRI 102-22 (Comprehensive)Composition of the highest governance body and its committees2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines Board of Directors GRI 102-23 (Comprehensive)Indicate whether the Chair of the highest governance body is also an executive officer, and if so, reason for this arrangementGovernance Board of Directors GRI 102-24 (Comprehensive)Report the nomination and selection processes for the highest governance body and its committees, and the criteria used for nominating and selecting highest governance body membersCorporate Governance Guidelines Composition and structure of the Board Committee on Directors and Corporate Governance 2021 ESG REPORT | 64 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-25 (Comprehensive)Processes in place for the highest governance body to ensure conflicts of interest are avoided and managedCorporate Governance Guidelines Board ResponsibilitiesItem 4 Compliance, Ethics and Conflicts of Interest GRI 102-26 (Comprehensive)Role of highest governance body and senior executives in developing, approving, and updating the purpose, value, or mission statements, strategies, policies and goals related to economic, environmental and social impacts2021 ESG Report: Introduction >> Our Approach to ESG; Environmental Responsibility >> Our Approach Environmental, Health and Safety Policy GRI 102-27 (Comprehensive)Measures taken to develop and enhance the highest governance body's collective knowledge of economic, environmental and social topics2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines GRI 102-28 (Comprehensive)Process for evaluating the highest governance body's own performance with respect to economic, environmental and social and if evaluation is independent or self-assessment2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines Evaluating the Boards Performance GRI 102-29 (Comprehensive)Process of the highest governance body's role for overseeing the organization's identification and management of economic, environmental, and social performance and if stakeholder consultation is used2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Environmental Responsibility >> Our Approach Governance Committee on Directors and Corporate Governance Charter GRI 102-30 (Comprehensive)Role of the highest governance body in reviewing the effectiveness of the organization's risk management processes for EES topics2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Board Committee & Charters Audit Committee Charter Responsibilities and DutiesItem 10 GRI 102-31 (Comprehensive)Frequency of the highest governance body's review of EES impacts, risks, and opportunities2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Environmental Responsibility >> Our Approach Board Committee & Charters Committee on Directors and Corporate Governance CharterResponsibilities and Duties Items 15 and 17 GRI 102-32 (Comprehensive)Highest committee or position that formally reviews and approves the organization's sustainability report and ensures all material Aspects are coveredBMS Leadership Team GRI 102-33 (Comprehensive)Process for communicating critical concerns to the highest governance body2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Ethical Business Board Committee & Charters Systems for Managing Risks GRI 102-34 (Comprehensive)Nature and total number of critical concerns that were communicated to the highest governance body and the mechanism(s) used to address and resolve them2021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical Business GRI 102-35 (Comprehensive)Remuneration policies for highest governance body and senior executives; linkage between compensation for members of the highest governance body, senior managers, and executives, and the organization's performance2021 10-K Corporate Governance Guidelines Governance & Executive Compensation Policies Corporate Governance Guidelines Annual Evaluation of the Chief Executive Officer Compensation and Management Development Committee Charter 2021 ESG REPORT | 65 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-36 (Comprehensive)Process for determining remuneration Corporate Governance Guidelines Governance & Executive Compensation Policies Corporate Governance Guidelines Annual Evaluation of the Chief Executive Officer Compensation and Management Development Committee Charter GRI 102-40 List of stakeholder groups engaged by the organizationCorporate engagement: World Health Organization UN Global Compact UN Global Compact Communication on Progress 2021 Pharmaceutical Supply Chain Initiative By issue: Access to Medicines Corporate Giving Drug Donations and Philanthropic Efforts Disaster Relief and Product Donations Community Support For more on our engagement, visit our company website .","('Business_Ethics', 0.9699843525886536)","('Management_Of_Legal_And_Regulatory_Framework', 0.003139335662126541)","('Systemic_Risk_Management', 0.002341354498639703)","(['Business Ethics'], 0.9699843525886536)","('NON-ESG', 0.003139335662126541)","('NON-ESG', 0.002341354498639703)"
Line 813,"GRI 102-11 Explanation of whether and how the precautionary approach or principle is addressed by the organization2021 ESG Report: Introduction >> UN Sustainable Development Goals >> Standing Up for Human Rights; Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Ethical and Safe Products GRI 102-12 External charters, principles, initiatives Overarching Policies Voluntary standards GRI 102-13 Memberships in associations Stakeholder Engagement Business association memberships GRI 102-14 Statement from senior management 2021 ESG Report: CEO Letter GRI 102-15 (Comprehensive)Description of key impacts, risks, and opportunities 2021 10-K 2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management GRI 102-16 Internally developed statements of mission or values, codes of conduct, codes of ethics, and principles relevant to sustainable developmentBMS Codes of Conduct GRI 102-17 (Comprehensive)Internal and external mechanisms for reporting concerns about unethical or unlawful behavior, and matters related to organizational integrity, such as escalation through line management, whistleblowing mechanisms or hotlinesBMS Codes of Conduct 2021 ESG Report: Ethics, Integrity, Quality and Governance >> EthicalBusiness GRI 102-18 Governance structure of the organization, including committees under the highest governance body; identify any committees responsible for decision-making on economic, environmental and social impacts2021 ESG Report: Introduction >> Our Approach to ESG Governance Board of Directors Board Committee & Charters GRI 102-19 (Comprehensive)Process for delegating authority for economic, environmental and social topics from highest governance body to senior executives and other employees2021 ESG Report: Introduction >> Our Approach to ESG; Ethics, Integrity, Quality and Governance >> Governance and Risk Management BMS Codes of Conduct GRI 102-20 (Comprehensive)Identify executive-level position with responsibility for economic, environmental and social topics and reporting to highest governance body2021 ESG Report: Introduction >> Our Approach to ESG Leadership Team GRI 102-21 (Comprehensive)Mechanisms for consultation between stakeholders and highest governance body on economic, environmental and social topicsBMS Codes of Conduct GRI 102-22 (Comprehensive)Composition of the highest governance body and its committees2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines Board of Directors GRI 102-23 (Comprehensive)Indicate whether the Chair of the highest governance body is also an executive officer, and if so, reason for this arrangementGovernance Board of Directors GRI 102-24 (Comprehensive)Report the nomination and selection processes for the highest governance body and its committees, and the criteria used for nominating and selecting highest governance body membersCorporate Governance Guidelines Composition and structure of the Board Committee on Directors and Corporate Governance 2021 ESG REPORT | 64 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-25 (Comprehensive)Processes in place for the highest governance body to ensure conflicts of interest are avoided and managedCorporate Governance Guidelines Board ResponsibilitiesItem 4 Compliance, Ethics and Conflicts of Interest GRI 102-26 (Comprehensive)Role of highest governance body and senior executives in developing, approving, and updating the purpose, value, or mission statements, strategies, policies and goals related to economic, environmental and social impacts2021 ESG Report: Introduction >> Our Approach to ESG; Environmental Responsibility >> Our Approach Environmental, Health and Safety Policy GRI 102-27 (Comprehensive)Measures taken to develop and enhance the highest governance body's collective knowledge of economic, environmental and social topics2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines GRI 102-28 (Comprehensive)Process for evaluating the highest governance body's own performance with respect to economic, environmental and social and if evaluation is independent or self-assessment2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines Evaluating the Boards Performance GRI 102-29 (Comprehensive)Process of the highest governance body's role for overseeing the organization's identification and management of economic, environmental, and social performance and if stakeholder consultation is used2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Environmental Responsibility >> Our Approach Governance Committee on Directors and Corporate Governance Charter GRI 102-30 (Comprehensive)Role of the highest governance body in reviewing the effectiveness of the organization's risk management processes for EES topics2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Board Committee & Charters Audit Committee Charter Responsibilities and DutiesItem 10 GRI 102-31 (Comprehensive)Frequency of the highest governance body's review of EES impacts, risks, and opportunities2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Environmental Responsibility >> Our Approach Board Committee & Charters Committee on Directors and Corporate Governance CharterResponsibilities and Duties Items 15 and 17 GRI 102-32 (Comprehensive)Highest committee or position that formally reviews and approves the organization's sustainability report and ensures all material Aspects are coveredBMS Leadership Team GRI 102-33 (Comprehensive)Process for communicating critical concerns to the highest governance body2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Ethical Business Board Committee & Charters Systems for Managing Risks GRI 102-34 (Comprehensive)Nature and total number of critical concerns that were communicated to the highest governance body and the mechanism(s) used to address and resolve them2021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical Business GRI 102-35 (Comprehensive)Remuneration policies for highest governance body and senior executives; linkage between compensation for members of the highest governance body, senior managers, and executives, and the organization's performance2021 10-K Corporate Governance Guidelines Governance & Executive Compensation Policies Corporate Governance Guidelines Annual Evaluation of the Chief Executive Officer Compensation and Management Development Committee Charter 2021 ESG REPORT | 65 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-36 (Comprehensive)Process for determining remuneration Corporate Governance Guidelines Governance & Executive Compensation Policies Corporate Governance Guidelines Annual Evaluation of the Chief Executive Officer Compensation and Management Development Committee Charter GRI 102-40 List of stakeholder groups engaged by the organizationCorporate engagement: World Health Organization UN Global Compact UN Global Compact Communication on Progress 2021 Pharmaceutical Supply Chain Initiative By issue: Access to Medicines Corporate Giving Drug Donations and Philanthropic Efforts Disaster Relief and Product Donations Community Support For more on our engagement, visit our company website .","('Business_Ethics', 0.9736608266830444)","('Management_Of_Legal_And_Regulatory_Framework', 0.0022172308526933193)","('Competitive_Behavior', 0.0018371227197349072)","(['Business Ethics'], 0.9736608266830444)","('NON-ESG', 0.0022172308526933193)","('NON-ESG', 0.0018371227197349072)"
Line 814,"GRI 102-11 Explanation of whether and how the precautionary approach or principle is addressed by the organization2021 ESG Report: Introduction >> UN Sustainable Development Goals >> Standing Up for Human Rights; Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Ethical and Safe Products GRI 102-12 External charters, principles, initiatives Overarching Policies Voluntary standards GRI 102-13 Memberships in associations Stakeholder Engagement Business association memberships GRI 102-14 Statement from senior management 2021 ESG Report: CEO Letter GRI 102-15 (Comprehensive)Description of key impacts, risks, and opportunities 2021 10-K 2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management GRI 102-16 Internally developed statements of mission or values, codes of conduct, codes of ethics, and principles relevant to sustainable developmentBMS Codes of Conduct GRI 102-17 (Comprehensive)Internal and external mechanisms for reporting concerns about unethical or unlawful behavior, and matters related to organizational integrity, such as escalation through line management, whistleblowing mechanisms or hotlinesBMS Codes of Conduct 2021 ESG Report: Ethics, Integrity, Quality and Governance >> EthicalBusiness GRI 102-18 Governance structure of the organization, including committees under the highest governance body; identify any committees responsible for decision-making on economic, environmental and social impacts2021 ESG Report: Introduction >> Our Approach to ESG Governance Board of Directors Board Committee & Charters GRI 102-19 (Comprehensive)Process for delegating authority for economic, environmental and social topics from highest governance body to senior executives and other employees2021 ESG Report: Introduction >> Our Approach to ESG; Ethics, Integrity, Quality and Governance >> Governance and Risk Management BMS Codes of Conduct GRI 102-20 (Comprehensive)Identify executive-level position with responsibility for economic, environmental and social topics and reporting to highest governance body2021 ESG Report: Introduction >> Our Approach to ESG Leadership Team GRI 102-21 (Comprehensive)Mechanisms for consultation between stakeholders and highest governance body on economic, environmental and social topicsBMS Codes of Conduct GRI 102-22 (Comprehensive)Composition of the highest governance body and its committees2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines Board of Directors GRI 102-23 (Comprehensive)Indicate whether the Chair of the highest governance body is also an executive officer, and if so, reason for this arrangementGovernance Board of Directors GRI 102-24 (Comprehensive)Report the nomination and selection processes for the highest governance body and its committees, and the criteria used for nominating and selecting highest governance body membersCorporate Governance Guidelines Composition and structure of the Board Committee on Directors and Corporate Governance 2021 ESG REPORT | 64 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-25 (Comprehensive)Processes in place for the highest governance body to ensure conflicts of interest are avoided and managedCorporate Governance Guidelines Board ResponsibilitiesItem 4 Compliance, Ethics and Conflicts of Interest GRI 102-26 (Comprehensive)Role of highest governance body and senior executives in developing, approving, and updating the purpose, value, or mission statements, strategies, policies and goals related to economic, environmental and social impacts2021 ESG Report: Introduction >> Our Approach to ESG; Environmental Responsibility >> Our Approach Environmental, Health and Safety Policy GRI 102-27 (Comprehensive)Measures taken to develop and enhance the highest governance body's collective knowledge of economic, environmental and social topics2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines GRI 102-28 (Comprehensive)Process for evaluating the highest governance body's own performance with respect to economic, environmental and social and if evaluation is independent or self-assessment2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines Evaluating the Boards Performance GRI 102-29 (Comprehensive)Process of the highest governance body's role for overseeing the organization's identification and management of economic, environmental, and social performance and if stakeholder consultation is used2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Environmental Responsibility >> Our Approach Governance Committee on Directors and Corporate Governance Charter GRI 102-30 (Comprehensive)Role of the highest governance body in reviewing the effectiveness of the organization's risk management processes for EES topics2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Board Committee & Charters Audit Committee Charter Responsibilities and DutiesItem 10 GRI 102-31 (Comprehensive)Frequency of the highest governance body's review of EES impacts, risks, and opportunities2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Environmental Responsibility >> Our Approach Board Committee & Charters Committee on Directors and Corporate Governance CharterResponsibilities and Duties Items 15 and 17 GRI 102-32 (Comprehensive)Highest committee or position that formally reviews and approves the organization's sustainability report and ensures all material Aspects are coveredBMS Leadership Team GRI 102-33 (Comprehensive)Process for communicating critical concerns to the highest governance body2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Ethical Business Board Committee & Charters Systems for Managing Risks GRI 102-34 (Comprehensive)Nature and total number of critical concerns that were communicated to the highest governance body and the mechanism(s) used to address and resolve them2021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical Business GRI 102-35 (Comprehensive)Remuneration policies for highest governance body and senior executives; linkage between compensation for members of the highest governance body, senior managers, and executives, and the organization's performance2021 10-K Corporate Governance Guidelines Governance & Executive Compensation Policies Corporate Governance Guidelines Annual Evaluation of the Chief Executive Officer Compensation and Management Development Committee Charter 2021 ESG REPORT | 65 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-36 (Comprehensive)Process for determining remuneration Corporate Governance Guidelines Governance & Executive Compensation Policies Corporate Governance Guidelines Annual Evaluation of the Chief Executive Officer Compensation and Management Development Committee Charter GRI 102-40 List of stakeholder groups engaged by the organizationCorporate engagement: World Health Organization UN Global Compact UN Global Compact Communication on Progress 2021 Pharmaceutical Supply Chain Initiative By issue: Access to Medicines Corporate Giving Drug Donations and Philanthropic Efforts Disaster Relief and Product Donations Community Support For more on our engagement, visit our company website .","('Business_Ethics', 0.9012213349342346)","('Management_Of_Legal_And_Regulatory_Framework', 0.019309604540467262)","('Director_Removal', 0.015124545432627201)","(['Business Ethics'], 0.9012213349342346)","('NON-ESG', 0.019309604540467262)","('NON-ESG', 0.015124545432627201)"
Line 815,"GRI 102-11 Explanation of whether and how the precautionary approach or principle is addressed by the organization2021 ESG Report: Introduction >> UN Sustainable Development Goals >> Standing Up for Human Rights; Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Ethical and Safe Products GRI 102-12 External charters, principles, initiatives Overarching Policies Voluntary standards GRI 102-13 Memberships in associations Stakeholder Engagement Business association memberships GRI 102-14 Statement from senior management 2021 ESG Report: CEO Letter GRI 102-15 (Comprehensive)Description of key impacts, risks, and opportunities 2021 10-K 2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management GRI 102-16 Internally developed statements of mission or values, codes of conduct, codes of ethics, and principles relevant to sustainable developmentBMS Codes of Conduct GRI 102-17 (Comprehensive)Internal and external mechanisms for reporting concerns about unethical or unlawful behavior, and matters related to organizational integrity, such as escalation through line management, whistleblowing mechanisms or hotlinesBMS Codes of Conduct 2021 ESG Report: Ethics, Integrity, Quality and Governance >> EthicalBusiness GRI 102-18 Governance structure of the organization, including committees under the highest governance body; identify any committees responsible for decision-making on economic, environmental and social impacts2021 ESG Report: Introduction >> Our Approach to ESG Governance Board of Directors Board Committee & Charters GRI 102-19 (Comprehensive)Process for delegating authority for economic, environmental and social topics from highest governance body to senior executives and other employees2021 ESG Report: Introduction >> Our Approach to ESG; Ethics, Integrity, Quality and Governance >> Governance and Risk Management BMS Codes of Conduct GRI 102-20 (Comprehensive)Identify executive-level position with responsibility for economic, environmental and social topics and reporting to highest governance body2021 ESG Report: Introduction >> Our Approach to ESG Leadership Team GRI 102-21 (Comprehensive)Mechanisms for consultation between stakeholders and highest governance body on economic, environmental and social topicsBMS Codes of Conduct GRI 102-22 (Comprehensive)Composition of the highest governance body and its committees2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines Board of Directors GRI 102-23 (Comprehensive)Indicate whether the Chair of the highest governance body is also an executive officer, and if so, reason for this arrangementGovernance Board of Directors GRI 102-24 (Comprehensive)Report the nomination and selection processes for the highest governance body and its committees, and the criteria used for nominating and selecting highest governance body membersCorporate Governance Guidelines Composition and structure of the Board Committee on Directors and Corporate Governance 2021 ESG REPORT | 64 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-25 (Comprehensive)Processes in place for the highest governance body to ensure conflicts of interest are avoided and managedCorporate Governance Guidelines Board ResponsibilitiesItem 4 Compliance, Ethics and Conflicts of Interest GRI 102-26 (Comprehensive)Role of highest governance body and senior executives in developing, approving, and updating the purpose, value, or mission statements, strategies, policies and goals related to economic, environmental and social impacts2021 ESG Report: Introduction >> Our Approach to ESG; Environmental Responsibility >> Our Approach Environmental, Health and Safety Policy GRI 102-27 (Comprehensive)Measures taken to develop and enhance the highest governance body's collective knowledge of economic, environmental and social topics2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines GRI 102-28 (Comprehensive)Process for evaluating the highest governance body's own performance with respect to economic, environmental and social and if evaluation is independent or self-assessment2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines Evaluating the Boards Performance GRI 102-29 (Comprehensive)Process of the highest governance body's role for overseeing the organization's identification and management of economic, environmental, and social performance and if stakeholder consultation is used2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Environmental Responsibility >> Our Approach Governance Committee on Directors and Corporate Governance Charter GRI 102-30 (Comprehensive)Role of the highest governance body in reviewing the effectiveness of the organization's risk management processes for EES topics2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Board Committee & Charters Audit Committee Charter Responsibilities and DutiesItem 10 GRI 102-31 (Comprehensive)Frequency of the highest governance body's review of EES impacts, risks, and opportunities2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Environmental Responsibility >> Our Approach Board Committee & Charters Committee on Directors and Corporate Governance CharterResponsibilities and Duties Items 15 and 17 GRI 102-32 (Comprehensive)Highest committee or position that formally reviews and approves the organization's sustainability report and ensures all material Aspects are coveredBMS Leadership Team GRI 102-33 (Comprehensive)Process for communicating critical concerns to the highest governance body2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Ethical Business Board Committee & Charters Systems for Managing Risks GRI 102-34 (Comprehensive)Nature and total number of critical concerns that were communicated to the highest governance body and the mechanism(s) used to address and resolve them2021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical Business GRI 102-35 (Comprehensive)Remuneration policies for highest governance body and senior executives; linkage between compensation for members of the highest governance body, senior managers, and executives, and the organization's performance2021 10-K Corporate Governance Guidelines Governance & Executive Compensation Policies Corporate Governance Guidelines Annual Evaluation of the Chief Executive Officer Compensation and Management Development Committee Charter 2021 ESG REPORT | 65 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-36 (Comprehensive)Process for determining remuneration Corporate Governance Guidelines Governance & Executive Compensation Policies Corporate Governance Guidelines Annual Evaluation of the Chief Executive Officer Compensation and Management Development Committee Charter GRI 102-40 List of stakeholder groups engaged by the organizationCorporate engagement: World Health Organization UN Global Compact UN Global Compact Communication on Progress 2021 Pharmaceutical Supply Chain Initiative By issue: Access to Medicines Corporate Giving Drug Donations and Philanthropic Efforts Disaster Relief and Product Donations Community Support For more on our engagement, visit our company website .","('Business_Ethics', 0.9352001547813416)","('Management_Of_Legal_And_Regulatory_Framework', 0.017379755154252052)","('Director_Removal', 0.005489924922585487)","(['Business Ethics'], 0.9352001547813416)","('NON-ESG', 0.017379755154252052)","('NON-ESG', 0.005489924922585487)"
Line 816,"GRI 102-11 Explanation of whether and how the precautionary approach or principle is addressed by the organization2021 ESG Report: Introduction >> UN Sustainable Development Goals >> Standing Up for Human Rights; Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Ethical and Safe Products GRI 102-12 External charters, principles, initiatives Overarching Policies Voluntary standards GRI 102-13 Memberships in associations Stakeholder Engagement Business association memberships GRI 102-14 Statement from senior management 2021 ESG Report: CEO Letter GRI 102-15 (Comprehensive)Description of key impacts, risks, and opportunities 2021 10-K 2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management GRI 102-16 Internally developed statements of mission or values, codes of conduct, codes of ethics, and principles relevant to sustainable developmentBMS Codes of Conduct GRI 102-17 (Comprehensive)Internal and external mechanisms for reporting concerns about unethical or unlawful behavior, and matters related to organizational integrity, such as escalation through line management, whistleblowing mechanisms or hotlinesBMS Codes of Conduct 2021 ESG Report: Ethics, Integrity, Quality and Governance >> EthicalBusiness GRI 102-18 Governance structure of the organization, including committees under the highest governance body; identify any committees responsible for decision-making on economic, environmental and social impacts2021 ESG Report: Introduction >> Our Approach to ESG Governance Board of Directors Board Committee & Charters GRI 102-19 (Comprehensive)Process for delegating authority for economic, environmental and social topics from highest governance body to senior executives and other employees2021 ESG Report: Introduction >> Our Approach to ESG; Ethics, Integrity, Quality and Governance >> Governance and Risk Management BMS Codes of Conduct GRI 102-20 (Comprehensive)Identify executive-level position with responsibility for economic, environmental and social topics and reporting to highest governance body2021 ESG Report: Introduction >> Our Approach to ESG Leadership Team GRI 102-21 (Comprehensive)Mechanisms for consultation between stakeholders and highest governance body on economic, environmental and social topicsBMS Codes of Conduct GRI 102-22 (Comprehensive)Composition of the highest governance body and its committees2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines Board of Directors GRI 102-23 (Comprehensive)Indicate whether the Chair of the highest governance body is also an executive officer, and if so, reason for this arrangementGovernance Board of Directors GRI 102-24 (Comprehensive)Report the nomination and selection processes for the highest governance body and its committees, and the criteria used for nominating and selecting highest governance body membersCorporate Governance Guidelines Composition and structure of the Board Committee on Directors and Corporate Governance 2021 ESG REPORT | 64 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-25 (Comprehensive)Processes in place for the highest governance body to ensure conflicts of interest are avoided and managedCorporate Governance Guidelines Board ResponsibilitiesItem 4 Compliance, Ethics and Conflicts of Interest GRI 102-26 (Comprehensive)Role of highest governance body and senior executives in developing, approving, and updating the purpose, value, or mission statements, strategies, policies and goals related to economic, environmental and social impacts2021 ESG Report: Introduction >> Our Approach to ESG; Environmental Responsibility >> Our Approach Environmental, Health and Safety Policy GRI 102-27 (Comprehensive)Measures taken to develop and enhance the highest governance body's collective knowledge of economic, environmental and social topics2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines GRI 102-28 (Comprehensive)Process for evaluating the highest governance body's own performance with respect to economic, environmental and social and if evaluation is independent or self-assessment2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines Evaluating the Boards Performance GRI 102-29 (Comprehensive)Process of the highest governance body's role for overseeing the organization's identification and management of economic, environmental, and social performance and if stakeholder consultation is used2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Environmental Responsibility >> Our Approach Governance Committee on Directors and Corporate Governance Charter GRI 102-30 (Comprehensive)Role of the highest governance body in reviewing the effectiveness of the organization's risk management processes for EES topics2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Board Committee & Charters Audit Committee Charter Responsibilities and DutiesItem 10 GRI 102-31 (Comprehensive)Frequency of the highest governance body's review of EES impacts, risks, and opportunities2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Environmental Responsibility >> Our Approach Board Committee & Charters Committee on Directors and Corporate Governance CharterResponsibilities and Duties Items 15 and 17 GRI 102-32 (Comprehensive)Highest committee or position that formally reviews and approves the organization's sustainability report and ensures all material Aspects are coveredBMS Leadership Team GRI 102-33 (Comprehensive)Process for communicating critical concerns to the highest governance body2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Ethical Business Board Committee & Charters Systems for Managing Risks GRI 102-34 (Comprehensive)Nature and total number of critical concerns that were communicated to the highest governance body and the mechanism(s) used to address and resolve them2021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical Business GRI 102-35 (Comprehensive)Remuneration policies for highest governance body and senior executives; linkage between compensation for members of the highest governance body, senior managers, and executives, and the organization's performance2021 10-K Corporate Governance Guidelines Governance & Executive Compensation Policies Corporate Governance Guidelines Annual Evaluation of the Chief Executive Officer Compensation and Management Development Committee Charter 2021 ESG REPORT | 65 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-36 (Comprehensive)Process for determining remuneration Corporate Governance Guidelines Governance & Executive Compensation Policies Corporate Governance Guidelines Annual Evaluation of the Chief Executive Officer Compensation and Management Development Committee Charter GRI 102-40 List of stakeholder groups engaged by the organizationCorporate engagement: World Health Organization UN Global Compact UN Global Compact Communication on Progress 2021 Pharmaceutical Supply Chain Initiative By issue: Access to Medicines Corporate Giving Drug Donations and Philanthropic Efforts Disaster Relief and Product Donations Community Support For more on our engagement, visit our company website .","('Director_Removal', 0.7347579598426819)","('Management_Of_Legal_And_Regulatory_Framework', 0.05271024629473686)","('Business_Ethics', 0.02413365989923477)","(['Business Ethics'], 0.7347579598426819)","('NON-ESG', 0.05271024629473686)","('NON-ESG', 0.02413365989923477)"
Line 817,"GRI 102-11 Explanation of whether and how the precautionary approach or principle is addressed by the organization2021 ESG Report: Introduction >> UN Sustainable Development Goals >> Standing Up for Human Rights; Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Ethical and Safe Products GRI 102-12 External charters, principles, initiatives Overarching Policies Voluntary standards GRI 102-13 Memberships in associations Stakeholder Engagement Business association memberships GRI 102-14 Statement from senior management 2021 ESG Report: CEO Letter GRI 102-15 (Comprehensive)Description of key impacts, risks, and opportunities 2021 10-K 2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management GRI 102-16 Internally developed statements of mission or values, codes of conduct, codes of ethics, and principles relevant to sustainable developmentBMS Codes of Conduct GRI 102-17 (Comprehensive)Internal and external mechanisms for reporting concerns about unethical or unlawful behavior, and matters related to organizational integrity, such as escalation through line management, whistleblowing mechanisms or hotlinesBMS Codes of Conduct 2021 ESG Report: Ethics, Integrity, Quality and Governance >> EthicalBusiness GRI 102-18 Governance structure of the organization, including committees under the highest governance body; identify any committees responsible for decision-making on economic, environmental and social impacts2021 ESG Report: Introduction >> Our Approach to ESG Governance Board of Directors Board Committee & Charters GRI 102-19 (Comprehensive)Process for delegating authority for economic, environmental and social topics from highest governance body to senior executives and other employees2021 ESG Report: Introduction >> Our Approach to ESG; Ethics, Integrity, Quality and Governance >> Governance and Risk Management BMS Codes of Conduct GRI 102-20 (Comprehensive)Identify executive-level position with responsibility for economic, environmental and social topics and reporting to highest governance body2021 ESG Report: Introduction >> Our Approach to ESG Leadership Team GRI 102-21 (Comprehensive)Mechanisms for consultation between stakeholders and highest governance body on economic, environmental and social topicsBMS Codes of Conduct GRI 102-22 (Comprehensive)Composition of the highest governance body and its committees2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines Board of Directors GRI 102-23 (Comprehensive)Indicate whether the Chair of the highest governance body is also an executive officer, and if so, reason for this arrangementGovernance Board of Directors GRI 102-24 (Comprehensive)Report the nomination and selection processes for the highest governance body and its committees, and the criteria used for nominating and selecting highest governance body membersCorporate Governance Guidelines Composition and structure of the Board Committee on Directors and Corporate Governance 2021 ESG REPORT | 64 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-25 (Comprehensive)Processes in place for the highest governance body to ensure conflicts of interest are avoided and managedCorporate Governance Guidelines Board ResponsibilitiesItem 4 Compliance, Ethics and Conflicts of Interest GRI 102-26 (Comprehensive)Role of highest governance body and senior executives in developing, approving, and updating the purpose, value, or mission statements, strategies, policies and goals related to economic, environmental and social impacts2021 ESG Report: Introduction >> Our Approach to ESG; Environmental Responsibility >> Our Approach Environmental, Health and Safety Policy GRI 102-27 (Comprehensive)Measures taken to develop and enhance the highest governance body's collective knowledge of economic, environmental and social topics2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines GRI 102-28 (Comprehensive)Process for evaluating the highest governance body's own performance with respect to economic, environmental and social and if evaluation is independent or self-assessment2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines Evaluating the Boards Performance GRI 102-29 (Comprehensive)Process of the highest governance body's role for overseeing the organization's identification and management of economic, environmental, and social performance and if stakeholder consultation is used2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Environmental Responsibility >> Our Approach Governance Committee on Directors and Corporate Governance Charter GRI 102-30 (Comprehensive)Role of the highest governance body in reviewing the effectiveness of the organization's risk management processes for EES topics2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Board Committee & Charters Audit Committee Charter Responsibilities and DutiesItem 10 GRI 102-31 (Comprehensive)Frequency of the highest governance body's review of EES impacts, risks, and opportunities2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Environmental Responsibility >> Our Approach Board Committee & Charters Committee on Directors and Corporate Governance CharterResponsibilities and Duties Items 15 and 17 GRI 102-32 (Comprehensive)Highest committee or position that formally reviews and approves the organization's sustainability report and ensures all material Aspects are coveredBMS Leadership Team GRI 102-33 (Comprehensive)Process for communicating critical concerns to the highest governance body2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Ethical Business Board Committee & Charters Systems for Managing Risks GRI 102-34 (Comprehensive)Nature and total number of critical concerns that were communicated to the highest governance body and the mechanism(s) used to address and resolve them2021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical Business GRI 102-35 (Comprehensive)Remuneration policies for highest governance body and senior executives; linkage between compensation for members of the highest governance body, senior managers, and executives, and the organization's performance2021 10-K Corporate Governance Guidelines Governance & Executive Compensation Policies Corporate Governance Guidelines Annual Evaluation of the Chief Executive Officer Compensation and Management Development Committee Charter 2021 ESG REPORT | 65 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-36 (Comprehensive)Process for determining remuneration Corporate Governance Guidelines Governance & Executive Compensation Policies Corporate Governance Guidelines Annual Evaluation of the Chief Executive Officer Compensation and Management Development Committee Charter GRI 102-40 List of stakeholder groups engaged by the organizationCorporate engagement: World Health Organization UN Global Compact UN Global Compact Communication on Progress 2021 Pharmaceutical Supply Chain Initiative By issue: Access to Medicines Corporate Giving Drug Donations and Philanthropic Efforts Disaster Relief and Product Donations Community Support For more on our engagement, visit our company website .","('Business_Ethics', 0.9151583909988403)","('Management_Of_Legal_And_Regulatory_Framework', 0.029943794012069702)","('Director_Removal', 0.00781446136534214)","(['Business Ethics'], 0.9151583909988403)","('NON-ESG', 0.029943794012069702)","('NON-ESG', 0.00781446136534214)"
Line 818,"GRI 102-11 Explanation of whether and how the precautionary approach or principle is addressed by the organization2021 ESG Report: Introduction >> UN Sustainable Development Goals >> Standing Up for Human Rights; Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Ethical and Safe Products GRI 102-12 External charters, principles, initiatives Overarching Policies Voluntary standards GRI 102-13 Memberships in associations Stakeholder Engagement Business association memberships GRI 102-14 Statement from senior management 2021 ESG Report: CEO Letter GRI 102-15 (Comprehensive)Description of key impacts, risks, and opportunities 2021 10-K 2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management GRI 102-16 Internally developed statements of mission or values, codes of conduct, codes of ethics, and principles relevant to sustainable developmentBMS Codes of Conduct GRI 102-17 (Comprehensive)Internal and external mechanisms for reporting concerns about unethical or unlawful behavior, and matters related to organizational integrity, such as escalation through line management, whistleblowing mechanisms or hotlinesBMS Codes of Conduct 2021 ESG Report: Ethics, Integrity, Quality and Governance >> EthicalBusiness GRI 102-18 Governance structure of the organization, including committees under the highest governance body; identify any committees responsible for decision-making on economic, environmental and social impacts2021 ESG Report: Introduction >> Our Approach to ESG Governance Board of Directors Board Committee & Charters GRI 102-19 (Comprehensive)Process for delegating authority for economic, environmental and social topics from highest governance body to senior executives and other employees2021 ESG Report: Introduction >> Our Approach to ESG; Ethics, Integrity, Quality and Governance >> Governance and Risk Management BMS Codes of Conduct GRI 102-20 (Comprehensive)Identify executive-level position with responsibility for economic, environmental and social topics and reporting to highest governance body2021 ESG Report: Introduction >> Our Approach to ESG Leadership Team GRI 102-21 (Comprehensive)Mechanisms for consultation between stakeholders and highest governance body on economic, environmental and social topicsBMS Codes of Conduct GRI 102-22 (Comprehensive)Composition of the highest governance body and its committees2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines Board of Directors GRI 102-23 (Comprehensive)Indicate whether the Chair of the highest governance body is also an executive officer, and if so, reason for this arrangementGovernance Board of Directors GRI 102-24 (Comprehensive)Report the nomination and selection processes for the highest governance body and its committees, and the criteria used for nominating and selecting highest governance body membersCorporate Governance Guidelines Composition and structure of the Board Committee on Directors and Corporate Governance 2021 ESG REPORT | 64 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-25 (Comprehensive)Processes in place for the highest governance body to ensure conflicts of interest are avoided and managedCorporate Governance Guidelines Board ResponsibilitiesItem 4 Compliance, Ethics and Conflicts of Interest GRI 102-26 (Comprehensive)Role of highest governance body and senior executives in developing, approving, and updating the purpose, value, or mission statements, strategies, policies and goals related to economic, environmental and social impacts2021 ESG Report: Introduction >> Our Approach to ESG; Environmental Responsibility >> Our Approach Environmental, Health and Safety Policy GRI 102-27 (Comprehensive)Measures taken to develop and enhance the highest governance body's collective knowledge of economic, environmental and social topics2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines GRI 102-28 (Comprehensive)Process for evaluating the highest governance body's own performance with respect to economic, environmental and social and if evaluation is independent or self-assessment2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines Evaluating the Boards Performance GRI 102-29 (Comprehensive)Process of the highest governance body's role for overseeing the organization's identification and management of economic, environmental, and social performance and if stakeholder consultation is used2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Environmental Responsibility >> Our Approach Governance Committee on Directors and Corporate Governance Charter GRI 102-30 (Comprehensive)Role of the highest governance body in reviewing the effectiveness of the organization's risk management processes for EES topics2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Board Committee & Charters Audit Committee Charter Responsibilities and DutiesItem 10 GRI 102-31 (Comprehensive)Frequency of the highest governance body's review of EES impacts, risks, and opportunities2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Environmental Responsibility >> Our Approach Board Committee & Charters Committee on Directors and Corporate Governance CharterResponsibilities and Duties Items 15 and 17 GRI 102-32 (Comprehensive)Highest committee or position that formally reviews and approves the organization's sustainability report and ensures all material Aspects are coveredBMS Leadership Team GRI 102-33 (Comprehensive)Process for communicating critical concerns to the highest governance body2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Ethical Business Board Committee & Charters Systems for Managing Risks GRI 102-34 (Comprehensive)Nature and total number of critical concerns that were communicated to the highest governance body and the mechanism(s) used to address and resolve them2021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical Business GRI 102-35 (Comprehensive)Remuneration policies for highest governance body and senior executives; linkage between compensation for members of the highest governance body, senior managers, and executives, and the organization's performance2021 10-K Corporate Governance Guidelines Governance & Executive Compensation Policies Corporate Governance Guidelines Annual Evaluation of the Chief Executive Officer Compensation and Management Development Committee Charter 2021 ESG REPORT | 65 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-36 (Comprehensive)Process for determining remuneration Corporate Governance Guidelines Governance & Executive Compensation Policies Corporate Governance Guidelines Annual Evaluation of the Chief Executive Officer Compensation and Management Development Committee Charter GRI 102-40 List of stakeholder groups engaged by the organizationCorporate engagement: World Health Organization UN Global Compact UN Global Compact Communication on Progress 2021 Pharmaceutical Supply Chain Initiative By issue: Access to Medicines Corporate Giving Drug Donations and Philanthropic Efforts Disaster Relief and Product Donations Community Support For more on our engagement, visit our company website .","('Business_Ethics', 0.6268092393875122)","('Management_Of_Legal_And_Regulatory_Framework', 0.14720524847507477)","('Human_Rights_And_Community_Relations', 0.05608536675572395)","(['Business Ethics'], 0.6268092393875122)","('NON-ESG', 0.14720524847507477)","('NON-ESG', 0.05608536675572395)"
Line 819,"GRI 102-11 Explanation of whether and how the precautionary approach or principle is addressed by the organization2021 ESG Report: Introduction >> UN Sustainable Development Goals >> Standing Up for Human Rights; Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Ethical and Safe Products GRI 102-12 External charters, principles, initiatives Overarching Policies Voluntary standards GRI 102-13 Memberships in associations Stakeholder Engagement Business association memberships GRI 102-14 Statement from senior management 2021 ESG Report: CEO Letter GRI 102-15 (Comprehensive)Description of key impacts, risks, and opportunities 2021 10-K 2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management GRI 102-16 Internally developed statements of mission or values, codes of conduct, codes of ethics, and principles relevant to sustainable developmentBMS Codes of Conduct GRI 102-17 (Comprehensive)Internal and external mechanisms for reporting concerns about unethical or unlawful behavior, and matters related to organizational integrity, such as escalation through line management, whistleblowing mechanisms or hotlinesBMS Codes of Conduct 2021 ESG Report: Ethics, Integrity, Quality and Governance >> EthicalBusiness GRI 102-18 Governance structure of the organization, including committees under the highest governance body; identify any committees responsible for decision-making on economic, environmental and social impacts2021 ESG Report: Introduction >> Our Approach to ESG Governance Board of Directors Board Committee & Charters GRI 102-19 (Comprehensive)Process for delegating authority for economic, environmental and social topics from highest governance body to senior executives and other employees2021 ESG Report: Introduction >> Our Approach to ESG; Ethics, Integrity, Quality and Governance >> Governance and Risk Management BMS Codes of Conduct GRI 102-20 (Comprehensive)Identify executive-level position with responsibility for economic, environmental and social topics and reporting to highest governance body2021 ESG Report: Introduction >> Our Approach to ESG Leadership Team GRI 102-21 (Comprehensive)Mechanisms for consultation between stakeholders and highest governance body on economic, environmental and social topicsBMS Codes of Conduct GRI 102-22 (Comprehensive)Composition of the highest governance body and its committees2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines Board of Directors GRI 102-23 (Comprehensive)Indicate whether the Chair of the highest governance body is also an executive officer, and if so, reason for this arrangementGovernance Board of Directors GRI 102-24 (Comprehensive)Report the nomination and selection processes for the highest governance body and its committees, and the criteria used for nominating and selecting highest governance body membersCorporate Governance Guidelines Composition and structure of the Board Committee on Directors and Corporate Governance 2021 ESG REPORT | 64 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-25 (Comprehensive)Processes in place for the highest governance body to ensure conflicts of interest are avoided and managedCorporate Governance Guidelines Board ResponsibilitiesItem 4 Compliance, Ethics and Conflicts of Interest GRI 102-26 (Comprehensive)Role of highest governance body and senior executives in developing, approving, and updating the purpose, value, or mission statements, strategies, policies and goals related to economic, environmental and social impacts2021 ESG Report: Introduction >> Our Approach to ESG; Environmental Responsibility >> Our Approach Environmental, Health and Safety Policy GRI 102-27 (Comprehensive)Measures taken to develop and enhance the highest governance body's collective knowledge of economic, environmental and social topics2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines GRI 102-28 (Comprehensive)Process for evaluating the highest governance body's own performance with respect to economic, environmental and social and if evaluation is independent or self-assessment2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines Evaluating the Boards Performance GRI 102-29 (Comprehensive)Process of the highest governance body's role for overseeing the organization's identification and management of economic, environmental, and social performance and if stakeholder consultation is used2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Environmental Responsibility >> Our Approach Governance Committee on Directors and Corporate Governance Charter GRI 102-30 (Comprehensive)Role of the highest governance body in reviewing the effectiveness of the organization's risk management processes for EES topics2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Board Committee & Charters Audit Committee Charter Responsibilities and DutiesItem 10 GRI 102-31 (Comprehensive)Frequency of the highest governance body's review of EES impacts, risks, and opportunities2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Environmental Responsibility >> Our Approach Board Committee & Charters Committee on Directors and Corporate Governance CharterResponsibilities and Duties Items 15 and 17 GRI 102-32 (Comprehensive)Highest committee or position that formally reviews and approves the organization's sustainability report and ensures all material Aspects are coveredBMS Leadership Team GRI 102-33 (Comprehensive)Process for communicating critical concerns to the highest governance body2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Ethical Business Board Committee & Charters Systems for Managing Risks GRI 102-34 (Comprehensive)Nature and total number of critical concerns that were communicated to the highest governance body and the mechanism(s) used to address and resolve them2021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical Business GRI 102-35 (Comprehensive)Remuneration policies for highest governance body and senior executives; linkage between compensation for members of the highest governance body, senior managers, and executives, and the organization's performance2021 10-K Corporate Governance Guidelines Governance & Executive Compensation Policies Corporate Governance Guidelines Annual Evaluation of the Chief Executive Officer Compensation and Management Development Committee Charter 2021 ESG REPORT | 65 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-36 (Comprehensive)Process for determining remuneration Corporate Governance Guidelines Governance & Executive Compensation Policies Corporate Governance Guidelines Annual Evaluation of the Chief Executive Officer Compensation and Management Development Committee Charter GRI 102-40 List of stakeholder groups engaged by the organizationCorporate engagement: World Health Organization UN Global Compact UN Global Compact Communication on Progress 2021 Pharmaceutical Supply Chain Initiative By issue: Access to Medicines Corporate Giving Drug Donations and Philanthropic Efforts Disaster Relief and Product Donations Community Support For more on our engagement, visit our company website .","('Business_Ethics', 0.8773285150527954)","('Management_Of_Legal_And_Regulatory_Framework', 0.030190756544470787)","('Human_Rights_And_Community_Relations', 0.012054589577019215)","(['Business Ethics'], 0.8773285150527954)","('NON-ESG', 0.030190756544470787)","('NON-ESG', 0.012054589577019215)"
Line 820,"GRI 102-11 Explanation of whether and how the precautionary approach or principle is addressed by the organization2021 ESG Report: Introduction >> UN Sustainable Development Goals >> Standing Up for Human Rights; Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Ethical and Safe Products GRI 102-12 External charters, principles, initiatives Overarching Policies Voluntary standards GRI 102-13 Memberships in associations Stakeholder Engagement Business association memberships GRI 102-14 Statement from senior management 2021 ESG Report: CEO Letter GRI 102-15 (Comprehensive)Description of key impacts, risks, and opportunities 2021 10-K 2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management GRI 102-16 Internally developed statements of mission or values, codes of conduct, codes of ethics, and principles relevant to sustainable developmentBMS Codes of Conduct GRI 102-17 (Comprehensive)Internal and external mechanisms for reporting concerns about unethical or unlawful behavior, and matters related to organizational integrity, such as escalation through line management, whistleblowing mechanisms or hotlinesBMS Codes of Conduct 2021 ESG Report: Ethics, Integrity, Quality and Governance >> EthicalBusiness GRI 102-18 Governance structure of the organization, including committees under the highest governance body; identify any committees responsible for decision-making on economic, environmental and social impacts2021 ESG Report: Introduction >> Our Approach to ESG Governance Board of Directors Board Committee & Charters GRI 102-19 (Comprehensive)Process for delegating authority for economic, environmental and social topics from highest governance body to senior executives and other employees2021 ESG Report: Introduction >> Our Approach to ESG; Ethics, Integrity, Quality and Governance >> Governance and Risk Management BMS Codes of Conduct GRI 102-20 (Comprehensive)Identify executive-level position with responsibility for economic, environmental and social topics and reporting to highest governance body2021 ESG Report: Introduction >> Our Approach to ESG Leadership Team GRI 102-21 (Comprehensive)Mechanisms for consultation between stakeholders and highest governance body on economic, environmental and social topicsBMS Codes of Conduct GRI 102-22 (Comprehensive)Composition of the highest governance body and its committees2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines Board of Directors GRI 102-23 (Comprehensive)Indicate whether the Chair of the highest governance body is also an executive officer, and if so, reason for this arrangementGovernance Board of Directors GRI 102-24 (Comprehensive)Report the nomination and selection processes for the highest governance body and its committees, and the criteria used for nominating and selecting highest governance body membersCorporate Governance Guidelines Composition and structure of the Board Committee on Directors and Corporate Governance 2021 ESG REPORT | 64 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-25 (Comprehensive)Processes in place for the highest governance body to ensure conflicts of interest are avoided and managedCorporate Governance Guidelines Board ResponsibilitiesItem 4 Compliance, Ethics and Conflicts of Interest GRI 102-26 (Comprehensive)Role of highest governance body and senior executives in developing, approving, and updating the purpose, value, or mission statements, strategies, policies and goals related to economic, environmental and social impacts2021 ESG Report: Introduction >> Our Approach to ESG; Environmental Responsibility >> Our Approach Environmental, Health and Safety Policy GRI 102-27 (Comprehensive)Measures taken to develop and enhance the highest governance body's collective knowledge of economic, environmental and social topics2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines GRI 102-28 (Comprehensive)Process for evaluating the highest governance body's own performance with respect to economic, environmental and social and if evaluation is independent or self-assessment2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines Evaluating the Boards Performance GRI 102-29 (Comprehensive)Process of the highest governance body's role for overseeing the organization's identification and management of economic, environmental, and social performance and if stakeholder consultation is used2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Environmental Responsibility >> Our Approach Governance Committee on Directors and Corporate Governance Charter GRI 102-30 (Comprehensive)Role of the highest governance body in reviewing the effectiveness of the organization's risk management processes for EES topics2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Board Committee & Charters Audit Committee Charter Responsibilities and DutiesItem 10 GRI 102-31 (Comprehensive)Frequency of the highest governance body's review of EES impacts, risks, and opportunities2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Environmental Responsibility >> Our Approach Board Committee & Charters Committee on Directors and Corporate Governance CharterResponsibilities and Duties Items 15 and 17 GRI 102-32 (Comprehensive)Highest committee or position that formally reviews and approves the organization's sustainability report and ensures all material Aspects are coveredBMS Leadership Team GRI 102-33 (Comprehensive)Process for communicating critical concerns to the highest governance body2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Ethical Business Board Committee & Charters Systems for Managing Risks GRI 102-34 (Comprehensive)Nature and total number of critical concerns that were communicated to the highest governance body and the mechanism(s) used to address and resolve them2021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical Business GRI 102-35 (Comprehensive)Remuneration policies for highest governance body and senior executives; linkage between compensation for members of the highest governance body, senior managers, and executives, and the organization's performance2021 10-K Corporate Governance Guidelines Governance & Executive Compensation Policies Corporate Governance Guidelines Annual Evaluation of the Chief Executive Officer Compensation and Management Development Committee Charter 2021 ESG REPORT | 65 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-36 (Comprehensive)Process for determining remuneration Corporate Governance Guidelines Governance & Executive Compensation Policies Corporate Governance Guidelines Annual Evaluation of the Chief Executive Officer Compensation and Management Development Committee Charter GRI 102-40 List of stakeholder groups engaged by the organizationCorporate engagement: World Health Organization UN Global Compact UN Global Compact Communication on Progress 2021 Pharmaceutical Supply Chain Initiative By issue: Access to Medicines Corporate Giving Drug Donations and Philanthropic Efforts Disaster Relief and Product Donations Community Support For more on our engagement, visit our company website .","('Business_Ethics', 0.9677417278289795)","('Management_Of_Legal_And_Regulatory_Framework', 0.004199482500553131)","('Director_Removal', 0.002452191663905978)","(['Business Ethics'], 0.9677417278289795)","('NON-ESG', 0.004199482500553131)","('NON-ESG', 0.002452191663905978)"
Line 821,"GRI 102-11 Explanation of whether and how the precautionary approach or principle is addressed by the organization2021 ESG Report: Introduction >> UN Sustainable Development Goals >> Standing Up for Human Rights; Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Ethical and Safe Products GRI 102-12 External charters, principles, initiatives Overarching Policies Voluntary standards GRI 102-13 Memberships in associations Stakeholder Engagement Business association memberships GRI 102-14 Statement from senior management 2021 ESG Report: CEO Letter GRI 102-15 (Comprehensive)Description of key impacts, risks, and opportunities 2021 10-K 2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management GRI 102-16 Internally developed statements of mission or values, codes of conduct, codes of ethics, and principles relevant to sustainable developmentBMS Codes of Conduct GRI 102-17 (Comprehensive)Internal and external mechanisms for reporting concerns about unethical or unlawful behavior, and matters related to organizational integrity, such as escalation through line management, whistleblowing mechanisms or hotlinesBMS Codes of Conduct 2021 ESG Report: Ethics, Integrity, Quality and Governance >> EthicalBusiness GRI 102-18 Governance structure of the organization, including committees under the highest governance body; identify any committees responsible for decision-making on economic, environmental and social impacts2021 ESG Report: Introduction >> Our Approach to ESG Governance Board of Directors Board Committee & Charters GRI 102-19 (Comprehensive)Process for delegating authority for economic, environmental and social topics from highest governance body to senior executives and other employees2021 ESG Report: Introduction >> Our Approach to ESG; Ethics, Integrity, Quality and Governance >> Governance and Risk Management BMS Codes of Conduct GRI 102-20 (Comprehensive)Identify executive-level position with responsibility for economic, environmental and social topics and reporting to highest governance body2021 ESG Report: Introduction >> Our Approach to ESG Leadership Team GRI 102-21 (Comprehensive)Mechanisms for consultation between stakeholders and highest governance body on economic, environmental and social topicsBMS Codes of Conduct GRI 102-22 (Comprehensive)Composition of the highest governance body and its committees2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines Board of Directors GRI 102-23 (Comprehensive)Indicate whether the Chair of the highest governance body is also an executive officer, and if so, reason for this arrangementGovernance Board of Directors GRI 102-24 (Comprehensive)Report the nomination and selection processes for the highest governance body and its committees, and the criteria used for nominating and selecting highest governance body membersCorporate Governance Guidelines Composition and structure of the Board Committee on Directors and Corporate Governance 2021 ESG REPORT | 64 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-25 (Comprehensive)Processes in place for the highest governance body to ensure conflicts of interest are avoided and managedCorporate Governance Guidelines Board ResponsibilitiesItem 4 Compliance, Ethics and Conflicts of Interest GRI 102-26 (Comprehensive)Role of highest governance body and senior executives in developing, approving, and updating the purpose, value, or mission statements, strategies, policies and goals related to economic, environmental and social impacts2021 ESG Report: Introduction >> Our Approach to ESG; Environmental Responsibility >> Our Approach Environmental, Health and Safety Policy GRI 102-27 (Comprehensive)Measures taken to develop and enhance the highest governance body's collective knowledge of economic, environmental and social topics2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines GRI 102-28 (Comprehensive)Process for evaluating the highest governance body's own performance with respect to economic, environmental and social and if evaluation is independent or self-assessment2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines Evaluating the Boards Performance GRI 102-29 (Comprehensive)Process of the highest governance body's role for overseeing the organization's identification and management of economic, environmental, and social performance and if stakeholder consultation is used2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Environmental Responsibility >> Our Approach Governance Committee on Directors and Corporate Governance Charter GRI 102-30 (Comprehensive)Role of the highest governance body in reviewing the effectiveness of the organization's risk management processes for EES topics2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Board Committee & Charters Audit Committee Charter Responsibilities and DutiesItem 10 GRI 102-31 (Comprehensive)Frequency of the highest governance body's review of EES impacts, risks, and opportunities2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Environmental Responsibility >> Our Approach Board Committee & Charters Committee on Directors and Corporate Governance CharterResponsibilities and Duties Items 15 and 17 GRI 102-32 (Comprehensive)Highest committee or position that formally reviews and approves the organization's sustainability report and ensures all material Aspects are coveredBMS Leadership Team GRI 102-33 (Comprehensive)Process for communicating critical concerns to the highest governance body2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Ethical Business Board Committee & Charters Systems for Managing Risks GRI 102-34 (Comprehensive)Nature and total number of critical concerns that were communicated to the highest governance body and the mechanism(s) used to address and resolve them2021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical Business GRI 102-35 (Comprehensive)Remuneration policies for highest governance body and senior executives; linkage between compensation for members of the highest governance body, senior managers, and executives, and the organization's performance2021 10-K Corporate Governance Guidelines Governance & Executive Compensation Policies Corporate Governance Guidelines Annual Evaluation of the Chief Executive Officer Compensation and Management Development Committee Charter 2021 ESG REPORT | 65 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-36 (Comprehensive)Process for determining remuneration Corporate Governance Guidelines Governance & Executive Compensation Policies Corporate Governance Guidelines Annual Evaluation of the Chief Executive Officer Compensation and Management Development Committee Charter GRI 102-40 List of stakeholder groups engaged by the organizationCorporate engagement: World Health Organization UN Global Compact UN Global Compact Communication on Progress 2021 Pharmaceutical Supply Chain Initiative By issue: Access to Medicines Corporate Giving Drug Donations and Philanthropic Efforts Disaster Relief and Product Donations Community Support For more on our engagement, visit our company website .","('Business_Ethics', 0.878136157989502)","('Director_Removal', 0.025633430108428)","('Management_Of_Legal_And_Regulatory_Framework', 0.02033330872654915)","(['Business Ethics'], 0.878136157989502)","('NON-ESG', 0.025633430108428)","('NON-ESG', 0.02033330872654915)"
Line 822,"GRI 102-11 Explanation of whether and how the precautionary approach or principle is addressed by the organization2021 ESG Report: Introduction >> UN Sustainable Development Goals >> Standing Up for Human Rights; Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Ethical and Safe Products GRI 102-12 External charters, principles, initiatives Overarching Policies Voluntary standards GRI 102-13 Memberships in associations Stakeholder Engagement Business association memberships GRI 102-14 Statement from senior management 2021 ESG Report: CEO Letter GRI 102-15 (Comprehensive)Description of key impacts, risks, and opportunities 2021 10-K 2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management GRI 102-16 Internally developed statements of mission or values, codes of conduct, codes of ethics, and principles relevant to sustainable developmentBMS Codes of Conduct GRI 102-17 (Comprehensive)Internal and external mechanisms for reporting concerns about unethical or unlawful behavior, and matters related to organizational integrity, such as escalation through line management, whistleblowing mechanisms or hotlinesBMS Codes of Conduct 2021 ESG Report: Ethics, Integrity, Quality and Governance >> EthicalBusiness GRI 102-18 Governance structure of the organization, including committees under the highest governance body; identify any committees responsible for decision-making on economic, environmental and social impacts2021 ESG Report: Introduction >> Our Approach to ESG Governance Board of Directors Board Committee & Charters GRI 102-19 (Comprehensive)Process for delegating authority for economic, environmental and social topics from highest governance body to senior executives and other employees2021 ESG Report: Introduction >> Our Approach to ESG; Ethics, Integrity, Quality and Governance >> Governance and Risk Management BMS Codes of Conduct GRI 102-20 (Comprehensive)Identify executive-level position with responsibility for economic, environmental and social topics and reporting to highest governance body2021 ESG Report: Introduction >> Our Approach to ESG Leadership Team GRI 102-21 (Comprehensive)Mechanisms for consultation between stakeholders and highest governance body on economic, environmental and social topicsBMS Codes of Conduct GRI 102-22 (Comprehensive)Composition of the highest governance body and its committees2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines Board of Directors GRI 102-23 (Comprehensive)Indicate whether the Chair of the highest governance body is also an executive officer, and if so, reason for this arrangementGovernance Board of Directors GRI 102-24 (Comprehensive)Report the nomination and selection processes for the highest governance body and its committees, and the criteria used for nominating and selecting highest governance body membersCorporate Governance Guidelines Composition and structure of the Board Committee on Directors and Corporate Governance 2021 ESG REPORT | 64 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-25 (Comprehensive)Processes in place for the highest governance body to ensure conflicts of interest are avoided and managedCorporate Governance Guidelines Board ResponsibilitiesItem 4 Compliance, Ethics and Conflicts of Interest GRI 102-26 (Comprehensive)Role of highest governance body and senior executives in developing, approving, and updating the purpose, value, or mission statements, strategies, policies and goals related to economic, environmental and social impacts2021 ESG Report: Introduction >> Our Approach to ESG; Environmental Responsibility >> Our Approach Environmental, Health and Safety Policy GRI 102-27 (Comprehensive)Measures taken to develop and enhance the highest governance body's collective knowledge of economic, environmental and social topics2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines GRI 102-28 (Comprehensive)Process for evaluating the highest governance body's own performance with respect to economic, environmental and social and if evaluation is independent or self-assessment2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines Evaluating the Boards Performance GRI 102-29 (Comprehensive)Process of the highest governance body's role for overseeing the organization's identification and management of economic, environmental, and social performance and if stakeholder consultation is used2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Environmental Responsibility >> Our Approach Governance Committee on Directors and Corporate Governance Charter GRI 102-30 (Comprehensive)Role of the highest governance body in reviewing the effectiveness of the organization's risk management processes for EES topics2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Board Committee & Charters Audit Committee Charter Responsibilities and DutiesItem 10 GRI 102-31 (Comprehensive)Frequency of the highest governance body's review of EES impacts, risks, and opportunities2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Environmental Responsibility >> Our Approach Board Committee & Charters Committee on Directors and Corporate Governance CharterResponsibilities and Duties Items 15 and 17 GRI 102-32 (Comprehensive)Highest committee or position that formally reviews and approves the organization's sustainability report and ensures all material Aspects are coveredBMS Leadership Team GRI 102-33 (Comprehensive)Process for communicating critical concerns to the highest governance body2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Ethical Business Board Committee & Charters Systems for Managing Risks GRI 102-34 (Comprehensive)Nature and total number of critical concerns that were communicated to the highest governance body and the mechanism(s) used to address and resolve them2021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical Business GRI 102-35 (Comprehensive)Remuneration policies for highest governance body and senior executives; linkage between compensation for members of the highest governance body, senior managers, and executives, and the organization's performance2021 10-K Corporate Governance Guidelines Governance & Executive Compensation Policies Corporate Governance Guidelines Annual Evaluation of the Chief Executive Officer Compensation and Management Development Committee Charter 2021 ESG REPORT | 65 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-36 (Comprehensive)Process for determining remuneration Corporate Governance Guidelines Governance & Executive Compensation Policies Corporate Governance Guidelines Annual Evaluation of the Chief Executive Officer Compensation and Management Development Committee Charter GRI 102-40 List of stakeholder groups engaged by the organizationCorporate engagement: World Health Organization UN Global Compact UN Global Compact Communication on Progress 2021 Pharmaceutical Supply Chain Initiative By issue: Access to Medicines Corporate Giving Drug Donations and Philanthropic Efforts Disaster Relief and Product Donations Community Support For more on our engagement, visit our company website .","('Business_Ethics', 0.9598371386528015)","('Systemic_Risk_Management', 0.004853740334510803)","('Management_Of_Legal_And_Regulatory_Framework', 0.0037304479628801346)","(['Business Ethics'], 0.9598371386528015)","('NON-ESG', 0.004853740334510803)","('NON-ESG', 0.0037304479628801346)"
Line 823,"GRI 102-11 Explanation of whether and how the precautionary approach or principle is addressed by the organization2021 ESG Report: Introduction >> UN Sustainable Development Goals >> Standing Up for Human Rights; Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Ethical and Safe Products GRI 102-12 External charters, principles, initiatives Overarching Policies Voluntary standards GRI 102-13 Memberships in associations Stakeholder Engagement Business association memberships GRI 102-14 Statement from senior management 2021 ESG Report: CEO Letter GRI 102-15 (Comprehensive)Description of key impacts, risks, and opportunities 2021 10-K 2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management GRI 102-16 Internally developed statements of mission or values, codes of conduct, codes of ethics, and principles relevant to sustainable developmentBMS Codes of Conduct GRI 102-17 (Comprehensive)Internal and external mechanisms for reporting concerns about unethical or unlawful behavior, and matters related to organizational integrity, such as escalation through line management, whistleblowing mechanisms or hotlinesBMS Codes of Conduct 2021 ESG Report: Ethics, Integrity, Quality and Governance >> EthicalBusiness GRI 102-18 Governance structure of the organization, including committees under the highest governance body; identify any committees responsible for decision-making on economic, environmental and social impacts2021 ESG Report: Introduction >> Our Approach to ESG Governance Board of Directors Board Committee & Charters GRI 102-19 (Comprehensive)Process for delegating authority for economic, environmental and social topics from highest governance body to senior executives and other employees2021 ESG Report: Introduction >> Our Approach to ESG; Ethics, Integrity, Quality and Governance >> Governance and Risk Management BMS Codes of Conduct GRI 102-20 (Comprehensive)Identify executive-level position with responsibility for economic, environmental and social topics and reporting to highest governance body2021 ESG Report: Introduction >> Our Approach to ESG Leadership Team GRI 102-21 (Comprehensive)Mechanisms for consultation between stakeholders and highest governance body on economic, environmental and social topicsBMS Codes of Conduct GRI 102-22 (Comprehensive)Composition of the highest governance body and its committees2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines Board of Directors GRI 102-23 (Comprehensive)Indicate whether the Chair of the highest governance body is also an executive officer, and if so, reason for this arrangementGovernance Board of Directors GRI 102-24 (Comprehensive)Report the nomination and selection processes for the highest governance body and its committees, and the criteria used for nominating and selecting highest governance body membersCorporate Governance Guidelines Composition and structure of the Board Committee on Directors and Corporate Governance 2021 ESG REPORT | 64 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-25 (Comprehensive)Processes in place for the highest governance body to ensure conflicts of interest are avoided and managedCorporate Governance Guidelines Board ResponsibilitiesItem 4 Compliance, Ethics and Conflicts of Interest GRI 102-26 (Comprehensive)Role of highest governance body and senior executives in developing, approving, and updating the purpose, value, or mission statements, strategies, policies and goals related to economic, environmental and social impacts2021 ESG Report: Introduction >> Our Approach to ESG; Environmental Responsibility >> Our Approach Environmental, Health and Safety Policy GRI 102-27 (Comprehensive)Measures taken to develop and enhance the highest governance body's collective knowledge of economic, environmental and social topics2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines GRI 102-28 (Comprehensive)Process for evaluating the highest governance body's own performance with respect to economic, environmental and social and if evaluation is independent or self-assessment2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines Evaluating the Boards Performance GRI 102-29 (Comprehensive)Process of the highest governance body's role for overseeing the organization's identification and management of economic, environmental, and social performance and if stakeholder consultation is used2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Environmental Responsibility >> Our Approach Governance Committee on Directors and Corporate Governance Charter GRI 102-30 (Comprehensive)Role of the highest governance body in reviewing the effectiveness of the organization's risk management processes for EES topics2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Board Committee & Charters Audit Committee Charter Responsibilities and DutiesItem 10 GRI 102-31 (Comprehensive)Frequency of the highest governance body's review of EES impacts, risks, and opportunities2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Environmental Responsibility >> Our Approach Board Committee & Charters Committee on Directors and Corporate Governance CharterResponsibilities and Duties Items 15 and 17 GRI 102-32 (Comprehensive)Highest committee or position that formally reviews and approves the organization's sustainability report and ensures all material Aspects are coveredBMS Leadership Team GRI 102-33 (Comprehensive)Process for communicating critical concerns to the highest governance body2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Ethical Business Board Committee & Charters Systems for Managing Risks GRI 102-34 (Comprehensive)Nature and total number of critical concerns that were communicated to the highest governance body and the mechanism(s) used to address and resolve them2021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical Business GRI 102-35 (Comprehensive)Remuneration policies for highest governance body and senior executives; linkage between compensation for members of the highest governance body, senior managers, and executives, and the organization's performance2021 10-K Corporate Governance Guidelines Governance & Executive Compensation Policies Corporate Governance Guidelines Annual Evaluation of the Chief Executive Officer Compensation and Management Development Committee Charter 2021 ESG REPORT | 65 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-36 (Comprehensive)Process for determining remuneration Corporate Governance Guidelines Governance & Executive Compensation Policies Corporate Governance Guidelines Annual Evaluation of the Chief Executive Officer Compensation and Management Development Committee Charter GRI 102-40 List of stakeholder groups engaged by the organizationCorporate engagement: World Health Organization UN Global Compact UN Global Compact Communication on Progress 2021 Pharmaceutical Supply Chain Initiative By issue: Access to Medicines Corporate Giving Drug Donations and Philanthropic Efforts Disaster Relief and Product Donations Community Support For more on our engagement, visit our company website .","('Business_Ethics', 0.970440149307251)","('Management_Of_Legal_And_Regulatory_Framework', 0.002911502029746771)","('Director_Removal', 0.0022458385210484266)","(['Business Ethics'], 0.970440149307251)","('NON-ESG', 0.002911502029746771)","('NON-ESG', 0.0022458385210484266)"
Line 824,"GRI 102-11 Explanation of whether and how the precautionary approach or principle is addressed by the organization2021 ESG Report: Introduction >> UN Sustainable Development Goals >> Standing Up for Human Rights; Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Ethical and Safe Products GRI 102-12 External charters, principles, initiatives Overarching Policies Voluntary standards GRI 102-13 Memberships in associations Stakeholder Engagement Business association memberships GRI 102-14 Statement from senior management 2021 ESG Report: CEO Letter GRI 102-15 (Comprehensive)Description of key impacts, risks, and opportunities 2021 10-K 2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management GRI 102-16 Internally developed statements of mission or values, codes of conduct, codes of ethics, and principles relevant to sustainable developmentBMS Codes of Conduct GRI 102-17 (Comprehensive)Internal and external mechanisms for reporting concerns about unethical or unlawful behavior, and matters related to organizational integrity, such as escalation through line management, whistleblowing mechanisms or hotlinesBMS Codes of Conduct 2021 ESG Report: Ethics, Integrity, Quality and Governance >> EthicalBusiness GRI 102-18 Governance structure of the organization, including committees under the highest governance body; identify any committees responsible for decision-making on economic, environmental and social impacts2021 ESG Report: Introduction >> Our Approach to ESG Governance Board of Directors Board Committee & Charters GRI 102-19 (Comprehensive)Process for delegating authority for economic, environmental and social topics from highest governance body to senior executives and other employees2021 ESG Report: Introduction >> Our Approach to ESG; Ethics, Integrity, Quality and Governance >> Governance and Risk Management BMS Codes of Conduct GRI 102-20 (Comprehensive)Identify executive-level position with responsibility for economic, environmental and social topics and reporting to highest governance body2021 ESG Report: Introduction >> Our Approach to ESG Leadership Team GRI 102-21 (Comprehensive)Mechanisms for consultation between stakeholders and highest governance body on economic, environmental and social topicsBMS Codes of Conduct GRI 102-22 (Comprehensive)Composition of the highest governance body and its committees2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines Board of Directors GRI 102-23 (Comprehensive)Indicate whether the Chair of the highest governance body is also an executive officer, and if so, reason for this arrangementGovernance Board of Directors GRI 102-24 (Comprehensive)Report the nomination and selection processes for the highest governance body and its committees, and the criteria used for nominating and selecting highest governance body membersCorporate Governance Guidelines Composition and structure of the Board Committee on Directors and Corporate Governance 2021 ESG REPORT | 64 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-25 (Comprehensive)Processes in place for the highest governance body to ensure conflicts of interest are avoided and managedCorporate Governance Guidelines Board ResponsibilitiesItem 4 Compliance, Ethics and Conflicts of Interest GRI 102-26 (Comprehensive)Role of highest governance body and senior executives in developing, approving, and updating the purpose, value, or mission statements, strategies, policies and goals related to economic, environmental and social impacts2021 ESG Report: Introduction >> Our Approach to ESG; Environmental Responsibility >> Our Approach Environmental, Health and Safety Policy GRI 102-27 (Comprehensive)Measures taken to develop and enhance the highest governance body's collective knowledge of economic, environmental and social topics2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines GRI 102-28 (Comprehensive)Process for evaluating the highest governance body's own performance with respect to economic, environmental and social and if evaluation is independent or self-assessment2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines Evaluating the Boards Performance GRI 102-29 (Comprehensive)Process of the highest governance body's role for overseeing the organization's identification and management of economic, environmental, and social performance and if stakeholder consultation is used2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Environmental Responsibility >> Our Approach Governance Committee on Directors and Corporate Governance Charter GRI 102-30 (Comprehensive)Role of the highest governance body in reviewing the effectiveness of the organization's risk management processes for EES topics2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Board Committee & Charters Audit Committee Charter Responsibilities and DutiesItem 10 GRI 102-31 (Comprehensive)Frequency of the highest governance body's review of EES impacts, risks, and opportunities2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Environmental Responsibility >> Our Approach Board Committee & Charters Committee on Directors and Corporate Governance CharterResponsibilities and Duties Items 15 and 17 GRI 102-32 (Comprehensive)Highest committee or position that formally reviews and approves the organization's sustainability report and ensures all material Aspects are coveredBMS Leadership Team GRI 102-33 (Comprehensive)Process for communicating critical concerns to the highest governance body2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Ethical Business Board Committee & Charters Systems for Managing Risks GRI 102-34 (Comprehensive)Nature and total number of critical concerns that were communicated to the highest governance body and the mechanism(s) used to address and resolve them2021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical Business GRI 102-35 (Comprehensive)Remuneration policies for highest governance body and senior executives; linkage between compensation for members of the highest governance body, senior managers, and executives, and the organization's performance2021 10-K Corporate Governance Guidelines Governance & Executive Compensation Policies Corporate Governance Guidelines Annual Evaluation of the Chief Executive Officer Compensation and Management Development Committee Charter 2021 ESG REPORT | 65 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-36 (Comprehensive)Process for determining remuneration Corporate Governance Guidelines Governance & Executive Compensation Policies Corporate Governance Guidelines Annual Evaluation of the Chief Executive Officer Compensation and Management Development Committee Charter GRI 102-40 List of stakeholder groups engaged by the organizationCorporate engagement: World Health Organization UN Global Compact UN Global Compact Communication on Progress 2021 Pharmaceutical Supply Chain Initiative By issue: Access to Medicines Corporate Giving Drug Donations and Philanthropic Efforts Disaster Relief and Product Donations Community Support For more on our engagement, visit our company website .","('Director_Removal', 0.28106293082237244)","('Labor_Practices', 0.15130217373371124)","('Management_Of_Legal_And_Regulatory_Framework', 0.1450853943824768)","('NON-ESG', 0.28106293082237244)","('NON-ESG', 0.15130217373371124)","('NON-ESG', 0.1450853943824768)"
Line 825,"GRI 102-11 Explanation of whether and how the precautionary approach or principle is addressed by the organization2021 ESG Report: Introduction >> UN Sustainable Development Goals >> Standing Up for Human Rights; Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Ethical and Safe Products GRI 102-12 External charters, principles, initiatives Overarching Policies Voluntary standards GRI 102-13 Memberships in associations Stakeholder Engagement Business association memberships GRI 102-14 Statement from senior management 2021 ESG Report: CEO Letter GRI 102-15 (Comprehensive)Description of key impacts, risks, and opportunities 2021 10-K 2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management GRI 102-16 Internally developed statements of mission or values, codes of conduct, codes of ethics, and principles relevant to sustainable developmentBMS Codes of Conduct GRI 102-17 (Comprehensive)Internal and external mechanisms for reporting concerns about unethical or unlawful behavior, and matters related to organizational integrity, such as escalation through line management, whistleblowing mechanisms or hotlinesBMS Codes of Conduct 2021 ESG Report: Ethics, Integrity, Quality and Governance >> EthicalBusiness GRI 102-18 Governance structure of the organization, including committees under the highest governance body; identify any committees responsible for decision-making on economic, environmental and social impacts2021 ESG Report: Introduction >> Our Approach to ESG Governance Board of Directors Board Committee & Charters GRI 102-19 (Comprehensive)Process for delegating authority for economic, environmental and social topics from highest governance body to senior executives and other employees2021 ESG Report: Introduction >> Our Approach to ESG; Ethics, Integrity, Quality and Governance >> Governance and Risk Management BMS Codes of Conduct GRI 102-20 (Comprehensive)Identify executive-level position with responsibility for economic, environmental and social topics and reporting to highest governance body2021 ESG Report: Introduction >> Our Approach to ESG Leadership Team GRI 102-21 (Comprehensive)Mechanisms for consultation between stakeholders and highest governance body on economic, environmental and social topicsBMS Codes of Conduct GRI 102-22 (Comprehensive)Composition of the highest governance body and its committees2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines Board of Directors GRI 102-23 (Comprehensive)Indicate whether the Chair of the highest governance body is also an executive officer, and if so, reason for this arrangementGovernance Board of Directors GRI 102-24 (Comprehensive)Report the nomination and selection processes for the highest governance body and its committees, and the criteria used for nominating and selecting highest governance body membersCorporate Governance Guidelines Composition and structure of the Board Committee on Directors and Corporate Governance 2021 ESG REPORT | 64 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-25 (Comprehensive)Processes in place for the highest governance body to ensure conflicts of interest are avoided and managedCorporate Governance Guidelines Board ResponsibilitiesItem 4 Compliance, Ethics and Conflicts of Interest GRI 102-26 (Comprehensive)Role of highest governance body and senior executives in developing, approving, and updating the purpose, value, or mission statements, strategies, policies and goals related to economic, environmental and social impacts2021 ESG Report: Introduction >> Our Approach to ESG; Environmental Responsibility >> Our Approach Environmental, Health and Safety Policy GRI 102-27 (Comprehensive)Measures taken to develop and enhance the highest governance body's collective knowledge of economic, environmental and social topics2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines GRI 102-28 (Comprehensive)Process for evaluating the highest governance body's own performance with respect to economic, environmental and social and if evaluation is independent or self-assessment2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Corporate Governance Guidelines Evaluating the Boards Performance GRI 102-29 (Comprehensive)Process of the highest governance body's role for overseeing the organization's identification and management of economic, environmental, and social performance and if stakeholder consultation is used2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Environmental Responsibility >> Our Approach Governance Committee on Directors and Corporate Governance Charter GRI 102-30 (Comprehensive)Role of the highest governance body in reviewing the effectiveness of the organization's risk management processes for EES topics2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management Board Committee & Charters Audit Committee Charter Responsibilities and DutiesItem 10 GRI 102-31 (Comprehensive)Frequency of the highest governance body's review of EES impacts, risks, and opportunities2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Environmental Responsibility >> Our Approach Board Committee & Charters Committee on Directors and Corporate Governance CharterResponsibilities and Duties Items 15 and 17 GRI 102-32 (Comprehensive)Highest committee or position that formally reviews and approves the organization's sustainability report and ensures all material Aspects are coveredBMS Leadership Team GRI 102-33 (Comprehensive)Process for communicating critical concerns to the highest governance body2021 ESG Report: Ethics, Integrity, Quality and Governance >> Governance and Risk Management; Ethical Business Board Committee & Charters Systems for Managing Risks GRI 102-34 (Comprehensive)Nature and total number of critical concerns that were communicated to the highest governance body and the mechanism(s) used to address and resolve them2021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical Business GRI 102-35 (Comprehensive)Remuneration policies for highest governance body and senior executives; linkage between compensation for members of the highest governance body, senior managers, and executives, and the organization's performance2021 10-K Corporate Governance Guidelines Governance & Executive Compensation Policies Corporate Governance Guidelines Annual Evaluation of the Chief Executive Officer Compensation and Management Development Committee Charter 2021 ESG REPORT | 65 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-36 (Comprehensive)Process for determining remuneration Corporate Governance Guidelines Governance & Executive Compensation Policies Corporate Governance Guidelines Annual Evaluation of the Chief Executive Officer Compensation and Management Development Committee Charter GRI 102-40 List of stakeholder groups engaged by the organizationCorporate engagement: World Health Organization UN Global Compact UN Global Compact Communication on Progress 2021 Pharmaceutical Supply Chain Initiative By issue: Access to Medicines Corporate Giving Drug Donations and Philanthropic Efforts Disaster Relief and Product Donations Community Support For more on our engagement, visit our company website .","('Supply_Chain_Management', 0.845895528793335)","('Access_And_Affordability', 0.017315097153186798)","('Energy_Management', 0.012775941751897335)","([], 0.845895528793335)","('NON-ESG', 0.017315097153186798)","('NON-ESG', 0.012775941751897335)"
Line 826,GRI 102-41 Percentage of total employees covered by collective bargaining agreementsWe currently do not track collective bargaining agreements in our supply chain.,"('Labor_Practices', 0.9769601821899414)","('Director_Removal', 0.0021169481333345175)","('Supply_Chain_Management', 0.0017556099919602275)","([], 0.9769601821899414)","('NON-ESG', 0.0021169481333345175)","('NON-ESG', 0.0017556099919602275)"
Line 827,"GRI 102-42 Basis for identification and selection of stakeholders with whom to engageStakeholder Engagement Partnering Science and Technology Areas of Interest Supporting Our Communities For more on our engagement, visit our company website .","('Human_Rights_And_Community_Relations', 0.6819416880607605)","('Business_Model_Resilience', 0.06435290724039078)","('Management_Of_Legal_And_Regulatory_Framework', 0.036246407777071)","([], 0.6819416880607605)","('NON-ESG', 0.06435290724039078)","('NON-ESG', 0.036246407777071)"
Line 828,"GRI 102-43 Approaches to stakeholder engagement, including frequency of engagement by type and by stakeholder groupStakeholder Engagement Board Committee and Charters Committee on Directors and Corporate Governance CharterResponsibilities and DutiesItem 13 GRI 102-44 Key topics and concerns that have been raised through stakeholder engagement, and how the organization has responded to those key topics and concerns.","('Human_Rights_And_Community_Relations', 0.4041476249694824)","('Business_Model_Resilience', 0.15163719654083252)","('Business_Ethics', 0.060624055564403534)","('NON-ESG', 0.4041476249694824)","('NON-ESG', 0.15163719654083252)","('NON-ESG', 0.060624055564403534)"
Line 829,"Report stakeholder groups that raised each key topic and concern.2021 ESG Report: Introduction >> Our Approach to ESG Position on Key Issues SEC Filings Proxy Filings GRI 102-45 Entities included in financial statements, and specify which are included/excluded from this report2021 10-K GRI 102-46 Process for defining report content and Aspect boundaries, explain implementation of reporting principles for defining report content2021 ESG Report: About This Report GRI 102-47 List all material Aspects identified in the process for defining report contentBMS Sustainability 2020 Goals Progress Update page 3 GRI 102-48 Explanation of the effect of any restatements of information provided in previous reportsAny restatement of information is included in the footnotes beneath the specific performance data tables GRI 102-49 Significant changes from previous reporting periods in the scope and Aspect boundaries2021 ESG Report: Introduction >> About Bristol Myers Squibb Learn more in our 2021 10-K GRI 102-50 Reporting period January 1, 2021December 31, 2021 2021 ESG REPORT | 66 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-51 Date of most recent report November, 2022 GRI 102-52 Reporting cycle Annual GRI 102-53 Contact information Sustainability Feedback Contact Us GRI 102-54 ""In accordance"" option and location of the GRI content indexWe are reporting in alignment with the Global Reporting Initiatives 2018 Sustainability Reporting Standards.","('Management_Of_Legal_And_Regulatory_Framework', 0.30572739243507385)","('Business_Model_Resilience', 0.2706923186779022)","('Systemic_Risk_Management', 0.08278419822454453)","('NON-ESG', 0.30572739243507385)","('NON-ESG', 0.2706923186779022)","('NON-ESG', 0.08278419822454453)"
Line 830,"Report stakeholder groups that raised each key topic and concern.2021 ESG Report: Introduction >> Our Approach to ESG Position on Key Issues SEC Filings Proxy Filings GRI 102-45 Entities included in financial statements, and specify which are included/excluded from this report2021 10-K GRI 102-46 Process for defining report content and Aspect boundaries, explain implementation of reporting principles for defining report content2021 ESG Report: About This Report GRI 102-47 List all material Aspects identified in the process for defining report contentBMS Sustainability 2020 Goals Progress Update page 3 GRI 102-48 Explanation of the effect of any restatements of information provided in previous reportsAny restatement of information is included in the footnotes beneath the specific performance data tables GRI 102-49 Significant changes from previous reporting periods in the scope and Aspect boundaries2021 ESG Report: Introduction >> About Bristol Myers Squibb Learn more in our 2021 10-K GRI 102-50 Reporting period January 1, 2021December 31, 2021 2021 ESG REPORT | 66 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-51 Date of most recent report November, 2022 GRI 102-52 Reporting cycle Annual GRI 102-53 Contact information Sustainability Feedback Contact Us GRI 102-54 ""In accordance"" option and location of the GRI content indexWe are reporting in alignment with the Global Reporting Initiatives 2018 Sustainability Reporting Standards.","('Management_Of_Legal_And_Regulatory_Framework', 0.2624844014644623)","('Systemic_Risk_Management', 0.17395520210266113)","('Business_Model_Resilience', 0.1253887414932251)","('NON-ESG', 0.2624844014644623)","('NON-ESG', 0.17395520210266113)","('NON-ESG', 0.1253887414932251)"
Line 831,"Report stakeholder groups that raised each key topic and concern.2021 ESG Report: Introduction >> Our Approach to ESG Position on Key Issues SEC Filings Proxy Filings GRI 102-45 Entities included in financial statements, and specify which are included/excluded from this report2021 10-K GRI 102-46 Process for defining report content and Aspect boundaries, explain implementation of reporting principles for defining report content2021 ESG Report: About This Report GRI 102-47 List all material Aspects identified in the process for defining report contentBMS Sustainability 2020 Goals Progress Update page 3 GRI 102-48 Explanation of the effect of any restatements of information provided in previous reportsAny restatement of information is included in the footnotes beneath the specific performance data tables GRI 102-49 Significant changes from previous reporting periods in the scope and Aspect boundaries2021 ESG Report: Introduction >> About Bristol Myers Squibb Learn more in our 2021 10-K GRI 102-50 Reporting period January 1, 2021December 31, 2021 2021 ESG REPORT | 66 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 102-51 Date of most recent report November, 2022 GRI 102-52 Reporting cycle Annual GRI 102-53 Contact information Sustainability Feedback Contact Us GRI 102-54 ""In accordance"" option and location of the GRI content indexWe are reporting in alignment with the Global Reporting Initiatives 2018 Sustainability Reporting Standards.","('Management_Of_Legal_And_Regulatory_Framework', 0.42752817273139954)","('Product_Quality_And_Safety', 0.08418984711170197)","('Business_Model_Resilience', 0.07643070816993713)","('NON-ESG', 0.42752817273139954)","('NON-ESG', 0.08418984711170197)","('NON-ESG', 0.07643070816993713)"
Line 832,"Our index facilitates access to Core reporting elements as well as additional Comprehensive level elements, where available.","('Management_Of_Legal_And_Regulatory_Framework', 0.31422099471092224)","('Systemic_Risk_Management', 0.2494402378797531)","('Access_And_Affordability', 0.08745142817497253)","('NON-ESG', 0.31422099471092224)","('NON-ESG', 0.2494402378797531)","('NON-ESG', 0.08745142817497253)"
Line 833,"GRI Content Index GRI 102-55 GRI content index GRI Content Index GRI 102-56 External assurance Verification Statements GRI 103-1 Boundary of the report within the organization and specific limitations2021 ESG Report: About This Report GRI 103-2 The management approach and its components 2021 ESG Report: About This Report; Introduction >> Our Approach to ESG GRI 103-3 Evaluation of the management approach Board Committee & Charters Committee on Directors and Corporate Governance CharterResponsibilities and Duties Items 15 and 17 GRI 201-1 Direct economic value generated and distributed, including revenues, operating costs, employee compensation, donations and other community investments, retained earnings, and payments to capital providers and governments2021 10-K Fair Value Measurement, pages 52, 56, 68-69 Accrued Employee Compensation and Benefits, page 104 Dividends, pages 35, 37 Interest, page 37 Chargebacks related to government programs, pages 44-45, 77 Corporate Giving Economic Performance GRI 201-2 Financial implications and other risks and opportunities for the organization's activities due to climate change2021 ESG Report: Environmental Responsibility >> Energy and Emissions CDP Bristol Myers Squibb Position Statement on Climate Change GRI 201-3 Coverage of the organization's defined benefit plan obligations2021 10-K , pages 107-115 GRI 203-1 Development and impact of infrastructure investments and services supportedBristol Myers Squibb Foundation GRI 203-2 Significant indirect economic impacts, including the extent of impacts2021 ESG Report: Innovation, Equity and Access to Healthcare 2021 ESG REPORT | 67 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 205-2 Percentage of employees trained in anti-corruption policies/procedures2021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical Business Our Principles All employees must read and sign off on the Principles of Integrity: BMS Standards of Business Conduct and Ethics as a condition of employment.","('Management_Of_Legal_And_Regulatory_Framework', 0.41145431995391846)","('Director_Removal', 0.24737128615379333)","('Business_Ethics', 0.08746886998414993)","('NON-ESG', 0.41145431995391846)","('NON-ESG', 0.24737128615379333)","('NON-ESG', 0.08746886998414993)"
Line 834,"GRI Content Index GRI 102-55 GRI content index GRI Content Index GRI 102-56 External assurance Verification Statements GRI 103-1 Boundary of the report within the organization and specific limitations2021 ESG Report: About This Report GRI 103-2 The management approach and its components 2021 ESG Report: About This Report; Introduction >> Our Approach to ESG GRI 103-3 Evaluation of the management approach Board Committee & Charters Committee on Directors and Corporate Governance CharterResponsibilities and Duties Items 15 and 17 GRI 201-1 Direct economic value generated and distributed, including revenues, operating costs, employee compensation, donations and other community investments, retained earnings, and payments to capital providers and governments2021 10-K Fair Value Measurement, pages 52, 56, 68-69 Accrued Employee Compensation and Benefits, page 104 Dividends, pages 35, 37 Interest, page 37 Chargebacks related to government programs, pages 44-45, 77 Corporate Giving Economic Performance GRI 201-2 Financial implications and other risks and opportunities for the organization's activities due to climate change2021 ESG Report: Environmental Responsibility >> Energy and Emissions CDP Bristol Myers Squibb Position Statement on Climate Change GRI 201-3 Coverage of the organization's defined benefit plan obligations2021 10-K , pages 107-115 GRI 203-1 Development and impact of infrastructure investments and services supportedBristol Myers Squibb Foundation GRI 203-2 Significant indirect economic impacts, including the extent of impacts2021 ESG Report: Innovation, Equity and Access to Healthcare 2021 ESG REPORT | 67 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 205-2 Percentage of employees trained in anti-corruption policies/procedures2021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical Business Our Principles All employees must read and sign off on the Principles of Integrity: BMS Standards of Business Conduct and Ethics as a condition of employment.","('Labor_Practices', 0.8222545385360718)","('Employee_Engagement_Inclusion_And_Diversity', 0.044264789670705795)","('Management_Of_Legal_And_Regulatory_Framework', 0.02338239923119545)","([], 0.8222545385360718)","('NON-ESG', 0.044264789670705795)","('NON-ESG', 0.02338239923119545)"
Line 835,"GRI Content Index GRI 102-55 GRI content index GRI Content Index GRI 102-56 External assurance Verification Statements GRI 103-1 Boundary of the report within the organization and specific limitations2021 ESG Report: About This Report GRI 103-2 The management approach and its components 2021 ESG Report: About This Report; Introduction >> Our Approach to ESG GRI 103-3 Evaluation of the management approach Board Committee & Charters Committee on Directors and Corporate Governance CharterResponsibilities and Duties Items 15 and 17 GRI 201-1 Direct economic value generated and distributed, including revenues, operating costs, employee compensation, donations and other community investments, retained earnings, and payments to capital providers and governments2021 10-K Fair Value Measurement, pages 52, 56, 68-69 Accrued Employee Compensation and Benefits, page 104 Dividends, pages 35, 37 Interest, page 37 Chargebacks related to government programs, pages 44-45, 77 Corporate Giving Economic Performance GRI 201-2 Financial implications and other risks and opportunities for the organization's activities due to climate change2021 ESG Report: Environmental Responsibility >> Energy and Emissions CDP Bristol Myers Squibb Position Statement on Climate Change GRI 201-3 Coverage of the organization's defined benefit plan obligations2021 10-K , pages 107-115 GRI 203-1 Development and impact of infrastructure investments and services supportedBristol Myers Squibb Foundation GRI 203-2 Significant indirect economic impacts, including the extent of impacts2021 ESG Report: Innovation, Equity and Access to Healthcare 2021 ESG REPORT | 67 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 205-2 Percentage of employees trained in anti-corruption policies/procedures2021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical Business Our Principles All employees must read and sign off on the Principles of Integrity: BMS Standards of Business Conduct and Ethics as a condition of employment.","('Physical_Impacts_Of_Climate_Change', 0.9520806074142456)","('Business_Model_Resilience', 0.011282786726951599)","('GHG_Emissions', 0.004593859892338514)","([], 0.9520806074142456)","('NON-ESG', 0.011282786726951599)","('NON-ESG', 0.004593859892338514)"
Line 836,"GRI Content Index GRI 102-55 GRI content index GRI Content Index GRI 102-56 External assurance Verification Statements GRI 103-1 Boundary of the report within the organization and specific limitations2021 ESG Report: About This Report GRI 103-2 The management approach and its components 2021 ESG Report: About This Report; Introduction >> Our Approach to ESG GRI 103-3 Evaluation of the management approach Board Committee & Charters Committee on Directors and Corporate Governance CharterResponsibilities and Duties Items 15 and 17 GRI 201-1 Direct economic value generated and distributed, including revenues, operating costs, employee compensation, donations and other community investments, retained earnings, and payments to capital providers and governments2021 10-K Fair Value Measurement, pages 52, 56, 68-69 Accrued Employee Compensation and Benefits, page 104 Dividends, pages 35, 37 Interest, page 37 Chargebacks related to government programs, pages 44-45, 77 Corporate Giving Economic Performance GRI 201-2 Financial implications and other risks and opportunities for the organization's activities due to climate change2021 ESG Report: Environmental Responsibility >> Energy and Emissions CDP Bristol Myers Squibb Position Statement on Climate Change GRI 201-3 Coverage of the organization's defined benefit plan obligations2021 10-K , pages 107-115 GRI 203-1 Development and impact of infrastructure investments and services supportedBristol Myers Squibb Foundation GRI 203-2 Significant indirect economic impacts, including the extent of impacts2021 ESG Report: Innovation, Equity and Access to Healthcare 2021 ESG REPORT | 67 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 205-2 Percentage of employees trained in anti-corruption policies/procedures2021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical Business Our Principles All employees must read and sign off on the Principles of Integrity: BMS Standards of Business Conduct and Ethics as a condition of employment.","('Business_Ethics', 0.9736238718032837)","('Data_Security', 0.002052872208878398)","('Product_Quality_And_Safety', 0.001762186293490231)","(['Business Ethics'], 0.9736238718032837)","('NON-ESG', 0.002052872208878398)","('NON-ESG', 0.001762186293490231)"
Line 837,"GRI 301-2 Percentage of materials used that are recycled input materials2021 ESG Report: Environmental Responsibility >> Packaging and Transportation; Waste and Recycling GRI 302-1 Direct energy consumption by primary energy source including coal, natural gas, distilled fuel, biofuels, ethanol, hydrogen.","('Energy_Management', 0.7246658802032471)","('Product_Design_And_Lifecycle_Management', 0.16143687069416046)","('Waste_And_Hazardous_Materials_Management', 0.018944457173347473)","(['Operational Eco-Efficiency'], 0.7246658802032471)","('NON-ESG', 0.16143687069416046)","('NON-ESG', 0.018944457173347473)"
Line 838,The indicator covers scope 1 of the WRI/WBCSD GHG Protocol.,"('GHG_Emissions', 0.963014543056488)","('Water_And_Wastewater_Management', 0.004293459001928568)","('Air_Quality', 0.0037916048895567656)","(['Operational Eco-Efficiency'], 0.963014543056488)","('NON-ESG', 0.004293459001928568)","('NON-ESG', 0.0037916048895567656)"
Line 839,"Report total direct energy consumption in joules or multiples by renewable/non-renewable primary source.2021 ESG Report: Environmental Responsibility >> Energy and Emissions Energy Conservation ENERGY STAR Award CDP EPA GRI 302-2 Energy consumption outside of the organization 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 302-3 Energy intensity 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 302-4 Reduction of energy consumption 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 303-1 Total water withdrawal by source 2021 ESG Report: Environmental Responsibility >> Water and Wastewater GRI 303-2 Water sources significantly affected by withdrawal of water2021 ESG Report: Environmental Responsibility >> Water and Wastewater GRI 303-3 Percentage and total volume of water recycled and reused2021 ESG Report: Environmental Responsibility >> Waste and Recycling GRI 304-3 Habitats protected or restored 2021 ESG Report: Environmental Responsibility >> Employee Engagement in Sustainability GRI 304-4 Number of IUCN Red List species and national conservation list species with habitats in areas affected by operations, by level of extinction riskNot reported 2021 ESG REPORT | 68 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 305-1 Direct greenhouse gas emissions (Scope 1) 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-2 Indirect greenhouse gas emissions (Scope 2) 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-3 Other relevant indirect greenhouse gas emissions (Scope 3)2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-4 Greenhouse gas emissions intensity 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-5 Reduction of greenhouse gas emissions 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-6 Emissions of ozone-depleting substances (ODS) Not reported GRI 305-7 NOx, SOx, and other significant air emissions by typeNot reported GRI 306-1 Total water discharge by quality and destination 2021 ESG Report: Environmental Responsibility >> Water and Wastewater GRI 306-2 Total weight of waste by type and disposal method 2021 ESG Report: Environmental Responsibility >> Waste and Recycling GRI 306-3 Total number and volume of significant spills Not reported GRI 306-4 Weight of transported, imported, exported, or treated waste deemed hazardous under the terms of the Basel Convention Annex I, II, III, and VIII, and percentage of transported waste shipped internationally2021 ESG Report: 2021 ESG Data GRI 307-1 Monetary value of significant fines and total number of non-monetary sanctions for non-compliance with environmental laws and regulations2021 10-K GRI 308-1 Percentage of new suppliers that were screened using environmental criteria2021 ESG Report: Our People >> Supply Chain Standards of Business Conduct and Ethics for Third Parties 2021 ESG REPORT | 69 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 401-2 Benefits to full time employees Benefits GRI 403-1 Percentage of total workforce represented in formal joint management-worker health and safety committees that help monitor and advise on occupational health and safety programs2021 ESG Report: Our People >> Employee Health and Safety GRI 403-2 Types of injury and rates of injury, occupational diseases, lost days, and absenteeism, and total number of work-related fatalities by region and by gender2021 ESG Report: Our People >> Employee Health and Safety GRI 404-2 Programs for skills management and lifelong learning that support continued employability of employees and assist them in managing career endings.2021 ESG Report: Our People >> Global Inclusion and Diversity 2021 Global Inclusion & Diversity Report Benefits Developing Our People Development Programs GRI 405-1 Composition of governance bodies and employee breakdown per employee category by gender, age, minority group member (other diversity)2021 ESG Report: Our People >> Global Inclusion and Diversity 2021 Global Inclusion & Diversity Report GRI 408-1 Child labor incidents and measures to eliminate child laborStandards of Business Conduct and Ethics for Third Parties Bristol Myers Squibb UN Global Compact Communication on Progress 202 1 Workplace Policies GRI 409-1 Forced labor incidents and measures to eliminate forced laborWe had zero incidents of forced labor for 2021.","('Energy_Management', 0.980217695236206)","('Management_Of_Legal_And_Regulatory_Framework', 0.0021990996319800615)","('Air_Quality', 0.0017559983534738421)","(['Operational Eco-Efficiency'], 0.980217695236206)","('NON-ESG', 0.0021990996319800615)","('NON-ESG', 0.0017559983534738421)"
Line 840,"Report total direct energy consumption in joules or multiples by renewable/non-renewable primary source.2021 ESG Report: Environmental Responsibility >> Energy and Emissions Energy Conservation ENERGY STAR Award CDP EPA GRI 302-2 Energy consumption outside of the organization 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 302-3 Energy intensity 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 302-4 Reduction of energy consumption 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 303-1 Total water withdrawal by source 2021 ESG Report: Environmental Responsibility >> Water and Wastewater GRI 303-2 Water sources significantly affected by withdrawal of water2021 ESG Report: Environmental Responsibility >> Water and Wastewater GRI 303-3 Percentage and total volume of water recycled and reused2021 ESG Report: Environmental Responsibility >> Waste and Recycling GRI 304-3 Habitats protected or restored 2021 ESG Report: Environmental Responsibility >> Employee Engagement in Sustainability GRI 304-4 Number of IUCN Red List species and national conservation list species with habitats in areas affected by operations, by level of extinction riskNot reported 2021 ESG REPORT | 68 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 305-1 Direct greenhouse gas emissions (Scope 1) 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-2 Indirect greenhouse gas emissions (Scope 2) 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-3 Other relevant indirect greenhouse gas emissions (Scope 3)2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-4 Greenhouse gas emissions intensity 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-5 Reduction of greenhouse gas emissions 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-6 Emissions of ozone-depleting substances (ODS) Not reported GRI 305-7 NOx, SOx, and other significant air emissions by typeNot reported GRI 306-1 Total water discharge by quality and destination 2021 ESG Report: Environmental Responsibility >> Water and Wastewater GRI 306-2 Total weight of waste by type and disposal method 2021 ESG Report: Environmental Responsibility >> Waste and Recycling GRI 306-3 Total number and volume of significant spills Not reported GRI 306-4 Weight of transported, imported, exported, or treated waste deemed hazardous under the terms of the Basel Convention Annex I, II, III, and VIII, and percentage of transported waste shipped internationally2021 ESG Report: 2021 ESG Data GRI 307-1 Monetary value of significant fines and total number of non-monetary sanctions for non-compliance with environmental laws and regulations2021 10-K GRI 308-1 Percentage of new suppliers that were screened using environmental criteria2021 ESG Report: Our People >> Supply Chain Standards of Business Conduct and Ethics for Third Parties 2021 ESG REPORT | 69 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 401-2 Benefits to full time employees Benefits GRI 403-1 Percentage of total workforce represented in formal joint management-worker health and safety committees that help monitor and advise on occupational health and safety programs2021 ESG Report: Our People >> Employee Health and Safety GRI 403-2 Types of injury and rates of injury, occupational diseases, lost days, and absenteeism, and total number of work-related fatalities by region and by gender2021 ESG Report: Our People >> Employee Health and Safety GRI 404-2 Programs for skills management and lifelong learning that support continued employability of employees and assist them in managing career endings.2021 ESG Report: Our People >> Global Inclusion and Diversity 2021 Global Inclusion & Diversity Report Benefits Developing Our People Development Programs GRI 405-1 Composition of governance bodies and employee breakdown per employee category by gender, age, minority group member (other diversity)2021 ESG Report: Our People >> Global Inclusion and Diversity 2021 Global Inclusion & Diversity Report GRI 408-1 Child labor incidents and measures to eliminate child laborStandards of Business Conduct and Ethics for Third Parties Bristol Myers Squibb UN Global Compact Communication on Progress 202 1 Workplace Policies GRI 409-1 Forced labor incidents and measures to eliminate forced laborWe had zero incidents of forced labor for 2021.","('Water_And_Wastewater_Management', 0.9736918210983276)","('Ecological_Impacts', 0.002763493452221155)","('GHG_Emissions', 0.0022104226518422365)","([], 0.9736918210983276)","('NON-ESG', 0.002763493452221155)","('NON-ESG', 0.0022104226518422365)"
Line 841,"Report total direct energy consumption in joules or multiples by renewable/non-renewable primary source.2021 ESG Report: Environmental Responsibility >> Energy and Emissions Energy Conservation ENERGY STAR Award CDP EPA GRI 302-2 Energy consumption outside of the organization 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 302-3 Energy intensity 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 302-4 Reduction of energy consumption 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 303-1 Total water withdrawal by source 2021 ESG Report: Environmental Responsibility >> Water and Wastewater GRI 303-2 Water sources significantly affected by withdrawal of water2021 ESG Report: Environmental Responsibility >> Water and Wastewater GRI 303-3 Percentage and total volume of water recycled and reused2021 ESG Report: Environmental Responsibility >> Waste and Recycling GRI 304-3 Habitats protected or restored 2021 ESG Report: Environmental Responsibility >> Employee Engagement in Sustainability GRI 304-4 Number of IUCN Red List species and national conservation list species with habitats in areas affected by operations, by level of extinction riskNot reported 2021 ESG REPORT | 68 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 305-1 Direct greenhouse gas emissions (Scope 1) 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-2 Indirect greenhouse gas emissions (Scope 2) 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-3 Other relevant indirect greenhouse gas emissions (Scope 3)2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-4 Greenhouse gas emissions intensity 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-5 Reduction of greenhouse gas emissions 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-6 Emissions of ozone-depleting substances (ODS) Not reported GRI 305-7 NOx, SOx, and other significant air emissions by typeNot reported GRI 306-1 Total water discharge by quality and destination 2021 ESG Report: Environmental Responsibility >> Water and Wastewater GRI 306-2 Total weight of waste by type and disposal method 2021 ESG Report: Environmental Responsibility >> Waste and Recycling GRI 306-3 Total number and volume of significant spills Not reported GRI 306-4 Weight of transported, imported, exported, or treated waste deemed hazardous under the terms of the Basel Convention Annex I, II, III, and VIII, and percentage of transported waste shipped internationally2021 ESG Report: 2021 ESG Data GRI 307-1 Monetary value of significant fines and total number of non-monetary sanctions for non-compliance with environmental laws and regulations2021 10-K GRI 308-1 Percentage of new suppliers that were screened using environmental criteria2021 ESG Report: Our People >> Supply Chain Standards of Business Conduct and Ethics for Third Parties 2021 ESG REPORT | 69 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 401-2 Benefits to full time employees Benefits GRI 403-1 Percentage of total workforce represented in formal joint management-worker health and safety committees that help monitor and advise on occupational health and safety programs2021 ESG Report: Our People >> Employee Health and Safety GRI 403-2 Types of injury and rates of injury, occupational diseases, lost days, and absenteeism, and total number of work-related fatalities by region and by gender2021 ESG Report: Our People >> Employee Health and Safety GRI 404-2 Programs for skills management and lifelong learning that support continued employability of employees and assist them in managing career endings.2021 ESG Report: Our People >> Global Inclusion and Diversity 2021 Global Inclusion & Diversity Report Benefits Developing Our People Development Programs GRI 405-1 Composition of governance bodies and employee breakdown per employee category by gender, age, minority group member (other diversity)2021 ESG Report: Our People >> Global Inclusion and Diversity 2021 Global Inclusion & Diversity Report GRI 408-1 Child labor incidents and measures to eliminate child laborStandards of Business Conduct and Ethics for Third Parties Bristol Myers Squibb UN Global Compact Communication on Progress 202 1 Workplace Policies GRI 409-1 Forced labor incidents and measures to eliminate forced laborWe had zero incidents of forced labor for 2021.","('GHG_Emissions', 0.9149572253227234)","('Ecological_Impacts', 0.04382103681564331)","('Management_Of_Legal_And_Regulatory_Framework', 0.0043966760858893394)","(['Operational Eco-Efficiency'], 0.9149572253227234)","('NON-ESG', 0.04382103681564331)","('NON-ESG', 0.0043966760858893394)"
Line 842,"Report total direct energy consumption in joules or multiples by renewable/non-renewable primary source.2021 ESG Report: Environmental Responsibility >> Energy and Emissions Energy Conservation ENERGY STAR Award CDP EPA GRI 302-2 Energy consumption outside of the organization 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 302-3 Energy intensity 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 302-4 Reduction of energy consumption 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 303-1 Total water withdrawal by source 2021 ESG Report: Environmental Responsibility >> Water and Wastewater GRI 303-2 Water sources significantly affected by withdrawal of water2021 ESG Report: Environmental Responsibility >> Water and Wastewater GRI 303-3 Percentage and total volume of water recycled and reused2021 ESG Report: Environmental Responsibility >> Waste and Recycling GRI 304-3 Habitats protected or restored 2021 ESG Report: Environmental Responsibility >> Employee Engagement in Sustainability GRI 304-4 Number of IUCN Red List species and national conservation list species with habitats in areas affected by operations, by level of extinction riskNot reported 2021 ESG REPORT | 68 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 305-1 Direct greenhouse gas emissions (Scope 1) 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-2 Indirect greenhouse gas emissions (Scope 2) 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-3 Other relevant indirect greenhouse gas emissions (Scope 3)2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-4 Greenhouse gas emissions intensity 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-5 Reduction of greenhouse gas emissions 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-6 Emissions of ozone-depleting substances (ODS) Not reported GRI 305-7 NOx, SOx, and other significant air emissions by typeNot reported GRI 306-1 Total water discharge by quality and destination 2021 ESG Report: Environmental Responsibility >> Water and Wastewater GRI 306-2 Total weight of waste by type and disposal method 2021 ESG Report: Environmental Responsibility >> Waste and Recycling GRI 306-3 Total number and volume of significant spills Not reported GRI 306-4 Weight of transported, imported, exported, or treated waste deemed hazardous under the terms of the Basel Convention Annex I, II, III, and VIII, and percentage of transported waste shipped internationally2021 ESG Report: 2021 ESG Data GRI 307-1 Monetary value of significant fines and total number of non-monetary sanctions for non-compliance with environmental laws and regulations2021 10-K GRI 308-1 Percentage of new suppliers that were screened using environmental criteria2021 ESG Report: Our People >> Supply Chain Standards of Business Conduct and Ethics for Third Parties 2021 ESG REPORT | 69 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 401-2 Benefits to full time employees Benefits GRI 403-1 Percentage of total workforce represented in formal joint management-worker health and safety committees that help monitor and advise on occupational health and safety programs2021 ESG Report: Our People >> Employee Health and Safety GRI 403-2 Types of injury and rates of injury, occupational diseases, lost days, and absenteeism, and total number of work-related fatalities by region and by gender2021 ESG Report: Our People >> Employee Health and Safety GRI 404-2 Programs for skills management and lifelong learning that support continued employability of employees and assist them in managing career endings.2021 ESG Report: Our People >> Global Inclusion and Diversity 2021 Global Inclusion & Diversity Report Benefits Developing Our People Development Programs GRI 405-1 Composition of governance bodies and employee breakdown per employee category by gender, age, minority group member (other diversity)2021 ESG Report: Our People >> Global Inclusion and Diversity 2021 Global Inclusion & Diversity Report GRI 408-1 Child labor incidents and measures to eliminate child laborStandards of Business Conduct and Ethics for Third Parties Bristol Myers Squibb UN Global Compact Communication on Progress 202 1 Workplace Policies GRI 409-1 Forced labor incidents and measures to eliminate forced laborWe had zero incidents of forced labor for 2021.","('GHG_Emissions', 0.9676997661590576)","('Air_Quality', 0.004869283642619848)","('Ecological_Impacts', 0.0037856095004826784)","(['Operational Eco-Efficiency'], 0.9676997661590576)","('NON-ESG', 0.004869283642619848)","('NON-ESG', 0.0037856095004826784)"
Line 843,"Report total direct energy consumption in joules or multiples by renewable/non-renewable primary source.2021 ESG Report: Environmental Responsibility >> Energy and Emissions Energy Conservation ENERGY STAR Award CDP EPA GRI 302-2 Energy consumption outside of the organization 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 302-3 Energy intensity 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 302-4 Reduction of energy consumption 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 303-1 Total water withdrawal by source 2021 ESG Report: Environmental Responsibility >> Water and Wastewater GRI 303-2 Water sources significantly affected by withdrawal of water2021 ESG Report: Environmental Responsibility >> Water and Wastewater GRI 303-3 Percentage and total volume of water recycled and reused2021 ESG Report: Environmental Responsibility >> Waste and Recycling GRI 304-3 Habitats protected or restored 2021 ESG Report: Environmental Responsibility >> Employee Engagement in Sustainability GRI 304-4 Number of IUCN Red List species and national conservation list species with habitats in areas affected by operations, by level of extinction riskNot reported 2021 ESG REPORT | 68 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 305-1 Direct greenhouse gas emissions (Scope 1) 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-2 Indirect greenhouse gas emissions (Scope 2) 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-3 Other relevant indirect greenhouse gas emissions (Scope 3)2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-4 Greenhouse gas emissions intensity 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-5 Reduction of greenhouse gas emissions 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-6 Emissions of ozone-depleting substances (ODS) Not reported GRI 305-7 NOx, SOx, and other significant air emissions by typeNot reported GRI 306-1 Total water discharge by quality and destination 2021 ESG Report: Environmental Responsibility >> Water and Wastewater GRI 306-2 Total weight of waste by type and disposal method 2021 ESG Report: Environmental Responsibility >> Waste and Recycling GRI 306-3 Total number and volume of significant spills Not reported GRI 306-4 Weight of transported, imported, exported, or treated waste deemed hazardous under the terms of the Basel Convention Annex I, II, III, and VIII, and percentage of transported waste shipped internationally2021 ESG Report: 2021 ESG Data GRI 307-1 Monetary value of significant fines and total number of non-monetary sanctions for non-compliance with environmental laws and regulations2021 10-K GRI 308-1 Percentage of new suppliers that were screened using environmental criteria2021 ESG Report: Our People >> Supply Chain Standards of Business Conduct and Ethics for Third Parties 2021 ESG REPORT | 69 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 401-2 Benefits to full time employees Benefits GRI 403-1 Percentage of total workforce represented in formal joint management-worker health and safety committees that help monitor and advise on occupational health and safety programs2021 ESG Report: Our People >> Employee Health and Safety GRI 403-2 Types of injury and rates of injury, occupational diseases, lost days, and absenteeism, and total number of work-related fatalities by region and by gender2021 ESG Report: Our People >> Employee Health and Safety GRI 404-2 Programs for skills management and lifelong learning that support continued employability of employees and assist them in managing career endings.2021 ESG Report: Our People >> Global Inclusion and Diversity 2021 Global Inclusion & Diversity Report Benefits Developing Our People Development Programs GRI 405-1 Composition of governance bodies and employee breakdown per employee category by gender, age, minority group member (other diversity)2021 ESG Report: Our People >> Global Inclusion and Diversity 2021 Global Inclusion & Diversity Report GRI 408-1 Child labor incidents and measures to eliminate child laborStandards of Business Conduct and Ethics for Third Parties Bristol Myers Squibb UN Global Compact Communication on Progress 202 1 Workplace Policies GRI 409-1 Forced labor incidents and measures to eliminate forced laborWe had zero incidents of forced labor for 2021.","('Waste_And_Hazardous_Materials_Management', 0.9838617444038391)","('Air_Quality', 0.0013806320494040847)","('Water_And_Wastewater_Management', 0.0012213770532980561)","([], 0.9838617444038391)","('NON-ESG', 0.0013806320494040847)","('NON-ESG', 0.0012213770532980561)"
Line 844,"Report total direct energy consumption in joules or multiples by renewable/non-renewable primary source.2021 ESG Report: Environmental Responsibility >> Energy and Emissions Energy Conservation ENERGY STAR Award CDP EPA GRI 302-2 Energy consumption outside of the organization 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 302-3 Energy intensity 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 302-4 Reduction of energy consumption 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 303-1 Total water withdrawal by source 2021 ESG Report: Environmental Responsibility >> Water and Wastewater GRI 303-2 Water sources significantly affected by withdrawal of water2021 ESG Report: Environmental Responsibility >> Water and Wastewater GRI 303-3 Percentage and total volume of water recycled and reused2021 ESG Report: Environmental Responsibility >> Waste and Recycling GRI 304-3 Habitats protected or restored 2021 ESG Report: Environmental Responsibility >> Employee Engagement in Sustainability GRI 304-4 Number of IUCN Red List species and national conservation list species with habitats in areas affected by operations, by level of extinction riskNot reported 2021 ESG REPORT | 68 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 305-1 Direct greenhouse gas emissions (Scope 1) 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-2 Indirect greenhouse gas emissions (Scope 2) 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-3 Other relevant indirect greenhouse gas emissions (Scope 3)2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-4 Greenhouse gas emissions intensity 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-5 Reduction of greenhouse gas emissions 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-6 Emissions of ozone-depleting substances (ODS) Not reported GRI 305-7 NOx, SOx, and other significant air emissions by typeNot reported GRI 306-1 Total water discharge by quality and destination 2021 ESG Report: Environmental Responsibility >> Water and Wastewater GRI 306-2 Total weight of waste by type and disposal method 2021 ESG Report: Environmental Responsibility >> Waste and Recycling GRI 306-3 Total number and volume of significant spills Not reported GRI 306-4 Weight of transported, imported, exported, or treated waste deemed hazardous under the terms of the Basel Convention Annex I, II, III, and VIII, and percentage of transported waste shipped internationally2021 ESG Report: 2021 ESG Data GRI 307-1 Monetary value of significant fines and total number of non-monetary sanctions for non-compliance with environmental laws and regulations2021 10-K GRI 308-1 Percentage of new suppliers that were screened using environmental criteria2021 ESG Report: Our People >> Supply Chain Standards of Business Conduct and Ethics for Third Parties 2021 ESG REPORT | 69 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 401-2 Benefits to full time employees Benefits GRI 403-1 Percentage of total workforce represented in formal joint management-worker health and safety committees that help monitor and advise on occupational health and safety programs2021 ESG Report: Our People >> Employee Health and Safety GRI 403-2 Types of injury and rates of injury, occupational diseases, lost days, and absenteeism, and total number of work-related fatalities by region and by gender2021 ESG Report: Our People >> Employee Health and Safety GRI 404-2 Programs for skills management and lifelong learning that support continued employability of employees and assist them in managing career endings.2021 ESG Report: Our People >> Global Inclusion and Diversity 2021 Global Inclusion & Diversity Report Benefits Developing Our People Development Programs GRI 405-1 Composition of governance bodies and employee breakdown per employee category by gender, age, minority group member (other diversity)2021 ESG Report: Our People >> Global Inclusion and Diversity 2021 Global Inclusion & Diversity Report GRI 408-1 Child labor incidents and measures to eliminate child laborStandards of Business Conduct and Ethics for Third Parties Bristol Myers Squibb UN Global Compact Communication on Progress 202 1 Workplace Policies GRI 409-1 Forced labor incidents and measures to eliminate forced laborWe had zero incidents of forced labor for 2021.","('Supply_Chain_Management', 0.8403348922729492)","('Waste_And_Hazardous_Materials_Management', 0.025782005861401558)","('Labor_Practices', 0.019061598926782608)","([], 0.8403348922729492)","('NON-ESG', 0.025782005861401558)","('NON-ESG', 0.019061598926782608)"
Line 845,"Report total direct energy consumption in joules or multiples by renewable/non-renewable primary source.2021 ESG Report: Environmental Responsibility >> Energy and Emissions Energy Conservation ENERGY STAR Award CDP EPA GRI 302-2 Energy consumption outside of the organization 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 302-3 Energy intensity 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 302-4 Reduction of energy consumption 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 303-1 Total water withdrawal by source 2021 ESG Report: Environmental Responsibility >> Water and Wastewater GRI 303-2 Water sources significantly affected by withdrawal of water2021 ESG Report: Environmental Responsibility >> Water and Wastewater GRI 303-3 Percentage and total volume of water recycled and reused2021 ESG Report: Environmental Responsibility >> Waste and Recycling GRI 304-3 Habitats protected or restored 2021 ESG Report: Environmental Responsibility >> Employee Engagement in Sustainability GRI 304-4 Number of IUCN Red List species and national conservation list species with habitats in areas affected by operations, by level of extinction riskNot reported 2021 ESG REPORT | 68 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 305-1 Direct greenhouse gas emissions (Scope 1) 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-2 Indirect greenhouse gas emissions (Scope 2) 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-3 Other relevant indirect greenhouse gas emissions (Scope 3)2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-4 Greenhouse gas emissions intensity 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-5 Reduction of greenhouse gas emissions 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-6 Emissions of ozone-depleting substances (ODS) Not reported GRI 305-7 NOx, SOx, and other significant air emissions by typeNot reported GRI 306-1 Total water discharge by quality and destination 2021 ESG Report: Environmental Responsibility >> Water and Wastewater GRI 306-2 Total weight of waste by type and disposal method 2021 ESG Report: Environmental Responsibility >> Waste and Recycling GRI 306-3 Total number and volume of significant spills Not reported GRI 306-4 Weight of transported, imported, exported, or treated waste deemed hazardous under the terms of the Basel Convention Annex I, II, III, and VIII, and percentage of transported waste shipped internationally2021 ESG Report: 2021 ESG Data GRI 307-1 Monetary value of significant fines and total number of non-monetary sanctions for non-compliance with environmental laws and regulations2021 10-K GRI 308-1 Percentage of new suppliers that were screened using environmental criteria2021 ESG Report: Our People >> Supply Chain Standards of Business Conduct and Ethics for Third Parties 2021 ESG REPORT | 69 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 401-2 Benefits to full time employees Benefits GRI 403-1 Percentage of total workforce represented in formal joint management-worker health and safety committees that help monitor and advise on occupational health and safety programs2021 ESG Report: Our People >> Employee Health and Safety GRI 403-2 Types of injury and rates of injury, occupational diseases, lost days, and absenteeism, and total number of work-related fatalities by region and by gender2021 ESG Report: Our People >> Employee Health and Safety GRI 404-2 Programs for skills management and lifelong learning that support continued employability of employees and assist them in managing career endings.2021 ESG Report: Our People >> Global Inclusion and Diversity 2021 Global Inclusion & Diversity Report Benefits Developing Our People Development Programs GRI 405-1 Composition of governance bodies and employee breakdown per employee category by gender, age, minority group member (other diversity)2021 ESG Report: Our People >> Global Inclusion and Diversity 2021 Global Inclusion & Diversity Report GRI 408-1 Child labor incidents and measures to eliminate child laborStandards of Business Conduct and Ethics for Third Parties Bristol Myers Squibb UN Global Compact Communication on Progress 202 1 Workplace Policies GRI 409-1 Forced labor incidents and measures to eliminate forced laborWe had zero incidents of forced labor for 2021.","('Employee_Health_And_Safety', 0.9855255484580994)","('Employee_Engagement_Inclusion_And_Diversity', 0.0015712969470769167)","('Critical_Incident_Risk_Management', 0.0012602622155100107)","(['Health Outcome Contribution'], 0.9855255484580994)","('NON-ESG', 0.0015712969470769167)","('NON-ESG', 0.0012602622155100107)"
Line 846,"Report total direct energy consumption in joules or multiples by renewable/non-renewable primary source.2021 ESG Report: Environmental Responsibility >> Energy and Emissions Energy Conservation ENERGY STAR Award CDP EPA GRI 302-2 Energy consumption outside of the organization 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 302-3 Energy intensity 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 302-4 Reduction of energy consumption 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 303-1 Total water withdrawal by source 2021 ESG Report: Environmental Responsibility >> Water and Wastewater GRI 303-2 Water sources significantly affected by withdrawal of water2021 ESG Report: Environmental Responsibility >> Water and Wastewater GRI 303-3 Percentage and total volume of water recycled and reused2021 ESG Report: Environmental Responsibility >> Waste and Recycling GRI 304-3 Habitats protected or restored 2021 ESG Report: Environmental Responsibility >> Employee Engagement in Sustainability GRI 304-4 Number of IUCN Red List species and national conservation list species with habitats in areas affected by operations, by level of extinction riskNot reported 2021 ESG REPORT | 68 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 305-1 Direct greenhouse gas emissions (Scope 1) 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-2 Indirect greenhouse gas emissions (Scope 2) 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-3 Other relevant indirect greenhouse gas emissions (Scope 3)2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-4 Greenhouse gas emissions intensity 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-5 Reduction of greenhouse gas emissions 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-6 Emissions of ozone-depleting substances (ODS) Not reported GRI 305-7 NOx, SOx, and other significant air emissions by typeNot reported GRI 306-1 Total water discharge by quality and destination 2021 ESG Report: Environmental Responsibility >> Water and Wastewater GRI 306-2 Total weight of waste by type and disposal method 2021 ESG Report: Environmental Responsibility >> Waste and Recycling GRI 306-3 Total number and volume of significant spills Not reported GRI 306-4 Weight of transported, imported, exported, or treated waste deemed hazardous under the terms of the Basel Convention Annex I, II, III, and VIII, and percentage of transported waste shipped internationally2021 ESG Report: 2021 ESG Data GRI 307-1 Monetary value of significant fines and total number of non-monetary sanctions for non-compliance with environmental laws and regulations2021 10-K GRI 308-1 Percentage of new suppliers that were screened using environmental criteria2021 ESG Report: Our People >> Supply Chain Standards of Business Conduct and Ethics for Third Parties 2021 ESG REPORT | 69 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 401-2 Benefits to full time employees Benefits GRI 403-1 Percentage of total workforce represented in formal joint management-worker health and safety committees that help monitor and advise on occupational health and safety programs2021 ESG Report: Our People >> Employee Health and Safety GRI 403-2 Types of injury and rates of injury, occupational diseases, lost days, and absenteeism, and total number of work-related fatalities by region and by gender2021 ESG Report: Our People >> Employee Health and Safety GRI 404-2 Programs for skills management and lifelong learning that support continued employability of employees and assist them in managing career endings.2021 ESG Report: Our People >> Global Inclusion and Diversity 2021 Global Inclusion & Diversity Report Benefits Developing Our People Development Programs GRI 405-1 Composition of governance bodies and employee breakdown per employee category by gender, age, minority group member (other diversity)2021 ESG Report: Our People >> Global Inclusion and Diversity 2021 Global Inclusion & Diversity Report GRI 408-1 Child labor incidents and measures to eliminate child laborStandards of Business Conduct and Ethics for Third Parties Bristol Myers Squibb UN Global Compact Communication on Progress 202 1 Workplace Policies GRI 409-1 Forced labor incidents and measures to eliminate forced laborWe had zero incidents of forced labor for 2021.","('Employee_Engagement_Inclusion_And_Diversity', 0.9770057797431946)","('Employee_Health_And_Safety', 0.0019066317472606897)","('Business_Model_Resilience', 0.0015312430914491415)","(['Talent Attraction & Retention'], 0.9770057797431946)","('NON-ESG', 0.0019066317472606897)","('NON-ESG', 0.0015312430914491415)"
Line 847,"Report total direct energy consumption in joules or multiples by renewable/non-renewable primary source.2021 ESG Report: Environmental Responsibility >> Energy and Emissions Energy Conservation ENERGY STAR Award CDP EPA GRI 302-2 Energy consumption outside of the organization 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 302-3 Energy intensity 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 302-4 Reduction of energy consumption 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 303-1 Total water withdrawal by source 2021 ESG Report: Environmental Responsibility >> Water and Wastewater GRI 303-2 Water sources significantly affected by withdrawal of water2021 ESG Report: Environmental Responsibility >> Water and Wastewater GRI 303-3 Percentage and total volume of water recycled and reused2021 ESG Report: Environmental Responsibility >> Waste and Recycling GRI 304-3 Habitats protected or restored 2021 ESG Report: Environmental Responsibility >> Employee Engagement in Sustainability GRI 304-4 Number of IUCN Red List species and national conservation list species with habitats in areas affected by operations, by level of extinction riskNot reported 2021 ESG REPORT | 68 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 305-1 Direct greenhouse gas emissions (Scope 1) 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-2 Indirect greenhouse gas emissions (Scope 2) 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-3 Other relevant indirect greenhouse gas emissions (Scope 3)2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-4 Greenhouse gas emissions intensity 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-5 Reduction of greenhouse gas emissions 2021 ESG Report: Environmental Responsibility >> Energy and Emissions GRI 305-6 Emissions of ozone-depleting substances (ODS) Not reported GRI 305-7 NOx, SOx, and other significant air emissions by typeNot reported GRI 306-1 Total water discharge by quality and destination 2021 ESG Report: Environmental Responsibility >> Water and Wastewater GRI 306-2 Total weight of waste by type and disposal method 2021 ESG Report: Environmental Responsibility >> Waste and Recycling GRI 306-3 Total number and volume of significant spills Not reported GRI 306-4 Weight of transported, imported, exported, or treated waste deemed hazardous under the terms of the Basel Convention Annex I, II, III, and VIII, and percentage of transported waste shipped internationally2021 ESG Report: 2021 ESG Data GRI 307-1 Monetary value of significant fines and total number of non-monetary sanctions for non-compliance with environmental laws and regulations2021 10-K GRI 308-1 Percentage of new suppliers that were screened using environmental criteria2021 ESG Report: Our People >> Supply Chain Standards of Business Conduct and Ethics for Third Parties 2021 ESG REPORT | 69 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 401-2 Benefits to full time employees Benefits GRI 403-1 Percentage of total workforce represented in formal joint management-worker health and safety committees that help monitor and advise on occupational health and safety programs2021 ESG Report: Our People >> Employee Health and Safety GRI 403-2 Types of injury and rates of injury, occupational diseases, lost days, and absenteeism, and total number of work-related fatalities by region and by gender2021 ESG Report: Our People >> Employee Health and Safety GRI 404-2 Programs for skills management and lifelong learning that support continued employability of employees and assist them in managing career endings.2021 ESG Report: Our People >> Global Inclusion and Diversity 2021 Global Inclusion & Diversity Report Benefits Developing Our People Development Programs GRI 405-1 Composition of governance bodies and employee breakdown per employee category by gender, age, minority group member (other diversity)2021 ESG Report: Our People >> Global Inclusion and Diversity 2021 Global Inclusion & Diversity Report GRI 408-1 Child labor incidents and measures to eliminate child laborStandards of Business Conduct and Ethics for Third Parties Bristol Myers Squibb UN Global Compact Communication on Progress 202 1 Workplace Policies GRI 409-1 Forced labor incidents and measures to eliminate forced laborWe had zero incidents of forced labor for 2021.","('Labor_Practices', 0.9694420099258423)","('Employee_Engagement_Inclusion_And_Diversity', 0.005292682908475399)","('Employee_Health_And_Safety', 0.002824165625497699)","([], 0.9694420099258423)","('NON-ESG', 0.005292682908475399)","('NON-ESG', 0.002824165625497699)"
Line 848,"Workplace Policies Principles of Integrity: BMS Standards of Business Conduct and Ethics GRI 410-1 Security personnel trained to understand human rightsWorkplace Policies Workplace PoliciesSecurity GRI 412-1 Percentage and total number of operations that have been subject to human rights reviews and/or impact assessmentsHuman Rights Bristol Myers Squibb UN Global Compact Communication on Progress 202 1 GRI 414-1 Percentage of new suppliers that were screened using social criteriaBristol Myers Squibb UN Global Compact Communication on Progress 202 1 GRI 415-1 Total value of financial and in-kind contributions to political parties, politicians, and related institutions by country2021 Corporate Contributions by State GRI 416-1 Percentage of significant product and service categories for which health and safety impacts are assessed for improvement2021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical and Safe Products; Innovation, Equity and Access to Healthcare >> Clinical Trials; Environmental Responsibility >> Water and Wastewater >> Pharmaceuticals in the Environment (PiE) Clinical Trials & Research Sharps Management Plan 2021 ESG REPORT | 70 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 416-2 Total number of incidents of non-compliance with regulations and voluntary codes concerning health and safety impacts of products and services during their life cycle, by type of outcomesClinical Trials Disclosure Clinical Trials & Research GRI 417-1 Type of product and service information required by procedures, and percentage of significant products and services subject to such information requirementsOur Medicines GRI 417-3 Total number of incidents of non-compliance with regulations and voluntary codes concerning marketing communications, including advertising, promotion, and sponsorship by type of outcomes2021 10-K GRI 419-1 Non-compliance with laws and regulations in the social and economic areaPrinciples of Integrity BMS Standards of Business Conduct and Ethics 2021 10-K Compliance and Remediation Data Privacy, page 7 2021 ESG REPORT | 71 2021 GRI IndexNorges Bank Investment Management (NBIM) 2021 Index Indicator Indicator Description 2021 Response Culture 1.1A baseline has been established to identify perceptions of the ethical culture/culture of integrity in the company.","('Business_Ethics', 0.5742096900939941)","('Human_Rights_And_Community_Relations', 0.25999701023101807)","('Labor_Practices', 0.01610049419105053)","(['Business Ethics'], 0.5742096900939941)","('NON-ESG', 0.25999701023101807)","('NON-ESG', 0.01610049419105053)"
Line 849,"Workplace Policies Principles of Integrity: BMS Standards of Business Conduct and Ethics GRI 410-1 Security personnel trained to understand human rightsWorkplace Policies Workplace PoliciesSecurity GRI 412-1 Percentage and total number of operations that have been subject to human rights reviews and/or impact assessmentsHuman Rights Bristol Myers Squibb UN Global Compact Communication on Progress 202 1 GRI 414-1 Percentage of new suppliers that were screened using social criteriaBristol Myers Squibb UN Global Compact Communication on Progress 202 1 GRI 415-1 Total value of financial and in-kind contributions to political parties, politicians, and related institutions by country2021 Corporate Contributions by State GRI 416-1 Percentage of significant product and service categories for which health and safety impacts are assessed for improvement2021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical and Safe Products; Innovation, Equity and Access to Healthcare >> Clinical Trials; Environmental Responsibility >> Water and Wastewater >> Pharmaceuticals in the Environment (PiE) Clinical Trials & Research Sharps Management Plan 2021 ESG REPORT | 70 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 416-2 Total number of incidents of non-compliance with regulations and voluntary codes concerning health and safety impacts of products and services during their life cycle, by type of outcomesClinical Trials Disclosure Clinical Trials & Research GRI 417-1 Type of product and service information required by procedures, and percentage of significant products and services subject to such information requirementsOur Medicines GRI 417-3 Total number of incidents of non-compliance with regulations and voluntary codes concerning marketing communications, including advertising, promotion, and sponsorship by type of outcomes2021 10-K GRI 419-1 Non-compliance with laws and regulations in the social and economic areaPrinciples of Integrity BMS Standards of Business Conduct and Ethics 2021 10-K Compliance and Remediation Data Privacy, page 7 2021 ESG REPORT | 71 2021 GRI IndexNorges Bank Investment Management (NBIM) 2021 Index Indicator Indicator Description 2021 Response Culture 1.1A baseline has been established to identify perceptions of the ethical culture/culture of integrity in the company.","('Product_Quality_And_Safety', 0.8090062141418457)","('Product_Design_And_Lifecycle_Management', 0.03573547303676605)","('Selling_Practices_And_Product_Labeling', 0.027407819405198097)","(['Product Quality & Recall Management'], 0.8090062141418457)","('NON-ESG', 0.03573547303676605)","('NON-ESG', 0.027407819405198097)"
Line 850,"Workplace Policies Principles of Integrity: BMS Standards of Business Conduct and Ethics GRI 410-1 Security personnel trained to understand human rightsWorkplace Policies Workplace PoliciesSecurity GRI 412-1 Percentage and total number of operations that have been subject to human rights reviews and/or impact assessmentsHuman Rights Bristol Myers Squibb UN Global Compact Communication on Progress 202 1 GRI 414-1 Percentage of new suppliers that were screened using social criteriaBristol Myers Squibb UN Global Compact Communication on Progress 202 1 GRI 415-1 Total value of financial and in-kind contributions to political parties, politicians, and related institutions by country2021 Corporate Contributions by State GRI 416-1 Percentage of significant product and service categories for which health and safety impacts are assessed for improvement2021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical and Safe Products; Innovation, Equity and Access to Healthcare >> Clinical Trials; Environmental Responsibility >> Water and Wastewater >> Pharmaceuticals in the Environment (PiE) Clinical Trials & Research Sharps Management Plan 2021 ESG REPORT | 70 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 416-2 Total number of incidents of non-compliance with regulations and voluntary codes concerning health and safety impacts of products and services during their life cycle, by type of outcomesClinical Trials Disclosure Clinical Trials & Research GRI 417-1 Type of product and service information required by procedures, and percentage of significant products and services subject to such information requirementsOur Medicines GRI 417-3 Total number of incidents of non-compliance with regulations and voluntary codes concerning marketing communications, including advertising, promotion, and sponsorship by type of outcomes2021 10-K GRI 419-1 Non-compliance with laws and regulations in the social and economic areaPrinciples of Integrity BMS Standards of Business Conduct and Ethics 2021 10-K Compliance and Remediation Data Privacy, page 7 2021 ESG REPORT | 71 2021 GRI IndexNorges Bank Investment Management (NBIM) 2021 Index Indicator Indicator Description 2021 Response Culture 1.1A baseline has been established to identify perceptions of the ethical culture/culture of integrity in the company.","('Product_Quality_And_Safety', 0.8000656366348267)","('Product_Design_And_Lifecycle_Management', 0.04658597335219383)","('Selling_Practices_And_Product_Labeling', 0.03835684806108475)","(['Product Quality & Recall Management'], 0.8000656366348267)","('NON-ESG', 0.04658597335219383)","('NON-ESG', 0.03835684806108475)"
Line 851,"Workplace Policies Principles of Integrity: BMS Standards of Business Conduct and Ethics GRI 410-1 Security personnel trained to understand human rightsWorkplace Policies Workplace PoliciesSecurity GRI 412-1 Percentage and total number of operations that have been subject to human rights reviews and/or impact assessmentsHuman Rights Bristol Myers Squibb UN Global Compact Communication on Progress 202 1 GRI 414-1 Percentage of new suppliers that were screened using social criteriaBristol Myers Squibb UN Global Compact Communication on Progress 202 1 GRI 415-1 Total value of financial and in-kind contributions to political parties, politicians, and related institutions by country2021 Corporate Contributions by State GRI 416-1 Percentage of significant product and service categories for which health and safety impacts are assessed for improvement2021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical and Safe Products; Innovation, Equity and Access to Healthcare >> Clinical Trials; Environmental Responsibility >> Water and Wastewater >> Pharmaceuticals in the Environment (PiE) Clinical Trials & Research Sharps Management Plan 2021 ESG REPORT | 70 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 416-2 Total number of incidents of non-compliance with regulations and voluntary codes concerning health and safety impacts of products and services during their life cycle, by type of outcomesClinical Trials Disclosure Clinical Trials & Research GRI 417-1 Type of product and service information required by procedures, and percentage of significant products and services subject to such information requirementsOur Medicines GRI 417-3 Total number of incidents of non-compliance with regulations and voluntary codes concerning marketing communications, including advertising, promotion, and sponsorship by type of outcomes2021 10-K GRI 419-1 Non-compliance with laws and regulations in the social and economic areaPrinciples of Integrity BMS Standards of Business Conduct and Ethics 2021 10-K Compliance and Remediation Data Privacy, page 7 2021 ESG REPORT | 71 2021 GRI IndexNorges Bank Investment Management (NBIM) 2021 Index Indicator Indicator Description 2021 Response Culture 1.1A baseline has been established to identify perceptions of the ethical culture/culture of integrity in the company.","('Business_Ethics', 0.5567611455917358)","('Selling_Practices_And_Product_Labeling', 0.12891320884227753)","('Management_Of_Legal_And_Regulatory_Framework', 0.04700040444731712)","(['Business Ethics'], 0.5567611455917358)","('NON-ESG', 0.12891320884227753)","('NON-ESG', 0.04700040444731712)"
Line 852,"Workplace Policies Principles of Integrity: BMS Standards of Business Conduct and Ethics GRI 410-1 Security personnel trained to understand human rightsWorkplace Policies Workplace PoliciesSecurity GRI 412-1 Percentage and total number of operations that have been subject to human rights reviews and/or impact assessmentsHuman Rights Bristol Myers Squibb UN Global Compact Communication on Progress 202 1 GRI 414-1 Percentage of new suppliers that were screened using social criteriaBristol Myers Squibb UN Global Compact Communication on Progress 202 1 GRI 415-1 Total value of financial and in-kind contributions to political parties, politicians, and related institutions by country2021 Corporate Contributions by State GRI 416-1 Percentage of significant product and service categories for which health and safety impacts are assessed for improvement2021 ESG Report: Ethics, Integrity, Quality and Governance >> Ethical and Safe Products; Innovation, Equity and Access to Healthcare >> Clinical Trials; Environmental Responsibility >> Water and Wastewater >> Pharmaceuticals in the Environment (PiE) Clinical Trials & Research Sharps Management Plan 2021 ESG REPORT | 70 2021 GRI IndexUN SDG AlignmentGRI StandardDescription 2021 Response GRI 416-2 Total number of incidents of non-compliance with regulations and voluntary codes concerning health and safety impacts of products and services during their life cycle, by type of outcomesClinical Trials Disclosure Clinical Trials & Research GRI 417-1 Type of product and service information required by procedures, and percentage of significant products and services subject to such information requirementsOur Medicines GRI 417-3 Total number of incidents of non-compliance with regulations and voluntary codes concerning marketing communications, including advertising, promotion, and sponsorship by type of outcomes2021 10-K GRI 419-1 Non-compliance with laws and regulations in the social and economic areaPrinciples of Integrity BMS Standards of Business Conduct and Ethics 2021 10-K Compliance and Remediation Data Privacy, page 7 2021 ESG REPORT | 71 2021 GRI IndexNorges Bank Investment Management (NBIM) 2021 Index Indicator Indicator Description 2021 Response Culture 1.1A baseline has been established to identify perceptions of the ethical culture/culture of integrity in the company.","('Business_Ethics', 0.9283717274665833)","('Customer_Privacy', 0.009055324830114841)","('Data_Security', 0.0075990427285432816)","(['Business Ethics'], 0.9283717274665833)","('NON-ESG', 0.009055324830114841)","('NON-ESG', 0.0075990427285432816)"
Line 853,"There is a methodology to measure/gauge changes to the culture over timeWe have established a baseline to measure integrity through a question in the quarterly pulse survey, asking employees to rate BMS has a culture that values integrity.","('Business_Ethics', 0.9299538731575012)","('Human_Rights_And_Community_Relations', 0.0059571582823991776)","('Director_Removal', 0.005943541880697012)","(['Business Ethics'], 0.9299538731575012)","('NON-ESG', 0.0059571582823991776)","('NON-ESG', 0.005943541880697012)"
Line 854,Results of the quarterly survey are regularly reviewed and actioned as needed by leadership teams throughout the organization.,"('Employee_Engagement_Inclusion_And_Diversity', 0.24315418303012848)","('Director_Removal', 0.11949596554040909)","('Business_Model_Resilience', 0.08448459953069687)","('NON-ESG', 0.24315418303012848)","('NON-ESG', 0.11949596554040909)","('NON-ESG', 0.08448459953069687)"
Line 855,"Integrity is one of BMS six Values, expected to be demonstrated consistently by every employee.","('Business_Ethics', 0.9503793716430664)","('Data_Security', 0.0040632588788867)","('Director_Removal', 0.003909183666110039)","(['Business Ethics'], 0.9503793716430664)","('NON-ESG', 0.0040632588788867)","('NON-ESG', 0.003909183666110039)"
Line 856,"Integrity is defined as how we demonstrate ethics, integrity and quality in everything we do for patients, customers and colleagues.","('Business_Ethics', 0.934848427772522)","('Customer_Privacy', 0.00591637659817934)","('Employee_Engagement_Inclusion_And_Diversity', 0.005247846245765686)","(['Business Ethics'], 0.934848427772522)","('NON-ESG', 0.00591637659817934)","('NON-ESG', 0.005247846245765686)"
Line 857,1.2The frequency (could be a % or absolute number) of references to ethics and compliance communicated internally and/ or externally by the defined C-levelpersonsOur leadership ensures a continuous emphasis on practicing a culture of integrity.,"('Business_Ethics', 0.9661834836006165)","('Product_Quality_And_Safety', 0.0028194966726005077)","('Management_Of_Legal_And_Regulatory_Framework', 0.0027273125015199184)","(['Business Ethics'], 0.9661834836006165)","('NON-ESG', 0.0028194966726005077)","('NON-ESG', 0.0027273125015199184)"
Line 858,"While we do not record the frequency of all such communications, several examples are detailed below: Internally : At Town Halls that occur several times a year, BMS Board Chair and CEO emphasizes the importance of integrity for all employees, and the company leadership team is encouraged to do the same in theircommunications.","('Business_Ethics', 0.7960481643676758)","('Director_Removal', 0.04501618072390556)","('Employee_Engagement_Inclusion_And_Diversity', 0.01978299207985401)","(['Business Ethics'], 0.7960481643676758)","('NON-ESG', 0.04501618072390556)","('NON-ESG', 0.01978299207985401)"
Line 859,"The Board Chair and CEO, and Chief Compliance & Ethics Officer (CCEO), communicate several times each year on integrity-related topics including company values, our Principles of Integrity, and anti-bribery policy training and compliance.","('Business_Ethics', 0.9752792716026306)","('Management_Of_Legal_And_Regulatory_Framework', 0.002149927895516157)","('Competitive_Behavior', 0.0019215818028897047)","(['Business Ethics'], 0.9752792716026306)","('NON-ESG', 0.002149927895516157)","('NON-ESG', 0.0019215818028897047)"
Line 860,"The I in Integrity initiative has been rolled out across the company under the leadership of the CCEO, and has provided tools and resources to encourage and facilitate conversations related to integrity.","('Business_Ethics', 0.9592778086662292)","('Management_Of_Legal_And_Regulatory_Framework', 0.006791586056351662)","('Competitive_Behavior', 0.003041336080059409)","(['Business Ethics'], 0.9592778086662292)","('NON-ESG', 0.006791586056351662)","('NON-ESG', 0.003041336080059409)"
Line 861,"The Reality Check series of articles, published monthly by the Compliance & Ethics department, based on real incidents, is intended to provide employees with a greater awareness of how to identify and escalate potential concerns.","('Business_Ethics', 0.9029338955879211)","('Management_Of_Legal_And_Regulatory_Framework', 0.03650709241628647)","('Product_Quality_And_Safety', 0.007475859951227903)","(['Business Ethics'], 0.9029338955879211)","('NON-ESG', 0.03650709241628647)","('NON-ESG', 0.007475859951227903)"
Line 862,"The Compliance & Ethics department, under the leadership of the CCEO, publishes regular companywide memos and articles on the internal news platform to support our commitment to ethics and integrity.","('Business_Ethics', 0.9701827764511108)","('Management_Of_Legal_And_Regulatory_Framework', 0.004124332219362259)","('Product_Quality_And_Safety', 0.0023381055798381567)","(['Business Ethics'], 0.9701827764511108)","('NON-ESG', 0.004124332219362259)","('NON-ESG', 0.0023381055798381567)"
Line 863,"Externally: The CEO highlights our commitment to integrity in the BMS annual report, as well as in the opening remarks and Q&A at our annual shareholder meeting In the 2021 proxy statement, integrity was highlighted as a measure of CEO performance, Board member selection criteria and employee compensation policies.","('Business_Ethics', 0.4499703347682953)","('Labor_Practices', 0.17955823242664337)","('Employee_Engagement_Inclusion_And_Diversity', 0.12409798055887222)","('NON-ESG', 0.4499703347682953)","('NON-ESG', 0.17955823242664337)","('NON-ESG', 0.12409798055887222)"
Line 864,Several references on bms.com.,"('Management_Of_Legal_And_Regulatory_Framework', 0.34299781918525696)","('Business_Ethics', 0.09450916945934296)","('Access_And_Affordability', 0.07950834929943085)","('NON-ESG', 0.34299781918525696)","('NON-ESG', 0.09450916945934296)","('NON-ESG', 0.07950834929943085)"
Line 865,1.3Does your performance management framework incorporate how ethics and integrity objectives are achieved?,"('Business_Ethics', 0.9666591286659241)","('Customer_Privacy', 0.002810514299198985)","('Product_Quality_And_Safety', 0.0024406914599239826)","(['Business Ethics'], 0.9666591286659241)","('NON-ESG', 0.002810514299198985)","('NON-ESG', 0.0024406914599239826)"
Line 866,(Y/N)Yes.,"('Competitive_Behavior', 0.278378427028656)","('Employee_Engagement_Inclusion_And_Diversity', 0.11147976666688919)","('Labor_Practices', 0.06246715784072876)","('NON-ESG', 0.278378427028656)","('NON-ESG', 0.11147976666688919)","('NON-ESG', 0.06246715784072876)"
Line 867,"BMS performance management process, which impacts employees compensation and career advancement, equally measures both achievement of individual objectives and how the individual demonstrates BMS Values.","('Employee_Engagement_Inclusion_And_Diversity', 0.852271556854248)","('Labor_Practices', 0.035362716764211655)","('Employee_Health_And_Safety', 0.01916148141026497)","(['Talent Attraction & Retention'], 0.852271556854248)","('NON-ESG', 0.035362716764211655)","('NON-ESG', 0.01916148141026497)"
Line 868,"Integrity is reflected in our companywide objective of Demonstrating ethics, integrity and quality in everything we do, which is adopted into every employees individual objectives.","('Business_Ethics', 0.9475864768028259)","('Customer_Privacy', 0.0050076572224497795)","('Employee_Engagement_Inclusion_And_Diversity', 0.004331591073423624)","(['Business Ethics'], 0.9475864768028259)","('NON-ESG', 0.0050076572224497795)","('NON-ESG', 0.004331591073423624)"
Line 869,"In addition, Integrity is one of six BMS Values.","('Business_Ethics', 0.9589362144470215)","('Competitive_Behavior', 0.0049642715603113174)","('Systemic_Risk_Management', 0.0037010691594332457)","(['Business Ethics'], 0.9589362144470215)","('NON-ESG', 0.0049642715603113174)","('NON-ESG', 0.0037010691594332457)"
Line 870,1.4Ethics and integrity are integral components in leadership decisionsOur performance management process approaches integrity at an individual level.,"('Business_Ethics', 0.967074453830719)","('Competitive_Behavior', 0.002777120331302285)","('Data_Security', 0.0024043864104896784)","(['Business Ethics'], 0.967074453830719)","('NON-ESG', 0.002777120331302285)","('NON-ESG', 0.0024043864104896784)"
Line 871,We also embed integrity into our hiring and critical talent decisions with professional and executive interview questions to explore a candidates integrity.,"('Business_Ethics', 0.9562942981719971)","('Employee_Engagement_Inclusion_And_Diversity', 0.0036280101630836725)","('Competitive_Behavior', 0.003263436257839203)","(['Business Ethics'], 0.9562942981719971)","('NON-ESG', 0.0036280101630836725)","('NON-ESG', 0.003263436257839203)"
Line 872,"When we look for talent in succession roles, it is a requirement that they possess leadership potential, which includes modeling BMS Values, including integrity.","('Employee_Engagement_Inclusion_And_Diversity', 0.5127912163734436)","('Business_Ethics', 0.13436110317707062)","('Human_Rights_And_Community_Relations', 0.06712950766086578)","(['Talent Attraction & Retention'], 0.5127912163734436)","('NON-ESG', 0.13436110317707062)","('NON-ESG', 0.06712950766086578)"
Line 873,"1.5The company actively engages in anti-corruption collective actionBMS has committed to the following anti-corruption collective action initiatives: Industry Association Codes such as the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Code of Practice, European Federation of Pharmaceutical Industries and Associations (EFPIA) Code of Practice and the Pharmaceutical Research and Manufacturers of America (PhRMA) Codes.","('Business_Ethics', 0.9643319845199585)","('Management_Of_Legal_And_Regulatory_Framework', 0.0035736658610403538)","('Data_Security', 0.0033025045413523912)","(['Business Ethics'], 0.9643319845199585)","('NON-ESG', 0.0035736658610403538)","('NON-ESG', 0.0033025045413523912)"
Line 874,UN Global Compact.,"('Management_Of_Legal_And_Regulatory_Framework', 0.41920414566993713)","('Human_Rights_And_Community_Relations', 0.14598600566387177)","('Competitive_Behavior', 0.06579142063856125)","('NON-ESG', 0.41920414566993713)","('NON-ESG', 0.14598600566387177)","('NON-ESG', 0.06579142063856125)"
Line 875,Participant in the 2020 Norges Bank Investment Management and the Basel Institute on Governance working group to develop guidance for companies to report on the effectiveness of their anti-corruption compliance program.,"('Business_Ethics', 0.9362274408340454)","('Management_Of_Legal_And_Regulatory_Framework', 0.0249722171574831)","('Product_Quality_And_Safety', 0.00424036243930459)","(['Business Ethics'], 0.9362274408340454)","('NON-ESG', 0.0249722171574831)","('NON-ESG', 0.00424036243930459)"
Line 876,This is BMS inaugural report in accordance with this guidance.,"('Management_Of_Legal_And_Regulatory_Framework', 0.8960437178611755)","('Access_And_Affordability', 0.012337020598351955)","('GHG_Emissions', 0.010676944628357887)","([], 0.8960437178611755)","('NON-ESG', 0.012337020598351955)","('NON-ESG', 0.010676944628357887)"
Line 877,"2021 ESG REPORT | 72Indicator Indicator Description 2021 Response Risk Management 2.1The company has an anti-corruption compliance risk program, which it uses to give regular updates to senior management and Board on how risks are being managedBMS anti-corruption compliance program is a cross-functional effort, including first-, second- and third-line risk management functions.","('Business_Ethics', 0.9651739597320557)","('Systemic_Risk_Management', 0.004514783155173063)","('Data_Security', 0.004032539669424295)","(['Business Ethics'], 0.9651739597320557)","('NON-ESG', 0.004514783155173063)","('NON-ESG', 0.004032539669424295)"
Line 878,First-line business owners establish systems and processes with anti-corruption controls; second-line functions such as Compliance and the Controller monitor relevant activities for anti- corruption compliance; and the independent internal audit function reviews first- and second-line activities.,"('Business_Ethics', 0.9738675951957703)","('Management_Of_Legal_And_Regulatory_Framework', 0.004005359951406717)","('Product_Quality_And_Safety', 0.0020149254705756903)","(['Business Ethics'], 0.9738675951957703)","('NON-ESG', 0.004005359951406717)","('NON-ESG', 0.0020149254705756903)"
Line 879,"Results of risk assessments, monitoring and auditing by these functions are shared with the BMS leadership team, other business unit leaders, the Board of Directors and its Audit Committee regularly.","('Systemic_Risk_Management', 0.3476525545120239)","('Business_Ethics', 0.29917609691619873)","('Management_Of_Legal_And_Regulatory_Framework', 0.11011487245559692)","('NON-ESG', 0.3476525545120239)","('NON-ESG', 0.29917609691619873)","('NON-ESG', 0.11011487245559692)"
Line 880,2.2The percentage of business functions that are included in the anti-corruption risk assessment100% of business functions are represented in BMS anti-corruption risk assessments.,"('Business_Ethics', 0.9697884321212769)","('Management_Of_Legal_And_Regulatory_Framework', 0.0034415770787745714)","('Data_Security', 0.002861856948584318)","(['Business Ethics'], 0.9697884321212769)","('NON-ESG', 0.0034415770787745714)","('NON-ESG', 0.002861856948584318)"
Line 881,2.3The company has established anti-corruption compliance KPIs that are used to measure the compliance programSeveral risk management functions capture and track metrics related to anti-corruption compliance.,"('Business_Ethics', 0.9723137617111206)","('Management_Of_Legal_And_Regulatory_Framework', 0.003460558829829097)","('Data_Security', 0.0025287126190960407)","(['Business Ethics'], 0.9723137617111206)","('NON-ESG', 0.003460558829829097)","('NON-ESG', 0.0025287126190960407)"
Line 882,"Examples include results of risk assessment and related mitigation activities, number and types of exceptions based on 100% review of expenditures and SOX control deficiencies.","('Systemic_Risk_Management', 0.5464581847190857)","('Business_Ethics', 0.28239762783050537)","('Management_Of_Legal_And_Regulatory_Framework', 0.03446279838681221)","([], 0.5464581847190857)","('NON-ESG', 0.28239762783050537)","('NON-ESG', 0.03446279838681221)"
Line 883,"Third Parties 3.1Percentage of third-party reviewsconductedThird-party reviews span the life cycle of a relationship, are coordinated among the second- and third-line functions, and are based on risk.","('Systemic_Risk_Management', 0.7357415556907654)","('Competitive_Behavior', 0.09384211897850037)","('Business_Ethics', 0.03421638160943985)","([], 0.7357415556907654)","('NON-ESG', 0.09384211897850037)","('NON-ESG', 0.03421638160943985)"
Line 884,"Specifically: 100% of high-risk third parties from an anti-corruption perspective (as determined based on several factors, including their services, location, and prior experience with BMS) are subject to due diligence at the time of selection or contract renewal, with a reassessment at regular intervals thereafter.","('Business_Ethics', 0.6993609070777893)","('Systemic_Risk_Management', 0.16255569458007812)","('Management_Of_Legal_And_Regulatory_Framework', 0.024071985855698586)","(['Business Ethics'], 0.6993609070777893)","('NON-ESG', 0.16255569458007812)","('NON-ESG', 0.024071985855698586)"
Line 885,"Additional deep-dive ongoing monitoring reviews, which include site visits and transaction testing, are also conducted on certain third parties based on risk.","('Ecological_Impacts', 0.49452489614486694)","('Business_Model_Resilience', 0.07708770036697388)","('GHG_Emissions', 0.051997747272253036)","('NON-ESG', 0.49452489614486694)","('NON-ESG', 0.07708770036697388)","('NON-ESG', 0.051997747272253036)"
Line 886,Internal audit scopes select third parties into their annual plan based on their risk assessment.,"('Management_Of_Legal_And_Regulatory_Framework', 0.3435758352279663)","('Business_Ethics', 0.29665473103523254)","('Systemic_Risk_Management', 0.20591653883457184)","('NON-ESG', 0.3435758352279663)","('NON-ESG', 0.29665473103523254)","('NON-ESG', 0.20591653883457184)"
Line 887,3.2How the findings from third-party reviews are addressedSecond-line risk management and the internal audit functions liaise with the relevant BMS business owner to share findings and expectations with third parties.,"('Systemic_Risk_Management', 0.3466200828552246)","('Business_Ethics', 0.3354197144508362)","('Management_Of_Legal_And_Regulatory_Framework', 0.16869589686393738)","('NON-ESG', 0.3466200828552246)","('NON-ESG', 0.3354197144508362)","('NON-ESG', 0.16869589686393738)"
Line 888,"Compliance standards are memorialized in third-party agreements, and BMS provides additional support where needed, such as anti-bribery training, to third parties.","('Business_Ethics', 0.969231903553009)","('Management_Of_Legal_And_Regulatory_Framework', 0.005337920505553484)","('Product_Quality_And_Safety', 0.0027578778099268675)","(['Business Ethics'], 0.969231903553009)","('NON-ESG', 0.005337920505553484)","('NON-ESG', 0.0027578778099268675)"
Line 889,"3.3Percentage of third parties that improve their anti-corruption compliance programsA vast majority (>95%) of third parties improve their anti-corruption programs in response to our findings, and doing so is a critical factor for BMS to continue its relationship with a third party.","('Business_Ethics', 0.9713061451911926)","('Management_Of_Legal_And_Regulatory_Framework', 0.0031838605646044016)","('Data_Security', 0.0027380436658859253)","(['Business Ethics'], 0.9713061451911926)","('NON-ESG', 0.0031838605646044016)","('NON-ESG', 0.0027380436658859253)"
Line 890,"Results of due diligence, ongoing monitoring and internal audits are shared with third parties and tracked regularly for on-time completion.","('Business_Ethics', 0.42149797081947327)","('Management_Of_Legal_And_Regulatory_Framework', 0.40044307708740234)","('Systemic_Risk_Management', 0.02347838692367077)","('NON-ESG', 0.42149797081947327)","('NON-ESG', 0.40044307708740234)","('NON-ESG', 0.02347838692367077)"
Line 891,"2021 ESG REPORT | 73 NBIM Index 2021Indicator Indicator Description 2021 Response Compliance 4.1The organizational structure of the company is transparent, including the location of the compliance function within the structure, and it identifies where the Chief Compliance Officer is situatedOur CCEO is part of the company leadership team and reports to the General Counsel, with accountability to the CEO and the Audit Committee of the Board of Directors.","('Management_Of_Legal_And_Regulatory_Framework', 0.5045412182807922)","('Business_Ethics', 0.2671794295310974)","('Director_Removal', 0.05870109051465988)","([], 0.5045412182807922)","('NON-ESG', 0.2671794295310974)","('NON-ESG', 0.05870109051465988)"
Line 892,Our CCEOs role on the company leadership team is detailed on the companys external website and annual reports.,"('Director_Removal', 0.3650428056716919)","('Business_Model_Resilience', 0.23209121823310852)","('Employee_Engagement_Inclusion_And_Diversity', 0.07077082246541977)","('NON-ESG', 0.3650428056716919)","('NON-ESG', 0.23209121823310852)","('NON-ESG', 0.07077082246541977)"
Line 893,4.2The governance structure of the company enables the Chief Compliance Officer to execute her/his responsibilities impartiallyThe CCEOs direct and private access to the CEO and the Audit Committee of the Board of Directors on a regular basis enables the CCEO to act independently.,"('Director_Removal', 0.7000002861022949)","('Management_Of_Legal_And_Regulatory_Framework', 0.1068863645195961)","('Business_Ethics', 0.026059769093990326)","(['Business Ethics'], 0.7000002861022949)","('NON-ESG', 0.1068863645195961)","('NON-ESG', 0.026059769093990326)"
Line 894,"4.3Ethics and integrity are integral components in all talent and leadership development programsAll our Growth & Development programs are anchored to, and aligned with, the six BMS Values, one of which is Integrity.","('Employee_Engagement_Inclusion_And_Diversity', 0.4947197139263153)","('Business_Ethics', 0.1945878565311432)","('Human_Rights_And_Community_Relations', 0.042487435042858124)","('NON-ESG', 0.4947197139263153)","('NON-ESG', 0.1945878565311432)","('NON-ESG', 0.042487435042858124)"
Line 895,"Our leadership development programs are designed around our Values, which inform expected leadership capabilities.","('Employee_Engagement_Inclusion_And_Diversity', 0.70684415102005)","('Human_Rights_And_Community_Relations', 0.04992036893963814)","('Business_Model_Resilience', 0.0482461117208004)","(['Talent Attraction & Retention'], 0.70684415102005)","('NON-ESG', 0.04992036893963814)","('NON-ESG', 0.0482461117208004)"
Line 896,"Nominations for these programs are based on consistent high performance, which includes demonstrating our Values as well as achieving our companywide objectives, which requires Demonstrating ethics, integrity and quality in everything we do.","('Business_Ethics', 0.9406461715698242)","('Customer_Privacy', 0.005379431881010532)","('Human_Rights_And_Community_Relations', 0.004905266687273979)","(['Business Ethics'], 0.9406461715698242)","('NON-ESG', 0.005379431881010532)","('NON-ESG', 0.004905266687273979)"
Line 897,4.4The program is adequately resourced and empowered to function effectivelyBMS Compliance & Ethics organization and its relevant partners are fully resourced to deliver on our anti- corruption compliance program priorities.,"('Business_Ethics', 0.9732164740562439)","('Management_Of_Legal_And_Regulatory_Framework', 0.0040846108458936214)","('Product_Quality_And_Safety', 0.002333821030333638)","(['Business Ethics'], 0.9732164740562439)","('NON-ESG', 0.0040846108458936214)","('NON-ESG', 0.002333821030333638)"
Line 898,Budget is evaluated several times a year and adjusted as needed.,"('Management_Of_Legal_And_Regulatory_Framework', 0.8121260404586792)","('Energy_Management', 0.028837742283940315)","('GHG_Emissions', 0.019053837284445763)","([], 0.8121260404586792)","('NON-ESG', 0.028837742283940315)","('NON-ESG', 0.019053837284445763)"
Line 899,The CCEOs independent role (access to CEO and Board) empowers the program to function effectively.,"('Director_Removal', 0.5555084943771362)","('Management_Of_Legal_And_Regulatory_Framework', 0.11599203944206238)","('Employee_Engagement_Inclusion_And_Diversity', 0.04904531314969063)","(['Business Ethics'], 0.5555084943771362)","('NON-ESG', 0.11599203944206238)","('NON-ESG', 0.04904531314969063)"
Line 900,BMS has also been awarded the Compliance Leader Verification seal by the Ethisphere Institute since 2012; results of this independent assessment indicate a strong and continuously improving compliance program.,"('Management_Of_Legal_And_Regulatory_Framework', 0.4764437973499298)","('Business_Ethics', 0.3025655746459961)","('Product_Quality_And_Safety', 0.045530714094638824)","('NON-ESG', 0.4764437973499298)","('NON-ESG', 0.3025655746459961)","('NON-ESG', 0.045530714094638824)"
Line 901,"4.5The frequency of the Board actively reviewing the sufficiency of resources allocated to the global anti-corruption and briberyprogram including the compliancefunctionOur CCEO presents to, and has private sessions with, the Audit Committee several times a year.","('Business_Ethics', 0.9754422307014465)","('Management_Of_Legal_And_Regulatory_Framework', 0.003075804328545928)","('Competitive_Behavior', 0.0020183229353278875)","(['Business Ethics'], 0.9754422307014465)","('NON-ESG', 0.003075804328545928)","('NON-ESG', 0.0020183229353278875)"
Line 902,The CCEO also presents annually to the full Board of Directors.,"('Director_Removal', 0.7506840825080872)","('Management_Of_Legal_And_Regulatory_Framework', 0.029304139316082)","('Business_Ethics', 0.02149828150868416)","(['Business Ethics'], 0.7506840825080872)","('NON-ESG', 0.029304139316082)","('NON-ESG', 0.02149828150868416)"
Line 903,"While resourcing is not an explicit agenda item in every meeting, these meetings provide the opportunity to address resource topics.","('Business_Model_Resilience', 0.7139220237731934)","('Supply_Chain_Management', 0.07022921741008759)","('Product_Design_And_Lifecycle_Management', 0.04365183040499687)","(['Human Capital Development', 'Innovation Management'], 0.7139220237731934)","('NON-ESG', 0.07022921741008759)","('NON-ESG', 0.04365183040499687)"
Line 904,"Oversight 5.1Access by the Chief Compliance Officer to the Board, including the Board committees (i.e., the supervisory level of the company) on a formalized basis and the actual frequency of that accessOur CCEO is present at every Audit Committee meeting and presents at several.","('Director_Removal', 0.6352552771568298)","('Management_Of_Legal_And_Regulatory_Framework', 0.1357530802488327)","('Business_Ethics', 0.03595958650112152)","(['Business Ethics'], 0.6352552771568298)","('NON-ESG', 0.1357530802488327)","('NON-ESG', 0.03595958650112152)"
Line 905,"In addition, the CCEO has scheduled private sessions with the Audit Committee at least once a quarter and presents annually to the full Board of Directors.","('Director_Removal', 0.7651338577270508)","('Management_Of_Legal_And_Regulatory_Framework', 0.04402027279138565)","('Business_Ethics', 0.0215808916836977)","(['Business Ethics'], 0.7651338577270508)","('NON-ESG', 0.04402027279138565)","('NON-ESG', 0.0215808916836977)"
Line 906,"In 2021, the CCEO attended all eight Audit Committee meetings, presented at three of these meetings and had four private sessions with the Audit Committee.","('Management_Of_Legal_And_Regulatory_Framework', 0.8760111927986145)","('Director_Removal', 0.027163568884134293)","('Business_Ethics', 0.015871554613113403)","([], 0.8760111927986145)","('NON-ESG', 0.027163568884134293)","('NON-ESG', 0.015871554613113403)"
Line 907,The CCEO also presented to the full Board of Directors in 2021.,"('Director_Removal', 0.7405592203140259)","('Management_Of_Legal_And_Regulatory_Framework', 0.03811975568532944)","('Business_Ethics', 0.02097167633473873)","(['Business Ethics'], 0.7405592203140259)","('NON-ESG', 0.03811975568532944)","('NON-ESG', 0.02097167633473873)"
Line 908,2021 ESG REPORT | 74 NBIM Index 2021Forward-Looking Information and Non-GAAP Financial Information This report contains statements about the Companys future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995.,"('Management_Of_Legal_And_Regulatory_Framework', 0.9053270220756531)","('Systemic_Risk_Management', 0.01577477902173996)","('Business_Ethics', 0.008886142633855343)","([], 0.9053270220756531)","('NON-ESG', 0.01577477902173996)","('NON-ESG', 0.008886142633855343)"
Line 909,"Actual results may differ materially from those indicated as a result of various important factors, including those discussed in the Companys most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K.","('Management_Of_Legal_And_Regulatory_Framework', 0.6853704452514648)","('Systemic_Risk_Management', 0.03324289992451668)","('Business_Model_Resilience', 0.03253680095076561)","([], 0.6853704452514648)","('NON-ESG', 0.03324289992451668)","('NON-ESG', 0.03253680095076561)"
Line 910,"These documents are available on the SECs website, on the Bristol Myers Squibb website or from Bristol Myers Squibb Investor Relations.","('Management_Of_Legal_And_Regulatory_Framework', 0.5072233080863953)","('Competitive_Behavior', 0.133793905377388)","('Systemic_Risk_Management', 0.06881264597177505)","([], 0.5072233080863953)","('NON-ESG', 0.133793905377388)","('NON-ESG', 0.06881264597177505)"
Line 911,"In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date.","('Business_Model_Resilience', 0.15958519279956818)","('Competitive_Behavior', 0.1307561695575714)","('Systemic_Risk_Management', 0.1019582748413086)","('NON-ESG', 0.15958519279956818)","('NON-ESG', 0.1307561695575714)","('NON-ESG', 0.1019582748413086)"
Line 912,"While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.","('Management_Of_Legal_And_Regulatory_Framework', 0.38877585530281067)","('Business_Model_Resilience', 0.11080248653888702)","('Director_Removal', 0.09663950651884079)","('NON-ESG', 0.38877585530281067)","('NON-ESG', 0.11080248653888702)","('NON-ESG', 0.09663950651884079)"
Line 913,"This report includes certain non-generally accepted accounting principles (GAAP), financial measures that we use to describe our companys performance.","('Management_Of_Legal_And_Regulatory_Framework', 0.5305310487747192)","('Systemic_Risk_Management', 0.2017233669757843)","('Competitive_Behavior', 0.05131291225552559)","([], 0.5305310487747192)","('NON-ESG', 0.2017233669757843)","('NON-ESG', 0.05131291225552559)"
Line 914,"The non-GAAP information presented provides investors with additional useful information, but should not be considered in isolation or as substitutes for the related GAAP measures.","('Management_Of_Legal_And_Regulatory_Framework', 0.9364268183708191)","('Systemic_Risk_Management', 0.006845548283308744)","('GHG_Emissions', 0.006101752165704966)","([], 0.9364268183708191)","('NON-ESG', 0.006845548283308744)","('NON-ESG', 0.006101752165704966)"
Line 915,"Moreover, other companies may define non-GAAP measures differently, which limits the usefulness of these measures for comparisons with such other companies.","('Management_Of_Legal_And_Regulatory_Framework', 0.7029778957366943)","('Systemic_Risk_Management', 0.09047367423772812)","('Competitive_Behavior', 0.051709890365600586)","([], 0.7029778957366943)","('NON-ESG', 0.09047367423772812)","('NON-ESG', 0.051709890365600586)"
Line 916,We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.,"('Management_Of_Legal_And_Regulatory_Framework', 0.5325868725776672)","('Systemic_Risk_Management', 0.1633695513010025)","('Business_Model_Resilience', 0.05194738507270813)","([], 0.5325868725776672)","('NON-ESG', 0.1633695513010025)","('NON-ESG', 0.05194738507270813)"
Line 917,"Beginning with the first quarter of 2022, Acquired IPRD charges are no longer excluded from our non-GAAP financial measures.","('Management_Of_Legal_And_Regulatory_Framework', 0.8742008209228516)","('Business_Ethics', 0.028837954625487328)","('Competitive_Behavior', 0.0171833373606205)","([], 0.8742008209228516)","('NON-ESG', 0.028837954625487328)","('NON-ESG', 0.0171833373606205)"
Line 918,We made these changes to our presentation of non-GAAP financial measures following comments from and discussions with the U.,"('Management_Of_Legal_And_Regulatory_Framework', 0.9442604780197144)","('Systemic_Risk_Management', 0.008380336686968803)","('Business_Ethics', 0.004406969994306564)","([], 0.9442604780197144)","('NON-ESG', 0.008380336686968803)","('NON-ESG', 0.004406969994306564)"
Line 919,S. Securities and Exchange Commission.,"('Management_Of_Legal_And_Regulatory_Framework', 0.8597405552864075)","('Business_Ethics', 0.024639589712023735)","('Competitive_Behavior', 0.02112600952386856)","([], 0.8597405552864075)","('NON-ESG', 0.024639589712023735)","('NON-ESG', 0.02112600952386856)"
Line 920,"For purposes of comparability, the non-GAAP financial measures for the prior periods have been updated to reflect this change.","('Management_Of_Legal_And_Regulatory_Framework', 0.820513129234314)","('Systemic_Risk_Management', 0.05545160919427872)","('Business_Model_Resilience', 0.013430719263851643)","([], 0.820513129234314)","('NON-ESG', 0.05545160919427872)","('NON-ESG', 0.013430719263851643)"
Line 921,An explanation of these non-GAAP financial measures and a reconciliation to the most directly comparable GAAP financial measures are available on our website at bms.com/investors .,"('Management_Of_Legal_And_Regulatory_Framework', 0.9146126508712769)","('Systemic_Risk_Management', 0.01818179525434971)","('Business_Ethics', 0.009916363283991814)","([], 0.9146126508712769)","('NON-ESG', 0.01818179525434971)","('NON-ESG', 0.009916363283991814)"
Line 922,2021 ESG REPORT | 75,"('Business_Model_Resilience', 0.37609171867370605)","('Systemic_Risk_Management', 0.2495439052581787)","('Physical_Impacts_Of_Climate_Change', 0.046619169414043427)","('NON-ESG', 0.37609171867370605)","('NON-ESG', 0.2495439052581787)","('NON-ESG', 0.046619169414043427)"
